RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use

ABSTRACT

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional PatentApplication Ser. No. 63/213,097, filed on Jun. 21, 2021, and U.S.Provisional Patent Application Ser. No. 63/323,430, filed on Mar. 24,2022, the contents of each of which are incorporated herein by referencein their entirety.

SEQUENCE LISTING

This application contains a Sequence Listing which has been submitted inASCII format and is hereby incorporated by reference in its entirety.The ASCII copy is named 58651_713_202SL.txt and is 411 kb in size.

FIELD OF THE INVENTION

The present disclosure relates to RNA interference (RNAi) agents, e.g.,double stranded RNAi agents, for inhibition Xanthine Dehydrogenase (XDH;alternatively referred to as XO, XOR, xanthine dehydrogenase/oxidase,xanthine oxidoreductase, or XAN1), pharmaceutical compositions thatinclude XDH RNAi agents, and methods of use thereof.

BACKGROUND

Gout is a progressive inflammatory arthritis caused by hyperuricemia(elevated serum uric acid levels) and deposition of monosodium uratecrystals in joints and tendons. Gout is estimated to affect 0.6% of theworld population with a substantially higher prevalence in certaingeographical regions and ethnic groups. Gout patients without receivinga urate-lowering therapy suffer from recurrent episodes of gout flare(inflammation response) and ultimately can develop advanced gout, whichis characterized by chronic joint pain and activity limitation.

Xanthine dehydrogenase is a molybdenum-containing hydroxylase thatcatalyzes the production of uric acid from xanthine. XDH is highlyexpressed in liver and gastrointestinal tract. Hepatocyte-specificablation of XDH or global inhibition of XDH activity reverseshyperuricemia phenotype in animal models.

Small molecule inhibitors of XDH have been widely used forurate-lowering therapies. However, a large population of gout patientsare intolerant of or refractory to these therapies, and some seriousside effects include increased risk of death. There remains an unmetneed for novel XDH inhibitors, such as XDH RNAi agents, to reducehepatic XDH levels and treat hyperuricemia and gout.

SUMMARY

Disclosed herein are RNAi agents for inhibiting expression of an XDHgene, comprising an antisense strand comprising at least 17 contiguousnucleotides differing by 0 or 1 nucleotide from any one of the sequencesof Table 2, Table 3, or Table 5C; and a sense strand comprising anucleotide sequence that is at least partially complementary to theantisense strand.

In some aspects, the antisense strand comprises nucleotides 2-18 of anyone of the sequences of Table 2, Table 3, or Table 5C.

In some aspects, the sense strand comprises a nucleotide sequence of atleast 15 contiguous nucleotides differing by 0 or 1 nucleotide from 15contiguous nucleotides of any one of the sense strand sequences of Table2 or Table 4, and wherein the sense strand has a region of at least 85%complementarity over the 15 contiguous nucleotides to the antisensestrand.

In some aspects, at least one nucleotide of the RNAi agent is a modifiednucleotide or includes a modified internucleoside linkage.

According to some aspects, all or substantially all of the nucleotidesof the sense and/or antisense strand of the RNAi agent are modifiednucleotides.

In some aspects, the modified nucleotide is selected from the groupconsisting of: 2′-O-methyl nucleotide, 2′-fluoro nucleotide, 2′-deoxynucleotide, 2′,3′-seco nucleotide mimic, locked nucleotide, 2°-F-arabinonucleotide, 2′-methoxyethyl nucleotide, abasic nucleotide, ribitol,inverted nucleotide, inverted 2′-O-methyl nucleotide, inverted 2′-deoxynucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide,morpholino nucleotide, vinyl phosphonate containing nucleotide,cyclopropyl phosphonate containing nucleotide, and 3′-O-methylnucleotide.

In certain aspects, the all or substantially all of the modifiednucleotides are 2′-O-methyl nucleotides, 2′-fluoro nucleotides, orcombinations thereof.

In some aspects, the antisense strand consists of, consists essentiallyof, or comprises the nucleotide sequence of any one of the modifiedantisense strand sequences of Table 3.

In some aspects, the sense strand consists of, consists essentially of,or comprises the nucleotide sequence of any of the modified sense strandsequences of Table 4.

In some aspects, the antisense strand comprises the nucleotide sequenceof any one of the modified sequences of Table 3 and the sense strandcomprises the nucleotide sequence of any one of the modified sequencesof Table 4.

In certain aspects, the RNAi agents are linked to a targeting ligand. Insome aspects, the targeting ligand comprises N-acetyl-galactosamine. Incertain aspects, the targeting ligand comprises the structure of (NAG37)or (NAG37)s. In certain aspects, the targeting ligand is linked to thesense strand. In some aspects, the targeting ligand is linked to the 5′terminal end of the sense strand.

In some aspects, the sense strand is between 15 and 30 nucleotides inlength, and the antisense strand is between 18 and 30 nucleotides inlength. In other aspects, the sense strand and the antisense strand areeach between 18 and 27 nucleotides in length. In other aspects, thesense strand and the antisense strand are each between 18 and 24nucleotides in length. In still other aspects, sense strand and theantisense strand are each 21 nucleotides in length.

In some aspects, the RNAi agents have two blunt ends.

In some aspects, the sense strand comprises one or two terminal caps. Inother aspects, the sense strand comprises one or two inverted abasicresidues.

In some aspects, the RNAi agents are comprised of a sense strand and anantisense strand that form a duplex sequence of any one of the duplexstructures shown in Table 5A, 5B or 5C.

In some aspects, the sense strand further includes inverted abasicresidues at the 3′ terminal end of the nucleotide sequence, at the 5′end of the nucleotide sequence, or at both.

In some aspects, the sense strand of the RNAi agents is linked to atargeting ligand. In some aspects, the targeting ligand has affinity forthe asialoglycoprotein receptor. In some aspects, the targeting ligandcomprises N-acetyl-galactosamine.

In further aspects, the targeting ligand comprises:

Also disclosed herein are compositions comprising the disclosed RNAiagents, wherein the compositions further comprise a pharmaceuticallyacceptable excipient.

Also provided herein are methods for inhibiting expression of an XDHgene in a cell, the methods comprising introducing into a cell aneffective amount of the disclosed RNAi agents or the disclosedcompositions.

In some aspects, the cell is within a subject. In some aspects, thesubject is a human subject.

In some aspects, the XDH gene expression is inhibited by at least about30%. In some aspects, the XDH gene expression is inhibited by at leastabout 50% in the cytoplasm of hepatocytes.

Further provided herein are methods of treating an XDH-related disease,disorder, or symptom, the methods comprising administering to a humansubject in need thereof a therapeutically effective amount of thedisclosed compositions.

In some aspects, the disease is gout.

In some aspects, the symptom is hyperuricemia.

In some aspects, the RNAi agents are administered at a dose of about0.05 mg/kg to about 5.0 mg/kg of body weight of the human subject.

In other aspects, the RNAi agent is administered in two or more doses.

Also provided herein are usages of the disclosed RNAi agents or thedisclosed compositions, for the treatment of a disease, disorder, orsymptom that is mediated at least in part by XDH gene expression.

In some aspects, the disease is gout.

In some aspects, the symptom is hyperuricemia.

Further provided herein are usages of the disclosed RNAi agents or thedisclosed compositions, for the preparation of a pharmaceuticalcompositions for treating a disease, disorder, or symptom that ismediated at least in part by XDH gene expression.

In some aspects, the RNAi agent is administered at a dose of about 0.05mg/kg to about 5.0 mg/kg of body weight of the human subject.

DETAILED DESCRIPTION

The disclosed RNAi agents, compositions thereof, and methods of use maybe understood more readily by reference to the following detaileddescription, which form a part of this disclosure. It is to beunderstood that the disclosure is not limited to what is specificallydescribed and/or shown herein, and that the terminology used herein isfor the purpose of describing particular embodiments by way of exampleonly and is not intended to be limiting.

It is to be appreciated that while certain features of the disclosuresincluded herein are, for clarity, described herein in the context ofseparate embodiments, they may also be provided in combination in asingle embodiment. Conversely, various features of the disclosed methodsthat are, for brevity, described in the context of a single embodiment,may also be provided separately or in any subcombination.

Definitions

As used herein, an “RNAi agent” means a composition that contains an RNAor RNA-like (e.g., chemically modified RNA) oligonucleotide moleculethat is capable of degrading or inhibiting (e.g., degrades or inhibitsunder appropriate conditions) translation of messenger RNA (mRNA)transcripts of a target gene in a sequence specific manner. As usedherein, RNAi agents may operate through the RNA interference mechanism(i.e., inducing RNA interference through interaction with the RNAinterference pathway machinery (RNA-induced silencing complex or RISC)of mammalian cells), or by any alternative mechanism(s) or pathway(s).While it is believed that RNAi agents, as that term is used herein,operate primarily through the RNA interference mechanism, the disclosedRNAi agents are not bound by or limited to any particular pathway ormechanism of action. RNAi agents disclosed herein are comprised of asense strand and an antisense strand, and include, but are not limitedto: short (or small) interfering RNAs (siRNAs), double stranded RNAs(dsRNA), micro RNAs (miRNAs), short hairpin RNAs (shRNA), and dicersubstrates. The antisense strand of the RNAi agents described herein isat least partially complementary to the mRNA being targeted (i.e. XDHmRNA). RNAi agents can include one or more modified nucleotides and/orone or more non-phosphodiester linkages.

As used herein, the terms “silence,” “reduce,” “inhibit,”“down-regulate,” or “knockdown” when referring to expression of a givengene, mean that the expression of the gene, as measured by the level ofRNA transcribed from the gene or the level of polypeptide, protein, orprotein subunit translated from the mRNA in a cell, group of cells,tissue, organ, or subject in which the gene is transcribed, is reducedwhen the cell, group of cells, tissue, organ, or subject is treated withthe RNAi agents described herein as compared to a second cell, group ofcells, tissue, organ, or subject that has not or have not been sotreated.

As used herein, the terms “sequence” and “nucleotide sequence” mean asuccession or order of nucleobases or nucleotides, described with asuccession of letters using standard nomenclature. A nucleic acidmolecule can comprise unmodified and/or modified nucleotides. Anucleotide sequence can comprise unmodified and/or modified nucleotides.

As used herein, a “base,” “nucleotide base,” or “nucleobase,” is aheterocyclic pyrimidine or purine compound that is a component of anucleotide, and includes the primary purine bases adenine and guanine,and the primary pyrimidine bases cytosine, thymine, and uracil. Anucleobase may further be modified to include, without limitation,universal bases, hydrophobic bases, promiscuous bases, size-expandedbases, and fluorinated bases. (See, e.g., Modified Nucleosides inBiochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH,2008). The synthesis of such modified nucleobases (includingphosphoramidite compounds that include modified nucleobases) is known inthe art.

As used herein, the term “nucleotide” has the same meaning as commonlyunderstood in the art. Thus, the term “nucleotide” as used herein,refers to a glycoside comprising a sugar moiety, a base moiety and acovalently linked group (linkage group), such as a phosphate orphosphorothioate internucleoside linkage group, and covers bothnaturally occurring nucleotides, such as DNA or RNA, and non-naturallyoccurring nucleotides comprising modified sugar and/or base moieties,which are also referred to as nucleotide analogs herein. Herein, asingle nucleotide can be referred to as a monomer or unit.

As used herein, and unless otherwise indicated, the term“complementary,” when used to describe a first nucleobase or nucleotidesequence (e.g., RNAi agent sense strand or targeted mRNA) in relation toa second nucleobase or nucleotide sequence (e.g., RNAi agent antisensestrand or a single-stranded antisense oligonucleotide), means theability of an oligonucleotide or polynucleotide including the firstnucleotide sequence to hybridize (form base pair hydrogen bonds undermammalian physiological conditions (or otherwise suitable in vivo or invitro conditions) and form a duplex or double helical structure undercertain standard conditions with an oligonucleotide that includes thesecond nucleotide sequence. The person of ordinary skill in the artwould be able to select the set of conditions most appropriate for ahybridization test. Complementary sequences include Watson-Crick basepairs or non-Watson-Crick base pairs and include natural or modifiednucleotides or nucleotide mimics, at least to the extent that the abovehybridization requirements are fulfilled. Sequence identity orcomplementarity is independent of modification. For example, a and Af,as defined herein, are complementary to U (or T) and identical to A forthe purposes of determining identity or complementarity.

As used herein, “perfectly complementary” or “fully complementary” meansthat in a hybridized pair of nucleobase or nucleotide sequencemolecules, all (100%) of the bases in a contiguous sequence of a firstoligonucleotide will hybridize with the same number of bases in acontiguous sequence of a second oligonucleotide. The contiguous sequencemay comprise all or a part of a first or second nucleotide sequence.

As used herein, “partially complementary” means that in a hybridizedpair of nucleobase or nucleotide sequence molecules, at least 70%, butnot all, of the bases in a contiguous sequence of a firstoligonucleotide will hybridize with the same number of bases in acontiguous sequence of a second oligonucleotide. The contiguous sequencemay comprise all or a part of a first or second nucleotide sequence.

As used herein, “substantially complementary” means that in a hybridizedpair of nucleobase or nucleotide sequence molecules, at least 85%, butnot all, of the bases in a contiguous sequence of a firstoligonucleotide will hybridize with the same number of bases in acontiguous sequence of a second oligonucleotide. The contiguous sequencemay comprise all or a part of a first or second nucleotide sequence.

As used herein, the terms “complementary,” “fully complementary,”“partially complementary,” and “substantially complementary” are usedwith respect to the nucleobase or nucleotide matching between the sensestrand and the antisense strand of an RNAi agent, or between theantisense strand of an RNAi agent and a sequence of an MUCSAC mRNA.

As used herein, the term “substantially identical” or “substantialidentity,” as applied to a nucleic acid sequence means the nucleotidesequence (or a portion of a nucleotide sequence) has at least about 85%sequence identity or more, e.g., at least 90%, at least 95%, or at least99% identity, compared to a reference sequence. Percentage of sequenceidentity is determined by comparing two optimally aligned sequences overa comparison window. The percentage is calculated by determining thenumber of positions at which the same type of nucleic acid base occursin both sequences to yield the number of matched positions, dividing thenumber of matched positions by the total number of positions in thewindow of comparison and multiplying the result by 100 to yield thepercentage of sequence identity. The subject matter disclosed hereinencompass nucleotide sequences substantially identical to thosedisclosed herein.

As used herein, the terms “individual”, “patient” and “subject”, areused interchangeably to refer to a member of any animal speciesincluding, but not limited to, birds, humans and other primates, andother mammals including commercially relevant mammals or animal modelssuch as mice, rats, monkeys, cattle, pigs, horses, sheep, cats, anddogs. Preferably, the subject is a human.

As used herein, the terms “treat,” “treatment,” and the like, mean themethods or steps taken to provide relief from or alleviation of thenumber, severity, and/or frequency of one or more symptoms of a diseasein a subject. As used herein, “treat” and “treatment” may include theprevention, management, prophylactic treatment, and/or inhibition orreduction of the number, severity, and/or frequency of one or moresymptoms of a disease in a subject.

As used herein, the phrase “introducing into a cell,” when referring toan RNAi agent, means functionally delivering the RNAi agent into a cell.The phrase “functional delivery,” means delivering the RNAi agent to thecell in a manner that enables the RNAi agent to have the expectedbiological activity, e.g., sequence-specific inhibition of geneexpression.

Unless stated otherwise, use of the symbol

as used herein means that any group or groups may be linked thereto thatis in accordance with the scope of the subject matters described herein.

As used herein, the term “isomers” refers to compounds that haveidentical molecular formulae, but that differ in the nature or thesequence of bonding of their atoms or in the arrangement of their atomsin space. Isomers that differ in the arrangement of their atoms in spaceare termed “stereoisomers.” Stereoisomers that are not mirror images ofone another are termed “diastereoisomers,” and stereoisomers that arenon-superimposable mirror images are termed “enantiomers,” or sometimesoptical isomers. A carbon atom bonded to four non-identical substituentsis termed a “chiral center.”

As used herein, unless specifically identified in a structure as havinga particular conformation, for each structure in which asymmetriccenters are present and thus give rise to enantiomers, diastereomers, orother stereoisomeric configurations, each structure disclosed herein isintended to represent all such possible isomers, including theiroptically pure and racemic forms. For example, the structures disclosedherein are intended to cover mixtures of diastereomers as well as singlestereoisomers.

As used in a claim herein, the phrase “consisting of” excludes anyelement, step, or ingredient not specified in the claim. When used in aclaim herein, the phrase “consisting essentially of” limits the scope ofa claim to the specified materials or steps and those that do notmaterially affect the basic and novel characteristic(s) of the claimedinvention.

The person of ordinary skill in the art would readily understand andappreciate that the compounds and compositions disclosed herein may havecertain atoms (e.g., N, O, or S atoms) in a protonated or deprotonatedstate, depending upon the environment in which the compound orcomposition is placed. Accordingly, as used herein, the structuresdisclosed herein envisage that certain functional groups, such as, forexample, OH, SH, or NH, may be protonated or deprotonated. Thedisclosure herein is intended to cover the disclosed compounds andcompositions regardless of their state of protonation based on theenvironment (such as pH), as would be readily understood by the personof ordinary skill in the art. Correspondingly, compounds describedherein with labile protons or basic atoms should also be understood torepresent salt forms of the corresponding compound. Compounds describedherein may be in a free acid, free base, or salt form. Pharmaceuticallyacceptable salts of the compounds described herein should be understoodto be within the scope of the invention.

As used herein, the term “linked” or “conjugated” when referring to theconnection between two compounds or molecules means that two compoundsor molecules are joined by a covalent bond. Unless stated, the terms“linked” and “conjugated” as used herein may refer to the connectionbetween a first compound and a second compound either with or withoutany intervening atoms or groups of atoms.

As used herein, the term “including” is used to herein mean, and is usedinterchangeably with, the phrase “including but not limited to.” Theterm “or” is used herein to mean, and is used interchangeably with, theterm “and/or,” unless the context clearly indicates otherwise.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. Although methods and materials similar or equivalent to thosedescribed herein can be used in the practice or testing of the presentinvention, suitable methods and materials are described below. Allpublications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety. Incase of conflict, the present specification, including definitions, willcontrol. In addition, the materials, methods, and examples areillustrative only and not intended to be limiting.

Where a value is explicitly recited, it is to be understood that valueswhich are about the same quantity or amount as the recited value arealso within the scope of the disclosure. Where a combination isdisclosed, each sub-combination of the elements of that combination isalso specifically disclosed and is within the scope of the disclosure.Conversely, where different elements or groups of elements areindividually disclosed, combinations thereof are also disclosed. Whereany element of a disclosure is disclosed as having a plurality ofalternatives, examples of that disclosure in which each alternative isexcluded singly or in any combination with the other alternatives arealso hereby disclosed; more than one element of a disclosure can havesuch exclusions, and all combinations of elements having such exclusionsare hereby disclosed.

The term “about” or “approximately” as used herein when referring to ameasurable value such as a parameter, an amount, a temporal duration,and the like, is meant to encompass variations of +/−20% or less, +/−10%or less, +/−5% or less, or +/−1% or less of and from the specifiedvalue, insofar such variations are appropriate to perform in the presentdisclosure. It is to be understood that the value to which the modifier“about” or “approximately” refers is itself. For example, “about 4”includes 4.

Other objects, features, aspects, and advantages of the invention willbe apparent from the following detailed description, accompanyingFIGURES, and from the claims.

DETAILED DESCRIPTION RNAi Agents

Described herein are RNAi agents for inhibiting expression of an XDHgene. Each XDH RNAi agent comprises a sense strand and an antisensestrand. The sense strand can be 15 to 49 nucleotides in length. Theantisense strand can be 18 to 49 nucleotides in length. The sense andantisense strands can be either the same length or they can be differentlengths. In some aspects, the sense and antisense strands are eachindependently 18 to 27 nucleotides in length. In some aspects, both thesense and antisense strands are each 21-26 nucleotides in length. Insome aspects, the sense and antisense strands are each 21-24 nucleotidesin length. In some aspects, the sense and antisense strands are eachindependently 19-21 nucleotides in length. In some aspects, the sensestrand is about 19 nucleotides in length while the antisense strand isabout 21 nucleotides in length. In some aspects, the sense strand isabout 21 nucleotides in length while the antisense strand is about 23nucleotides in length. In some aspects, a sense strand is 23 nucleotidesin length and an antisense strand is 21 nucleotides in length. In someaspects, both the sense and antisense strands are each 21 nucleotides inlength. In some aspects, the RNAi agent antisense strands are each 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length.In some embodiments, the RNAi agent sense strands are each 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 nucleotides inlength. The sense and antisense strands are annealed to form a duplex,and in some aspects, a double-stranded RNAi agent has a duplex length ofabout 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides.

Examples of nucleotide sequences used in forming XDH RNAi agents areprovided in Tables 2, 3, 4, and 5C. Examples of RNAi agent duplexes,that include the sense strand and antisense strand sequences in Tables2, 3, 4 and 5C, are shown in Tables 5A, 5B and 5C.

In some aspects, the region of perfect, substantial, or partialcomplementarity between the sense strand and the antisense strand is15-26 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26)nucleotides in length and occurs at or near the 5′ end of the antisensestrand (e.g., this region may be separated from the 5′ end of theantisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly,substantially, or partially complementary).

A sense strand of the XDH RNAi agents described herein includes at least15 consecutive nucleotides that have at least 85% identity to a corestretch sequence (also referred to herein as a “core stretch” or “coresequence”) of the same number of nucleotides in an XDH mRNA. In someaspects, a sense strand core stretch sequence is 100% (perfectly)complementary or at least about 85% (substantially) complementary to acore stretch sequence in the antisense strand, and thus the sense strandcore stretch sequence is typically perfectly identical or at least about85% identical to a nucleotide sequence of the same length (sometimesreferred to, e.g., as a target sequence) present in the XDH mRNA target.In some aspects, this sense strand core stretch is 15, 16, 17, 18, 19,20, 21, 22, or 23 nucleotides in length. In some aspects, this sensestrand core stretch is 17 nucleotides in length. In some aspects, thissense strand core stretch is 19 nucleotides in length.

An antisense strand of an XDH RNAi agent described herein includes atleast 15 consecutive nucleotides that have at least 85% complementarityto a core stretch of the same number of nucleotides in an XDH mRNA andto a core stretch of the same number of nucleotides in the correspondingsense strand. In some aspects, an antisense strand core stretch is 100%(perfectly) complementary or at least about 85% (substantially)complementary to a nucleotide sequence (e.g., target sequence) of thesame length present in the XDH mRNA target. In some aspects, thisantisense strand core stretch is 15, 16, 17, 18, 19, 20, 21, 22, or 23nucleotides in length. In some aspects, this antisense strand corestretch is 19 nucleotides in length. In some aspects, this antisensestrand core stretch is 17 nucleotides in length. A sense strand corestretch sequence can be the same length as a corresponding antisensecore sequence or it can be a different length.

The XDH RNAi agent sense and antisense strands anneal to form a duplex.A sense strand and an antisense strand of an XDH RNAi agent can bepartially, substantially, or fully complementary to each other. Withinthe complementary duplex region, the sense strand core stretch sequenceis at least 85% complementary or 100% complementary to the antisensecore stretch sequence. In some aspects, the sense strand core stretchsequence contains a sequence of at least 15, at least 16, at least 17,at least 18, at least 19, at least 20, at least 21, at least 22, atleast 23, at least 24, or at least 25 nucleotides that is at least 85%or 100% complementary to a corresponding 15, 16, 17, 18, 19, 20, 21, 22,23, 24, or 25 nucleotide sequence of the antisense strand core stretchsequence (i.e., the sense and antisense core stretch sequences of an XDHRNAi agent have a region of at least 15, at least 16, at least 17, atleast 18, at least 19, at least 20, at least 21, at least 22, at least23, at least 24, or at least 25 nucleotides that is at least 85% basepaired or 100% base paired.)

In some aspects, the antisense strand of an XDH RNAi agent disclosedherein differs by 0, 1, 2, or 3 nucleotides from any of the antisensestrand sequences in Table 2, Table 3, or Table 5C. In some aspects, thesense strand of an XDH RNAi agent disclosed herein differs by 0, 1, 2,or 3 nucleotides from any of the sense strand sequences in Table 2,Table 4, or Table 5C.

In some aspects, the sense strand and/or the antisense strand canoptionally and independently contain an additional 1, 2, 3, 4, 5, or 6nucleotides (extension) at the 3′ end, the 5′ end, or both the 3′ and 5′ends of the core stretch sequences. The antisense strand additionalnucleotides, if present, may or may not be complementary to thecorresponding sequence in the XDH mRNA. The sense strand additionalnucleotides, if present, may or may not be identical to thecorresponding sequence in the XDH mRNA. The antisense strand additionalnucleotides, if present, may or may not be complementary to thecorresponding sense strand's additional nucleotides, if present.

As used herein, an extension comprises 1, 2, 3, 4, 5, or 6 nucleotidesat the 5′ and/or 3′ end of the sense strand core stretch sequence and/orantisense strand core stretch sequence. The extension nucleotides on asense strand may or may not be complementary to nucleotides, either corestretch sequence nucleotides or extension nucleotides, in thecorresponding antisense strand. Conversely, the extension nucleotides onan antisense strand may or may not be complementary to nucleotides,either core stretch nucleotides or extension nucleotides, in thecorresponding sense strand. In some aspects, both the sense strand andthe antisense strand of an RNAi agent contain 3′ and 5′ extensions. Insome aspects, one or more of the 3′ extension nucleotides of one strandbase pairs with one or more 5′ extension nucleotides of the otherstrand. In other aspects, one or more of 3′ extension nucleotides of onestrand do not base pair with one or more 5′ extension nucleotides of theother strand. In some aspects, an XDH RNAi agent has an antisense strandhaving a 3′ extension and a sense strand having a 5′ extension. In someaspects, the extension nucleotide(s) are unpaired and form an overhang.As used herein, an “overhang” refers to a stretch of one or moreunpaired nucleotides located at a terminal end of either the sensestrand or the antisense strand that does not form part of the hybridizedor duplexed portion of an RNAi agent disclosed herein.

In some aspects, an XDH RNAi agent comprises an antisense strand havinga 3′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In otheraspects, an XDH RNAi agent comprises an antisense strand having a 3′extension of 1, 2, or 3 nucleotides in length. In some aspects, one ormore of the antisense strand extension nucleotides comprise nucleotidesthat are complementary to the corresponding XDH mRNA sequence. In someaspects, one or more of the antisense strand extension nucleotidescomprise nucleotides that are not complementary to the corresponding XDHmRNA sequence.

In some aspects, an XDH RNAi agent comprises a sense strand having a 3′extension of 1, 2, 3, 4, or 5 nucleotides in length. In some aspects,one or more of the sense strand extension nucleotides comprisesadenosine, uracil, or thymidine nucleotides, AT dinucleotide, ornucleotides that correspond to or are the identical to nucleotides inthe XDH mRNA sequence. In some aspects, the 3′ sense strand extensionincludes or consists of one of the following sequences, but is notlimited to: T, UT, TT, UU, UUT, TTT, or TTTT (each listed 5′ to 3′).

A sense strand can have a 3′ extension and/or a 5′ extension. In someaspects, an XDH RNAi agent comprises a sense strand having a 5′extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In some aspects,one or more of the sense strand extension nucleotides comprisenucleotides that correspond to or are identical to nucleotides in theXDH mRNA sequence.

Examples of sequences used in forming XDH RNAi agents are provided inTables 2, 3, 4, and 5C. In some aspects, an XDH RNAi agent antisensestrand includes a sequence of any of the sequences in Tables 2, 3, or5C. In certain aspects, an XDH RNAi agent antisense strand comprises orconsists of any one of the modified sequences in Table 3. In someaspects, an XDH RNAi agent antisense strand includes the sequence ofnucleotides (from 5′ end→3′ end) at positions 1-17, 2-15, 2-17, 1-18,2-18, 1-19, 2-19, 1-20, 2-20, 1-21, or 2-21, of any of the sequences inTables 2, 3, or 5C. in some aspects, an XDH RNAi agent sense strandincludes the sequence of any of the sequences in Tables 2, 4, or 5C. Insome aspects, an XDH RNAi agent sense strand includes the sequence ofnucleotides (from 5′ end→3′ end) at positions 1-18, 1-19, 1-20, 1-21,2-19, 2-20, 2-21, 3-20, 3-21, or 4-21 of any of the sequences in Tables2, 4, or 5C. In certain aspects, an XDH RNAi agent sense strandcomprises or consists of a modified sequence of any one of the modifiedsequences in Table 4.

In some aspects, the sense and antisense strands of the RNAi agentsdescribed herein contain the same number of nucleotides. In someaspects, the sense and antisense strands of the RNAi agents describedherein contain different numbers of nucleotides. In some aspects, thesense strand 5′ end and the antisense strand 3′ end of an RNAi agentform a blunt end. In some aspects, the sense strand 3′ end and theantisense strand 5′ end of an RNAi agent form a blunt end. In someaspects, both ends of an RNAi agent form blunt ends. In some aspects,neither end of an RNAi agent is blunt-ended. As used herein a “bluntend” refers to an end of a double stranded RNAi agent in which theterminal nucleotides of the two annealed strands are complementary (forma complementary base-pair).

In some aspects, the sense strand 5′ end and the antisense strand 3′ endof an RNAi agent form a frayed end. In some aspects, the sense strand 3′end and the antisense strand 5′ end of an RNAi agent form a frayed end.In some aspects, both ends of an RNAi agent form a frayed end. In someaspects, neither end of an RNAi agent is a frayed end. As used herein afrayed end refers to an end of a double stranded RNAi agent in which theterminal nucleotides of the two annealed strands from a pair (i.e., donot form an overhang) but are not complementary (i.e. form anon-complementary pair). In some aspects, one or more unpairednucleotides at the end of one strand of a double stranded RNAi agentform an overhang. The unpaired nucleotides may be on the sense strand orthe antisense strand, creating either 3′ or 5′ overhangs. In someaspects, the RNAi agent contains: a blunt end and a frayed end, a bluntend and 5′ overhang end, a blunt end and a 3′ overhang end, a frayed endand a 5′ overhang end, a frayed end and a 3′ overhang end, two 5′overhang ends, two 3′ overhang ends, a 5′ overhang end and a 3′ overhangend, two frayed ends, or two blunt ends. Typically, when present,overhangs are located at the 3′ terminal ends of the sense strand, theantisense strand, or both the sense strand and the antisense strand.

The XDH RNAi agents disclosed herein may also be comprised of one ormore modified nucleotides. In some aspects, substantially all of thenucleotides of the sense strand and substantially all of the nucleotidesof the antisense strand of the XDH RNAi agent are modified nucleotides.The XDH RNAi agents disclosed herein may further be comprised of one ormore modified internucleoside linkages, e.g., one or morephosphorothioate linkages. In some aspects, an XDH RNAi agent containsone or more modified nucleotides and one or more modifiedinternucleoside linkages. In some aspects, a 2′-modified nucleotide iscombined with modified internucleoside linkage.

In some aspects, an XDH RNAi agent is prepared or provided as a salt,mixed salt, or a free-acid. In some aspects, an XDH RNAi agent isprepared as a pharmaceutically acceptable salt. In some aspects, an XDHRNAi agent is prepared as a pharmaceutically acceptable sodium salt.Such forms that are well known in the art are within the scope of theinventions disclosed herein.

Modified Nucleotides

Modified nucleotides, when used in various oligonucleotide constructs,can preserve activity of the compound in cells while at the same timeincreasing the serum stability of these compounds, and can also minimizethe possibility of activating interferon activity in humans uponadministering of the oligonucleotide construct.

In some aspects, an XDH RNAi agent contains one or more modifiednucleotides. As used herein, a “modified nucleotide” is a nucleotideother than a ribonucleotide (2′-hydroxyl nucleotide). In some aspects,at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) ofthe nucleotides are modified nucleotides. As used herein, modifiednucleotides can include, but are not limited to, deoxyribonucleotides,nucleotide mimics, abasic nucleotides, 2′-modified nucleotides, invertednucleotides, modified nucleobase-comprising nucleotides, bridgednucleotides, peptide nucleic acids (PNAs), 2′,3′-seco nucleotide mimics(unlocked nucleobase analogues), locked nucleotides, 3′-O-methoxy (2′internucleoside linked) nucleotides, 2′-F-Arabino nucleotides, 5′-Me,2′-fluoro nucleotide, morpholino nucleotides, vinyl phosphonatedeoxyribonucleotides, vinyl phosphonate containing nucleotides, andcyclopropyl phosphonate containing nucleotides. 2′-modified nucleotides(i.e., a nucleotide with a group other than a hydroxyl group at the 2′position of the five-membered sugar ring) include, but are not limitedto, 2′-O-methyl nucleotides, 2′-fluoro nucleotides (also referred toherein as 2′-deoxy-2′-fluoro nucleotides), 2′-deoxy nucleotides,2′-methoxyethyl (2′-O-2-methoxylethyl) nucleotides (also referred to as2′-MOE), 2′-amino nucleotides, and 2′-alkyl nucleotides. It is notnecessary for all positions in a given compound to be uniformlymodified. Conversely, more than one modification can be incorporated ina single XDH RNAi agent or even in a single nucleotide thereof. The XDHRNAi agent sense strands and antisense strands can be synthesized and/ormodified by methods known in the art. Modification at one nucleotide isindependent of modification at another nucleotide.

Modified nucleobases include synthetic and natural nucleobases, such as5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6substituted purines, (e.g., 2-aminopropyladenine, 5-propynyluracil, or5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, inosine, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl(e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives ofadenine and guanine, 2-alkyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or2-n-butyl) and other alkyl derivatives of adenine and guanine,2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, cytosine,5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine,6-azo thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino,8-sulfhydryl, 8-thioalkyl, 8-hydroxyl and other 8-substituted adeninesand guanines, 5-halo (e.g., 5-bromo), 5-trifluoromethyl, and other5-substituted uracils and cytosines, 7-methylguanine and7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine,7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.

In some aspects, the 5′ and/or 3′ end of the antisense strand caninclude abasic residues (Ab), which can also be referred to as an“abasic site” or “abasic nucleotide.” An abasic residue (Ab) is anucleotide or nucleoside that lacks a nucleobase at the 1′ position ofthe sugar moiety. In some aspects, an abasic residue can be placedinternally in a nucleotide sequence. In some aspects, Ab or AbAb can beadded to the 3′ end of the antisense strand. In some aspects, the 5′ endof the sense strand can include one or more additional abasic residues(e.g., (Ab) or (AbAb)). In some aspects, UUAb, UAb, or Ab are added tothe 3′ end of the sense strand. In some aspects, an abasic (deoxyribose)residue can be replaced with a ribitol (abasic ribose) residue.

In some aspects, all or substantially all of the nucleotides of an RNAiagent are modified nucleotides. As used herein, an RNAi agent whereinsubstantially all of the nucleotides present are modified nucleotides isan RNAi agent having four or fewer (i.e., 0, 1, 2, 3, or 4) nucleotidesin both the sense strand and the antisense strand being ribonucleotides(i.e., unmodified). As used herein, a sense strand wherein substantiallyall of the nucleotides present are modified nucleotides is a sensestrand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sensestrand being unmodified ribonucleotides. As used herein, an antisensesense strand wherein substantially all of the nucleotides present aremodified nucleotides is an antisense strand having two or fewer (i.e.,0, 1, or 2) nucleotides in the sense strand being unmodifiedribonucleotides. In some aspects, one or more nucleotides of an RNAiagent is an unmodified ribonucleotide. Chemical structures for certainmodified nucleotides are set forth in Table 6 herein.

Modified Internucleoside Linkages

In some aspects, one or more nucleotides of an XDH RNAi agent are linkedby non-standard linkages or backbones (i.e., modified internucleosidelinkages or modified backbones). Modified internucleoside linkages orbackbones include, but are not limited to, phosphorothioate groups(represented herein as a lower case “s”), chiral phosphorothioates,thiophosphates, phosphorodithioates, phosphotriesters,aminoalkyl-phosphotriesters, alkyl phosphonates (e.g., methylphosphonates or 3′-alkylene phosphonates), chiral phosphonates,phosphinates, phosphoramidates (e.g., 3′-amino phosphoramidate,aminoalkylphosphoramidates, or thionophosphoramidates),thionoalkyl-phosphonates, thionoalkylphosphotriesters, morpholinolinkages, boranophosphates having normal 3′-5′ linkages, 2′-5′ linkedanalogs of boranophosphates, or boranophosphates having invertedpolarity wherein the adjacent pairs of nucleoside units are linked 3′-5′to 5′-3′ or 2′-5′ to 5′-2′. In some aspects, a modified internucleosidelinkage or backbone lacks a phosphorus atom. Modified internucleosidelinkages lacking a phosphorus atom include, but are not limited to,short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatomand alkyl or cycloalkyl inter-sugar linkages, or one or more short chainheteroatomic or heterocyclic inter-sugar linkages. In some aspects,modified internucleoside backbones include, but are not limited to,siloxane backbones, sulfide backbones, sulfoxide backbones, sulfonebackbones, formacetyl and thioformacetyl backbones, methylene formacetyland thioformacetyl backbones, alkene-containing backbones, sulfamatebackbones, methyleneimino and methylenehydrazino backbones, sulfonateand sulfonamide backbones, amide backbones, and other backbones havingmixed N, O, S, and CH₂ components.

In some aspects, a sense strand of an XDH RNAi agent can contain 1, 2,3, 4, 5, or 6 phosphorothioate linkages, an antisense strand of an XDHRNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, orboth the sense strand and the antisense strand independently can contain1, 2, 3, 4, 5, or 6 phosphorothioate linkages. In some aspects, a sensestrand of an XDH RNAi agent can contain 1, 2, 3, or 4 phosphorothioatelinkages, an antisense strand of an XDH RNAi agent can contain 1, 2, 3,or 4 phosphorothioate linkages, or both the sense strand and theantisense strand independently can contain 1, 2, 3, or 4phosphorothioate linkages.

In some aspects, an XDH RNAi agent sense strand contains at least twophosphorothioate internucleoside linkages. In some aspects, thephosphorothioate internucleoside linkages are between the nucleotides atpositions 1-3 from the 3′ end of the sense strand. In some aspects, onephosphorothioate internucleoside linkage is at the 5′ end of the sensestrand nucleotide sequence, and another phosphorothioate linkage is atthe 3′ end of the sense strand nucleotide sequence. In some aspects, twophosphorothioate internucleoside linkages are located at the 5′ end ofthe sense strand, and another phosphorothioate linkage is at the 3′ endof the sense strand. In some aspects, the sense strand does not includeany phosphorothioate internucleoside linkages between the nucleotides,but contains one, two, or three phosphorothioate linkages between theterminal nucleotides on both the 5′ and 3′ ends and the optionallypresent inverted abasic residue terminal caps. In some aspects, thetargeting ligand is linked to the sense strand via a phosphorothioatelinkage.

In some aspects, an XDH RNAi agent antisense strand contains fourphosphorothioate internucleoside linkages. In some aspects, the fourphosphorothioate internucleoside linkages are between the nucleotides atpositions 1-3 from the 5′ end of the antisense strand and between thenucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24-26from the 5′ end. In some aspects, three phosphorothioate internucleosidelinkages are located between positions 1-4 from the 5′ end of theantisense strand, and a fourth phosphorothioate internucleoside linkageis located between positions 20-21 from the 5′ end of the antisensestrand. In some aspects, an XDH RNAi agent contains at least three orfour phosphorothioate internucleoside linkages in the antisense strand.

Capping Residues or Moieties

In some aspects, the sense strand may include one or more cappingresidues or moieties, sometimes referred to in the art as a “cap,” a“terminal cap,” or a “capping residue.” As used herein, a “cappingresidue” is a non-nucleotide compound or other moiety that can beincorporated at one or more termini of a nucleotide sequence of an RNAiagent disclosed herein. A capping residue can provide the RNAi agent, insome instances, with certain beneficial properties, such as, forexample, protection against exonuclease degradation. In some aspects,inverted abasic residues (invAb) (also referred to in the art as“inverted abasic sites”) are added as capping residues. (See, e.g., F.Czaudema, Nucleic Acids Res., 2003, 31(11), 2705-16; U.S. Pat. No.5,998,203). Capping residues are generally known in the art, andinclude, for example, inverted abasic residues as well as carbon chainssuch as a terminal C₃H₇ (propyl), C₆H₁₃ (hexyl), or C₁₂H₂₅ (dodecyl)groups. In some aspects, a capping residue is present at either the 5′terminal end, the 3′ terminal end, or both the 5′ and 3′ terminal endsof the sense strand. In some aspects, the 5′ end and/or the 3′ end ofthe sense strand may include more than one inverted abasic deoxyribosemoiety as a capping residue.

In some aspects, one or more inverted abasic residues (invAb) are addedto the 3′ end of the sense strand. In some aspects, one or more invertedabasic residues (invAb) are added to the 5′ end of the sense strand. Insome aspects, one or more inverted abasic residues or inverted abasicsites are inserted between the targeting ligand and the nucleotidesequence of the sense strand of the RNAi agent. In some aspects, theinclusion of one or more inverted abasic residues or inverted abasicsites at or near the terminal end or terminal ends of the sense strandof an RNAi agent allows for enhanced activity or other desiredproperties of an RNAi agent.

In some aspects, one or more inverted abasic residues (invAb) are addedto the 5′ end of the sense strand. In some aspects, one or more invertedabasic residues can be inserted between the targeting ligand and thenucleotide sequence of the sense strand of the RNAi agent. The invertedabasic residues may be linked via phosphate, phosphorothioate (e.g.,shown herein as (invAb)s), or other linkages. In some aspects, theinclusion of one or more inverted abasic residues at or near theterminal end or terminal ends of the sense strand of an RNAi agent mayallow for enhanced activity or other desired properties of an RNAiagent. In some aspects, an inverted abasic (deoxyribose) residue can bereplaced with an inverted ribitol (abasic ribose) residue. In someaspects, the 3′ end of the antisense strand core stretch sequence, orthe 3′ end of the antisense strand sequence, may include an invertedabasic residue. The chemical structures for inverted abasic deoxyriboseresidues are shown in Table 6 below.

XDH RNAi Agents

The XDH RNAi agents disclosed herein are designed to target specificpositions on an XDH gene (e.g., SEQ ID NO:1),

NM_000379.4 Homo sapiens xanthine dehydrogenase (XDH), mRNA transcript(SEQ ID NO: 1):

   1 acagagcagt gataactacc tgccagtgtc tcttaggagt gaggtacctg gagttcgggg  61 accccaacct gtgacaatga cagcagacaa attggttttc tttgtgaatg gcagaaaggt 121 ggtggagaaa aatgcagatc cagagacaac ccttttggcc tacctgagaa gaaagttggg 181 gctgagtgga accaagctcg gctgtggaga ggggggctgc ggggcttgca cagtgatgct 241 ctccaagtat gatcgtctgc agaacaagat cgtccacttt tctgccaatg cctgcctggc 301 ccccatctgc tccttgcacc atgttgcagt gacaactgtg gaaggaatag gaagcaccaa 361 gacgaggctg catcctgtgc aggagagaat tgccaaaagc cacggctccc agtgcgggtt 421 ctgcacccct ggcatcgtca tgagtatgta cacactgctc cggaatcagc ccgagcccac 481 catggaggag attgagaatg ccttccaagg aaatctgtgc cgctgcacag gctacagacc 541 catcctccag ggcttccgga cctttgccag ggatggtgga tgctgtggag gagatgggaa 601 taatccaaat tgctgcatga accagaagaa agaccactca gtcagcctct cgccatcttt 661 attcaaacca gaggagttca cgcccctgga tccaacccag gagcccattt ttcccccaga 721 gttgctgagg ctgaaagaca ctcctcggaa gcagctgcga tttgaagggg agcgtgtgac 781 gtggatacag gcctcaaccc tcaaggagct gctggacctc aaggctcagc accctgacgc 841 caagctggtc gtggggaaca cggagattgg cattgagatg aagttcaaga atatgctgtt 901 tcctatgatt gtctgcccag cctggatccc tgagctgaat tcggtagaac atggacccga 961 cggtatctcc tttggagctg cttgccccct gagcattgtg gaaaaaaccc tggtggatgc1021 tgttgctaag cttcctgccc aaaagacaga ggtgttcaga ggggtcctgg agcagctgcg1081 ctggtttgct gggaagcaag tcaagtctgt ggcgtccgtt ggagggaaca tcatcactgc1141 cagccccatc tccgacctca accccgtgtt catggccagt ggggccaagc tgacacttgt1201 gtccagaggc accaggagaa ctgtccagat ggaccacacc ttcttccctg gctacagaaa1261 gaccctgctg agcccggagg agatactgct ctccatagag atcccctaca gcagggaggg1321 ggagtatttc tcagcattca agcaggcctc ccggagagaa gatgacattg ccaaggtaac1381 cagtggcatg agagttttat tcaagccagg aaccacagag gtacaggagc tggccctttg1441 ctatggtgga atggccaaca gaaccatctc agccctcaag accactcaga ggcagctttc1501 caagctctgg aaggaggagc tgctgcagga cgtgtgtgca ggactggcag aggagctgca1561 tctgcctccc gatgcccctg gtggcatggt ggacttccgg tgcaccctca ccctcagctt1621 cttcttcaag ttctacctga cagtccttca gaagctgggc caagagaacc tggaagacaa1681 gtgtggtaaa ctggacccca ctttcgccag tgcaacttta ctgtttcaga aagacccccc1741 agccgatgtc cagctcttcc aagaggtgcc caagggtcag tctgaggagg acatggtggg1801 ccggcccctg ccccacctgg cagcggacat gcaggcctct ggtgaggccg tgtactgtga1861 cgacattcct cgctacgaga atgagctgtc tctccggctg gtcaccagca cccgggccca1921 cgccaagatc aagtccatag atacatcaga agctaagaag gttccagggt ttgtttgttt1981 catttccgct gatgatgttc ctgggagtaa cataactgga atttgtaatg atgagacagt2041 ctttgcgaag gataaggtta cttgtgttgg gcatatcatt ggtgctgtgg ttgctgacac2101 cccggaacac acacagagag ctgcccaagg ggtgaaaatc acctatgaag aactaccagc2161 cattatcaca attgaggatg ctataaagaa caactccttt tatggacctg agctgaagat2221 cgagaaaggg gacctaaaga aggggttttc cgaagcagat aatgttgtgt caggggagat2281 atacatcggt ggccaagagc acttctacct ggagactcac tgcaccattg ctgttccaaa2341 aggcgaggca ggggagatgg agctctttgt gtctacacag aacaccatga agacccagag2401 ctttgttgca aaaatgttgg gggttccagc aaaccggatt gtggttcgag tgaagagaat2461 gggaggaggc tttggaggca aggagacccg gagcactgtg gtgtccacgg cagtggccct2521 ggctgcatat aagaccggcc gccctgtgcg atgcatgctg gaccgtgatg aggacatgct2581 gataactggt ggcagacatc ccttcctggc cagatacaag gttggcttca tgaagactgg2641 gacagttgtg gctcttgagg tggaccactt cagcaatgtg gggaacaccc aggatctctc2701 tcagagtatt atggaacgag ctttattcca catggacaac tgctataaaa tccccaacat2761 ccggggcact gggcggctgt gcaaaaccaa ccttccctcc aacacggcct tccggggctt2821 tggggggccc caggggatgc tcattgccga gtgctggatg agtgaagttg cagtgacctg2881 tgggatgcct gcagaggagg tgcggagaaa aaacctgtac aaagaagggg acctgacaca2941 cttcaaccag aagcttgagg gtttcacctt gcccagatgc tgggaagaat gcctagcaag3001 ctctcagtat catgctcgga agagtgaggt tgacaagttc aacaaggaga attgttggaa3061 aaagagagga ttgtgcataa ttcccaccaa gtttggaata agctttacag ttccttttct3121 gaatcaggca ggagccctac ttcatgtgta cacagatggc tctgtgctgc tgacccacgg3181 ggggactgag atgggccaag gccttcatac caaaatggtc caggtggcca gtagagctct3241 gaaaatcccc acctctaaga tttatatcag cgagacaagc actaacactg tgcccaacac3301 ctctcccacg gctgcctctg tcagcgctga cctcaatgga caggccgtct atgcggcttg3361 tcagaccatc ttgaaaaggc tggaacccta caagaagaag aatcccagtg gctcctggga3421 agactgggtc acagctgcct acatggacac agtgagcttg tctgccactg ggttttatag3481 aacacccaat ctgggctaca gctttgagac taactcaggg aaccccttcc actacttcag3541 ctatggggtg gcttgctctg aagtagaaat cgactgccta acaggagatc ataagaacct3601 ccgcacagat attgtcatgg atgttggctc cagtctaaac cctgccattg atattggaca3661 ggtggaaggg gcatttgtcc agggccttgg cctcttcacc ctagaggagc tacactattc3721 ccccgagggg agcctgcaca cccgtggccc tagcacctac aagatcccgg catttggcag3781 catccccatt gagttcaggg tgtccctgct ccgcgactgc cccaacaaga aggccatcta3841 tgcatcgaag gctgttggag agccgcccct cttcctggct gcttctatct tctttgccat3901 caaagatgcc atccgtgcag ctcgagctca gcacacaggt aataacgtga aggaactctt3961 ccggctagac agccctgcca ccccggagaa gatccgcaat gcctgcgtgg acaagttcac4021 caccctgtgt gtcactggtg tcccagaaaa ctgcaaaccc tggtctgtga gggtctaaag4081 agagagtcct cagcagagtc ttcttgtgct gcctttgggc ttccatggag caggaggaac4141 ataccacaga acatggatct attaaagtca cagaatgaca gacctgtgat ttgtcaagat4201 gggatttgga agacaagtga atgcaatgga agattttgat caaaaatgta atttgtaaac4261 acaatgataa gcaaattcaa aactgttatg cctaaatggt gaatatgcaa ttaggatcat4321 tttctgtctg ttttaatcat gtatctggaa tagggtcggg aagggtttgt gctattcccc4381 acttactgga cagcctgtat aacctcaagt tctgatggtg tctgtccttt gaagaggatt4441 cccacaaacc tctagaagct taaaccgaag ttactttaaa tcgtgtgcct tcctgtgaaa4501 gcctggcctt caaaccaatg aacagcaaag cataaccttg aatctatact caaattttgc4561 aatgaggcag tggggtaagg ttaaatcctc taaccatctt tgaatcattg gaaagaataa4621 agaatgaaac aaattcaagg ttaattggat ctgattttgt gaagctgcat aaagcaagat4681 tactctataa tacaaaaatc caaccaactc aattattgag cacgtacaat gttctagatt4741 tctttccctt cctctttgaa gagaatattt gtattccaaa tactctttga gtatttacaa4801 aaaagattat gtttaatctt tacatttgaa gccaaagtaa tttccaccta gaaatgatgc4861 tatcagtcct ggcatggtgg ctcaccccta taatcccagc actttgggag gctaaggcag4921 gagaattgct tgagcccagc agtttgagac cagcctgggc aacatagaga gctcctgtct4981 ttaaaaaaaa tttttttaat tagttggtct tgatagtgca tgcctgtagt cccaactact5041 tgaaaggctg aggtggagag atcatttgag ctcaggaggt tgaggctgca gtgagctatg5101 attgcgccac tgcactcctg cctgagcgac tgagcaagat cttgtctctg aagaaaaaaa5161 aagaaataaa aatgctgcta tcaaaatcaa gcccaaccag aggtagaaga gccaagaagc5221 ctgggttctc atcctagctc tgtctcttct gtctctatct ttgtgatctt ggactgtcaa5281 ttccccttcc tgtgatccat tttactgcaa acataagggt tgcagtaaag ggttgtctca5341 cgtcttctgc tttaaaagcc tataaatata tgacctgaaa actccagtta cataaaggat5401 ctgcagctat ctaaggcttg gttttcttac tgtcatatga tacctgggtc taatgaactc5461 tgctgagatc acctcaagtt tctgcggttg gtaaagagaa caagggaaga acaaacatcc5521 cttttattgc tccaaatggt gatttaatcc ctacatggtg ctgggtggac aatgtgtcac5581 tgtcacatgc cttcactgta taaatccaac cttctgccag agagaatctg tggttctggc5641 catggaggga ggatagtgga aatgatatag ttggactggt gcttgatgtc actaataaat5701 gaaactgtca gctgg

As defined herein, an antisense strand sequence is designed to target anXDH gene at a given position on the gene when the 5′ terminal nucleobaseof the antisense strand is aligned with a position that is 21nucleotides downstream (towards the 3′ end) from the position on thegene when base pairing to the gene. For example, as illustrated inTables 1 and 2 herein, an antisense strand sequence designed to targetan XDH gene at position 1322 requires that when base pairing to thegene, the 5′ terminal nucleobase of the antisense strand is aligned withposition 1342 of the XDH gene.

As provided herein, an XDH RNAi agent does not require that thenucleobase at position 1 (5′→3′) of the antisense strand becomplementary to the gene, provided that there is at least 85%complementarity (e.g., at least 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,95, 96, 97, 98, 99, or 100% complementarity) of the antisense strand andthe gene across a core stretch sequence of at least 16 consecutivenucleotides. For example, for an XDH RNAi agent disclosed herein that isdesigned to target position 1322 of an XDH gene, the 5′ terminalnucleobase of the antisense strand of the of the XDH RNAi agent isaligned with position 1342 of the gene; however, the 5′ terminalnucleobase of the antisense strand may be, but is not required to be,complementary to position 1342 of an XDH gene, provided that there is atleast 85% complementarity (e.g., at least 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, or 100% complementarity) of theantisense strand and the gene across a core stretch sequence of at least16 consecutive nucleotides. As shown by, among other things, the variousexamples disclosed herein, the specific site of binding of the gene bythe antisense strand of the XDH RNAi agent (e.g., whether the XDH RNAiagent is designed to target an XDH gene at position 238, at position1322, at position 1963, at position 2696, at position 2995, at position3041, at position 3016, at position 3598, at position 4289, at position2612, or at some other position) is important to the level of inhibitionachieved by the XDH RNAi agent.

In some aspects, the XDH RNAi agents disclosed herein target an XDH geneat or near the positions of the XDH gene sequence shown in Table 1. Insome aspects, the antisense strand of an XDH RNAi agent disclosed hereinincludes a core stretch sequence that is fully, substantially, or atleast partially complementary to a target XDH 19-mer sequence disclosedin Table 1.

TABLE 1 XDH 19-mer mRNA Target Sequences (taken from homo sapiens xanthine dehydrogenase (XDH), mRNA, GenBank NM_000379.4 (SEQ ID NO: 1)) Corresponding Targeted Gene SEQXDH 19-mer Positions of Position ID Target Sequences Sequence on(as referred No. (5′→3′) SEQ ID NO: 1 to herein)   2 UCAGCUUCUUCUUCAAGUU1614-1632 1612   3 AGCUUCUUCUUCAAGUUCU 1616-1634 1614   4UUCUUCUUCAAGUUCUACC 1619-1637 1617   5 GGGUGAAAAUCACCUAUGA 2130-21482128   6 GUGAAAAUCACCUAUGAAG 2132-2150 2130   7 UGAAAAUCACCUAUGAAGA2133-2151 2131   8 GAAAAUCACCUAUGAAGAA 2134-2152 2132   9ACCAGCCAUUAUCACAAUU 2155-2173 2153  10 AGAACAACUCCUUUUAUGG 2187-22052185  11 GAACAACUCCUUUUAUGGA 2188-2206 2186  12 GACAAGCACUAACACUGUG3274-3292 3272  13 GUCAUGAGUAUGUACACAC 437-455  435  14GACAUGCUGAUAACUGGUG 2573-2591 2571  15 AUACAAGGUUGGCUUCAUG 2614-26322612  16 AAGGUUGGCUUCAUGAAGA 2618-2636 2616  17 AGGUUGGCUUCAUGAAGAC2619-2637 2617  18 GUUGGCUUCAUGAAGACUG 2621-2639 2619  19GAGAAUUGUUGGAAAAAGA 3047-3065 3045  20 GGCUUGCUCUGAAGUAGAA 3550-35683548  21 UUGCUCUGAAGUAGAAAUC 3553-3571 3551  22 CUGCCAUUGAUAUUGGACA3642-3660 3640  23 AGAUCGUCCACUUUUCUGC 267-285  265  24CCGAAGCAGAUAAUGUUGU 2250-2268 2248  25 CUCUCUCAGAGUAUUAUGG 2696-27142694  26 CACCAAGUUUGGAAUAAGC 3085-3103 3083  27 GCAUAAAGCAAGAUUACUC4667-4685 4665  28 CAAUGUUCUAGAUUUCUUU 4727-4745 4725  29UGCUGGAUGAGUGAAGUUG 2852-2870 2850  30 GCUGGAUGAGUGAAGUUGC 2853-28712851  31 CUGGAUGAGUGAAGUUGCA 2854-2872 2852  32 UGCUCUCCAAGUAUGAUCG237-255  235  33 GAUCGUCUGCAGAACAAGA 251-269  249  34CGUCUGCAGAACAAGAUCG 254-272  252  35 CGCCAGUGCAACUUUACUG 1705-1723 1703 36 GAUAAGGUUACUUGUGUUG 2051-2069 2049  37 CAGCCAUUAUCACAAUUGA 2157-21752155  38 AGCUCUCAGUAUCAUGCUC 2999-3017 2997  39 AGAGUGAGGUUGACAAGUU3021-3038 3019  40 GAGUGAGGUUGACAAGUUC 3022-3040 3020  41UCAACAAGGAGAAUUGUUG 3039-3057 3037  42 AACAUACCACAGAACAUGG 4138-41564136  43 ACAUGGAUCUAUUAAAGUC 4151-4169 4149  44 CAUGGAUCUAUUAAAGUCA4152-4170 4150  45 CCUAAAUGGUGAAUAUGCA 4291-4309 4289  46ACCUCUAGAAGCUUAAACC 4448-4466 4446  47 CCUUCAAACCAAUGAACAG 4507-45254505  48 AAUGAACAGCAAAGCAUAA 4517-4535 4515  49 UGAACAGCAAAGCAUAACC4519-4537 4517  50 GAACAGCAAAGCAUAACCU 4520-4538 4518  51ACAGCAAAGCAUAACCUUG 4522-4540 4520  52 AAAGCAUAACCUUGAAUCU 4527-45454525  53 AACCAACUCAAUUAUUGAG 4702-4720 4700  54 UCCUGUGAUCCAUUUUACU5288-5306 5286  55 UUUUCUUACUGUCAUAUGA 5422-5440 5420  56GGAGAAAAAUGCAGAUCCA 124-142  122  57 CAGAGACAACCCUUUUGGC 141-159  139 58 CUCCAAGUAUGAUCGUCUG 241-259  239  59 AACUGUGGAAGGAAUAGGA 334-352 332  60 GCAUCGUCAUGAGUAUGUA 432-450  430  61 CUUCCAAGGAAAUCUGUGC502-520  500  62 GGCAUUGAGAUGAAGUUCA 869-887  867  63UGAAGUUCAAGAAUAUGCU 879-897  877  64 AAUAUGCUGUUUCCUAUGA 890-908  888 65 UGCUCUCCAUAGAGAUCCC 1287-1305 1285  66 GUAUUUCUCAGCAUUCAAG 1324-13421322  67 CCAAGAUCAAGUCCAUAGA 1923-1941 1921  68 CAGGGUUUGUUUGUUUCAU1965-1983 1963  69 CACCUAUGAAGAACUACCA 2140-2158 2138  70GAACUACCAGCCAUUAUCA 2150-2168 2148  71 GCCAUUAUCACAAUUGAGG 2159-21772157  72 AGCUGAAGAUCGAGAAAGG 2211-2229 2209  73 GCACCAUUGCUGUUCCAAA2322-2340 2320  74 GGAGCUCUUUGUGUCUACA 2359-2377 2357  75CUCUUUGUGUCUACACAGA 2363-2381 2361  76 CUCUCAGAGUAUUAUGGAA 2698-27162696  77 AGAGUAUUAUGGAACGAGC 2703-2721 2701  78 AGGGUUUGUUUGUUUCAUU1966-1984 1964  79 GGGUUUGUUUGUUUCAUUU 1967-1985 1965  80GUUUGUUUGUUUCAUUUCC 1969-1987 1967  81 UCUCCAAGUAUGAUCGUCU 240-258  238 82 AGGAGAUUGAGAAUGCCUU 486-504  484  83 AGAAUGCCUUCCAAGGAAA 495-513 493  84 UGCCUUCCAAGGAAAUCUG 499-517  497  85 AGAAUAUGCUGUUUCCUAU888-906  886  86 UUGGAGGGAACAUCAUCAC 1119-1137 1117  87GCUUCUUCUUCAAGUUCUA 1617-1635 1615  88 GUUGGGCAUAUCAUUGGUG 2066-20842064  89 UCUACACAGAACACCAUGA 2372-2390 2370  90 CACCCAGGAUCUCUCUCAG2686-2704 2684  91 CAAGCUCUCAGUAUCAUGC 2997-3015 2995  92GGAAGAGUGAGGUUGACAA 3018-3036 3016  93 CAAGGAGAAUUGUUGGAAA 3043-30613041  94 AGCUUUGAGACUAACUCAG 3500-3518 3498  95 UCCGCACAGAUAUUGUCAU3600-3618 3598  96 CGCACAGAUAUUGUCAUGG 3602-3620 3600  97CUGCUUCUAUCUUCUUUGC 3879-3897 3877  98 CACACAGGUAAUAACGUGA 3932-39503930  99 UGUAUAACCUCAAGUUCUG 4396-4414 4394 100 CCAAUGAACAGCAAAGCAU4515-4533 4513 101 UAACCUUGAAUCUAUACUC 4533-4551 4531 102CAUAAAGCAAGAUUACUCU 4668-4686 4666 103 CACCUAGAAAUGAUGCUAU 4845-48634843 104 AGCUCUGUCUCUUCUGUCU 5236-5254 5234 105 AAGGCUUGGUUUUCUUACU5413-5431 5411 106 GUGAUGCUCUCCAAGUAUG 233-251  231 107CAAGUAUGAUCGUCUGCAG 244-262  242 108 GCAUGAGAGUUUUAUUCAA 1386-1404 1384109 CAAGAUCGUCCACUUUUCU 265-283  263 110 CAUGUUGCAGUGACAACUG 320-338 318 111 UGACAACUGUGGAAGGAAU 330-348  328 112 GGAGGAGAUUGAGAAUGCC484-502  482 113 CACGGAGAUUGGCAUUGAG 859-877  857 114AGAUGAAGUUCAAGAAUAU 876-894  874 115 GAGAUACUGCUCUCCAUAG 1280-1298 1278116 GGAGUAUUUCUCAGCAUUC 1321-1339 1319 117 GAGUAUUUCUCAGCAUUCA 1322-13401320 118 GGAGAGAAGAUGACAUUGC 1353-1371 1351 119 UAACAUAACUGGAAUUUGU2008-2026 2006 120 AGCCAUUAUCACAAUUGAG 2158-2176 2156 121GCUUUGUUGCAAAAAUGUU 2400-2418 2398 122 UUUGUUGCAAAAAUGUUGG 2402-24202400 123 GAUUGUGGUUCGAGUGAAG 2437-2455 2435 124 GAUUGAGAAUGCCUUCCAA490-508  488

in some aspects, an XDH RNAi agent includes an antisense strand whereinposition 19 of the antisense strand (5′→3′) is capable of forming a basepair with position 1 of a 19-mer target sequence disclosed in Table 1.In some aspects, an XDH RNAi agent includes an antisense strand whereinposition 1 of the antisense strand (5′→3′) is capable of forming a basepair with position 19 of the 19-mer target sequence disclosed in Table1.

In some aspects, an XDH RNAi agent includes an antisense strand whereinposition 2 of the antisense strand (5′→3′) is capable of forming a basepair with position 18 of the 19-mer target sequence disclosed inTable 1. In some aspects, an XDH RNAi agent includes an antisense strandwherein positions 2 through 18 of the antisense strand (5′→3′) arecapable of forming base pairs with each of the respective complementarybases located at positions 18 through 2 of the 19-mer target sequencedisclosed in Table 1.

For the RNAi agents disclosed herein, the nucleotide at position 1 ofthe antisense strand (from 5′ end→3′ end) can be perfectly complementaryto the XDH gene, or can be non-complementary to the XDH gene. In someaspects, the nucleotide at position 1 of the antisense strand (from 5′end→3′ end) is a U, A, or dT. In some aspects, the nucleotide atposition 1 of the antisense strand (from 5′ end→3′ end) forms an A:U orU:A base pair with the sense strand.

In some aspects, an XDH RNAi agent antisense strand comprises thesequence of nucleotides (from 5′ end→3′ end) at positions 2-18, 2-19,2-20, or 2-21 of any of the antisense strand sequences in Table 2, Table3, or Table 5C. In some aspects, an XDH RNAi sense strand comprises thesequence of nucleotides (from 5′ end→3′ end) at positions 3-21, 2-21,1-21, 3-20, 2-20, 1-20, 3-19, 2-19, 1-19, 3-18, 2-18, or 1-18 of any ofthe sense strand sequences in Table 2, Table 4, or Table 5C.

In some aspects, an XDH RNAi agent antisense strand comprises thesequence of nucleotides (from 5′ end→3′ end) at positions 2-18, 2-19,2-20, or 2-21 of any of the antisense strand sequences of Table 2, Table3, or Table 5C. In some aspects, an XDH RNAi sense strand comprises thesequence of nucleotides (from 5′ end→3′ end) at positions 3-21, 2-21,1-21, 3-20, 2-20, 1-20, 3-19, 2-19, 1-19, 3-18, 2-18, or 1-18 of any ofthe sense strand sequences of Table 2, Table 4, or Table 5C.

In some aspects, an XDH RNAi agent is comprised of (i) an antisensestrand comprising the sequence of nucleotides (from 5′ end→3′ end) atpositions 2-18 or 2-19 of any of the antisense strand sequences in Table2 or Table 3, and (ii) a sense strand comprising the sequence ofnucleotides (from 5′ end→3′ end) at positions 3-21, 2-21, 1-21, 3-20,2-20, 1-20, 3-19, 2-19, 1-19, 3-18, 2-18, or 1-18 of any of the sensestrand sequences in Table 2 or Table 4.

In some aspects, the XDH RNAi agents include core 19-mer nucleotidesequences shown in the following Table 2.

TABLE 2 XDH RNAi Agent Antisense Strand and SenseStrand Core Stretch Base Sequences(N = any nucleobase; I = hypoxanthine (inosinenucleotide); (A^(2N)) = 2-aminoadenine nucleotide) Antisense StrandSense Strand Base Sequence Base Sequence Corresponding (5′→3′) (Shown as(5′→3′) (Shown as Positions of SEQ an Unmodified SEQ an UnmodifiedIdentified Targeted ID Nucleotide  ID Nucleotide Sequence on Gene No.Sequence) No. Sequence) SEQ ID NO: 1 Position 125 AACUUGAAGAAGAAGCUGA535 UCAGCUUCUUCUUCAAGUU 1614-1632 1612 126 UACUUGAAGAAGAAGCUGA 536UCAGCUUCUUCUUCAAGUA 1614-1632 1612 127 NACUUGAAGAAGAAGCUGA 537UCAGCUUCUUCUUCAAGUN 1614-1632 1612 128 NACUUGAAGAAGAAGCUGN 538NCAGCUUCUUCUUCAAGUN 1614-1632 1612 129 AGAACUUGAAGAAGAAGCU 539AGCUUCUUCUUCAAGUUCU 1616-1634 1614 130 UGAACUUGAAGAAGAAGCU 540AGCUUCUUCUUCAAGUUCA 1616-1634 1614 131 NGAACUUGAAGAAGAAGCU 541AGCUUCUUCUUCAAGUUCN 1616-1634 1614 132 NGAACUUGAAGAAGAAGCN 542NGCUUCUUCUUCAAGUUCN 1616-1634 1614 133 UGUAGAACUUGAAGAAGAA 543UUCUUCUUCAAGUUCUACA 1619-1637 1617 134 NGUAGAACUUGAAGAAGAA 544UUCUUCUUCAAGUUCUACN 1619-1637 1617 135 NGUAGAACUUGAAGAAGAN 545NUCUUCUUCAAGUUCUACN 1619-1637 1617 136 UCAUAGGUGAUUUUCACCC 546GGGUGAAAAUCACCUAUGA 2130-2148 2128 137 NCAUAGGUGAUUUUCACCC 547GGGUGAAAAUCACCUAUGN 2130-2148 2128 138 NCAUAGGUGAUUUUCACCN 548NGGUGAAAAUCACCUAUGN 2130-2148 2128 139 UUUCAUAGGUGAUUUUCAC 549GUGAAAAUCACCUAUGAAA 2132-2150 2130 140 NUUCAUAGGUGAUUUUCAC 550GUGAAAAUCACCUAUGAAN 2132-2150 2130 141 NUUCAUAGGUGAUUUUCAN 551NUGAAAAUCACCUAUGAAN 2132-2150 2130 142 UCUUCAUAGGUGAUUUUCA 552UGAAAAUCACCUAUGAAGA 2133-2151 2131 143 NCUUCAUAGGUGAUUUUCA 553UGAAAAUCACCUAUGAAGN 2133-2151 2131 144 NCUUCAUAGGUGAUUUUCN 554NGAAAAUCACCUAUGAAGN 2133-2151 2131 145 UUCUUCAUAGGUGAUUUUC 555GAAAAUCACCUAUGAAGAA 2134-2152 2132 146 NUCUUCAUAGGUGAUUUUC 556GAAAAUCACCUAUGAAGAN 2134-2152 2132 147 NUCUUCAUAGGUGAUUUUN 557NAAAAUCACCUAUGAAGAN 2134-2152 2132 148 AAUUGUGAUAAUGGCUGGU 558ACCAGCCAUUAUCACAAUU 2155-2173 2153 149 UAUUGUGAUAAUGGCUGGU 559ACCAGCCAUUAUCACAAUA 2155-2173 2153 150 NAUUGUGAUAAUGGCUGGU 560ACCAGCCAUUAUCACAAUN 2155-2173 2153 151 NAUUGUGAUAAUGGCUGGN 561NCCAGCCAUUAUCACAAUN 2155-2173 2153 152 UCAUAAAAGGAGUUGUUCU 562AGAACAACUCCUUUUAUGA 2187-2205 2185 153 NCAUAAAAGGAGUUGUUCU 563AGAACAACUCCUUUUAUGN 2187-2205 2185 154 NCAUAAAAGGAGUUGUUCN 564NGAACAACUCCUUUUAUGN 2187-2205 2185 155 UCCAUAAAAGGAGUUGUUC 565GAACAACUCCUUUUAUGGA 2188-2206 2186 156 NCCAUAAAAGGAGUUGUUC 566GAACAACUCCUUUUAUGGN 2188-2206 2186 157 NCCAUAAAAGGAGUUGUUN 567NAACAACUCCUUUUAUGGN 2188-2206 2186 158 UACAGUGUUAGUGCUUGUC 568GACAAGCACUAACACUGUA 3274-3292 3272 159 NACAGUGUUAGUGCUUGUC 569GACAAGCACUAACACUGUN 3274-3292 3272 160 NACAGUGUUAGUGCUUGUN 570NACAAGCACUAACACUGUN 3274-3292 3272 161 UUGUGUACAUACUCAUGAC 571GUCAUGAGUAUGUACACAA 437-455  435 162 NUGUGUACAUACUCAUGAC 572GUCAUGAGUAUGUACACAN 437-455  435 163 NUGUGUACAUACUCAUGAN 573NUCAUGAGUAUGUACACAN 437-455  435 164 UACCAGUUAUCAGCAUGUC 574GACAUGCUGAUAACUGIUA 2573-2591 2571 165 NACCAGUUAUCAGCAUGUC 575GACAUGCUGAUAACUGIUN 2573-2591 2571 166 NACCAGUUAUCAGCAUGUN 576NACAUGCUGAUAACUGIUN 2573-2591 2571 167 UACCAGUUAUCAGCAUGUC 577GACAUGCUGAUAACUGGUA 2573-2591 2571 168 NACCAGUUAUCAGCAUGUC 578GACAUGCUGAUAACUGGUA 2573-2591 2571 169 NACCAGUUAUCAGCAUGUN 579GACAUGCUGAUAACUGGUA 2573-2591 2571 170 UAUGAAGCCAACCUUGUAU 580AUACAAGGUUGGCUUCAUA 2614-2632 2612 171 NAUGAAGCCAACCUUGUAU 581AUACAAGGUUGGCUUCAUN 2614-2632 2612 172 NAUGAAGCCAACCUUGUAN 582NUACAAGGUUGGCUUCAUN 2614-2632 2612 173 UCUUCAUGAAGCCAACCUU 583AAGGUUGGCUUCAUGAAGA 2618-2636 2616 174 NCUUCAUGAAGCCAACCUU 584AAGGUUGGCUUCAUGAAGN 2618-2636 2616 175 NCUUCAUGAAGCCAACCUN 585NAGGUUGGCUUCAUGAAGN 2618-2636 2616 176 UUCUUCAUGAAGCCAACCU 586AGGUUGGCUUCAUGAAGAA 2619-2637 2617 177 NUCUUCAUGAAGCCAACCU 587AGGUUGGCUUCAUGAAGAN 2619-2637 2617 178 NUCUUCAUGAAGCCAACCN 588NGGUUGGCUUCAUGAAGAN 2619-2637 2617 179 UAGUCUUCAUGAAGCCAAC 589GUUGGCUUCAUGAAGACUA 2621-2639 2619 180 NAGUCUUCAUGAAGCCAAC 590GUUGGCUUCAUGAAGACUN 2621-2639 2619 181 NAGUCUUCAUGAAGCCAAN 591NUUGGCUUCAUGAAGACUN 2621-2639 2619 182 UCUUUUUCCAACAAUUCUC 592GAGAAUUGUUGGAAAAAGA 3047-3065 3045 183 NCUUUUUCCAACAAUUCUC 593GAGAAUUGUUGGAAAAAGN 3047-3065 3045 184 NCUUUUUCCAACAAUUCUN 594NAGAAUUGUUGGAAAAAGN 3047-3065 3045 185 UUCUACUUCAGAGCAAGCC 595GGCUUGCUCUGAAGUAGAA 3550-3568 3548 186 NUCUACUUCAGAGCAAGCC 596GGCUUGCUCUGAAGUAGAN 3550-3568 3548 187 NUCUACUUCAGAGCAAGCN 597NGCUUGCUCUGAAGUAGAN 3550-3568 3548 188 UAUUUCUACUUCAGAGCAA 598UUGCUCUGAAGUAGAAAUA 3553-3571 3551 189 NAUUUCUACUUCAGAGCAA 599UUGCUCUGAAGUAGAAAUN 3553-3571 3551 190 NAUUUCUACUUCAGAGCAN 600NUGCUCUGAAGUAGAAAUN 3553-3571 3551 191 UGUCCAAUAUCAAUGGCAG 601CUGCCAUUGAUAUUIGACA 3642-3660 3640 192 NGUCCAAUAUCAAUGGCAG 602CUGCCAUUGAUAUUIGACN 3642-3660 3640 193 NGUCCAAUAUCAAUGGCAN 603NUGCCAUUGAUAUUIGACN 3642-3660 3640 194 UCAGAAAAGUGGACGAUCU 604AGAUCGUCCACUUUUCUGA 267-285  265 195 NCAGAAAAGUGGACGAUCU 605AGAUCGUCCACUUUUCUGN 267-285  265 196 NCAGAAAAGUGGACGAUCN 606NGAUCGUCCACUUUUCUGN 267-285  265 197 ACAACAUUAUCUGCUUCGG 607CCGAAGCAGAUAAUGUUGU 2250-2268 2248 198 UCAACAUUAUCUGCUUCGG 608CCGAAGCAGAUAAUGUUGU 2250-2268 2248 199 NCAACAUUAUCUGCUUCGG 609CCGAAGCAGAUAAUGUUGN 2250-2268 2248 200 NCAACAUUAUCUGCUUCGN 610NCGAAGCAGAUAAUGUUGN 2250-2268 2248 201 UCAUAAUACUCUGAGAGAG 611CUCUCUCAGAGUAUUAUGA 2696-2714 2694 202 NCAUAAUACUCUGAGAGAG 612CUCUCUCAGAGUAUUAUGN 2696-2714 2694 203 NCAUAAUACUCUGAGAGAN 613NUCUCUCAGAGUAUUAUGN 2696-2714 2694 204 UCUUAUUCCAAACUUGGUG 614CACCAAGUUUGGAAUAAGA 3085-3103 3083 205 NCUUAUUCCAAACUUGGUG 615CACCAAGUUUGGAAUAAGN 3085-3103 3083 206 NCUUAUUCCAAACUUGGUN 616NACCAAGUUUGGAAUAAGN 3085-3103 3083 207 UAGUAAUCUUGCUUUAUGC 617GCAUAAAGCAAGAUUACUA 4667-4685 4665 208 NAGUAAUCUUGCUUUAUGC 618GCAUAAAGCAAGAUUACUN 4667-4685 4665 209 NAGUAAUCUUGCUUUAUGN 619NCAUAAAGCAAGAUUACUN 4667-4685 4665 210 AAAGAAAUCUAGAACAUUG 620CAAUGUUCUAGAUUUCUUU 4727-4745 4725 211 UAAGAAAUCUAGAACAUUG 621CAAUGUUCUAGAUUUCUUA 4727-4745 4725 212 NAAGAAAUCUAGAACAUUG 622CAAUGUUCUAGAUUUCUUN 4727-4745 4725 213 NAAGAAAUCUAGAACAUUN 623NAAUGUUCUAGAUUUCUUN 4727-4745 4725 214 UAACUUCACUCAUCCAGCA 624UGCUGGAUGAGUGAAGUUA 2852-2870 2850 215 NAACUUCACUCAUCCAGCA 625UGCUGGAUGAGUGAAGUUN 2852-2870 2850 216 NAACUUCACUCAUCCAGCN 626NGCUGGAUGAGUGAAGUUN 2852-2870 2850 217 UCAACUUCACUCAUCCAGC 627GCUIGAUGAGUGAAGUUGA 2853-2871 2851 218 NCAACUUCACUCAUCCAGC 628GCUIGAUGAGUGAAGUUGN 2853-2871 2851 219 NCAACUUCACUCAUCCAGN 629NCUIGAUGAGUGAAGUUGN 2853-2871 2851 220 UGCAACUUCACUCAUCCAG 630CUGGAUGAGUGAAGUUICA 2854-2872 2852 221 NGCAACUUCACUCAUCCAG 631CUGGAUGAGUGAAGUUICN 2854-2872 2852 222 NGCAACUUCACUCAUCCAN 632NUGGAUGAGUGAAGUUICN 2854-2872 2852 223 UGAUCAUACUUGGAGAGCA 633UGCUCUCCAAGUAUGAUCA 237-255  235 224 NGAUCAUACUUGGAGAGCA 634UGCUCUCCAAGUAUGAUCN 237-255  235 225 NGAUCAUACUUGGAGAGCN 635NGCUCUCCAAGUAUGAUCN 237-255  235 226 UCUUGUUCUGCAGACGAUC 636GAUCGUCUGCAGAACAAGA 251-269  249 227 NCUUGUUCUGCAGACGAUC 637GAUCGUCUGCAGAACAAGN 251-269  249 228 NCUUGUUCUGCAGACGAUC 638GAUCGUCUGCAGAACAAGN 251-269  249 229 UGAUCUUGUUCUGCAGACG 639CGUCUGCAGAACAAGAUCA 254-272  252 230 NGAUCUUGUUCUGCAGACG 640CGUCUGCAGAACAAGAUCN 254-272  252 231 NGAUCUUGUUCUGCAGACN 641NGUCUGCAGAACAAGAUCN 254-272  252 232 UAGUAAAGUUGCACUGGCG 642CGCCAGUGCAACUUUACUA 1705-1723 1703 233 NAGUAAAGUUGCACUGGCG 643CGCCAGUGCAACUUUACUN 1705-1723 1703 234 NAGUAAAGUUGCACUGGCN 644NGCCAGUGCAACUUUACUN 1705-1723 1703 235 UAACACAAGUAACCUUAUC 645GAUAAGGUUACUUGUGUUA 2051-2069 2049 236 NAACACAAGUAACCUUAUC 646GAUAAGGUUACUUGUGUUN 2051-2069 2049 237 NAACACAAGUAACCUUAUN 647NAUAAGGUUACUUGUGUUN 2051-2069 2049 238 UCAAUUGUGAUAAUGGCUG 648CAGCCAUUAUCACAAUUGA 2157-2175 2155 239 NCAAUUGUGAUAAUGGCUG 649CAGCCAUUAUCACAAUUGN 2157-2175 2155 240 NCAAUUGUGAUAAUGGCUN 650NAGCCAUUAUCACAAUUGN 2157-2175 2155 241 UAGCAUGAUACUGAGAGCU 651AGCUCUCAGUAUCAUGCUA 2999-3017 2997 242 NAGCAUGAUACUGAGAGCU 652AGCUCUCAGUAUCAUGCUN 2999-3017 2997 243 NAGCAUGAUACUGAGAGCN 653NGCUCUCAGUAUCAUGCUN 2999-3017 2997 244 AACUUGUCAACCUCACUCU 654AGAGUGAGGUUGACAAGUU 3021-3039 3019 245 UACUUGUCAACCUCACUCU 655AGAGUGAGGUUGACAAGUA 3021-3039 3019 246 NACUUGUCAACCUCACUCU 656AGAGUGAGGUUGACAAGUN 3021-3039 3019 247 NACUUGUCAACCUCACUCN 657NGAGUGAGGUUGACAAGUN 3021-3039 3019 248 UAACUUGUCAACCUCACUC 658GAGUGAGGUUGACAAGUUA 3022-3040 3020 249 NAACUUGUCAACCUCACUC 659GAGUGAGGUUGACAAGUUN 3022-3040 3020 250 NAACUUGUCAACCUCACUN 660NAGUGAGGUUGACAAGUUN 3022-3040 3020 251 UAACAAUUCUCCUUGUUGA 661UCAACAAGGAGAAUUGUUA 3039-3057 3037 252 NAACAAUUCUCCUUGUUGA 662UCAACAAGGAGAAUUGUUN 3039-3057 3037 253 NAACAAUUCUCCUUGUUGN 663NCAACAAGGAGAAUUGUUN 3039-3057 3037 254 UCAUGUUCUGUGGUAUGUU 664AACAUACCACAGAACAUGA 4138-4156 4136 255 NCAUGUUCUGUGGUAUGUU 665AACAUACCACAGAACAUGN 4138-4156 4136 256 NCAUGUUCUGUGGUAUGUN 666NACAUACCACAGAACAUGN 4138-4156 4136 257 UACUUUAAUAGAUCCAUGU 667ACAUGGAUCUAUUAAAGUA 4151-4169 4149 258 NACUUUAAUAGAUCCAUGU 668ACAUGGAUCUAUUAAAGUN 4151-4169 4149 259 NACUUUAAUAGAUCCAUGN 669NCAUGGAUCUAUUAAAGUN 4151-4169 4149 260 UGACUUUAAUAGAUCCAUG 670CAUGGAUCUAUUAAAGUCA 4152-4170 4150 261 NGACUUUAAUAGAUCCAUG 671CAUGGAUCUAUUAAAGUCN 4152-4170 4150 262 NGACUUUAAUAGAUCCAUN 672NAUGGAUCUAUUAAAGUCN 4152-4170 4150 263 UGCAUAUUCACCAUUUAGG 673CCUAAAUGGUGAAUAUGCA 4291-4309 4289 264 NGCAUAUUCACCAUUUAGG 674CCUAAAUGGUGAAUAUGCN 4291-4309 4289 265 NGCAUAUUCACCAUUUAGN 675NCUAAAUGGUGAAUAUGCN 4291-4309 4289 266 UGUUUAAGCUUCUAGAGGU 676ACCUCUAGAAGCUUAAACA 4448-4466 4446 267 NGUUUAAGCUUCUAGAGGU 677ACCUCUAGAAGCUUAAACN 4448-4466 4446 268 NGUUUAAGCUUCUAGAGGN 678NCCUCUAGAAGCUUAAACN 4448-4466 4446 269 UUGUUCAUUGGUUUGAAGG 679CCUUCAAACCAAUGAACAA 4507-4525 4505 270 NUGUUCAUUGGUUUGAAGG 680CCUUCAAACCAAUGAACAN 4507-4525 4505 271 NUGUUCAUUGGUUUGAAGN 681NCUUCAAACCAAUGAACAN 4507-4525 4505 272 UUAUGCUUUGCUGUUCAUU 682AAUGAACAGCAAAGCAUAA 4517-4535 4515 273 NUAUGCUUUGCUGUUCAUU 683AAUGAACAGCAAAGCAUAN 4517-4535 4515 274 NUAUGCUUUGCUGUUCAUN 684NAUGAACAGCAAAGCAUAN 4517-4535 4515 275 UGUUAUGCUUUGCUGUUCA 685UGAACAGCAAAGCAUAACA 4519-4537 4517 276 NGUUAUGCUUUGCUGUUCA 686UGAACAGCAAAGCAUAACN 4519-4537 4517 277 NGUUAUGCUUUGCUGUUCN 687NGAACAGCAAAGCAUAACN 4519-4537 4517 278 AGGUUAUGCUUUGCUGUUC 688GAACAGCAAAGCAUAACCU 4520-4538 4518 279 UGGUUAUGCUUUGCUGUUC 689GAACAGCAAAGCAUAACCA 4520-4538 4518 280 NGGUUAUGCUUUGCUGUUC 690GAACAGCAAAGCAUAACCN 4520-4538 4518 281 NGGUUAUGCUUUGCUGUUN 691NAACAGCAAAGCAUAACCN 4520-4538 4518 282 UAAGGUUAUGCUUUGCUGU 692ACAGCAAAGCAUAACCUUA 4522-4540 4520 283 NAAGGUUAUGCUUUGCUGU 693ACAGCAAAGCAUAACCUUN 4522-4540 4520 284 NAAGGUUAUGCUUUGCUGN 694NCAGCAAAGCAUAACCUUN 4522-4540 4520 285 AGAUUCAAGGUUAUGCUUU 695AAAGCAUAACCUUGAAUCU 4527-4545 4525 286 UGAUUCAAGGUUAUGCUUU 696AAAGCAUAACCUUGAAUCA 4527-4545 4525 287 NGAUUCAAGGUUAUGCUUU 697AAAGCAUAACCUUGAAUCN 4527-4545 4525 288 NGAUUCAAGGUUAUGCUUN 698NAAGCAUAACCUUGAAUCN 4527-4545 4525 289 UUCAAUAAUUGAGUUGGUU 699AACCAACUCAAUUAUUGAA 4702-4720 4700 290 NUCAAUAAUUGAGUUGGUU 700AACCAACUCAAUUAUUGAN 4702-4720 4700 291 NUCAAUAAUUGAGUUGGUN 701NACCAACUCAAUUAUUGAN 4702-4720 4700 292 AGUAAAAUGGAUCACAGGA 702UCCUGUGAUCCAUUUUACU 5288-5306 5286 293 UGUAAAAUGGAUCACAGGA 703UCCUGUGAUCCAUUUUACA 5288-5306 5286 294 NGUAAAAUGGAUCACAGGA 704UCCUGUGAUCCAUUUUACN 5288-5306 5286 295 NGUAAAAUGGAUCACAGGN 705NCCUGUGAUCCAUUUUACN 5288-5306 5286 296 UCAUAUGACAGUAAGAAAA 706UUUUCUUACUGUCAUAUGA 5422-5440 5420 297 NCAUAUGACAGUAAGAAAA 707UUUUCUUACUGUCAUAUGN 5422-5440 5420 298 NCAUAUGACAGUAAGAAAN 708NUUUCUUACUGUCAUAUGN 5422-5440 5420 299 UGGAUCUGCAUUUUUCUCC 709GGAGAAAAAUGCAIAUCCA 124-142  122 300 NGGAUCUGCAUUUUUCUCC 710GGAGAAAAAUGCAIAUCCN 124-142  122 301 NGGAUCUGCAUUUUUCUCN 711NGAGAAAAAUGCAIAUCCN 124-142  122 302 UCCAAAAGGGUUGUCUCUG 712CAGAGACAACUCUUUUGGA 141-159  139 303 NCCAAAAGGGUUGUCUCUG 713CAGAGACAACUCUUUUGGN 141-159  139 304 NCCAAAAGGGUUGUCUCUN 714NAGAGACAACUCUUUUGGN 141-159  139 305 UAGACGAUCAUACUUGGAG 715CUCCAAGUAUGAUCIUCUA 241-259  239 306 NAGACGAUCAUACUUGGAG 716CUCCAAGUAUGAUCIUCUN 241-259  239 307 NAGACGAUCAUACUUGGAN 717NUCCAAGUAUGAUCIUCUN 241-259  239 308 UCCUAUUCCUUCCACAGUU 718AACUGUGGAAGGAAUAGGA 334-352  332 309 NCCUAUUCCUUCCACAGUU 719AACUGUGGAAGGAAUAGGN 334-352  332 310 NCCUAUUCCUUCCACAGUN 720NACUGUGGAAGGAAUAGGN 334-352  332 311 UACAUACUCAUGACGAUGC 721GCAUCGUCAUGAGUAUGUA 432-450  430 312 NACAUACUCAUGACGAUGC 722GCAUCGUCAUGAGUAUGUN 432-450  430 313 NACAUACUCAUGACGAUGN 723NCAUCGUCAUGAGUAUGUN 432-450  430 314 UCACAGAUUUCCUUGGAAG 724CUUCCAAGGAAAUCUGUIA 502-520  500 315 NCACAGAUUUCCUUGGAAG 725CUUCCAAGGAAAUCUGUIN 502-520  500 316 NCACAGAUUUCCUUGGAAN 726NUUCCAAGGAAAUCUGUIN 502-520  500 317 UGAACUUCAUCUCAAUGCC 727GGCAUUGAGAUGAAGUUCA 869-887  867 318 NGAACUUCAUCUCAAUGCC 728GGCAUUGAGAUGAAGUUCN 869-887  867 319 NGAACUUCAUCUCAAUGCN 729NGCAUUGAGAUGAAGUUCN 869-887  867 320 AGCAUAUUCUUGAACUUCA 730UGAAGUUCAAGAAUAUGCU 879-897  877 321 UGCAUAUUCUUGAACUUCA 731UGAAGUUCAAGAAUAUGCA 879-897  877 322 NGCAUAUUCUUGAACUUCA 732UGAAGUUCAAGAAUAUGCN 879-897  877 323 NGCAUAUUCUUGAACUUCN 733NGAAGUUCAAGAAUAUGCN 879-897  877 324 UCAUAGGAAACAGCAUAUU 734AAUAUGCUGUUUCCUAUGA 890-908  888 325 NCAUAGGAAACAGCAUAUU 735AAUAUGCUGUUUCCUAUGN 890-908  888 326 NCAUAGGAAACAGCAUAUN 736NAUAUGCUGUUUCCUAUGN 890-908  888 327 UGGAUCUCUAUGGAGAGCA 737UGCUCUCCAUAGAIAUCCA 1287-1305 1285 328 NGGAUCUCUAUGGAGAGCA 738UGCUCUCCAUAGAIAUCCN 1287-1305 1285 329 NGGAUCUCUAUGGAGAGCN 739NGCUCUCCAUAGAIAUCCN 1287-1305 1285 330 UUUGAAUGCUGAGAAAUAC 740GUAUUUCUCAGCAUUCAAA 1324-1342 1322 331 NUUGAAUGCUGAGAAAUAC 741GUAUUUCUCAGCAUUCAAN 1324-1342 1322 332 NUUGAAUGCUGAGAAAUAN 742NUAUUUCUCAGCAUUCAAN 1324-1342 1322 333 UCUAUGGACUUGAUCUUGG 743CCAAGAUCAAGUCCAUAGA 1923-1941 1921 334 NCUAUGGACUUGAUCUUGG 744CCAAGAUCAAGUCCAUAGN 1923-1941 1921 335 NCUAUGGACUUGAUCUUGN 745NCAAGAUCAAGUCCAUAGN 1923-1941 1921 336 AUGAAACAAACAAACCCUG 746CAGGGUUUGUUUGUUUCAU 1965-1983 1963 337 UUGAAACAAACAAACCCUG 747CAGGGUUUGUUUGUUUCAA 1965-1983 1963 338 NUGAAACAAACAAACCCUG 748CAGGGUUUGUUUGUUUCAN 1965-1983 1963 339 NUGAAACAAACAAACCCUN 749NAGGGUUUGUUUGUUUCAN 1965-1983 1963 340 UGGUAGUUCUUCAUAGGUG 750CACCUAUGAAGAACUACCA 2140-2158 2138 341 NGGUAGUUCUUCAUAGGUG 751CACCUAUGAAGAACUACCN 2140-2158 2138 342 NGGUAGUUCUUCAUAGGUN 752NACCUAUGAAGAACUACCN 2140-2158 2138 343 UGAUAAUGGCUGGUAGUUC 753GAACUACCAGCCAUUAUCA 2150-2168 2148 344 NGAUAAUGGCUGGUAGUUC 754GAACUACCAGCCAUUAUCN 2150-2168 2148 345 NGAUAAUGGCUGGUAGUUN 755NAACUACCAGCCAUUAUCN 2150-2168 2148 346 UCUCAAUUGUGAUAAUGGC 756GCCAUUAUCACAAUUGAGA 2159-2177 2157 347 NCUCAAUUGUGAUAAUGGC 757GCCAUUAUCACAAUUGAGN 2159-2177 2157 348 NCUCAAUUGUGAUAAUGGN 758NCCAUUAUCACAAUUGAGN 2159-2177 2157 349 UCUUUCUCGAUCUUCAGCU 759AGCUGAAGAUCGAGAAAGA 2211-2229 2209 350 NCUUUCUCGAUCUUCAGCU 760AGCUGAAGAUCGAGAAAGN 2211-2229 2209 351 NCUUUCUCGAUCUUCAGCN 761NGCUGAAGAUCGAGAAAGN 2211-2229 2209 352 UUUGGAACAGCAAUGGUGC 762GCACCAUUGCUGUUCCAAA 2322-2340 2320 353 NUUGGAACAGCAAUGGUGC 763GCACCAUUGCUGUUCCAAN 2322-2340 2320 354 NUUGGAACAGCAAUGGUGN 764NCACCAUUGCUGUUCCAAN 2322-2340 2320 355 UGUAGACACAAAGAGCUCC 765GGAGCUCUUUGUGUUUACA 2359-2377 2357 356 NGUAGACACAAAGAGCUCC 766GGAGCUCUUUGUGUUUACN 2359-2377 2357 357 NGUAGACACAAAGAGCUCN 767NGAGCUCUUUGUGUUUACN 2359-2377 2357 358 UCUGUGUAGACACAAAGAG 768CUCUUUGUGUCUACACAIA 2363-2381 2361 359 NCUGUGUAGACACAAAGAG 769CUCUUUGUGUCUACACAIN 2363-2381 2361 360 NCUGUGUAGACACAAAGAN 770NUCUUUGUGUCUACACAIN 2363-2381 2361 361 UUCCAUAAUACUCUGAGAG 771CUCUCAGAGUAUUAUGGAA 2698-2716 2696 362 NUCCAUAAUACUCUGAGAG 772CUCUCAGAGUAUUAUGGAN 2698-2716 2696 363 NUCCAUAAUACUCUGAGAN 773NUCUCAGAGUAUUAUGGAN 2698-2716 2696 364 UCUCGUUCCAUAAUACUCU 774AGAGUAUUAUGGAACGAIA 2703-2721 2701 365 NCUCGUUCCAUAAUACUCU 775AGAGUAUUAUGGAACGAIN 2703-2721 2701 366 NCUCGUUCCAUAAUACUCN 776NGAGUAUUAUGGAACGAIN 2703-2721 2701 367 AAUGAAACAAACAAACCCU 777AGGGUUUGUUUGUUUCAUU 1966-1984 1964 368 UAUGAAACAAACAAACCCU 778AGGGUUUGUUUGUUUCAUA 1966-1984 1964 369 NAUGAAACAAACAAACCCU 779AGGGUUUGUUUGUUUCAUN 1966-1984 1964 370 NAUGAAACAAACAAACCCN 780NGGGUUUGUUUGUUUCAUN 1966-1984 1964 371 AAAUGAAACAAACAAACCC 781GGGUUUGUUUGUUUCAUUU 1967-1985 1965 372 UAAUGAAACAAACAAACCC 782GGGUUUGUUUGUUUCAUUA 1967-1985 1965 373 NAAUGAAACAAACAAACCC 783GGGUUUGUUUGUUUCAUUN 1967-1985 1965 374 NAAUGAAACAAACAAACCN 784NGGUUUGUUUGUUUCAUUN 1967-1985 1965 375 UGAAAUGAAACAAACAAAC 785GUUUGUUUGUUUCAUUUCA 1969-1987 1967 376 NGAAAUGAAACAAACAAAC 786GUUUGUUUGUUUCAUUUCN 1969-1987 1967 377 NGAAAUGAAACAAACAAAN 787NUUUGUUUGUUUCAUUUCN 1969-1987 1967 378 AGACGAUCAUACUUGGAGA 788UCUCCAAGUAUGAUCIUCU 240-258  238 379 UGACGAUCAUACUUGGAGA 789UCUCCAAGUAUGAUCIUCA 240-258  238 380 NGACGAUCAUACUUGGAGA 790UCUCCAAGUAUGAUCIUCN 240-258  238 381 NGACGAUCAUACUUGGAGN 791NCUCCAAGUAUGAUCIUCN 240-258  238 382 AAGGCAUUCUCAAUCUCCU 792AGGAGAUUGAGAAUICCUU 486-504  484 383 UAGGCAUUCUCAAUCUCCU 793AGGAGAUUGAGAAUICCUA 486-504  484 384 NAGGCAUUCUCAAUCUCCU 794AGGAGAUUGAGAAUICCUN 486-504  484 385 NAGGCAUUCUCAAUCUCCN 795NGGAGAUUGAGAAUICCUN 486-504  484 386 UUUCCUUGGAAGGCAUUCU 796AGAAUGCCUUCCAAGGAAA 495-513  493 387 NUUCCUUGGAAGGCAUUCU 797AGAAUGCCUUCCAAGGAAN 495-513  493 388 NUUCCUUGGAAGGCAUUCN 798NGAAUGCCUUCCAAGGAAN 495-513  493 389 UAGAUUUCCUUGGAAGGCA 799UGCCUUCCAAGGAAAUCUA 499-517  497 390 NAGAUUUCCUUGGAAGGCA 800UGCCUUCCAAGGAAAUCUN 499-517  497 391 NAGAUUUCCUUGGAAGGCN 801NGCCUUCCAAGGAAAUCUN 499-517  497 392 AUAGGAAACAGCAUAUUCU 802AGAAUAUGCUGUUUCCUAU 888-906  886 393 UUAGGAAACAGCAUAUUCU 803AGAAUAUGCUGUUUCCUAA 888-906  886 394 NUAGGAAACAGCAUAUUCU 804AGAAUAUGCUGUUUCCUAN 888-906  886 395 NUAGGAAACAGCAUAUUCN 805NGAAUAUGCUGUUUCCUAN 888-906  886 396 UUGAUGAUGUUCCCUCCAA 806UUGGAGGGAACAUCAUCAA 1119-1137 1117 397 NUGAUGAUGUUCCCUCCAA 807UUGGAGGGAACAUCAUCAN 1119-1137 1117 398 NUGAUGAUGUUCCCUCCAN 808NUGGAGGGAACAUCAUCAN 1119-1137 1117 399 UAGAACUUGAAGAAGAAGC 809GCUUCUUCUUCAAGUUCUA 1617-1635 1615 400 NAGAACUUGAAGAAGAAGC 810GCUUCUUCUUCAAGUUCUN 1617-1635 1615 401 NAGAACUUGAAGAAGAAGN 811NCUUCUUCUUCAAGUUCUN 1617-1635 1615 402 UACCAAUGAUAUGCCCAAC 812GUUGGGCAUAUCAUUGGUA 2066-2084 2064 403 NACCAAUGAUAUGCCCAAC 813GUUGGGCAUAUCAUUGGUN 2066-2084 2064 404 NACCAAUGAUAUGCCCAAN 814NUUGGGCAUAUCAUUGGUN 2066-2084 2064 405 UCAUGGUGUUCUGUGUAGA 815UCUACACAGAACACCAUGA 2372-2390 2370 406 NCAUGGUGUUCUGUGUAGA 816UCUACACAGAACACCAUGN 2372-2390 2370 407 NCAUGGUGUUCUGUGUAGN 817NCUACACAGAACACCAUGN 2372-2390 2370 408 UUGAGAGAGAUCCUGGGUG 818CACCCAGGAUCUCUUUCAA 2686-2704 2684 409 NUGAGAGAGAUCCUGGGUG 819CACCCAGGAUCUCUUUCAN 2686-2704 2684 410 NUGAGAGAGAUCCUGGGUN 820NACCCAGGAUCUCUUUCAN 2686-2704 2684 411 UCAUGAUACUGAGAGCUUG 821CAAGCUCUCAGUAUCAUGA 2997-3015 2995 412 NCAUGAUACUGAGAGCUUG 822CAAGCUCUCAGUAUCAUGN 2997-3015 2995 413 NCAUGAUACUGAGAGCUUN 823NAAGCUCUCAGUAUCAUGN 2997-3015 2995 414 UUGUCAACCUCACUCUUCC 824GGAAGAGUGAGGUUGACAA 3018-3036 3016 415 NUGUCAACCUCACUCUUCC 825GGAAGAGUGAGGUUGACAN 3018-3036 3016 416 NUGUCAACCUCACUCUUCN 826NGAAGAGUGAGGUUGACAN 3018-3036 3016 417 UUUCCAACAAUUCUCCUUG 827CAAGGAGAAUUGUUGGAAA 3043-3061 3041 418 NUUCCAACAAUUCUCCUUG 828CAAGGAGAAUUGUUGGAAN 3043-3061 3041 419 NUUCCAACAAUUCUCCUUN 829NAAGGAGAAUUGUUGGAAN 3043-3061 3041 420 UUGAGUUAGUCUCAAAGCU 830AGCUUUGAGACUAACUCAA 3500-3518 3498 421 NUGAGUUAGUCUCAAAGCU 831AGCUUUGAGACUAACUCAN 3500-3518 3498 422 NUGAGUUAGUCUCAAAGCN 832NGCUUUGAGACUAACUCAN 3500-3518 3498 423 AUGACAAUAUCUGUGCGGA 833UCCGCACAGAUAUUGUCAU 3600-3618 3598 424 UUGACAAUAUCUGUGCGGA 834UCCGCACAGAUAUUGUCAA 3600-3618 3598 425 NUGACAAUAUCUGUGCGGA 835UCCGCACAGAUAUUGUCAN 3600-3618 3598 426 NUGACAAUAUCUGUGCGGN 836NCCGCACAGAUAUUGUCAN 3600-3618 3598 427 UCAUGACAAUAUCUGUGCG 837CGCACAGAUAUUGUCAUGA 3602-3620 3600 428 NCAUGACAAUAUCUGUGCG 838CGCACAGAUAUUGUCAUGN 3602-3620 3600 429 NCAUGACAAUAUCUGUGCN 839NGCACAGAUAUUGUCAUGN 3602-3620 3600 430 UCAAAGAAGAUAGAAGCAG 840CUGCUUCUAUCUUCUUUGA 3879-3897 3877 431 NCAAAGAAGAUAGAAGCAG 841CUGCUUCUAUCUUCUUUGN 3879-3897 3877 432 NCAAAGAAGAUAGAAGCAN 842NUGCUUCUAUCUUCUUUGN 3879-3897 3877 433 UCACGUUAUUACCUGUGUG 843CACACAGGUAAUAACGUIA 3932-3950 3930 434 NCACGUUAUUACCUGUGUG 844CACACAGGUAAUAACGUIN 3932-3950 3930 435 NCACGUUAUUACCUGUGUN 845NACACAGGUAAUAACGUIN 3932-3950 3930 436 UAGAACUUGAGGUUAUACA 846UGUAUAACCUCAAGUUCUA 4396-4414 4394 437 NAGAACUUGAGGUUAUACA 847UGUAUAACCUCAAGUUCUN 4396-4414 4394 438 NAGAACUUGAGGUUAUACN 848NGUAUAACCUCAAGUUCUN 4396-4414 4394 439 AUGCUUUGCUGUUCAUUGG 849CCAAUGAACAGCAAAGCAU 4515-4533 4513 440 UUGCUUUGCUGUUCAUUGG 850CCAAUGAACAGCAAAGCAA 4515-4533 4513 441 NUGCUUUGCUGUUCAUUGG 851CCAAUGAACAGCAAAGCAN 4515-4533 4513 442 NUGCUUUGCUGUUCAUUGN 852NCAAUGAACAGCAAAGCAN 4515-4533 4513 443 UAGUAUAGAUUCAAGGUUA 853UAACCUUGAAUCUAUACUA 4533-4551 4531 444 NAGUAUAGAUUCAAGGUUA 854UAACCUUGAAUCUAUACUN 4533-4551 4531 445 NAGUAUAGAUUCAAGGUUN 855NAACCUUGAAUCUAUACUN 4533-4551 4531 446 AGAGUAAUCUUGCUUUAUG 856CAUAAAGCAAGAUUACUCU 4668-4686 4666 447 UGAGUAAUCUUGCUUUAUG 857CAUAAAGCAAGAUUACUCA 4668-4686 4666 448 NGAGUAAUCUUGCUUUAUG 858CAUAAAGCAAGAUUACUCN 4668-4686 4666 449 NGAGUAAUCUUGCUUUAUN 859NAUAAAGCAAGAUUACUCN 4668-4686 4666 450 AUAGCAUCAUUUCUAGGUG 860CACCUAGAAAUGAUGCUAU 4845-4863 4843 451 UUAGCAUCAUUUCUAGGUG 861CACCUAGAAAUGAUGCUAA 4845-4863 4843 452 NUAGCAUCAUUUCUAGGUG 862CACCUAGAAAUGAUGCUAN 4845-4863 4843 453 NUAGCAUCAUUUCUAGGUN 863NACCUAGAAAUGAUGCUAN 4845-4863 4843 454 AGACAGAAGAGACAGAGCU 864AGCUCUGUCUCUUCUIUCU 5236-5254 5234 455 UGACAGAAGAGACAGAGCU 865AGCUCUGUCUCUUCUIUCA 5236-5254 5234 456 NGACAGAAGAGACAGAGCU 866AGCUCUGUCUCUUCUIUCN 5236-5254 5234 457 NGACAGAAGAGACAGAGCN 867NGCUCUGUCUCUUCUIUCN 5236-5254 5234 458 AGUAAGAAAACCAAGCCUU 868(A^(2N))AGGCUUGGUUUUCUUACU 5413-5431 5411 459 UGUAAGAAAACCAAGCCUU 869(A^(2N))AGGCUUGGUUUUCUUACA 5413-5431 5411 460 NGUAAGAAAACCAAGCCUU 870(A^(2N))AGGCUUGGUUUUCUUACN 5413-5431 5411 461 NGUAAGAAAACCAAGCCUN 871NAGGCUUGGUUUUCUUACN 5413-5431 5411 462 AGUAAGAAAACCAAGCCUU 872AAGGCUUGGUUUUCUUACU 5413-5431 5411 463 UGUAAGAAAACCAAGCCUU 873AAGGCUUGGUUUUCUUACA 5413-5431 5411 464 NGUAAGAAAACCAAGCCUU 874AAGGCUUGGUUUUCUUACN 5413-5431 5411 465 NGUAAGAAAACCAAGCCUN 875NAGGCUUGGUUUUCUUACN 5413-5431 5411 466 UAUACUUGGAGAGCAUCAC 876GUGAUGCUCUCCAAGUAUA 233-251  231 467 NAUACUUGGAGAGCAUCAC 877GUGAUGCUCUCCAAGUAUN 233-251  231 468 NAUACUUGGAGAGCAUCAN 878NUGAUGCUCUCCAAGUAUN 233-251  231 469 UUGCAGACGAUCAUACUUG 879CAAGUAUGAUCGUCUICAA 244-262  242 470 NUGCAGACGAUCAUACUUG 880CAAGUAUGAUCGUCUICAN 244-262  242 471 NUGCAGACGAUCAUACUUN 881NAAGUAUGAUCGUCUICAN 244-262  242 472 UUGAAUAAAACUCUCAUGC 882GCAUGAGAGUUUUAUUCAA 1386-1404 1384 473 NUGAAUAAAACUCUCAUGC 883GCAUGAGAGUUUUAUUCAN 1386-1404 1384 474 NUGAAUAAAACUCUCAUGN 884NCAUGAGAGUUUUAUUCAN 1386-1404 1384 475 UUGAAUAAAACUCUCAUGC 885GCAUGAGAGUUUU(A^(2N))UUCAA 1386-1404 1384 476 NUGAAUAAAACUCUCAUGC 886GCAUGAGAGUUUU(A^(2N))UUCAN 1386-1404 1384 477 NUGAAUAAAACUCUCAUGN 887NCAUGAGAGUUUU(A^(2N))UUCAN 1386-1404 1384 478 AGAAAAGUGGACGAUCUUG 888CAAGAUCGUCCACUUUUCU 265-283  263 479 UGAAAAGUGGACGAUCUUG 889CAAGAUCGUCCACUUUUCU 265-283  263 480 NGAAAAGUGGACGAUCUUG 890CAAGAUCGUCCACUUUUCN 265-283  263 481 NGAAAAGUGGACGAUCUUN 891NAAGAUCGUCCACUUUUCN 265-283  263 482 UAGUUGUCACUGCAACAUG 892CAUGUUGCAGUGACAACUA 320-338  318 483 NAGUUGUCACUGCAACAUG 893CAUGUUGCAGUGACAACUN 320-338  318 484 NAGUUGUCACUGCAACAUN 894NAUGUUGCAGUGACAACUN 320-338  318 485 AUUCCUUCCACAGUUGUCA 895UGACAACUGUGGAAGGAAU 330-348  328 486 UUUCCUUCCACAGUUGUCA 896UGACAACUGUGGAAGGAAA 330-348  328 487 NUUCCUUCCACAGUUGUCA 897UGACAACUGUGGAAGGAAN 330-348  328 488 NUUCCUUCCACAGUUGUCN 898NGACAACUGUGGAAGGAAN 330-348  328 489 UGCAUUCUCAAUCUCCUCC 899GGAGGAGAUUGAGAAUGCA 484-502  482 490 NGCAUUCUCAAUCUCCUCC 900GGAGGAGAUUGAGAAUGCN 484-502  482 491 NGCAUUCUCAAUCUCCUCN 901NGAGGAGAUUGAGAAUGCN 484-502  482 492 UUCAAUGCCAAUCUCCGUG 902CACGGAGAUUGGCAUUGAA 859-877  857 493 NUCAAUGCCAAUCUCCGUG 903CACGGAGAUUGGCAUUGAN 859-877  857 494 NUCAAUGCCAAUCUCCGUN 904NACGGAGAUUGGCAUUGAN 859-877  857 495 AUAUUCUUGAACUUCAUCU 905AGAUGAAGUUCAAGAAU(A^(2N))U 876-894  874 496 UUAUUCUUGAACUUCAUCU 906AGAUGAAGUUCAAGAAU(A^(2N))A 876-894  874 497 NUAUUCUUGAACUUCAUCU 907AGAUGAAGUUCAAGAAU(A^(2N))N 876-894  874 498 NUAUUCUUGAACUUCAUCN 908NGAUGAAGUUCAAGAAU(A^(2N))N 876-894  874 499 AUAUUCUUGAACUUCAUCU 909AGAUGAAGUUCAAGAAUAU 876-894  874 500 UUAUUCUUGAACUUCAUCU 910AGAUGAAGUUCAAGAAUAA 876-894  874 501 NUAUUCUUGAACUUCAUCU 911AGAUGAAGUUCAAGAAUAN 876-894  874 502 NUAUUCUUGAACUUCAUCN 912NGAUGAAGUUCAAGAAUAN 876-894  874 503 UUAUGGAGAGCAGUAUCUC 913GAGAUACUGCUCUCCAUAA 1280-1298 1278 504 NUAUGGAGAGCAGUAUCUC 914GAGAUACUGCUCUCCAUAN 1280-1298 1278 505 NUAUGGAGAGCAGUAUCUN 915NAGAUACUGCUCUCCAUAN 1280-1298 1278 506 UAAUGCUGAGAAAUACUCC 916GGAGUAUUUCUCAGCAUUA 1321-1339 1319 507 NAAUGCUGAGAAAUACUCC 917GGAGUAUUUCUCAGCAUUN 1321-1339 1319 508 NAAUGCUGAGAAAUACUCN 918NGAGUAUUUCUCAGCAUUN 1321-1339 1319 509 UGAAUGCUGAGAAAUACUC 919GAGUAUUUCUCAGCAUUCA 1322-1340 1320 510 NGAAUGCUGAGAAAUACUC 920GAGUAUUUCUCAGCAUUCN 1322-1340 1320 511 NGAAUGCUGAGAAAUACUN 921NAGUAUUUCUCAGCAUUCN 1322-1340 1320 512 UCAAUGUCAUCUUCUCUCC 922GGAGAGAAGAUGACAUUGA 1353-1371 1351 513 NCAAUGUCAUCUUCUCUCC 923GGAGAGAAGAUGACAUUGN 1353-1371 1351 514 NCAAUGUCAUCUUCUCUCN 924NGAGAGAAGAUGACAUUGN 1353-1371 1351 515 ACAAAUUCCAGUUAUGUUA 925UAACAUAACUGGAAUUUGU 2008-2026 2006 516 UCAAAUUCCAGUUAUGUUA 926UAACAUAACUGGAAUUUGA 2008-2026 2006 517 NCAAAUUCCAGUUAUGUUA 927UAACAUAACUGGAAUUUGN 2008-2026 2006 518 NCAAAUUCCAGUUAUGUUN 928NAACAUAACUGGAAUUUGN 2008-2026 2006 519 UUCAAUUGUGAUAAUGGCU 929AGCCAUUAUCACAAUUGAA 2158-2176 2156 520 NUCAAUUGUGAUAAUGGCU 930AGCCAUUAUCACAAUUGAN 2158-2176 2156 521 NUCAAUUGUGAUAAUGGCN 931NGCCAUUAUCACAAUUGAN 2158-2176 2156 522 AACAUUUUUGCAACAAAGC 932GCUUUGUUGCAAAAAUGUU 2400-2418 2398 523 UACAUUUUUGCAACAAAGC 933GCUUUGUUGCAAAAAUGUA 2400-2418 2398 524 NACAUUUUUGCAACAAAGC 934GCUUUGUUGCAAAAAUGUN 2400-2418 2398 525 NACAUUUUUGCAACAAAGN 935NCUUUGUUGCAAAAAUGUN 2400-2418 2398 526 UCAACAUUUUUGCAACAAA 936UUUGUUGCAAAAAUGUUGA 2402-2420 2400 527 NCAACAUUUUUGCAACAAA 937UUUGUUGCAAAAAUGUUGN 2402-2420 2400 528 NCAACAUUUUUGCAACAAN 938NUUGUUGCAAAAAUGUUGN 2402-2420 2400 529 UUUCACUCGAACCACAAUC 939GAUUGUGGUUCGAGUGAAA 2437-2455 2435 530 NUUCACUCGAACCACAAUC 940GAUUGUGGUUCGAGUGAAN 2437-2455 2435 531 NUUCACUCGAACCACAAUN 941NAUUGUGGUUCGAGUGAAN 2437-2455 2435 532 UUGGAAGGCAUUCUCAAUC 942GAUUGAGAAUGCCUUCCAA 490-508  488 533 NUGGAAGGCAUUCUCAAUC 943GAUUGAGAAUGCCUUCCAN 490-508  488 534 NUGGAAGGCAUUCUCAAUN 944NAUUGAGAAUGCCUUCCAN 490-508  488

The XDH RNAi agent sense strands and antisense strands that comprise orconsist of the sequences in Table 2 can be modified nucleotides orunmodified nucleotides. In some aspects, the XDH RNAi agents having thesense and antisense strand sequences that comprise or consist of thesequences in Table 2 are all or substantially all modified nucleotides,

In some aspects, the antisense strand of an XDH RNAi agent disclosedherein differs by 0, 1, 2, or 3 nucleotides from any of the antisensestrand sequences in Table 2. In some aspects, the sense strand of an XDHRNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides fromany of the sense strand sequences in Table 2.

As used herein, each N listed in a sequence disclosed in Table 2 may beindependently selected from any and all nucleobases (including thosefound on both modified and unmodified nucleotides), In some aspects, anN nucleotide listed in a sequence disclosed in Table 2 has a nucleobasethat is complementary to the N nucleotide at the corresponding positionon the other strand. In some aspects, an N nucleotide listed in asequence disclosed in Table 2 has a nucleobase that is not complementaryto the N nucleotide at the corresponding position on the other strand.In some aspects, an N nucleotide listed in a sequence disclosed in Table2 has a nucleobase that is the same as the N nucleotide at thecorresponding position on the other strand. In some aspects, an Nnucleotide listed in a sequence disclosed in Table 2 has a nucleobasethat is different from the N nucleotide at the corresponding position onthe other strand.

Certain modified XDH RNAi agent antisense strands, as well as theirunderlying unmodified nucleobase sequences, are provided in Table 3.Certain modified XDH RNAi agent sense strands, as well as theirunderlying unmodified nucleobase sequences, are provided in Table 4. Informing XDH RNAi agents, each of the nucleotides in each of theunderlying base sequences listed in Tables 3 and 4, as well as in Table2, above, can be a modified nucleotide.

The XDH RNAi agents described herein are formed by annealing anantisense strand with a sense strand. A sense strand containing asequence listed in Table 2 or Table 4, can be hybridized to anyantisense strand containing a sequence listed in Table 2 or Table 3,provided the two sequences have a region of at least 85% complementarityover a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.

In some aspects, an XDH RNAi agent antisense strand comprises anucleotide sequence of any of the sequences in Table 2 or Table 3.

In some aspects, an XDH RNAi agent comprises or consists of a duplexhaving the nucleobase sequences of the sense strand and the antisensestrand of any of the sequences in Table 2, Table 3, or Table 4.

Examples of antisense strands containing modified nucleotides areprovided in Table 3 and Table 5C. Examples of sense strands containingmodified nucleotides are provided in Table 4 and Table 5C.

As used in Tables 3, 4, and 5C the following notations are used toindicate modified nucleotides and linking groups:

-   -   A=adenosine-3′-phosphate;    -   C=cytidine-3′-phosphate;    -   G=guanosine-3′-phosphate;    -   U=uridine-3′-phosphate    -   I=inosine-3′-phosphate    -   a=2′-O-methyladenosine-3′-phosphate    -   as=2′-O-methyladenosine-3′-phosphorothioate    -   c=2′-O-methylcytidine-3′-phosphate    -   cs=2′-O-methylcytidine-3′-phosphorothioate    -   g=2′-O-methylguanosine-3′-phosphate    -   gs=2′-O-methylguanosine-3′-phosphorothioate    -   t=2′-O-methyl-5-methyluridine-3′-phosphate    -   ts=2′-O-methyl-5-methyluridine-3′-phosphorothioate    -   u=2′-O-methyluridine-3′-phosphate    -   us=2′-O-methyluridine-3′-phosphorothioate    -   i=2′-O-methylinosine-3′-phosphate    -   is=2′-O-methylinosine-3′-phosphorothioate    -   Af=2′-fluoroadenosine-3′-phosphate    -   Afs=2′-fluoroadenosine-3′-phosporothioate    -   Cf=2′-fluorocytidine-3′-phosphate    -   Cfs=2′-fluorocytidine-3′-phosphorothioate    -   Gf=2′-fluoroguanosine-3′-phosphate    -   Gfs=2′-fluoroguanosine-3′-phosphorothioate    -   Tf=2′-fluoro-5′-methyluridine-3′-phosphate    -   Tfs=2′-fluoro-5′-methyluridine-3′-phosphorothioate    -   Uf=2′-fluorouridine-3′-phosphate    -   Ufs=2′-fluorouridine-3′-phosphorothioate    -   A_(UNA)=2′,3′-seco-adenosine-3′-phosphate, see Table 6    -   A_(UNA)s=2′,3′-seco-adenosine-3′-phosphorothioate, see Table 6    -   C_(UNA)=2′,3′-seco-cytidine-3′-phosphate, see Table 6    -   C_(UNA)s=2′,3′-seco-cytidine-3′-phosphorothioate, see Table 6    -   G_(UNA)=2′,3′-seco-guanosine-3′-phosphate, see Table 6    -   G_(UNA)s=2′,3′-seco-guanosine-3′-phosphorothioate, see Table 6    -   U_(UNA)=2′,3′-seco-uridine-3′-phosphate, see Table 6    -   U_(UNA)s=2′,3′-seco-uridine-3′-phosphorothioate, see Table 6    -   a_2N=2′-O-methyl-2-aminoadenosine-3′-phosphate, see Table 6    -   a_2Ns=2′-O-methyl-2-aminoadenosine-3′-phosphorothioate, see        Table 6    -   (invAb)=inverted abasic deoxyribonucleotide, see Table 6    -   (invAb)s=inverted abasic        deoxyribonucleotide-5′-phosphorothioate, see Table 6    -   cPrpa=5′-cyclopropyl        phosphonate-2′-O-methyladenosine-3′-phosphate (see Table 6)    -   cPrpas=5′-cyclopropyl        phosphonate-2′-O-methyladenosine-3′-phosphorothioate (see Table        6)    -   cPrpu=5′-cyclopropyl phosphonate-2′-O-methyluridine-3′-phosphate        (see Table 6)    -   cPrpus=5′-cyclopropyl        phosphonate-2′-O-methyluridine-3′-phosphorothioate (see Table 6)

As the person of ordinary skill in the art would readily understand,unless otherwise indicated by the sequence (such as, for example, by aphosphorothioate linkage “s”), when present in an oligonucleotide, thenucleotide monomers are mutually linked by 5′-3′-phosphodiester bonds.As the person of ordinary skill in the art would clearly understand, theinclusion of a phosphorothioate linkage as shown in the modifiednucleotide sequences disclosed herein replaces the phosphodiesterlinkage typically present in oligonucleotides. Further, the person ofordinary skill in the art would readily understand that the terminalnucleotide at the 3′ end of a given oligonucleotide sequence wouldtypically have a hydroxyl (—OH) group at the respective 3′ position ofthe given monomer instead of a phosphate moiety ex vivo. Additionally,for the various aspects disclosed herein, when viewing the respectivestrand 5′→3′, the inverted abasic residues are inserted such that the 3′position of the deoxyribose is linked at the 3′ end of the precedingmonomer on the respective strand (see, e.g., Table 6). Moreover, as theperson of ordinary skill would readily understand and appreciate, whilethe phosphorothioate chemical structures depicted herein typically showthe anion on the sulfur atom, the inventions disclosed herein encompassall phosphorothioate tautomers and resonance structures (e.g., where thesulfur atom has a double-bond and the anion is on an oxygen atom).Unless expressly indicated otherwise herein, such understandings of theperson of ordinary skill in the art are used when describing the XDHRNAi agents and compositions of XDH RNAi agents disclosed herein.

Certain examples of targeting ligands, targeting groups, and linkinggroups used with the XDH RNAi agents disclosed herein are provided belowin Table 6. More specifically, targeting groups and linking groups(which together can form a targeting ligand) include (NAG37) and(NAG37)s, for which their chemical structures are provided below inTable 6. Each sense strand and/or antisense strand can have anytargeting ligands, targeting groups, or linking groups listed herein, aswell as other groups, conjugated to the 5′ and/or 3′ end of thesequence.

TABLE 3 XDH RNAi Agent Antisense Strand SequencesUnderlying Base Sequence Antisense SEQ (5′→3′) SEQ StrandModified Antisense Strand ID (Shown as an Unmodified ID ID: (5′→3′) NO.Nucleotide Sequence) NO. AM13029-AS usUfsgsGfaAfgGfcAfuUfcUfcAfaUfcUfsc 945 UUGGAAGGCAUUCUCAAUCUC 1352 AM13031-ASusUfsggaAfgGfCfauucUfcAfaucusc  946 UUGGAAGGCAUUCUCAAUCUC 1352AM13033-AS asAfscsUfuGfaAfgAfaGfaAfgCfuGfaGfsg  947AACUUGAAGAAGAAGCUGAGG 1353 AM13035-ASasGfsasAfcUfuGfaAfgAfaGfaAfgCfuGfsc  948 AGAACUUGAAGAAGAAGCUGC 1354AM13037-AS usGfsusAfgAfaCfuUfgAfaGfaAfgAfaGfsc  949UGUAGAACUUGAAGAAGAAGC 1355 AM13039-ASusCfsasUfaGfgUfgAfuUfuUfcAfcCfcCfsu  950 UCAUAGGUGAUUUUCACCCCU 1356AM13041-AS usUfsusCfaUfaGfgUfgAfuUfuUfcAfcCfsc  951UUUCAUAGGUGAUUUUCACCC 1357 AM13043-ASusCfsusUfcAfuAfgGfuGfaUfuUfuCfaCfsc  952 UCUUCAUAGGUGAUUUUCACC 1358AM13045-AS usUfscsUfuCfaUfaGfgUfgAfuUfuUfcAfsc  953UUCUUCAUAGGUGAUUUUCAC 1359 AM13047-ASasAfsusUfgUfgAfuAfaUfgGfcUfgGfuAfsg  954 AAUUGUGAUAAUGGCUGGUAG 1360AM13049-AS usCfsasUfaAfaAfgGfaGfuUfgUfuCfuUfsc  955UCAUAAAAGGAGUUGUUCUUC 1361 AM13051-ASusCfscsAfuAfaAfaGfgAfgUfuGfuUfcUfsc  956 UCCAUAAAAGGAGUUGUUCUC 1362AM13053-AS usAfscsAfgUfgUfuAfgUfgCfuUfgUfcUfsc  957UACAGUGUUAGUGCUUGUCUC 1363 AM13055-ASusUfsgsUfgUfaCfaUfaCfuCfaUfgAfcGfsa  958 UUGUGUACAUACUCAUGACGA 1364AM13057-AS usAfscsCfaGfuUfaUfcAfgCfaUfgUfcCfsu  959UACCAGUUAUCAGCAUGUCCU 1365 AM13059-ASusAfsusGfaAfgCfcAfaCfcUfuGfuAfuCfsc  960 UAUGAAGCCAACCUUGUAUCC 1366AM13061-AS usCfsusUfcAfuGfaAfgCfcAfaCfcUfuGfsc  961UCUUCAUGAAGCCAACCUUGC 1367 AM13063-ASusUfscsUfuCfaUfgAfaGfcCfaAfcCfuUfsg  962 UUCUUCAUGAAGCCAACCUUG 1368AM13065-AS usAfsgsUfcUfuCfaUfgAfaGfcCfaAfcCfsu  963UAGUCUUCAUGAAGCCAACCU 1369 AM13067-ASusCfsusUfuUfuCfcAfaCfaAfuUfcUfcCfsu  964 UCUUUUUCCAACAAUUCUCCU 1370AM13069-AS usUfscsUfaCfuUfcAfgAfgCfaAfgCfcAfsc  965UUCUACUUCAGAGCAAGCCAC 1371 AM13071-ASusAfsusUfuCfuAfcUfuCfaGfaGfcAfaGfsc  966 UAUUUCUACUUCAGAGCAAGC 1372AM13073-AS usGfsusCfcAfaUfaUfcAfaUfgGfcAfgGfsg  967UGUCCAAUAUCAAUGGCAGGG 1373 AM13164-ASusCfsasGfaAfaAfgUfgGfaCfgAfuCfuUfsg  968 UCAGAAAAGUGGACGAUCUUG 1374AM13166-AS asCfsasAfcAfuUfaUfcUfgCfuUfcGfgAfsc  969ACAACAUUAUCUGCUUCGGAC 1375 AM13168-ASusCfsasUfaAfuAfcUfcUfgAfgAfgAfgAfsc  970 UCAUAAUACUCUGAGAGAGAC 1376AM13170-AS usCfsusUfaUfuCfcAfaAfcUfuGfgUfgGfsg  971UCUUAUUCCAAACUUGGUGGG 1377 AM13172-ASusAfsgsUfaAfuCfuUfgCfuUfuAfuGfcAfsg  972 UAGUAAUCUUGCUUUAUGCAG 1378AM13174-AS asAfsasGfaAfaUfcUfaGfaAfcAfuUfgUfsc  973AAAGAAAUCUAGAACAUUGUC 1379 AM13176-AS usCfsasgaaaagugGfaCfgAfuCfuUfsg 974 UCAGAAAAGUGGACGAUCUUG 1374 AM13177-ASasCfsasacauUfaUfcUfgCfuUfcggasc  975 ACAACAUUAUCUGCUUCGGAC 1375AM13179-AS usCfsasUfaAfuacucUfgAfgAfgagasc  976 UCAUAAUACUCUGAGAGAGAC1376 AM13181-AS asAfsasGfaAfaUfcUfaGfaAfcAfuUfuUfsc  977AAAGAAAUCUAGAACAUUUUC 1380 AM13204-AS usCfsasGfaAfaagugGfaCfgAfuCfuUfsg 978 UCAGAAAAGUGGACGAUCUUG 1374 AM13205-ASusCfsasUfaAfuacucUfgAfgAfgAfgAfsc  979 UCAUAAUACUCUGAGAGAGAC 1376AMI3206-AS usCfsusUfaUfuccaaAfcUfuGfgUfggsg  980 UCUUAUUCCAAACUUGGUGGG1377 AM13207-AS usAfsgsUfaAfucuugCfuUfuAfuGfcAfsg  981UAGUAAUCUUGCUUUAUGCAG 1378 AMI3600-AS usAfsasCfuUfcacucAfuCfcAfgCfacsu 982 UAACUUCACUCAUCCAGCACU 1381 AM13602-ASusCfsasAfcuucacuCfaUfcCfagcasc  983 UCAACUUCACUCAUCCAGCAC 1382AM13604-AS usGfscsAfacuucacUfcAfuCfcagcsa  984 UGCAACUUCACUCAUCCAGCA1383 AM13648-AS usGfsasucauacuuGfgAfgAfgcausc  985 UGAUCAUACUUGGAGAGCAUC1384 AM13650-AS usCfsusuguucugcAfgAfcGfaucasc  986 UCUUGUUCUGCAGACGAUCAC1385 AM13652-AS usGfsasucuuguucUfgCfaGfacgasc  987 UGAUCUUGUUCUGCAGACGAC1386 AM13654-AS usAfsgsuaaaguugCfaCfuGfgcgasc  988 UAGUAAAGUUGCACUGGCGAC1387 AM13656-AS usAfsasCfacaaguaAfcCfuUfauccsu  989UAACACAAGUAACCUUAUCCU 1388 AM13658-AS usCfsasAfuugugauAfaUfgGfcuggsu 990 UCAAUUGUGAUAAUGGCUGGU 1389 AM13660-AS usAfsgscaugauacUfgAfgAfgcuusg 991 UAGCAUGAUACUGAGAGCUUG 1390 AM13662-ASasAfscsUfugucaacCfuCfaCfucuusc  992 AACUUGUCAACCUCACUCUUC 1391AM13664-AS usAfsasCfuugucaaCfcUfcAfcucusc  993 UAACUUGUCAACCUCACUCUC1392 AM13666-AS usAfsasCfaauucucCfuUfgUfugaasc  994UAACAAUUCUCCUUGUUGAAC 1393 AM13668-AS usCfsasuguucuguGfgUfaUfguucsc  995UCAUGUUCUGUGGUAUGUUCC 1394 AM13670-AS usAfscsUfuUfaauagAfuCfcAfuguusc 996 UACUUUAAUAGAUCCAUGUUC 1395 AM13672-ASusGfsascuuuAfaUfaGfaUfcCfaugusc  997 UGACUUUAAUAGAUCCAUGUC 1396AM13674-AS usGfscsauauucacCfaUfuUfaggcsa  998 UGCAUAUUCACCAUUUAGGCA 1397AM13676-AS usGfsusUfuaagcuuCfuAfgAfgguusc  999 UGUUUAAGCUUCUAGAGGUUC1398 AM13678-AS usUfsgsuucauuggUfuUfgAfaggcsc 1000 UUGUUCAUUGGUUUGAAGGCC1399 AM13680-AS usUfsasUfgCfuuugcUfgUfuCfauugsg 1001UUAUGCUUUGCUGUUCAUUGG 1400 AM13682-AS usGfsusUfaugcuuuGfcUfgUfuCfausc1002 UGUUAUGCUUUGCUGUUCAUC 1401 AM13684-ASasGfsgsUfuaugcuuUfgCfuGfuucasc 1003 AGGUUAUGCUUUGCUGUUCAC 1402AM13686-AS usAfsasgguuaugcUfuUfgCfuguusc 1004 UAAGGUUAUGCUUUGCUGUUC 1403AM13688-AS asGfsasUfucaagguUfaUfgCfuuugsc 1005 AGAUUCAAGGUUAUGCUUUGC1404 AM13690-AS usUfscsAfauaauugAfgUfuGfguugsg 1006UUCAAUAAUUGAGUUGGUUGG 1405 AM13692-AS asGfsusAfaaauggaUfcAfcAfggaasg1007 AGUAAAAUGGAUCACAGGAAG 1406 AM13694-ASusCfsasUfaugacagUfaAfgAfaaacsc 1008 UCAUAUGACAGUAAGAAAACC 1407AM13696-AS usUfsgsgaaggcauUfcUfcGfaucusc 1009 UUGGAAGGCAUUCUCGAUCUC 1408AM13698-AS usCfsasUfcauugaaAfaUfgCfcagusc 1010 UCAUCAUUGAAAAUGCCAGUC1409 AM13700-AS asAfsasGfacaguuuCfaUfcAfuugasc 1011AAAGACAGUUUCAUCAUUGAC 1410 AM13702-AS asAfscsacaaguaaCfcUfcAfuccusc 1012AACACAAGUAACCUCAUCCUC 1411 AM13704-AS asGfsascaacauugUfcAfgCfuucasg 1013AGACAACAUUGUCAGCUUCAG 1412 AM13706-AS usCfsasacaucuuuGfcAfaUfaaagsc 1014UCAACAUCUUUGCAAUAAAGC 1413 AM13708-AS asGfsasUfuagucuuAfcAfaAfuccusc1015 AGAUUAGUCUUACAAAUCCUC 1414 AM13710-ASusCfsusUfauuccaaAfcUfuAfgucgsg 1016 UCUUAUUCCAAACUUAGUCGG 1415AM13712-AS usCfsasGfaaaagaaAfgUfgUfgaagsc 1017 UCAGAAAAGAAAGUGUGAAGC1416 AM13714-AS usAfsgsAfguuugucUfcAfaAfgcugsc 1018UAGAGUUUGUCUCAAAGCUGC 1417 AM13716-AS usUfsgsUfuaagcagUfcAfaUfuUfcusc1019 UUGUUAAGCAGUCAAUUUCUC 1418 AM13718-ASusUfsgsGfaaaucugGfaUfaCfuacgsg 1020 UUGGAAAUCUGGAUACUACGG 1419AM13720-AS usCfsusUfgaaaaugCfcAfuCfcugcsu 1021 UCUUGAAAAUGCCAUCCUGCU1420 AM13722-AS asUfsgsAfuuuggauCfaCfaAfuugusc 1022AUGAUUUGGAUCACAAUUGUC 1421 AM13724-AS usAfsgsAfauuacucAfaAfaCfugccsa1023 UAGAAUUACUCAAAACUGCCA 1422 AM13726-ASusGfsasucaaAfAfauGfgAfcUfcagasc 1024 UGAUCAAAAAUGGACUCAGAC 1423AM13728-AS usAfsasGfaaagcauGfcAfgAfucuasg 1025 UAAGAAAGCAUGCAGAUCUAG1424 AM13730-AS usCfsasgauauaagCfuCfuCfugaasg 1026 UCAGAUAUAAGCUCUCUGAAG1425 AM13747-AS usAfsusGfaagccaaCfcUfuGfuAfucsc 1027UAUGAAGCCAACCUUGUAUCC 1366 AM13748-AS usAfsusGfaagccaaCfcUfuGfuaucsc1028 UAUGAAGCCAACCUUGUAUCC 1366 AM13749-ASusAfsusGfaagC_(UNA)caaCfcUfuGfuaucsc 1029 UAUGAAGCCAACCUUGUAUCC 1366AM13753-AS usAfsusGfaagucaaCfcUfuGfuaucsc 1030 UAUGAAGUCAACCUUGUAUCC1426 AM13754-AS usAfsusGfaagcuaaCfcUfuGfuaucsc 1031UAUGAAGCCAACCUUGUAUCC 1427 AM13755-AS cPrpusAfsusGfaagccaaCfcUfuGfuaucsc1032 UAUGAAGCCAACCUUGUAUCC 1366 AM13758-ASusCfsusUfcaugaagCfcAfaCfcuugsc 1033 UCUUCAUGAAGCCAACCUUGC 1367AM13759-AS cPrpusCfsusUfcaugaagCfcAfaCfcuugsc 1034 UCUUCAUGAAGCCAACCUUGC1367 AM13761-AS usCfsusUfcaU_(UNA)gaagCfcAfaCfcuugsc 1035UCUUCAUGAAGCCAACCUUGC 1367 AM13858-AS usGfsgsAfuCfugcauUfuUfuCfuCfcasc1036 UGGAUCUGCAUUUUUCUCCAC 1428 AM13860-ASusCfscsAfaAfaggguUfgUfcUfcUfggsa 1037 UCCAAAAGGGUUGUCUCUGGA 1429AM13862-AS usAfsgsAfcGfaucauAfcUfuGfgAfgasg 1038 UAGACGAUCAUACUUGGAGAG1430 AM13864-AS usCfscsUfaUfuccuuCfcAfcAfgUfugsc 1039UCCUAUUCCUUCCACAGUUGC 1431 AM13866-AS usAfscsAfuAfcucauGfaCfgAfuGfccsa1040 UACAUACUCAUGACGAUGCCA 1432 AM13868-ASusCfsasCfaGfauuucCfuUfgGfaAfggsc 1041 UCACAGAUUUCCUUGGAAGGC 1433AM13870-AS usGfsasAfcUfucaucUfcAfaUfgCfcasc 1042 UGAACUUCAUCUCAAUGCCAC1434 AM13872-AS asGfscsAfuAfuucuuGfaAfcUfuCfausc 1043AGCAUAUUCUUGAACUUCAUC 1435 AM13874-AS usCfsasUfaGfgaaacAfgCfaUfaUfucsc1044 UCAUAGGAAACAGCAUAUUCC 1436 AM13876-ASusGfsgsAfuCfucuauGfgAfgAfgCfagsc 1045 UGGAUCUCUAUGGAGAGCAGC 1437AM13878-AS usUfsusGfaAfugcugAfgAfaAfuAfcusc 1046 UUUGAAUGCUGAGAAAUACUC1438 AM13880-AS usCfsusAfuGfgacuuGfaUfcUfuGfgcsg 1047UCUAUGGACUUGAUCUUGGCG 1439 AM13882-AS asUfsgsAfaAfcaaacAfaAfcCfcUfggsa1048 AUGAAACAAACAAACCCUGGA 1440 AM13884-ASusGfsgsUfaGfuucuuCfaUfaGfgUfgasc 1049 UGGUAGUUCUUCAUAGGUGAC 1441AM13886-AS usGfsasUfaAfuggcuGfgUfaGfuUfcusc 1050 UGAUAAUGGCUGGUAGUUCUC1442 AM13888-AS usCfsusCfaAfuugugAfuAfaUfgGfcusg 1051UCUCAAUUGUGAUAAUGGCUG 1443 AM13890-AS usCfsusUfuCfucgauCfuUfcAfgCfucsa1052 UCUUUCUCGAUCUUCAGCUCA 1444 AM13892-ASusUfsusGfgAfacagcAfaUfgGfuGfcasg 1053 UUUGGAACAGCAAUGGUGCAG 1445AM13894-AS usGfsusAfgAfcacaaAfgAfgCfuCfcasc 1054 UGUAGACACAAAGAGCUCCAC1446 AM13896-AS usCfsusGfuGfuagacAfcAfaAfgAfgcsu 1055UCUGUGUAGACACAAAGAGCU 1447 AM13898-AS usUfscsCfaUfaauacUfcUfgAfgAfgasg1056 UUCCAUAAUACUCUGAGAGAG 1448 AMI3900-ASusCfsusCfgUfuccauAfaUfaCfuCfugsc 1057 UCUCGUUCCAUAAUACUCUGC 1449AM14175-AS cPrpusUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1058UUGAAACAAACAAACCCUGGA 1450 AM14176-AScPrpusUfscsCfaUfaauacUfcUfgAfgAfgasg 1059 UUCCAUAAUACUCUGAGAGAG 1448AM14204-AS asAfsusGfaaacaaaCfaAfaCfccugsg 1060 AAUGAAACAAACAAACCCUGG1451 AM14206-AS asAfsasUfgaaacaaAfcAfaAfcccusg 1061AAAUGAAACAAACAAACCCUG 1452 AM14208-AS usGfsasAfaugaaacAfaAfcAfaaccsc1062 UGAAAUGAAACAAACAAACCC 1453 AM14209-ASusUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1063 UUGAAACAAACAAACCCUGGA 1450AM14210-AS cPrpusUfsgsAfaacaaacAfaAfcCfcuggsa 1064 UUGAAACAAACAAACCCUGGA1450 AM14211-AS cPrpuUfgAfaacaaacAfaAfcCfcuggsa 1065UUGAAACAAACAAACCCUGGA 1450 AM14212-AS cPrpuUfgAfaacaaacAfaAfcCfcugsgsa1066 UUGAAACAAACAAACCCUGGA 1450 AM14216-ASasGfsasCfgaucauaCfuUfgGfagagsc 1067 AGACGAUCAUACUUGGAGAGC 1454AM14218-AS asAfsgsGfcauucucAfaUfcUfccucsc 1068 AAGGCAUUCUCAAUCUCCUCC1455 AM14220-AS usUfsusCfcuuggaaGfgCfaUfucucsg 1069UUUCCUUGGAAGGCAUUCUCG 1456 AM14222-AS usAfsgsAfuuuccuuGfgAfaGfgcausc1070 UAGAUUUCCUUGGAAGGCAUC 1457 AM14224-ASasUfsasGfgaaacagCfaUfaUfucuusg 1071 AUAGGAAACAGCAUAUUCUUG 1458AM14226-AS usUfsgsAfugauguuCfcCfuCfcaacsg 1072 UUGAUGAUGUUCCCUCCAACG1459 AM14228-AS usAfsgsAfacuugaaGfaAfgAfagcusg 1073UAGAACUUGAAGAAGAAGCUG 1460 AM14230-AS usAfscsCfaaugauaUfgCfcCfaacasc1074 UACCAAUGAUAUGCCCAACAC 1461 AM14232-ASusCfsasUfggU_(UNA)guucUfgUfgUfagacsg 1075 UCAUGGUGUUCUGUGUAGACG 1462AM14234-AS usUfsgsAfgagagauCfcUfgGfgugusc 1076 UUGAGAGAGAUCCUGGGUGUC1463 AM14236-AS usCfsasUfgauacugAfgAfgCfuugcsu 1077UCAUGAUACUGAGAGCUUGCU 1464 AM14238-AS usUfsgsUfcaaccucAfcUfcUfuccgsa1078 UUGUCAACCUCACUCUUCCGA 1465 AM14240-ASusUfsusCfcaacaauUfcUfcCfuugusc 1079 UUUCCAACAAUUCUCCUUGUC 1466AM14242-AS usUfsgsAfguuagucUfcAfaAfgcugsc 1080 UUGAGUUAGUCUCAAAGCUGC1467 AM14244-AS asUfsgsAfcaauaucUfgUfgCfggagsg 1081AUGACAAUAUCUGUGCGGAGG 1468 AM14246-AS usCfsasUfgacaauaUfcUfgUfgcggsa1082 UCAUGACAAUAUCUGUGCGGA 1469 AM14248-ASusCfsasAfagaagauAfgAfaGfcagcsc 1083 UCAAAGAAGAUAGAAGCAGCC 1470AM14250-AS usCfsasCfguuauuaCfcUfgUfgugcsu 1084 UCACGUUAUUACCUGUGUGCU1471 AM14252-AS usAfsgsAfacuugagGfuUfaUfacagsg 1085UAGAACUUGAGGUUAUACAGG 1472 AM14254-AS asUfsgsCfuuugcugUfuCfaUfuggusc1086 AUGCUUUGCUGUUCAUUGGUC 1473 AM14256-ASusAfsgsUfauagauuCfaAfgGfuuausg 1087 UAGUAUAGAUUCAAGGUUAUG 1474AM14258-AS asGfsasGfuaaucuuGfcUfuUfaugcsc 1088 AGAGUAAUCUUGCUUUAUGCC1475 AM14260-AS asUfsasGfcaucauuUfcUfaGfguggsa 1089AUAGCAUCAUUUCUAGGUGGA 1476 AM14262-AS asGfsasCfagaagagAfcAfgAfgcuasg1090 AGACAGAAGAGACAGAGCUAG 1477 AM14264-ASasGfsusAfagaaaacCfaAfgCfcuuasg 1091 AGUAAGAAAACCAAGCCUUAG 1478AM14280-AS usUfscsCfauaauacUfcUfgAfgagasg 1092 UUCCAUAAUACUCUGAGAGAG1448 AM14281-AS cPrpusUfscsCfauaauacUfcUfgAfgagasg 1093UUCCAUAAUACUCUGAGAGAG 1448 AM14282-AS cPrpuUfcCfauaauacUfcUfgAfgagasg1094 UUCCAUAAUACUCUGAGAGAG 1448 AM14283-AScPrpuUfcCfauaauacUfcUfgAfgagsasg 1095 UUCCAUAAUACUCUGAGAGAG 1448AM14285-AS cPrpuUfccauaaUfacUfcUfgAfgagasg 1096 UUCCAUAAUACUCUGAGAGAG1448 AM14288-AS usAfsusAfcuuggagAfgCfaUfcacusg 1097UAUACUUGGAGAGCAUCACUG 1479 AM14290-AS usUfsgsCfagacgauCfaUfaCfuuggsc1098 UUGCAGACGAUCAUACUUGGC 1480 AM14292-ASusUfsgsAfaUfaaaacUfcUfcAfugccsa 1099 UUGAAUAAAACUCUCAUGCCA 1481AM14293-AS cPrpusUfsgsAfaUfaaaacUfcUfcAfugccsa 1100UUGAAUAAAACUCUCAUGCCA 1482 AM14296-ASusAfscsUfuGfaAfgAfaGfaAfgCfuGfaGfsg 1101 UACUUGAAGAAGAAGCUGAGG 1482AM14297-AS usAfscsUfugaagaaGfaAfgCfugagsg 1102 UACUUGAAGAAGAAGCUGAGG1482 AM14298-AS cPrpusAfscsUfugaagaaGfaAfgCfugagsg 1103UACUUGAAGAAGAAGCUGAGG 1482 AM14299-AS cPrpuAfcUfugaagaaGfaAfgCfugagsg1104 UACUUGAAGAAGAAGCUGAGG 1482 AM14301-AScPrpuAfcUfugaagaaGfaAfgCfugasgsg 1105 UACUUGAAGAAGAAGCUGAGG 1482AM14304-AS cPrpuAfcuugAfagaaGfaAfgCfugagsg 1106 UACUUGAAGAAGAAGCUGAGG1482 AM14305-AS cPrpuAfcuugaaGfaaGfaAfgCfugagsg 1107UACUUGAAGAAGAAGCUGAGG 1482 AM14383-AScPrpusUfsusGfaAfugcugAfgAfaAfuAfcusc 1108 UUUGAAUGCUGAGAAAUACUC 1438AM14384-AS cPrpusUfsusGfaaugcugAfgAfaAfuacusc 1109 UUUGAAUGCUGAGAAAUACUC1438 AM14385-AS cPrpusUfsusgaaUfgcugAfgAfaAfuacusc 1110UUUGAAUGCUGAGAAAUACUC 1438 AM14387-AS cPrpuUfuGfaaugcugAfgAfaAfuacusc1111 UUUGAAUGCUGAGAAAUACUC 1438 AM14388-AScPrpuUfuGfaaugcugAfgAfaAfuacsusc 1112 UUUGAAUGCUGAGAAAUACUC 1438AM14391-AS asGfsasAfaAfguggaCfgAfuCfuUfgusc 1113 AGAAAAGUGGACGAUCUUGUC1483 AM14393-AS usAfsgsUfuGfucacuGfcAfaCfaUfggsu 1114UAGUUGUCACUGCAACAUGGU 1484 AM14395-AS asUfsusCfcUfuccacAfgUfuGfuCfacsc1115 AUUCCUUCCACAGUUGUCACC 1485 AM14397-ASusGfscsAfuUfcucaaUfcUfcCfuCfcasc 1116 UGCAUUCUCAAUCUCCUCCAC 1486AM14399-AS usUfscsAfaUfgccaaUfcUfcCfgUfgusc 1117 UUCAAUGCCAAUCUCCGUGUC1487 AM14401-AS asUfsasUfuCfuugaaCfuUfcAfuCfucsg 1118AUAUUCUUGAACUUCAUCUCG 1488 AM14403-AS usUfsasUfgGfagagcAfgUfaUfcUfccsu1119 UUAUGGAGAGCAGUAUCUCCU 1489 AM14405-ASusAfsasUfgCfugagaAfaUfaCfuCfccsc 1120 UAAUGCUGAGAAAUACUCCCC 1490AM14407-AS usGfsasAfuGfcugagAfaAfuAfcUfccsc 1121 UGAAUGCUGAGAAAUACUCCC1491 AM14409-AS usCfsasAfuGfucaucUfuCfuCfuCfcgsg 1122UCAAUGUCAUCUUCUCUCCGG 1492 AM14411-AS asCfsasAfaUfuccagUfuAfuGfuUfacsc1123 ACAAAUUCCAGUUAUGUUACC 1493 AM14413-ASusUfscsAfaUfugugaUfaAfuGfgCfugsg 1124 UUCAAUUGUGAUAAUGGCUGG 1494AM14415-AS asAfscsAfuUfuuugcAfaCfaAfaGfcusc 1125 AACAUUUUUGCAACAAAGCUC1495 AM14417-AS usCfsasAfcAfuuuuuGfcAfaCfaAfagsc 1126UCAACAUUUUUGCAACAAAGC 1496 AM14419-AS usUfsusCfaCfucgaaCfcAfcAfaUfccsg1127 UUUCACUCGAACCACAAUCCG 1497 AM14522-AScPrpusCfsusUfaUfuccaaAfcUfuGfgUfggsg 1128 UCUUAUUCCAAACUUGGUGGG 1377AM14523-AS cPrpuCfuUfaUfuccaaAfcUfuGfgUfggsg 1129 UCUUAUUCCAAACUUGGUGGG1377 AM14524-AS cPrpuCfuuauucCfaaAfcUfuGfguggsg 1130UCUUAUUCCAAACUUGGUGGG 1377 AM14527-AS cPrpuGfcauauucacCfaUfuUfaggcsa1131 UGCAUAUUCACCAUUUAGGCA 1397 AM14529-AScPrpuGfcauaUfucacCfaUfuUfaggcsa 1132 UGCAUAUUCACCAUUUAGGCA 1397AM14530-AS cPrpuGfcauauuCfacCfaUfuUfaggcsa 1133 UGCAUAUUCACCAUUUAGGCA1397 AM14543-AS usGfscauauucacCfaUfuUfaggcsa 1134 UGCAUAUUCACCAUUUAGGCA1397 AM14544-AS usGfscauaUfucacCfaUfuUfaggcsa 1135 UGCAUAUUCACCAUUUAGGCA1397 AM14545-AS usGfscauauuCfacCfaUfuUfaggcsa 1136 UGCAUAUUCACCAUUUAGGCA1397 AM14642-AS cPrpasUfsgsAfaacaaacAfaAfcCfcuggsa 1137AUGAAACAAACAAACCCUGGA 1440 AM14643-AScPrpasUfsgsAfaacaaacAfaAfcCfcugsgsa 1138 AUGAAACAAACAAACCCUGGA 1440AM14644-AS cPrpasUfsgAfaacaaacAfaAfcCfcugsgsa 1139 AUGAAACAAACAAACCCUGGA1440 AM14645-AS cPrpaUfgAfaacaaacAfaAfcCfcugsgsa 1140AUGAAACAAACAAACCCUGGA 1440 AM14647-AS cPrpasUfsgaaacaAfacAfaAfcCfcugsgsa1141 AUGAAACAAACAAACCCUGGA 1440 AM14648-AScPrpasUfsgaaaCfaaacAfaAfcCfcugsgsa 1142 AUGAAACAAACAAACCCUGGA 1440AM14649-AS cPrpasUfsgaAfacaaacAfaAfcCfcugsgsa 1143 AUGAAACAAACAAACCCUGGA1440 AM14650-AS cPrpasUfsgAfaaCfaAfacAfaAfcCfcugsgsa 1144AUGAAACAAACAAACCCUGGA 1440 AM15134-AS cPrpusUfscCfauaauacUfcUfgAfgagasg1145 UUCCAUAAUACUCUGAGAGAG 1448 AM15135-AScPrpusUfscCfauaauacUfcUfgAfgagsasg 1146 UUCCAUAAUACUCUGAGAGAG 1448AM15137-AS cPrpuUfcCfauaauacUfcUfgAfgagasc 1147 UUCCAUAAUACUCUGAGAGAG1498 AM15139-AS cPrpuUfcCfauaauacUfcUfgAfgaggsg 1148UUCCAUAAUACUCUGAGAGGG 1499 AM15141-AS cPrpuUfcCfauaauacUfcUfgAfgaggsc1149 UUCCAUAAUACUCUGAGAGGC 1500 AM15143-AScPrpuUfcCfauaauacUfcUfgAfgaggsu 1150 UUCCAUAAUACUCUGAGAGGU 1501AM15145-AS cPrpuUfcCfauaauacUfcUfgAfgaggsa 1151 UUCCAUAAUACUCUGAGAGGA1502 AM15146-AS cPrpuUfccauAfauacUfcUfgAfgagasg 1152UUCCAUAAUACUCUGAGAGAG 1448 AM15147-AS cPrpusGfscsauauuCfacCfaUfuUfaggcsa1153 UGCAUAUUCACCAUUUAGGCA 1397 AM15148-AScPrpusGfscauauuCfacCfaUfuUfaggcsa 1154 UGCAUAUUCACCAUUUAGGCA 1397AM15149-AS cPrpusGfscauauuCfacCfaUfuUfaggscsa 1155 UGCAUAUUCACCAUUUAGGCA1397 AM15150-AS cPrpuGfcauauuCfacCfaUfuUfaggscsa 1156UGCAUAUUCACCAUUUAGGCA 1397 AM15151-AS cPrpusGfscsauaUfucacCfaUfuUfaggcsa1157 UGCAUAUUCACCAUUUAGGCA 1397 AM15152-AScPrpusGfscauaUfucacCfaUfuUfaggcsa 1158 UGCAUAUUCACCAUUUAGGCA 1397AM15153-AS cPrpusGfscauaUfucacCfaUfuUfaggscsa 1159 UGCAUAUUCACCAUUUAGGCA1397 AM15154-AS cPrpuGfcauaUfucacCfaUfuUfaggscsa 1160UGCAUAUUCACCAUUUAGGCA 1397 AM15285-AS asUfsgsacaAfuaucUfgUfgCfggagsg1161 AUGACAAUAUCUGUGCGGAGG 1468 AM15286-ASasUfsgsacaauAfucUfgUfgCfggagsg 1162 AUGACAAUAUCUGUGCGGAGG 1468AM15287-AS cPrpasUfsgsacaauAfucUfgUfgCfggagsg 1163 AUGACAAUAUCUGUGCGGAGG1468 AM15289-AS cPrpusUfsgsacaauAfucUfgUfgCfggagsg 1164UUGACAAUAUCUGUGCGGAGG 1503 AM15290-AS cPrpaUfgacaauAfucUfgUfgCfggagsg1165 AUGACAAUAUCUGUGCGGAGG 1468 AM15291-AScPrpaUfgacaauAfucUfgUfgCfggasgsg 1166 AUGACAAUAUCUGUGCGGAGG 1468AM15292-AS cPrpasUfsgacaauAfucUfgUfgCfggasgsg 1167 AUGACAAUAUCUGUGCGGAGG1468 AM15294-AS cPrpasUfsgsacaauAfucUfgUfgCfggasg 1168AUGACAAUAUCUGUGCGGAG 1504 AM15296-AS cPrpasUfsgsacaauAfucUfgUfgCfggsa1169 AUGACAAUAUCUGUGCGGA 1505 AM15606-AScPrpusUfsccauaaUfacUfcUfgAfgagsasg 1170 UUCCAUAAUACUCUGAGAGAG 1448AM15607-AS cPrpusUfscCfauaauacUfcUfgAfgagsasc 1171 UUCCAUAAUACUCUGAGAGAC1498 AM15608-AS cPrpusUfsgaaaCfaaacAfaAfcCfcugsgsa 1172UUGAAACAAACAAACCCUGGA 1450 AM15626-AS asUfsgAfaAfcaaacAfaAfcCfcUfgsgsa1173 AUGAAACAAACAAACCCUGGA 1440 AM15627-ASasUfsgAfaacaaacAfaAfcCfcugsgsa 1174 AUGAAACAAACAAACCCUGGA 1440AM17243-AS asCfsucgUfuccauaaUfaCfucugasgsa 1672 ACUCGUUCCAUAAUACUCUGAGA1674 AM17245-AS asUfsccaUfaauacucUfgAfgagagsasu 1673AUCCAUAAUACUCUGAGAGAGAU 1675

TABLE 4 XDH RNAi Agent Sense Strand Sequences Underlying Base SequenceSense SEQ (5′→3′) SEQ Strand Modified Sense Strand ID(Shown as an Unmodified ID ID: (5′→3′) NO. Nucleotide Sequence) NO.AM13028-SS (NAG37)s(invAb)sgagauugaGfAfAfugccuuccaas(invAb) 1175GAGAUUGAGAAUGCCUUCCAA 1506 AM13030-SS(NAG37)s(invAb)sgagauuGfaGfAfAfugccuuccaas(invAb) 1176GAGAUUGAGAAUGCCUUCCAA 1506 AM13032-SS(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguus(invAb) 1177CCUCAGCUUCUUCUUCAAGUU 1507 AM13034-SS(NAG37)s(invAb)sgcagcuucUfUfCfuucaaguucus(invAb) 1178GCAGCUUCUUCUUCAAGUUCU 1508 AM13036-SS(NAG37)s(invAb)sgcuucuucUfUfCfaaguucuacas(invAb) 1179GCUUCUUCUUCAAGUUCUACA 1509 AM13038-SS(NAG37)s(invAb)saggggugaAfAfAfucaccuaugas(invAb) 1180AGGGGUGAAAAUCACCUAUGA 1510 AM13040-SS(NAG37)s(invAb)sgggugaaaAfUfCfaccuaugaaas(invAb) 1181GGGUGAAAAUCACCUAUGAAA 1511 AM13042-SS(NAG37)s(invAb)sggugaaaaUfCfAfccuaugaagas(invAb) 1182GGUGAAAAUCACCUAUGAAGA 1512 AM13044-SS(NAG37)s(invAb)sgugaaaauCfAfCfcuaugaagaas(invAb) 1183GUGAAAAUCACCUAUGAAGAA 1513 AM13046-SS(NAG37)s(invAb)scuaccagcCfAfUfuaucacaauus(invAb) 1184CUACCAGCCAUUAUCACAAUU 1514 AM13048-SS(NAG37)s(invAb)sgaagaacaAfCfUfccuuuuaugas(invAb) 1185GAAGAACAACUCCUUUUAUGA 1515 AM13050-SS(NAG37)s(invAb)sgagaacaaCfUfCfcuuuuauggas(invAb) 1186GAGAACAACUCCUUUUAUGGA 1516 AM13052-SS(NAG37)s(invAb)sgagacaagCfAfCfuaacacuguas(invAb) 1187GAGACAAGCACUAACACUGUA 1517 AM13054-SS(NAG37)s(invAb)sucgucaugAfGfUfauguacacaas(invAb) 1188UCGUCAUGAGUAUGUACACAA 1518 AM13056-SS(NAG37)s(invAb)saggacaugCfUfGfauaacugiuas(invAb) 1189AGGACAUGCUGAUAACUGIUA 1519 AM13058-SS(NAG37)s(invAb)sggauacaaGfGfUfuggcuucauas(invAb) 1190GGAUACAAGGUUGGCUUCAUA 1520 AM13060-SS(NAG37)s(invAb)sgcaagguuGfGfCfuucaugaagas(invAb) 1191GCAAGGUUGGCUUCAUGAAGA 1521 AM13062-SS(NAG37)s(invAb)scaagguugGfCfUfucaugaagaas(invAb) 1192CAAGGUUGGCUUCAUGAAGAA 1522 AM13064-SS(NAG37)s(invAb)sagguuggcUfUfCfaugaagacuas(invAb) 1193AGGUUGGCUUCAUGAAGACUA 1523 AM13066-SS(NAG37)s(invAb)saggagaauUfGfUfuggaaaaagas(invAb) 1194AGGAGAAUUGUUGGAAAAAGA 1524 AM13068-SS(NAG37)s(invAb)sguggcuugCfUfCfugaaguagaas(invAb) 1195GUGGCUUGCUCUGAAGUAGAA 1525 AM13070-SS(NAG37)s(invAb)sgcuugcucUfGfAfaguagaaauas(invAb) 1196GCUUGCUCUGAAGUAGAAAUA 1526 AM13072-SS(NAG37)s(invAb)scccugccaUfUfGfauauuigacas(invAb) 1197CCCUGCCAUUGAUAUUIGACA 1527 AM13163-SS(NAG37)s(invAb)scaagaucgUfCfCfacuuuucugas(invAb) 1198CAAGAUCGUCCACUUUUCUGA 1528 AM13165-SS(NAG37)s(invAb)sguccgaagCfAfGfauaauguugus(invAb) 1199GUCCGAAGCAGAUAAUGUUGU 1529 AM13167-SS(NAG37)s(invAb)sgucucucuCfAfGfaguauuaugas(invAb) 1200GUCUCUCUCAGAGUAUUAUGA 1530 AM13169-SS(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201CCCACCAAGUUUGGAAUAAGA 1531 AM13171-SS(NAG37)s(invAb)scugcauaaAfGfCfaagauuacuas(invAb) 1202CUGCAUAAAGCAAGAUUACUA 1532 AM13173-SS(NAG37)s(invAb)sgacaauguUfCfUfagauuucuuus(invAb) 1203GACAAUGUUCUAGAUUUCUUU 1533 AM13175-SS(NAG37)s(invAb)scaagaucgUfcCfaCfuuuucugas(invAb) 1204CAAGAUCGUCCACUUUUCUGA 1528 AM13178-SS(NAG37)s(invAb)sgucucucuCfaGfaGfuauuaugas(invAb) 1205GUCUCUCUCAGAGUAUUAUGA 1530 AM13180-SS(NAG37)s(invAb)sgaaaauguUfCfUfagauuucuuus(invAb) 1206GAAAAUGUUCUAGAUUUCUUU 1534 AM13599-SS(NAG37)s(invAb)sagugcuggAfUfGfagugaaguuas(invAb) 1207AGUGCUGGAUGAGUGAAGUUA 1535 AM13601-SS(NAG37)s(invAb)sgugcuigaUfGfAfgugaaguugas(invAb) 1208GUGCUIGAUGAGUGAAGUUGA 1536 AM13603-SS(NAG37)s(invAb)sugcuggauGfAfGfugaaguuicas(invAb) 1209UGCUGGAUGAGUGAAGUUICA 1537 AM13647-SS(NAG37)s(invAb)sgaugcucuCfcAfaGfuaugaucas(invAb) 1210GAUGCUCUCCAAGUAUGAUCA 1538 AM13649-SS(NAG37)s(invAb)sgugaucguCfuGfcAfgaacaagas(invAb) 1211GUGAUCGUCUGCAGAACAAGA 1539 AM13651-SS(NAG37)s(invAb)sgucgucugCfaGfaAfcaagaucas(invAb) 1212GUCGUCUGCAGAACAAGAUCA 1540 AM13653-SS(NAG37)s(invAb)sgucgccagUfgCfaAfcuuuacuas(invAb) 1213GUCGCCAGUGCAACUUUACUA 1541 AM13655-SS(NAG37)s(invAb)saggauaAfgGfuUfacuuguguuas(invAb) 1214AGGAUAAGGUUACUUGUGUUA 1542 AM13657-SS(NAG37)s(invAb)saccagccaUfuAfuCfacaauugas(invAb) 1215ACCAGCCAUUAUCACAAUUGA 1543 AM13659-SS(NAG37)s(invAb)scaagcucuCfaGfuAfucaugcuas(invAb) 1216CAAGCUCUCAGUAUCAUGCUA 1544 AM13661-SS(NAG37)s(invAb)sgaagagugAfgGfuUfgacaaguus(invAb) 1217GAAGAGUGAGGUUGACAAGUU 1545 AM13663-SS(NAG37)s(invAb)sgagagugaGfGfUfugacaaguuas(invAb) 1218GAGAGUGAGGUUGACAAGUUA 1546 AM13665-SS(NAG37)s(invAb)sguucaacaAfGfGfagaauuguuas(invAb) 1219GUUCAACAAGGAGAAUUGUUA 1547 AM13667-SS(NAG37)s(invAb)sggaacaUfaCfcAfcagaacaugas(invAb) 1220GGAACAUACCACAGAACAUGA 1548 AM13669-SS(NAG37)s(invAb)sgaacauggAfuCfuAfuuaaaguas(invAb) 1221GAACAUGGAUCUAUUAAAGUA 1549 AM13671-SS(NAG37)s(invAb)sgacauggaUfcUfaUfuaaagucas(invAb) 1222GACAUGGAUCUAUUAAAGUCA 1550 AM13673-SS(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223UGCCUAAAUGGUGAAUAUGCA 1551 AM13675-SS(NAG37)s(invAb)sgaaccucuAfGfAfagcuuaaacas(invAb) 1224GAACCUCUAGAAGCUUAAACA 1552 AM13677-SS(NAG37)s(invAb)sggccuucaAfaCfcAfaugaacaas(invAb) 1225GGCCUUCAAACCAAUGAACAA 1553 AM13679-SS(NAG37)s(invAb)sccaaugAfaCfaGfcaaagcauaas(invAb) 1226CCAAUGAACAGCAAAGCAUAA 1554 AM13681-SS(NAG37)s(invAb)sgaugaacaGfcAfAfagcauaacas(invAb) 1227GAUGAACAGCAAAGCAUAACA 1555 AM13683-SS(NAG37)s(invAb)sgugaacagCfAfAfagcauaaccus(invAb) 1228GUGAACAGCAAAGCAUAACCU 1556 AM13685-SS(NAG37)s(invAb)sgaacagcaAfaGfcAfuaaccuuas(invAb) 1229GAACAGCAAAGCAUAACCUUA 1557 AM13687-SS(NAG37)s(invAb)sgcaaagcaUfAfAfccuugaaucus(invAb) 1230GCAAAGCAUAACCUUGAAUCU 1558 AM13689-SS(NAG37)s(invAb)sccaaccaaCfuCfaAfuuauugaas(invAb) 1231CCAACCAACUCAAUUAUUGAA 1559 AM13691-SS(NAG37)s(invAb)scuuccuguGfAfUfccauuuuacus(invAb) 1232CUUCCUGUGAUCCAUUUUACU 1560 AM13693-SS(NAG37)s(invAb)sgguuuucuUfAfCfugucauaugas(invAb) 1233GGUUUUCUUACUGUCAUAUGA 1561 AM13695-SS(NAG37)s(invAb)sgagaucgaGfAfAfugccuuccaas(invAb) 1234GAGAUCGAGAAUGCCUUCCAA 1562 AM13697-SS(NAG37)s(invAb)sgacuggcaUfUfUfucaaugaugas(invAb) 1235GACUGGCAUUUUCAAUGAUGA 1563 AM13699-SS(NAG37)s(invAb)sgucaaugaUfGfAfaacugucuuus(invAb) 1236GUCAAUGAUGAAACUGUCUUU 1564 AM13701-SS(NAG37)s(invAb)sgaggaugaGfGfUfuacuuguguus(invAb) 1237GAGGAUGAGGUUACUUGUGUU 1565 AM13703-SS(NAG37)s(invAb)scugaagcuGfAfCfaauguugucus(invAb) 1238CUGAAGCUGACAAUGUUGUCU 1566 AM13705-SS(NAG37)s(invAb)sgcuuuauuGfCfAfaagauguugas(invAb) 1239GCUUUAUUGCAAAGAUGUUGA 1567 AM13707-SS(NAG37)s(invAb)sgaggauuuGfUfAfagacuaaucus(invAb) 1240GAGGAUUUGUAAGACUAAUCU 1568 AM13709-SS(NAG37)s(invAb)sccgacuaaGfUfUfuggaauaagas(invAb) 1241CCGACUAAGUUUGGAAUAAGA 1569 AM13711-SS(NAG37)s(invAb)sgcuucacaCfUfUfucuuuucugas(invAb) 1242GCUUCACACUUUCUUUUCUGA 1570 AM13713-SS(NAG37)s(invAb)sgcagcuuuGfAfGfacaaacucuas(invAb) 1243GCAGCUUUGAGACAAACUCUA 1571 AM13715-SS(NAG37)s(invAb)sgagaaauuGfAfCfugcuuaacaas(invAb) 1244GAGAAAUUGACUGCUUAACAA 1572 AM13717-SS(NAG37)s(invAb)sccguaguaUfCfCfagauuuccaas(invAb) 1245CCGUAGUAUCCAGAUUUCCAA 1573 AM13719-SS(NAG37)s(invAb)sagcaggauGfGfCfauuuucaagas(invAb) 1246AGCAGGAUGGCAUUUUCAAGA 1574 AM13721-SS(NAG37)s(invAb)sgacaauugUfGfAfuccaaaucaus(invAb) 1247GACAAUUGUGAUCCAAAUCAU 1575 AM13723-SS(NAG37)s(invAb)suggcaguuUfUfGfaguaauucuas(invAb) 1248UGGCAGUUUUGAGUAAUUCUA 1576 AM13725-SS(NAG37)s(invAb)sgucugaguCfCfAfuuuuugaucas(invAb) 1249GUCUGAGUCCAUUUUUGAUCA 1577 AM13727-SS(NAG37)s(invAb)scuagaucuGfCfAfugcuuucuuas(invAb) 1250CUAGAUCUGCAUGCUUUCUUA 1578 AM13729-SS(NAG37)s(invAb)scuucagagAfGfCfuuauaucugas(invAb) 1251CUUCAGAGAGCUUAUAUCUGA 1579 AM13746-SS(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252GGAUACAAGGUUGGCUUCAUA 1520 AM13750-SS(NAG37)s(invAb)sggauacAfaGfgUfugicuucauas(invAb) 1253GGAUACAAGGUUGICUUCAUA 1580 AM13751-SS(NAG37)s(invAb)sggauacAfaGfgUfuigcuucauas(invAb) 1254GGAUACAAGGUUIGCUUCAUA 1581 AM13752-SS(NAG37)s(invAb)sggauacAfaGfgUfugguuucauas(invAb) 1255GGAUACAAGGUUGGUUUCAUA 1582 AM13756-SS(NAG37)s(invAb)sggauacaaGfgUfUfggcuucauas(invAb) 1256GGAUACAAGGUUGGCUUCAUA 1520 AM13757-SS(NAG37)s(invAb)sggauacaaGfgUfuGfgcuucauas(invAb) 1257GGAUACAAGGUUGGCUUCAUA 1520 AM13760-SS(NAG37)s(invAb)sgcaagguuGfgCfuUfcaugaagas(invAb) 1258GCAAGGUUGGCUUCAUGAAGA 1521 AM13857-SS(NAG37)s(invAb)sguggagaaAfAfAfugcaiauccas(invAb) 1259GUGGAGAAAAAUGCAIAUCCA 1583 AM13859-SS(NAG37)s(invAb)succagagaCfAfAfcucuuuuggas(invAb) 1260UCCAGAGACAACUCUUUUGGA 1584 AM13861-SS(NAG37)s(invAb)scucuccaaGfUfAfugauciucuas(invAb) 1261CUCUCCAAGUAUGAUCIUCUA 1585 AM13863-SS(NAG37)s(invAb)sgcaacuguGfGfAfaggaauaggas(invAb) 1262GCAACUGUGGAAGGAAUAGGA 1586 AM13865-SS(NAG37)s(invAb)suggcaucgUfCfAfugaguauguas(invAb) 1263UGGCAUCGUCAUGAGUAUGUA 1587 AM13867-SS(NAG37)s(invAb)sgccuuccaAfGfGfaaaucuguias(invAb) 1264GCCUUCCAAGGAAAUCUGUIA 1588 AM13869-SS(NAG37)s(invAb)sguggcauuGfAfGfaugaaguucas(invAb) 1265GUGGCAUUGAGAUGAAGUUCA 1589 AM13871-SS(NAG37)s(invAb)sga_2NugaaguUfCfAfagaauaugcus 1266G(A^(2N))UGAAGUUCAAGAAUAUGCU 1590 (invAb) AM13873-SS(NAG37)s(invAb)sggaauaugCfUfGfuuuccuaugas(invAb) 1267GGAAUAUGCUGUUUCCUAUGA 1591 AM13875-SS(NAG37)s(invAb)sgcugcucuCfCfAfuagaiauccas(invAb) 1268GCUGCUCUCCAUAGAIAUCCA 1592 AM13877-SS(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269GAGUAUUUCUCAGCAUUCAAA 1593 AM13879-SS(NAG37)s(invAb)scgccaagaUfCfAfaguccauagas(invAb) 1270CGCCAAGAUCAAGUCCAUAGA 1594 AM13881-SS(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271UCCAGGGUUUGUUUGUUUCAU 1595 AM13883-SS(NAG37)s(invAb)sgucaccuaUfGfAfagaacuaccas(invAb) 1272GUCACCUAUGAAGAACUACCA 1596 AM13885-SS(NAG37)s(invAb)sgagaacuaCfCfAfgccauuaucas(invAb) 1273GAGAACUACCAGCCAUUAUCA 1597 AM13887-SS(NAG37)s(invAb)scagccauuAfUfCfacaauugagas(invAb) 1274CAGCCAUUAUCACAAUUGAGA 1598 AM13889-SS(NAG37)s(invAb)sugagcugaAfGfAfucgagaaagas(invAb) 1275UGAGCUGAAGAUCGAGAAAGA 1599 AM13891-SS(NAG37)s(invAb)scugcaccaUfUfGfcuguuccaaas(invAb) 1276CUGCACCAUUGCUGUUCCAAA 1600 AM13893-SS(NAG37)s(invAb)sguggagcuCfUfUfuguguuuacas(invAb) 1277GUGGAGCUCUUUGUGUUUACA 1601 AM13895-SS(NAG37)s(invAb)sagcucuuuGfUfGfucuacacaias(invAb) 1278AGCUCUUUGUGUCUACACAIA 1602 AM13897-SS(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279CUCUCUCAGAGUAUUAUGGAA 1603 AM13899-SS(NAG37)s(invAb)sgcagaguaUfUfAfuggaacgaias(invAb) 1280GCAGAGUAUUAUGGAACGAIA 1604 AM14174-SS(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281UCCAGGGUUUGUUUGUUUCAA 1605 AM14203-SS(NAG37)s(invAb)sccaggguuUfGfUfuuguuucauus(invAb) 1282CCAGGGUUUGUUUGUUUCAUU 1606 AM14205-SS(NAG37)s(invAb)scaggguuuGfUfUfuguuucauuus(invAb) 1283CAGGGUUUGUUUGUUUCAUUU 1607 AM14207-SS(NAG37)s(invAb)sggguuuguUfUfGfuuucauuucas(invAb) 1284GGGUUUGUUUGUUUCAUUUCA 1608 AM14213-SS(NAG37)s(invAb)succaggguUfuGfuUfuguuucaas(invAb) 1285UCCAGGGUUUGUUUGUUUCAA 1605 AM14214-SS(NAG37)s(invAb)succaggguUfuGfUfuuguuucaas(invAb) 1286UCCAGGGUUUGUUUGUUUCAA 1605 AM14215-SS(NAG37)s(invAb)sgcucuccaAfGfUfaugauciucus(invAb) 1287GCUCUCCAAGUAUGAUCIUCU 1609 AM14217-SS(NAG37)s(invAb)sggaggagaUfUfGfagaauiccuus(invAb) 1288GGAGGAGAUUGAGAAUICCUU 1610 AM14219-SS(NAG37)s(invAb)scgagaaugCfCfUfuccaaggaaas(invAb) 1289CGAGAAUGCCUUCCAAGGAAA 1611 AM14221-SS(NAG37)s(invAb)sgaugccuuCfCfAfaggaaaucuas(invAb) 1290GAUGCCUUCCAAGGAAAUCUA 1612 AM14223-SS(NAG37)s(invAb)sca_2NagaauaUfGfCfuguuuccuaus 1291C(A^(2N))AGAAUAUGCUGUUUCCUAU 1613 (invAb) AM14225-SS(NAG37)s(invAb)scguuggagGfGfAfacaucaucaas(invAb) 1292CGUUGGAGGGAACAUCAUCAA 1614 AM14227-SS(NAG37)s(invAb)scagcuucuUfCfUfucaaguucuas(invAb) 1293CAGCUUCUUCUUCAAGUUCUA 1615 AM14229-SS(NAG37)s(invAb)sguguugggCfAfUfaucauugguas(invAb) 1294GUGUUGGGCAUAUCAUUGGUA 1616 AM14231-SS(NAG37)s(invAb)scgucuacaCfAfGfaacaccaugas(invAb) 1295CGUCUACACAGAACACCAUGA 1617 AM14233-SS(NAG37)s(invAb)sgacacccaGfGfAfucucuuucaas(invAb) 1296GACACCCAGGAUCUCUUUCAA 1618 AM14235-SS(NAG37)s(invAb)sagcaagcuCfUfCfaguaucaugas(invAb) 1297AGCAAGCUCUCAGUAUCAUGA 1619 AM14237-SS(NAG37)s(invAb)sucggaagaGfUfGfagguugacaas(invAb) 1298UCGGAAGAGUGAGGUUGACAA 1620 AM14239-SS(NAG37)s(invAb)sgacaaggaGfAfAfuuguuggaaas(invAb) 1299GACAAGGAGAAUUGUUGGAAA 1621 AM14241-SS(NAG37)s(invAb)sgcagcuuuGfAfGfacuaacucaas(invAb) 1300GCAGCUUUGAGACUAACUCAA 1622 AM14243-SS(NAG37)s(invAb)sccuccgcaCfAfGfauauugucaus(invAb) 1301CCUCCGCACAGAUAUUGUCAU 1623 AM14245-SS(NAG37)s(invAb)succgcacaGfAfUfauugucaugas(invAb) 1302UCCGCACAGAUAUUGUCAUGA 1624 AM14247-SS(NAG37)s(invAb)sggcugcuuCfUfAfucuucuuugas(invAb) 1303GGCUGCUUCUAUCUUCUUUGA 1625 AM14249-SS(NAG37)s(invAb)sagcacacaGfGfUfaauaacguias(invAb) 1304AGCACACAGGUAAUAACGUIA 1626 AM14251-SS(NAG37)s(invAb)sccuguauaAfCfCfucaaguucuas(invAb) 1305CCUGUAUAACCUCAAGUUCUA 1627 AM14253-SS(NAG37)s(invAb)sgaccaaugAfAfCfagcaaagcaus(invAb) 1306GACCAAUGAACAGCAAAGCAU 1628 AM14255-SS(NAG37)s(invAb)sca_2NuaaccuUfGfAfaucuauacuas 1307C(A^(2N))UAACCUUGAAUCUAUACUA 1629 (invAb) AM14257-SS(NAG37)s(invAb)sggcauaaaGfCfAfagauuacucus(invAb) 1308GGCAUAAAGCAAGAUUACUCU 1630 AM14259-SS(NAG37)s(invAb)succaccuaGfAfAfaugaugcuaus(invAb) 1309UCCACCUAGAAAUGAUGCUAU 1631 AM14261-SS(NAG37)s(invAb)scuagcucuGfUfCfucuucuiucus(invAb) 1310CUAGCUCUGUCUCUUCUIUCU 1632 AM14263-SS(NAG37)s(invAb)scua_2NaggcuUfGfGfuuuucuuacus 1311CU(A^(2N))AGGCUUGGUUUUCUUACU 1633 (invAb) AM14284-SS(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312CUCUCUCAGAGUAUUAUGGAA 1603 AM14286-SS(NAG37)s(invAb)scucucucaGfaGfUfauuauggaas(invAb) 1313CUCUCUCAGAGUAUUAUGGAA 1603 AM14287-SS(NAG37)s(invAb)scagugaugCfUfCfuccaaguauas(invAb) 1314CAGUGAUGCUCUCCAAGUAUA 1634 AM14289-SS(NAG37)s(invAb)sgccaaguaUfGfAfucgucuicaas(invAb) 1315GCCAAGUAUGAUCGUCUICAA 1635 AM14291-SS(NAG37)s(invAb)suggcaugaGfAfGfuuuuauucaas(invAb) 1316UGGCAUGAGAGUUUUAUUCAA 1636 AM14294-SS(NAG37)s(invAb)suggcaugaGfAfGfuuuua_2Nuucaas 1317UGGCAUGAGAGUUUU(A^(2N))UUCAA 1637 (invAb) AM14295-SS(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318CCUCAGCUUCUUCUUCAAGUA 1638 AM14300-SS(NAG37)s(invAb)sccucagcuUfCfUfucuuuaaguas(invAb) 1319CCUCAGCUUCUUCUUUAAGUA 1639 AM14302-SS(NAG37)s(invAb)sccucagcuUfcUfUfcuucaaguas(invAb) 1320CCUCAGCUUCUUCUUCAAGUA 1638 AM14303-SS(NAG37)s(invAb)sccucagcuUfcUfuCfuucaaguas(invAb) 1321CCUCAGCUUCUUCUUCAAGUA 1638 AM14386-SS(NAG37)s(invAb)sgaguauuuCfuCfAfgcauucaaas(invAb) 1322GAGUAUUUCUCAGCAUUCAAA 1593 AM14390-SS(NAG37)s(invAb)sgacaagauCfGfUfccacuuuucus(invAb) 1323GACAAGAUCGUCCACUUUUCU 1640 AM14392-SS(NAG37)s(invAb)saccauguuGfCfAfgugacaacuas(invAb) 1324ACCAUGUUGCAGUGACAACUA 1641 AM14394-SS(NAG37)s(invAb)sggugacaaCfUfGfuggaaggaaus(invAb) 1325GGUGACAACUGUGGAAGGAAU 1642 AM14396-SS(NAG37)s(invAb)sguggaggaGfAfUfugagaaugcas(invAb) 1326GUGGAGGAGAUUGAGAAUGCA 1643 AM14398-SS(NAG37)s(invAb)sgacacggaGfAfUfuggcauugaas(invAb) 1327GACACGGAGAUUGGCAUUGAA 1644 AM14400-SS(NAG37)s(invAb)scgagaugaAfGfUfucaagaaua_2Nus 1328CGAGAUGAAGUUCAAGAAU(A^(2N))U 1645 (invAb) AM14402-SS(NAG37)s(invAb)saggagauaCfUfGfcucuccauaas(invAb) 1329AGGAGAUACUGCUCUCCAUAA 1646 AM14404-SS(NAG37)s(invAb)sggggaguaUfUfUfcucagcauuas(invAb) 1330GGGGAGUAUUUCUCAGCAUUA 1647 AM14406-SS(NAG37)s(invAb)sgggaguauUfUfCfucagcauucas(invAb) 1331GGGAGUAUUUCUCAGCAUUCA 1648 AM14408-SS(NAG37)s(invAb)sccggagagAfAfGfaugacauugas(invAb) 1332CCGGAGAGAAGAUGACAUUGA 1649 AM14410-SS(NAG37)s(invAb)sgguaacauAfAfCfuggaauuugus(invAb) 1333GGUAACAUAACUGGAAUUUGU 1650 AM14412-SS(NAG37)s(invAb)sccagccauUfAfUfcacaauugaas(invAb) 1334CCAGCCAUUAUCACAAUUGAA 1651 AM14414-SS(NAG37)s(invAb)sgagcuuugUfUfGfcaaaaauguus(invAb) 1335GAGCUUUGUUGCAAAAAUGUU 1652 AM14416-SS(NAG37)s(invAb)sgcuuuguuGfCfAfaaaauguugas(invAb) 1336GCUUUGUUGCAAAAAUGUUGA 1653 AM14418-SS(NAG37)s(invAb)scggauuguGfGfUfucgagugaaas(invAb) 1337CGGAUUGUGGUUCGAGUGAAA 1654 AM14525-SS(NAG37)s(invAb)scccaccaaGfuUfuGfgaauaagas(invAb) 1338CCCACCAAGUUUGGAAUAAGA 1531 AM14526-SS(NAG37)s(invAb)scccaccaaGfuUfUfggaauaagas(invAb) 1339CCCACCAAGUUUGGAAUAAGA 1531 AM14528-SS(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340UGCCUAAAUGGUGAAUAUGCA 1551 AM14531-SS(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341UGCCUAAAUGGUGAAUAUGCA 1551 AM14646-SS(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342UCCAGGGUUUGUUUGUUUCAU 1595 AM15136-SS(NAG37)s(invAb)sgucucucaGfaGfuAfuuauggaas(invAb) 1343GUCUCUCAGAGUAUUAUGGAA 1655 AM15138-SS(NAG37)s(invAb)scccucucaGfaGfuAfuuauggaas(invAb) 1344CCCUCUCAGAGUAUUAUGGAA 1656 AM15140-SS(NAG37)s(invAb)sgccucucaGfaGfuAfuuauggaas(invAb) 1345GUCUCUCAGAGUAUUAUGGAA 1657 AM15142-SS(NAG37)s(invAb)saccucucaGfaGfuAfuuauggaas(invAb) 1346ACCUCUCAGAGUAUUAUGGAA 1658 AM15144-SS(NAG37)s(invAb)succucucaGfaGfuAfuuauggaas(invAb) 1347UCCUCUCAGAGUAUUAUGGAA 1659 AM15284-SS(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348CCUCCGCACAGAUAUUGUCAU 1623 AM15288-SS(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaas(invAb) 1349CCUCCGCACAGAUAUUGUCAA 1660 AM15293-SS(NAG37)s(invAb)scuccgcaCfaGfaUfauugucaus(invAb) 1350CUCCGCACAGAUAUUGUCAU 1661 AM15295-SS(NAG37)s(invAb)succgcaCfaGfaUfauugucaus(invAb) 1351 UCCGCACAGAUAUUGUCAU1662 AM17242-SS (NAG37)suscagagUfaUfUfAfuggaacgagus(invAb) 1676UCAGAGUAUUAUGGAACGAGU 1678 AM17244-SS(NAG37)scsucucuCfaGfAfGfuauuauggaus(invAb) 1677 CUCUCUCAGAGUAUUAUGGAU1679 (A^(2N)) = 2-aminoadenine nucleotide; 1 = hypoxanthine (inosine)nucleotide

The XDH RNAi agents described herein are formed by annealing anantisense strand with a sense strand. A sense strand containing asequence listed in Table 2, Table 4, or Table 5C can be hybridized toany antisense strand containing a sequence listed in Table 2, Table 3,or Table 5C provided the two sequences have a region of at least 85%complementarity over a contiguous 15, 16, 17, 18, 19, 20, or 21nucleotide sequence.

In some aspects, the antisense strand of an XDH RNAi agent disclosedherein differs by 0, 1, 2, or 3 nucleotides from any of the antisensestrand sequences in Table 3 or Table 5C. In some aspects, the sensestrand of an XDH RNAi agent disclosed herein differs by 0, 1, 2, or 3nucleotides from any of the sense strand sequences in Table 4 or Table5C.

In some aspects, an XDH RNAi agent antisense strand comprises anucleotide sequence of any of the sequences in Table 2, Table 3, orTable 5C. In some aspects, an XDH RNAi agent antisense strand comprisesthe sequence of nucleotides (from 5′ end→3′ end) at positions 1-17,2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, or 2-21, of any of thesequences in Table 2, Table 3, or Table 5C. In certain aspects, an XDHRNAi agent antisense strand comprises or consists of a modified sequenceof any one of the modified sequences in Table 3 or Table 5C.

In some aspects, an XDH RNAi agent sense strand comprises the nucleotidesequence of any of the sequences in Table 2, Table 4, or Table 5C. Insome aspects, an XDH RNAi agent sense strand comprises the sequence ofnucleotides (from 5′ end→3′ end) at positions 1-17, 2-17, 3-17, 4-17,1-18, 2-18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20,1-21, 2-21, 3-21, or 4-21, of any of the sequences in Table 2, Table 4,or Table 5C. In certain aspects, an XDH RNAi agent sense strandcomprises or consists of a modified sequence of any one of the modifiedsequences in Table 4 or Table 5C.

For the XDH RNAi agents disclosed herein, the nucleotide at position 1of the antisense strand (from 5′ end→3′ end) can be perfectlycomplementary to an XDH gene, or can be non-complementary to an XDHgene. In some aspects, the nucleotide at position 1 of the antisensestrand (from 5′ end→3′ end) is a U, A, or dT (or a modified versionthereof). In some aspects, the nucleotide at position 1 of the antisensestrand (from 5′ end→3′ end) forms an A:U or U:A base pair with the sensestrand.

A sense strand containing a sequence listed in Table 2, Table 4, orTable 5C can be hybridized to any antisense strand containing a sequencelisted in Table 2. Table 3, or Table 5C, provided the two sequences havea region of at least 85% complementarity over a contiguous 16, 17, 18,19, 20, or 21 nucleotide sequence. In some aspects, the XDH RNAi agenthas a sense strand consisting of the modified sequence of any of themodified sequences in Table 4 or Table 5C, and an antisense strandconsisting of the modified sequence of any of the modified sequences inTable 3 or Table 5C. Certain representative sequence pairings areexemplified by the Duplex ID Nos. shown in Tables 5A, 5B, and 5C.

In some aspects, an XDH RNAi agent comprises, consists of, or consistsessentially of a duplex represented by any one of the Duplex ID Nos.presented herein. In some aspects, an XDH RNAi agent comprises the sensestrand and antisense strand nucleotide sequences of any of the duplexesrepresented by any of the Duplex ID NOs. presented herein. In someaspects, an XDH RNAi agent comprises the sense strand and antisensestrand nucleotide sequences of any of the duplexes represented by any ofthe Duplex ID NOs. presented herein and a targeting group and/or linkinggroup wherein the targeting group and/or linking group is covalentlylinked (i.e., conjugated) to the sense strand or the antisense strand.In some aspects, an XDH RNAi agent includes the sense strand andantisense strand modified nucleotide sequences of any of the Duplex IDNOs. presented herein. In some aspects, an XDH RNAi agent comprises thesense strand and antisense strand modified nucleotide sequences of anyof the Duplex ID NOs. presented herein and a targeting group and/orlinking group, wherein the targeting group and/or linking group iscovalently linked to the sense strand or the antisense strand.

In some aspects, an XDH RNAi agent comprises an antisense strand and asense strand having the nucleotide sequences of any of the antisensestrand/sense strand duplexes of Table 2 or Tables 5A, 5B, and 5C, andfurther comprises a targeting group or targeting ligand. In someaspects, an XDH RNAi agent comprises an antisense strand and a sensestrand having the nucleotide sequences of any of the antisensestrand/sense strand duplexes of Table 2 or Tables 5A, 5B, and 5C, andfurther comprises an asialoglycoprotein receptor ligand targeting group.

A targeting group, with or without a linker, can be linked to the 5′ or3′ end of any of the sense and/or antisense strands disclosed in Tables2, 3, 4, or 5C. A linker, with or without a targeting group, can beattached to the 5′ or 3′ end of any of the sense and/or antisensestrands disclosed in Tables 2, 3, 4, and 5C.

In some aspects, an XDH RNAi agent comprises an antisense strand and asense strand having the nucleotide sequences of any of the antisensestrand/sense strand duplexes of Table 2 or Tables 5A, 5B and 5C, andfurther comprises a targeting ligand selected from the group consistingof: (NAG37) and (NAG37)s, each as defined in Table 6.

In some aspects, an XDH RNAi agent comprises an antisense strand and asense strand having the modified nucleotide sequence of any of theantisense strand and/or sense strand nucleotide sequences in Table 3 orTable 4.

In some aspects, an XDH RNAi agent comprises an antisense strand and asense strand having a modified nucleotide sequence of any of theantisense strand and/or sense strand nucleotide sequences of any of theduplexes Tables 5A, 5B, and 5C, and further comprises anasialoglycoprotein receptor ligand targeting group.

In some aspects, an XDH RNAi agent comprises, consists of, or consistsessentially of any of the duplexes of Tables 5A, 5B, and 5C.

TABLE 5A XDH RNAi Agents Duplexes with Corresponding Sense and AntisenseStrand ID Numbers and Sequence ID numbers for the modified andunmodified nucleotide sequences. AS AS SS SS modified unmodifiedmodified unmodified SEQ ID SEQ ID SEQ ID SEQ ID Duplex AS ID NO: NO: SSID NO: NO: AD09217 AM13029-AS 945 1352 AM13028-SS 1175 1506 AD09218AM13031-AS 946 1352 AM13030-SS 1176 1506 AD09219 AM13033-AS 947 1353AM13032-SS 1177 1507 AD09220 AM13035-AS 948 1354 AM13034-SS 1178 1508AD09221 AM13037-AS 949 1355 AM13036-SS 1179 1509 AD09222 AM13039-AS 9501356 AM13038-SS 1180 1510 AD09223 AM13041-AS 951 1357 AM13040-SS 11811511 AD09224 AM13043-AS 952 1358 AM13042-SS 1182 1512 AD09225 AM13045-AS953 1359 AM13044-SS 1183 1513 AD09226 AM13047-AS 954 1360 AM13046-SS1184 1514 AD09227 AM13049-AS 955 1361 AM13048-SS 1185 1515 AD09228AM13051-AS 956 1362 AM13050-SS 1186 1516 AD09229 AM13053-AS 957 1363AM13052-SS 1187 1517 AD09230 AM13055-AS 958 1364 AM13054-SS 1188 1518AD09231 AM13057-AS 959 1365 AM13056-SS 1189 1519 AD09232 AM13059-AS 9601366 AM13058-SS 1190 1520 AD09233 AM13061-AS 961 1367 AM13060-SS 11911521 AD09234 AM13063-AS 962 1368 AM13062-SS 1192 1522 AD09235 AM13065-AS963 1369 AM13064-SS 1193 1523 AD09236 AM13067-AS 964 1370 AM13066-SS1194 1524 AD09237 AM13069-AS 965 1371 AM13068-SS 1195 1525 AD09238AM13071-AS 966 1372 AM13070-SS 1196 1526 AD09239 AM13073-AS 967 1373AM13072-SS 1197 1527 AD09302 AM13164-AS 968 1374 AM13163-SS 1198 1528AD09303 AM13166-AS 969 1375 AM13165-SS 1199 1529 AD09304 AM13168-AS 9701376 AM13167-SS 1200 1530 AD09305 AM13170-AS 971 1377 AM13169-SS 12011531 AD09306 AM13172-AS 972 1378 AM13171-SS 1202 1532 AD09307 AM13174-AS973 1379 AM13173-SS 1203 1533 AD09308 AM13176-AS 974 1374 AM13175-SS1204 1528 AD09309 AM13177-AS 975 1375 AM13165-SS 1199 1529 AD09310AM13179-AS 976 1376 AM13178-SS 1205 1530 AD09311 AM13181-AS 977 1380AM13180-SS 1206 1534 AD09323 AM13204-AS 978 1374 AM13163-SS 1198 1528AD09324 AM13205-AS 979 1376 AM13167-SS 1200 1530 AD09325 AM13206-AS 9801377 AM13169-SS 1201 1531 AD09326 AM13207-AS 981 1378 AM13171-SS 12021532 AD09571 AM13600-AS 982 1381 AM13599-SS 1207 1535 AD09572 AM13602-AS983 1382 AM13601-SS 1208 1536 AD09573 AM13604-AS 984 1383 AM13603-SS1209 1537 AD09598 AM13648-AS 985 1384 AM13647-SS 1210 1538 AD09599AM13650-AS 986 1385 AM13649-SS 1211 1539 AD09600 AM13652-AS 987 1386AM13651-SS 1212 1540 AD09601 AM13654-AS 988 1387 AM13653-SS 1213 1541AD09602 AM13656-AS 989 1388 AM13655-SS 1214 1542 AD09603 AM13658-AS 9901389 AM13657-SS 1215 1543 AD09604 AM13660-AS 991 1390 AM13659-SS 12161544 AD09605 AM13662-AS 992 1391 AM13661-SS 1217 1545 AD09606 AM13664-AS993 1392 AM13663-SS 1218 1546 AD09607 AM13666-AS 994 1393 AM13665-SS1219 1547 AD09608 AM13668-AS 995 1394 AM13667-SS 1220 1548 AD09609AM13670-AS 996 1395 AM13669-SS 1221 1549 AD09610 AM13672-AS 997 1396AM13671-SS 1222 1550 AD09611 AM13674-AS 998 1397 AM13673-SS 1223 1551AD09612 AM13676-AS 999 1398 AM13675-SS 1224 1552 AD09613 AM13678-AS 10001399 AM13677-SS 1225 1553 AD09614 AM13680-AS 1001 1400 AM13679-SS 12261554 AD09615 AM13682-AS 1002 1401 AM13681-SS 1227 1555 AD09616AM13684-AS 1003 1402 AM13683-SS 1228 1556 AD09617 AM13686-AS 1004 1403AM13685-SS 1229 1557 AD09618 AM13688-AS 1005 1404 AM13687-SS 1230 1558AD09619 AM13690-AS 1006 1405 AM13689-SS 1231 1559 AD09620 AM13692-AS1007 1406 AM13691-SS 1232 1560 AD09621 AM13694-AS 1008 1407 AM13693-SS1233 1561 AD09623 AM13696-AS 1009 1408 AM13695-SS 1234 1262 AD09624AM13698-AS 1010 1409 AM13697-SS 1235 1563 AD09625 AM13700-AS 1011 1410AM13699-SS 1236 1564 AD09626 AM13702-AS 1012 1411 AM13701-SS 1237 1565AD09627 AM13704-AS 1013 1412 AM13703-SS 1238 1566 AD09628 AM13706-AS1014 1413 AM13705-SS 1239 1567 AD09629 AM13708-AS 1015 1414 AM13707-SS1240 1568 AD09630 AM13710-AS 1016 1415 AM13709-SS 1241 1569 AD09631AM13712-AS 1017 1416 AM13711-SS 1242 1570 AD09632 AM13714-AS 1018 1417AM13713-SS 1243 1571 AD09633 AM13716-AS 1019 1418 AM13715-SS 1244 1572AD09634 AM13718-AS 1020 1419 AM13717-SS 1245 1573 AD09635 AM13720-AS1021 1420 AM13719-SS 1246 1574 AD09636 AM13722-AS 1022 1421 AM13721-SS1247 1575 AD09637 AM13724-AS 1023 1422 AM13723-SS 1248 1576 AD09638AM13726-AS 1024 1423 AM13725-SS 1249 1577 AD09639 AM13728-AS 1025 1424AM13727-SS 1250 1578 AD09640 AM13730-AS 1026 1425 AM13729-SS 1251 1579AD09650 AM13747-AS 1027 1366 AM13746-SS 1252 1520 AD09651 AM13748-AS1028 1366 AM13746-SS 1252 1520 AD09652 AM13749-AS 1029 1366 AM13746-SS1252 1520 AD09653 AM13748-AS 1028 1366 AM13750-SS 1253 1580 AD09654AM13748-AS 1028 1366 AM13751-SS 1254 1581 AD09655 AM13748-AS 1028 1366AM13752-SS 1255 1582 AD09656 AM13753-AS 1030 1426 AM13746-SS 1252 1520AD09657 AM13754-AS 1031 1427 AM13746-SS 1252 1520 AD09658 AM13755-AS1032 1366 AM13746-SS 1252 1520 AD09659 AM13748-AS 1028 1366 AM13058-SS1190 1520 AD09660 AM13748-AS 1028 1366 AM13756-SS 1256 1520 AD09661AM13748-AS 1028 1366 AM13757-SS 1257 1520 AD09662 AM13758-AS 1028 1366AM13060-SS 1191 1521 AD09663 AM13759-AS 1034 1367 AM13060-SS 1191 1521AD09664 AM13758-AS 1033 1367 AM13760-SS 1258 1521 AD09665 AM13761-AS1035 1367 AM13760-SS 1258 1521 AD09724 AM13858-AS 1036 1428 AM13857-SS1259 1583 AD09725 AM13860-AS 1037 1429 AM13859-SS 1260 1584 AD09726AM13862-AS 1038 1430 AM13861-SS 1261 1585 AD09727 AM13864-AS 1039 1431AM13863-SS 1262 1586 AD09728 AM13866-AS 1040 1432 AM13865-SS 1263 1587AD09729 AM13868-AS 1041 1433 AM13867-SS 1264 1588 AD09730 AM13870-AS1042 1434 AM13869-SS 1265 1589 AD09731 AM13872-AS 1043 1435 AM13871-SS1266 1590 AD09732 AM13874-AS 1044 1436 AM13873-SS 1267 1591 AD09733AM13876-AS 1045 1437 AM13875-SS 1268 1592 AD09734 AM13878-AS 1046 1438AM13877-SS 1269 1593 AD09735 AM13880-AS 1047 1439 AM13879-SS 1270 1594AD09736 AM13882-AS 1048 1440 AM13881-SS 1271 1595 AD09737 AM13884-AS1049 1441 AM13883-SS 1272 1596 AD09738 AM13886-AS 1050 1442 AM13885-SS1273 1597 AD09739 AM13888-AS 1051 1443 AM13887-SS 1274 1598 AD09740AM13890-AS 1052 1444 AM13889-SS 1275 1599 AD09741 AM13892-AS 1053 1445AM13891-SS 1276 1600 AD09742 AM13894-AS 1054 1446 AM13893-SS 1277 1601AD09743 AM13896-AS 1055 1447 AM13895-SS 1278 1602 AD09744 AM13898-AS1056 1448 AM13897-SS 1279 1603 AD09745 AM13900-AS 1057 1449 AM13899-SS1280 1604 AD09937 AM14175-AS 1058 1450 AM14174-SS 1281 1605 AD09938AM14176-AS 1059 1448 AM13897-SS 1279 1603 AD09962 AM14204-AS 1060 1451AM14203-SS 1282 1606 AD09963 AM14206-AS 1061 1452 AM14205-SS 1283 1607AD09964 AM14208-AS 1062 1453 AM14207-SS 1284 1608 AD09965 AM14209-AS1063 1450 AM14174-SS 1281 1605 AD09966 AM14210-AS 1064 1450 AM14174-SS1281 1605 AD09967 AM14211-AS 1065 1450 AM14174-SS 1281 1605 AD09968AM14212-AS 1066 1450 AM14174-SS 1281 1605 AD09969 AM14211-AS 1065 1450AM14213-SS 1285 1605 AD09970 AM14211-AS 1065 1450 AM14214-SS 1286 1605AD09971 AM14216-AS 1067 1454 AM14215-SS 1287 1609 AD09972 AM14218-AS1068 1455 AM14217-SS 1288 1610 AD09973 AM14220-AS 1069 1456 AM14219-SS1289 1611 AD09974 AM14222-AS 1070 1457 AM14221-SS 1290 1612 AD09975AM14224-AS 1071 1458 AM14223-SS 1291 1613 AD09976 AM14226-AS 1072 1459AM14225-SS 1292 1614 AD09977 AM14228-AS 1073 1460 AM14227-SS 1293 1615AD09978 AM14230-AS 1074 1461 AM14229-SS 1294 1616 AD09979 AM14232-AS1075 1462 AM14231-SS 1295 1617 AD09980 AM14234-AS 1076 1463 AM14233-SS1296 1618 AD09981 AM14236-AS 1077 1464 AM14235-SS 1297 1619 AD09982AM14238-AS 1078 1465 AM14237-SS 1298 1620 AD09983 AM14240-AS 1079 1466AM14239-SS 1299 1621 AD09984 AM14242-AS 1080 1467 AM14241-SS 1300 1622AD09985 AM14244-AS 1081 1468 AM14243-SS 1301 1623 AD09986 AM14246-AS1082 1469 AM14245-SS 1302 1624 AD09987 AM14248-AS 1083 1470 AM14247-SS1303 1625 AD09988 AM14250-AS 1084 1471 AM14249-SS 1304 1626 AD09989AM14252-AS 1085 1472 AM14251-SS 1305 1627 AD09990 AM14254-AS 1086 1473AM14253-SS 1306 1628 AD09991 AM14256-AS 1087 1474 AM14255-SS 1307 1629AD09992 AM14258-AS 1088 1475 AM14257-SS 1308 1630 AD09993 AM14260-AS1089 1476 AM14259-SS 1309 1631 AD09994 AM14262-AS 1090 1477 AM14261-SS1310 1632 AD09995 AM14264-AS 1091 1478 AM14263-SS 1311 1633 AD10008AM14280-AS 1092 1448 AM13897-SS 1279 1603 AD10009 AM14281-AS 1093 1448AM13897-SS 1279 1603 AD10010 AM14282-AS 1094 1448 AM13897-SS 1279 1603AD10011 AM14283-AS 1095 1448 AM13897-SS 1279 1603 AD10012 AM14282-AS1094 1448 AM14284-SS 1312 1603 AD10013 AM14285-AS 1096 1448 AM14284-SS1312 1603 AD10014 AM14282-AS 1094 1448 AM14286-SS 1313 1603 AD10015AM14285-AS 1096 1448 AM14286-SS 1313 1603 AD10016 AM14288-AS 1097 1479AM14287-SS 1314 1634 AD10017 AM14290-AS 1098 1480 AM14289-SS 1315 1635AD10018 AM14292-AS 1099 1481 AM14291-SS 1316 1636 AD10019 AM14293-AS1100 1482 AM14291-SS 1316 1636 AD10020 AM14292-AS 1099 1481 AM14294-SS1317 1637 AD10021 AM14296-AS 1101 1482 AM14295-SS 1318 1638 AD10022AM14297-AS 1102 1482 AM14295-SS 1318 1638 AD10023 AM14298-AS 1103 1482AM14295-SS 1318 1638 AD10024 AM14299-AS 1104 1482 AM14295-SS 1318 1638AD10025 AM14299-AS 1104 1482 AM14300-SS 1319 1639 AD10026 AM14301-AS1105 1482 AM14295-SS 1318 1638 AD10027 AM14299-AS 1104 1482 AM14302-SS1320 1638 AD10028 AM14299-AS 1104 1482 AM14303-SS 1321 1638 AD10029AM14304-AS 1106 1482 AM14303-SS 1321 1638 AD10030 AM14305-AS 1107 1482AM14302-SS 1320 1638 AD10091 AM14383-AS 1108 1438 AM13877-SS 1269 1593AD10092 AM14384-AS 1109 1438 AM13877-SS 1269 1593 AD10093 AM14385-AS1110 1438 AM13877-SS 1269 1593 AD10094 AM14384-AS 1109 1438 AM14386-SS1322 1593 AD10095 AM14385-AS 1110 1438 AM14386-SS 1322 1593 AD10096AM14387-AS 1111 1438 AM13877-SS 1269 1593 AD10097 AM14388-AS 1112 1438AM13877-SS 1269 1593 AD10099 AM14391-AS 1113 1483 AM14390-SS 1323 1640AD10100 AM14393-AS 1114 1484 AM14392-SS 1324 1641 AD10101 AM14395-AS1115 1485 AM14394-SS 1325 1642 AD10102 AM14397-AS 1116 1486 AM14396-SS1326 1643 AD10103 AM14399-AS 1117 1487 AM14398-SS 1327 1644 AD10104AM14401-AS 1118 1488 AM14400-SS 1328 1645 AD10105 AM14403-AS 1119 1489AM14402-SS 1329 1646 AD10106 AM14405-AS 1120 1490 AM14404-SS 1330 1647AD10107 AM14407-AS 1121 1491 AM14406-SS 1331 1648 AD10108 AM14409-AS1122 1492 AM14408-SS 1332 1649 AD10109 AM14411-AS 1123 1493 AM14410-SS1333 1650 AD10110 AM14413-AS 1124 1494 AM14412-SS 1334 1651 AD10111AM14415-AS 1125 1495 AM14414-SS 1335 1652 AD10112 AM14417-AS 1126 1496AM14416-SS 1336 1653 AD10113 AM14419-AS 1127 1497 AM14418-SS 1337 1654AD10176 AM14522-AS 1128 1377 AM13169-SS 1201 1531 AD10177 AM14523-AS1129 1377 AM13169-SS 1201 1531 AD10178 AM14524-AS 1130 1377 AM13169-SS1201 1531 AD10179 AM14524-AS 1130 1377 AM14525-SS 1338 1531 AD10180AM14524-AS 1130 1377 AM14526-SS 1339 1531 AD10181 AM14527-AS 1131 1397AM13673-SS 1223 1551 AD10182 AM14529-AS 1132 1397 AM14528-SS 1340 1551AD10183 AM14530-AS 1133 1397 AM14528-SS 1340 1551 AD10184 AM14529-AS1132 1397 AM14531-SS 1341 1551 AD10200 AM14543-AS 1134 1397 AM13673-SS1223 1551 AD10201 AM14544-AS 1135 1397 AM13673-SS 1223 1551 AD10202AM14545-AS 1136 1397 AM13673-SS 1223 1551 AD10203 AM14544-AS 1135 1397AM14528-SS 1340 1551 AD10204 AM14545-AS 1136 1397 AM14528-SS 1340 1551AD10205 AM14544-AS 1135 1397 AM14531-SS 1341 1551 AD10275 AM14642-AS1137 1440 AM13881-SS 1271 1595 AD10276 AM14643-AS 1138 1440 AM13881-SS1271 1595 AD10277 AM14644-AS 1139 1440 AM13881-SS 1271 1595 AD10278AM14645-AS 1140 1440 AM13881-SS 1271 1595 AD10279 AM14644-AS 1139 1440AM14646-SS 1342 1595 AD10280 AM14647-AS 1141 1440 AM14646-SS 1342 1595AD10281 AM14648-AS 1142 1440 AM14646-SS 1342 1595 AD10282 AM14649-AS1143 1440 AM14646-SS 1342 1595 AD10283 AM14650-AS 1144 1440 AM14646-SS1342 1595 AD10619 AM14281-AS 1093 1448 AM14284-SS 1312 1603 AD10620AM15134-AS 1145 1448 AM14284-SS 1312 1603 AD10621 AM15135-AS 1146 1448AM14284-SS 1312 1603 AD10622 AM14283-AS 1095 1448 AM14284-SS 1312 1603AD10623 AM15137-AS 1147 1498 AM15136-SS 1343 1655 AD10624 AM15139-AS1148 1499 AM15138-SS 1344 1656 AD10625 AM15141-AS 1149 1500 AM15140-SS1345 1657 AD10626 AM15143-AS 1150 1501 AM15142-SS 1346 1658 AD10627AM15145-AS 1151 1502 AM15144-SS 1347 1659 AD10628 AM15146-AS 1152 1448AM14284-SS 1312 1603 AD10629 AM15147-AS 1153 1397 AM14528-SS 1340 1551AD10630 AM15148-AS 1154 1397 AM14528-SS 1340 1551 AD10631 AM15149-AS1155 1397 AM14528-SS 1340 1551 AD10632 AM15150-AS 1156 1397 AM14528-SS1340 1551 AD10633 AM15151-AS 1157 1397 AM14531-SS 1341 1551 AD10634AM15152-AS 1158 1397 AM14531-SS 1341 1551 AD10635 AM15153-AS 1159 1397AM14531-SS 1341 1551 AD10636 AM15154-AS 1160 1397 AM14531-SS 1341 1551AD10728 AM14244-AS 1081 1468 AM15284-SS 1348 1623 AD10729 AM15285-AS1161 1468 AM15284-SS 1348 1623 AD10730 AM15286-AS 1162 1468 AM15284-SS1348 1623 AD10731 AM15287-AS 1163 1468 AM15284-SS 1348 1623 AD10732AM15289-AS 1164 1503 AM15288-SS 1349 1660 AD10733 AM15290-AS 1165 1468AM15284-SS 1348 1623 AD10734 AM15291-AS 1166 1468 AM15284-SS 1348 1623AD10735 AM15292-AS 1167 1468 AM15284-SS 1348 1623 AD10736 AM15294-AS1168 1504 AM15293-SS 1350 1661 AD10737 AM15296-AS 1169 1505 AM15295-SS1351 1662 AD10952 AM15606-AS 1170 1448 AM14284-SS 1312 1603 AD10953AM15607-AS 1171 1498 AM15136-SS 1343 1655 AD10954 AM15608-AS 1172 1450AM14213-SS 1285 1605 AD10967 AM13882-AS 1048 1440 AM14646-SS 1342 1595AD10968 AM15626-AS 1173 1440 AM14646-SS 1342 1595 AD10969 AM15627-AS1174 1440 AM14646-SS 1342 1595 AD12167 AM17243-AS 1672 1674 AM17242-SS1676 1678 AD12168 AM17245-AS 1673 1675 AM17244-SS 1677 1679

TABLE 5B XDH RNAi Agents Duplexes with Corresponding Sense and AntisenseStrand ID Numbers Referencing Position Targeted on XDH Gene (SEQ IDNO:1) Targeted XDH Antisense Gene Position Duplex ID Strand ID SenseStrand ID (Of SEQ ID NO:1) AD09217 AM13029-AS AM13028-SS 488 AD09218AM13031-AS AM13030-SS 488 AD09219 AM13033-AS AM13032-SS 1612 AD09220AM13035-AS AM13034-SS 1614 AD09221 AM13037-AS AM13036-SS 1617 AD09222AM13039-AS AM13038-SS 2128 AD09223 AM13041-AS AM13040-SS 2130 AD09224AM13043-AS AM13042-SS 2131 AD09225 AM13045-AS AM13044-SS 2132 AD09226AM13047-AS AM13046-SS 2153 AD09227 AM13049-AS AM13048-SS 2185 AD09228AM13051-AS AM13050-SS 2186 AD09229 AM13053-AS AM13052-SS 3272 AD09230AM13055-AS AM13054-SS 435 AD09231 AM13057-AS AM13056-SS 2571 AD09232AM13059-AS AM13058-SS 2612 AD09233 AM13061-AS AM13060-SS 2616 AD09234AM13063-AS AM13062-SS 2617 AD09235 AM13065-AS AM13064-SS 2619 AD09236AM13067-AS AM13066-SS 3045 AD09237 AM13069-AS AM13068-SS 3548 AD09238AM13071-AS AM13070-SS 3551 AD09239 AM13073-AS AM13072-SS 3640 AD09302AM13164-AS AM13163-SS 265 AD09303 AM13166-AS AM13165-SS 2248 AD09304AM13168-AS AM13167-SS 2694 AD09305 AM13170-AS AM13169-SS 3083 AD09306AM13172-AS AM13171-SS 4665 AD09307 AM13174-AS AM13173-SS 4725 AD09308AM13176-AS AM13175-SS 265 AD09309 AM13177-AS AM13165-SS 2248 AD09310AM13179-AS AM13178-SS 2694 AD09311 AM13181-AS AM13180-SS 4725 AD09323AM13204-AS AM13163-SS 265 AD09324 AM13205-AS AM13167-SS 2694 AD09325AM13206-AS AM13169-SS 3083 AD09326 AM13207-AS AM13171-SS 4665 AD09571AM13600-AS AM13599-SS 2850 AD09572 AM13602-AS AM13601-SS 2851 AD09573AM13604-AS AM13603-SS 2852 AD09598 AM13648-AS AM13647-SS 235 AD09599AM13650-AS AM13649-SS 249 AD09600 AM13652-AS AM13651-SS 252 AD09601AM13654-AS AM13653-SS 1703 AD09602 AM13656-AS AM13655-SS 2049 AD09603AM13658-AS AM13657-SS 2155 AD09604 AM13660-AS AM13659-SS 2997 AD09605AM13662-AS AM13661-SS 3019 AD09606 AM13664-AS AM13663-SS 3020 AD09607AM13666-AS AM13665-SS 3037 AD09608 AM13668-AS AM13667-SS 4136 AD09609AM13670-AS AM13669-SS 4149 AD09610 AM13672-AS AM13671-SS 4150 AD09611AM13674-AS AM13673-SS 4289 AD09612 AM13676-AS AM13675-SS 4446 AD09613AM13678-AS AM13677-SS 4505 AD09614 AM13680-AS AM13679-SS 4515 AD09615AM13682-AS AM13681-SS 4517 AD09616 AM13684-AS AM13683-SS 4518 AD09617AM13686-AS AM13685-SS 4520 AD09618 AM13688-AS AM13687-SS 4525 AD09619AM13690-AS AM13689-SS 4700 AD09620 AM13692-AS AM13691-SS 5286 AD09621AM13694-AS AM13693-SS 5420 ADO9623 AM13696-AS AM13695-SS N/A(mouse-specific RNAi agent) AD09624 AM13698-AS AM13697-SS N/A(mouse-specific RNAi agent) AD09625 AM13700-AS AM13699-SS N/A(mouse-specific RNAi agent) AD09626 AM13702-AS AM13701-SS N/A(mouse-specific RNAi agent) AD09627 AM13704-AS AM13703-SS N/A(mouse-specific RNAi agent) AD09628 AM13706-AS AM13705-SS N/A(mouse-specific RNAi agent) AD09629 AM13708-AS AM13707-SS N/A(mouse-specific RNAi agent) AD09630 AM13710-AS AM13709-SS N/A(mouse-specific RNAi agent) AD09631 AM13712-AS AM13711-SS N/A(mouse-specific RNAi agent) AD09632 AM13714-AS AM13713-SS N/A(mouse-specific RNAi agent) AD09633 AM13716-AS AM13715-SS N/A(mouse-specific RNAi agent) AD09634 AM13718-AS AM13717-SS N/A(mouse-specific RNAi agent) AD09635 AM13720-AS AM13719-SS N/A(mouse-specific RNAi agent) AD09636 AM13722-AS AM13721-SS N/A(mouse-specific RNAi agent) AD09637 AM13724-AS AM13723-SS N/A(mouse-specific RNAi agent) AD09638 AM13726-AS AM13725-SS N/A(mouse-specific RNAi agent) AD09639 AM13728-AS AM13727-SS N/A(mouse-specific RNAi agent) AD09640 AM13730-AS AM13729-SS N/A(mouse-specific RNAi agent) AD09650 AM13747-AS AM13746-SS 2612 AD09651AM13748-AS AM13746-SS 2612 AD09652 AM13749-AS AM13746-SS 2612 AD09653AM13748-AS AM13750-SS 2612 AD09654 AM13748-AS AM13751-SS 2612 AD09655AM13748-AS AM13752-SS 2612 AD09656 AM13753-AS AM13746-SS 2612 AD09657AM13754-AS AM13746-SS 2612 AD09658 AM13755-AS AM13746-SS 2612 AD09659AM13748-AS AM13058-SS 2612 AD09660 AM13748-AS AM13756-SS 2612 AD09661AM13748-AS AM13757-SS 2612 AD09662 AM13758-AS AM13060-SS 2616 AD09663AM13759-AS AM13060-SS 2616 AD09664 AM13758-AS AM13760-SS 2616 AD09665AM13761-AS AM13760-SS 2616 AD09724 AM13858-AS AM13857-SS 122 AD09725AM13860-AS AM13859-SS 139 AD09726 AM13862-AS AM13861-SS 239 AD09727AM13864-AS AM13863-SS 332 AD09728 AM13866-AS AM13865-SS 430 AD09729AM13868-AS AM13867-SS 500 AD09730 AM13870-AS AM13869-SS 867 AD09731AM13872-AS AM13871-SS 877 AD09732 AM13874-AS AM13873-SS 888 AD09733AM13876-AS AM13875-SS 1285 AD09734 AM13878-AS AM13877-SS 1322 AD09735AM13880-AS AM13879-SS 1921 AD09736 AM13882-AS AM13881-SS 1963 AD09737AM13884-AS AM13883-SS 2138 AD09738 AM13886-AS AM13885-SS 2148 AD09739AM13888-AS AM13887-SS 2157 AD09740 AM13890-AS AM13889-SS 2209 AD09741AM13892-AS AM13891-SS 2320 AD09742 AM13894-AS AM13893-SS 2357 AD09743AM13896-AS AM13895-SS 2361 AD09744 AM13898-AS AM13897-SS 2696 AD09745AM13900-AS AM13899-SS 2701 AD09937 AM14175-AS AM14174-SS 1963 AD09938AM14176-AS AM13897-SS 2696 AD09962 AM14204-AS AM14203-SS 1964 AD09963AM14206-AS AM14205-SS 1965 AD09964 AM14208-AS AM14207-SS 1967 AD09965AM14209-AS AM14174-SS 1963 AD09966 AM14210-AS AM14174-SS 1963 AD09967AM14211-AS AM14174-SS 1963 AD09968 AM14212-AS AM14174-SS 1963 AD09969AM14211-AS AM14213-SS 1963 AD09970 AM14211-AS AM14214-SS 1963 AD09971AM14216-AS AM14215-SS 238 AD09972 AM14218-AS AM14217-SS 484 AD09973AM14220-AS AM14219-SS 493 AD09974 AM14222-AS AM14221-SS 497 AD09975AM14224-AS AM14223-SS 886 AD09976 AM14226-AS AM14225-SS 1117 AD09977AM14228-AS AM14227-SS 1615 AD09978 AM14230-AS AM14229-SS 2064 AD09979AM14232-AS AM14231-SS 2370 AD09980 AM14234-AS AM14233-SS 2684 AD09981AM14236-AS AM14235-SS 2995 AD09982 AM14238-AS AM14237-SS 3016 AD09983AM14240-AS AM14239-SS 3041 AD09984 AM14242-AS AM14241-SS 3498 AD09985AM14244-AS AM14243-SS 3598 AD09986 AM14246-AS AM14245-SS 3600 AD09987AM14248-AS AM14247-SS 3877 AD09988 AM14250-AS AM14249-SS 3930 AD09989AM14252-AS AM14251-SS 4394 AD09990 AM14254-AS AM14253-SS 4513 AD09991AM14256-AS AM14255-SS 4531 AD09992 AM14258-AS AM14257-SS 4666 AD09993AM14260-AS AM14259-SS 4843 AD09994 AM14262-AS AM14261-SS 5234 AD09995AM14264-AS AM14263-SS 5411 AD10008 AM14280-AS AM13897-SS 2696 AD10009AM14281-AS AM13897-SS 2696 AD10010 AM14282-AS AM13897-SS 2696 AD10011AM14283-AS AM13897-SS 2696 AD10012 AM14282-AS AM14284-SS 2696 AD10013AM14285-AS AM14284-SS 2696 AD10014 AM14282-AS AM14286-SS 2696 AD10015AM14285-AS AM14286-SS 2696 AD10016 AM14288-AS AM14287-SS 231 AD10017AM14290-AS AM14289-SS 242 AD10018 AM14292-AS AM14291-SS 1384 AD10019AM14293-AS AM14291-SS 1384 AD10020 AM14292-AS AM14294-SS 1384 AD10021AM14296-AS AM14295-SS 1612 AD10022 AM14297-AS AM14295-SS 1612 AD10023AM14298-AS AM14295-SS 1612 AD10024 AM14299-AS AM14295-SS 1612 AD10025AM14299-AS AM14300-SS 1612 AD10026 AM14301-AS AM14295-SS 1612 AD10027AM14299-AS AM14302-SS 1612 AD10028 AM14299-AS AM14303-SS 1612 AD10029AM14304-AS AM14303-SS 1612 AD10030 AM14305-AS AM14302-SS 1612 AD10091AM14383-AS AM13877-SS 1322 AD10092 AM14384-AS AM13877-SS 1322 AD10093AM14385-AS AM13877-SS 1322 AD10094 AM14384-AS AM14386-SS 1322 AD10095AM14385-AS AM14386-SS 1322 AD10096 AM14387-AS AM13877-SS 1322 AD10097AM14388-AS AM13877-SS 1322 AD10099 AM14391-AS AM14390-SS 263 AD10100AM14393-AS AM14392-SS 318 AD10101 AM14395-AS AM14394-SS 328 AD10102AM14397-AS AM14396-SS 482 AD10103 AM14399-AS AM14398-SS 857 AD10104AM14401-AS AM14400-SS 874 AD10105 AM14403-AS AM14402-SS 1278 AD10106AM14405-AS AM14404-SS 1319 AD10107 AM14407-AS AM14406-SS 1320 AD10108AM14409-AS AM14408-SS 1351 AD10109 AM14411-AS AM14410-SS 2006 AD10110AM14413-AS AM14412-SS 2156 AD10111 AM14415-AS AM14414-SS 2398 AD10112AM14417-AS AM14416-SS 2400 AD10113 AM14419-AS AM14418-SS 2435 AD10176AM14522-AS AM13169-SS 3083 AD10177 AM14523-AS AM13169-SS 3083 AD10178AM14524-AS AM13169-SS 3083 AD10179 AM14524-AS AM14525-SS 3083 AD10180AM14524-AS AM14526-SS 3083 AD10181 AM14527-AS AM13673-SS 4289 AD10182AM14529-AS AM14528-SS 4289 AD10183 AM14530-AS AM14528-SS 4289 AD10184AM14529-AS AM14531-SS 4289 AD10200 AM14543-AS AM13673-SS 4289 AD10201AM14544-AS AM13673-SS 4289 AD10202 AM14545-AS AM13673-SS 4289 AD10203AM14544-AS AM14528-SS 4289 AD10204 AM14545-AS AM14528-SS 4289 AD10205AM14544-AS AM14531-SS 4289 AD10275 AM14642-AS AM13881-SS 1963 AD10276AM14643-AS AM13881-SS 1963 AD10277 AM14644-AS AM13881-SS 1963 AD10278AM14645-AS AM13881-SS 1963 AD10279 AM14644-AS AM14646-SS 1963 AD10280AM14647-AS AM14646-SS 1963 AD10281 AM14648-AS AM14646-SS 1963 AD10282AM14649-AS AM14646-SS 1963 AD10283 AM14650-AS AM14646-SS 1963 AD10619AM14281-AS AM14284-SS 2696 AD10620 AM15134-AS AM14284-SS 2696 AD10621AM15135-AS AM14284-SS 2696 AD10622 AM14283-AS AM14284-SS 2696 AD10623AM15137-AS AM15136-SS 2696 AD10624 AM15139-AS AM15138-SS 2696 AD10625AM15141-AS AM15140-SS 2696 AD10626 AM15143-AS AM15142-SS 2696 AD10627AM15145-AS AM15144-SS 2696 AD10628 AM15146-AS AM14284-SS 2696 AD10629AM15147-AS AM14528-SS 4289 AD10630 AM15148-AS AM14528-SS 4289 AD10631AM15149-AS AM14528-SS 4289 AD10632 AM15150-AS AM14528-SS 4289 AD10633AM15151-AS AM14531-SS 4289 AD10634 AM15152-AS AM14531-SS 4289 AD10635AM15153-AS AM14531-SS 4289 AD10636 AM15154-AS AM14531-SS 4289 AD10728AM14244-AS AM15284-SS 3598 AD10729 AM15285-AS AM15284-SS 3598 AD10730AM15286-AS AM15284-SS 3598 AD10731 AM15287-AS AM15284-SS 3598 AD10732AM15289-AS AM15288-SS 3598 AD10733 AM15290-AS AM15284-SS 3598 AD10734AM15291-AS AM15284-SS 3598 AD10735 AM15292-AS AM15284-SS 3598 AD10736AM15294-AS AM15293-SS 3598 AD10737 AM15296-AS AM15295-SS 3598 AD10952AM15606-AS AM14284-SS 2696 AD10953 AM15607-AS AM15136-SS 2696 AD10954AM15608-AS AM14213-SS 1963 AD10967 AM13882-AS AM14646-SS 1963 AD10968AM15626-AS AM14646-SS 1963 AD10969 AM15627-AS AM14646-SS 1963 AD12167AM17243-AS AM17242-SS 2701 AD12168 AM17245-AS AM17244-SS 2696

TABLE 5CXDH RNAi Agent Duplexes Showing Chemically Modified Antisense Strand and Sense Strand SequencesSense Strand Modified Antisense Strand SEQ ID SEQ ID ID: (5′→3′) NO.Modified Sense Strand (5′→3′) NO. AD09217usUfsgsGfaAfgGfcAfuUfcUfcAfaUfcUfsc  945(NAG37)s(invAb)sgagauugaGfAfAfugccuuccaas(invAb) 1175 AD09218usUfsggaAfgGfCfauucUfcAfaucusc  946(NAG37)s(invAb)sgagauuGfaGfAfAfugccuuccaas(invAb) 1176 AD09219asAfscsUfuGfaAfgAfaGfaAfgCfuGfaGfsg  947(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguus(invAb) 1177 AD09220asGfsasAfcUfuGfaAfgAfaGfaAfgCfuGfsc  948(NAG37)s(invAb)sgcagcuucUfUfCfuucaaguucus(invAb) 1178 AD09221usGfsusAfgAfaCfuUfgAfaGfaAfgAfaGfsc  949(NAG37)s(invAb)sgcuucuucUfUfCfaaguucuacas(invAb) 1179 AD09222usCfsasUfaGfgUfgAfuUfuUfcAfcCfcCfsu  950(NAG37)s(invAb)saggggugaAfAfAfucaccuaugas(invAb) 1180 AD09223usUfsusCfaUfaGfgUfgAfuUfuUfcAfcCfsc  951(NAG37)s(invAb)sgggugaaaAfUfCfaccuaugaaas(invAb) 1181 AD09224usCfsusUfcAfuAfgGfuGfaUfuUfuCfaCfsc  952(NAG37)s(invAb)sggugaaaaUfCfAfccuaugaagas(invAb) 1182 AD09225usUfscsUfuCfaUfaGfgUfgAfuUfuUfcAfsc  953(NAG37)s(invAb)sgugaaaauCfAfCfcuaugaagaas(invAb) 1183 AD09226asAfsusUfgUfgAfuAfaUfgGfcUfgGfuAfsg  954(NAG37)s(invAb)scuaccagcCfAfUfuaucacaauus(invAb) 1184 AD09227usCfsasUfaAfaAfgGfaGfuUfgUfuCfuUfsc  955(NAG37)s(invAb)sgaagaacaAfCfUfccuuuuaugas(invAb) 1185 AD09228usCfscsAfuAfaAfaGfgAfgUfuGfuUfcUfsc  956(NAG37)s(invAb)sgagaacaaCfUfCfcuuuuauggas(invAb) 1186 AD09229usAfscsAfgUfgUfuAfgUfgCfuUfgUfcUfsc  957(NAG37)s(invAb)sgagacaagCfAfCfuaacacuguas(invAb) 1187 AD09230usUfsgsUfgUfaCfaUfaCfuCfaUfgAfcGfsa  958(NAG37)s(invAb)sucgucaugAfGfUfauguacacaas(invAb) 1188 AD09231usAfscsCfaGfuUfaUfcAfgCfaUfgUfcCfsu  959(NAG37)s(invAb)saggacaugCfUfGfauaacugiuas(invAb) 1189 AD09232usAfsusGfaAfgCfcAfaCfcUfuGfuAfuCfsc  960(NAG37)s(invAb)sggauacaaGfGfUfuggcuucauas(invAb) 1190 AD09233usCfsusUfcAfuGfaAfgCfcAfaCfcUfuGfsc  961(NAG37)s(invAb)sgcaagguuGfGfCfuucaugaagas(invAb) 1191 AD09234usUfscsUfuCfaUfgAfaGfcCfaAfcCfuUfsg  962(NAG37)s(invAb)scaagguugGfCfUfucaugaagaas(invAb) 1192 AD09235usAfsgsUfcUfuCfaUfgAfaGfcCfaAfcCfsu  963(NAG37)s(invAb)sagguuggcUfUfCfaugaagacuas(invAb) 1193 AD09236usCfsusUfuUfuCfcAfaCfaAfuUfcUfcCfsu  964(NAG37)s(invAb)saggagaauUfGfUfuggaaaaagas(invAb) 1194 AD09237usUfscsUfaCfuUfcAfgAfgCfaAfgCfcAfsc  965(NAG37)s(invAb)sguggcuugCfUfCfugaaguagaas(invAb) 1195 AD09238usAfsusUfuCfuAfcUfuCfaGfaGfcAfaGfsc  966(NAG37)s(invAb)sgcuugcucUfGfAfaguagaaauas(invAb) 1196 AD09239usGfsusCfcAfaUfaUfcAfaUfgGfcAfgGfsg  967(NAG37)s(invAb)scccugccaUfUfGfauauuigacas(invAb) 1197 AD09302usCfsasGfaAfaAfgUfgGfaCfgAfuCfuUfsg  968(NAG37)s(invAb)scaagaucgUfCfCfacuuuucugas(invAb) 1198 AD09303asCfsasAfcAfuUfaUfcUfgCfuUfcGfgAfsc  969(NAG37)s(invAb)sguccgaagCfAfGfauaauguugus(invAb) 1199 AD09304usCfsasUfaAfuAfcUfcUfgAfgAfgAfgAfsc  970(NAG37)s(invAb)sgucucucuCfAfGfaguauuaugas(invAb) 1200 AD09305usCfsusUfaUfuCfcAfaAfcUfuGfgUfgGfsg  971(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201 AD09306usAfsgsUfaAfuCfuUfgCfuUfuAfuGfcAfsg  972(NAG37)s(invAb)scugcauaaAfGfCfaagauuacuas(invAb) 1202 AD09307asAfsasGfaAfaUfcUfaGfaAfcAfuUfgUfsc  973(NAG37)s(invAb)sgacaauguUfCfUfagauuucuuus(invAb) 1203 AD09308usCfsasgaaaagugGfaCfgAfuCfuUfsg  974(NAG37)s(invAb)scaagaucgUfcCfaCfuuuucugas(invAb) 1204 AD09309asCfsasacauUfaUfcUfgCfuUfcggasc  975(NAG37)s(invAb)sguccgaagCfAfGfauaauguugus(invAb) 1199 AD09310usCfsasUfaAfuacucUfgAfgAfgagasc  976(NAG37)s(invAb)sgucucucuCfaGfaGfuauuaugas(invAb) 1205 AD09311asAfsasGfaAfaUfcUfaGfaAfcAfuUfuUfsc  977(NAG37)s(invAb)sgaaaauguUfCfUfagauuucuuus(invAb) 1206 AD09323usCfsasGfaAfaagugGfaCfgAfuCfuUfsg  978(NAG37)s(invAb)scaagaucgUfCfCfacuuuucugas(invAb) 1198 AD09324usCfsasUfaAfuacucUfgAfgAfgAfgAfsc  979(NAG37)s(invAb)sgucucucuCfAfGfaguauuaugas(invAb) 1200 AD09325usCfsusUfaUfuccaaAfcUfuGfgUfggsg  980(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201 AD09326usAfsgsUfaAfucuugCfuUfuAfuGfcAfsg  981(NAG37)s(invAb)scugcauaaAfGfCfaagauuacuas(invAb) 1202 AD09571usAfsasCfuUfcacucAfuCfcAfgCfacsu  982(NAG37)s(invAb)sagugcuggAfUfGfagugaaguuas(invAb) 1207 AD09572usCfsasAfcuucacuCfaUfcCfagcasc  983(NAG37)s(invAb)sgugcuigaUfGfAfgugaaguugas(invAb) 1208 AD09573usGfscsAfacuucacUfcAfuCfcagcsa  984(NAG37)s(invAb)sugcuggauGfAfGfugaaguuicas(invAb) 1209 AD09598usGfsasucauacuuGfgAfgAfgcausc  985(NAG37)s(invAb)sgaugcucuCfcAfaGfuaugaucas(invAb) 1210 AD09599usCfsusuguucugcAfgAfcGfaucasc  986(NAG37)s(invAb)sgugaucguCfuGfcAfgaacaagas(invAb) 1211 AD09600usGfsasucuuguucUfgCfaGfacgasc  987(NAG37)s(invAb)sgucgucugCfaGfaAfcaagaucas(invAb) 1212 AD09601usAfsgsuaaaguugCfaCfuGfgcgasc  988(NAG37)s(invAb)sgucgccagUfgCfaAfcuuuacuas(invAb) 1213 AD09602usAfsasCfacaaguaAfcCfuUfauccsu  989(NAG37)s(invAb)saggauaAfgGfuUfacuuguguuas(invAb) 1214 AD09603usCfsasAfuugugauAfaUfgGfcuggsu  990(NAG37)s(invAb)saccagccaUfuAfuCfacaauugas(invAb) 1215 AD09604usAfsgscaugauacUfgAfgAfgcuusg  991(NAG37)s(invAb)scaagcucuCfaGfuAfucaugcuas(invAb) 1216 AD09605asAfscsUfugucaacCfuCfaCfucuusc  992(NAG37)s(invAb)sgaagagugAfgGfuUfgacaaguus(invAb) 1217 AD09606usAfsasCfuugucaaCfcUfcAfcucusc  993(NAG37)s(invAb)sgagagugaGfGfUfugacaaguuas(invAb) 1218 AD09607usAfsasCfaauucucCfuUfgUfugaasc  994(NAG37)s(invAb)sguucaacaAfGfGfagaauuguuas(invAb) 1219 AD09608usCfsasuguucuguGfgUfaUfguucsc  995(NAG37)s(invAb)sggaacaUfaCfcAfcagaacaugas(invAb) 1220 AD09609usAfscsUfuUfaauagAfuCfcAfuguusc  996(NAG37)s(invAb)sgaacauggAfuCfuAfuuaaaguas(invAb) 1221 AD09610usGfsascuuuAfaUfaGfaUfcCfaugusc  997(NAG37)s(invAb)sgacauggaUfcUfaUfuaaagucas(invAb) 1222 AD09611usGfscsauauucacCfaUfuUfaggcsa  998(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223 AD09612usGfsusUfuaagcuuCfuAfgAfgguusc  999(NAG37)s(invAb)sgaaccucuAfGfAfagcuuaaacas(invAb) 1224 AD09613usUfsgsuucauuggUfuUfgAfaggcsc 1000(NAG37)s(invAb)sggccuucaAfaCfcAfaugaacaas(invAb) 1225 AD09614usUfsasUfgCfuuugcUfgUfuCfauugsg 1001(NAG37)s(invAb)sccaaugAfaCfaGfcaaagcauaas(invAb) 1226 AD09615usGfsusUfaugcuuuGfcUfgUfuCfausc 1002(NAG37)s(invAb)sgaugaacaGfcAfAfagcauaacas(invAb) 1227 AD09616asGfsgsUfuaugcuuUfgCfuGfuucasc 1003(NAG37)s(invAb)sgugaacagCfAfAfagcauaaccus(invAb) 1228 AD09617usAfsasgguuaugcUfuUfgCfuguusc 1004(NAG37)s(invAb)sgaacagcaAfaGfcAfuaaccuuas(invAb) 1229 AD09618asGfsasUfucaagguUfaUfgCfuuugsc 1005(NAG37)s(invAb)sgcaaagcaUfAfAfccuugaaucus(invAb) 1230 AD09619usUfscsAfauaauugAfgUfuGfguugsg 1006(NAG37)s(invAb)sccaaccaaCfuCfaAfuuauugaas(invAb) 1231 AD09620asGfsusAfaaauggaUfcAfcAfggaasg 1007(NAG37)s(invAb)scuuccuguGfAfUfccauuuuacus(invAb) 1232 AD09621usCfsasUfaugacagUfaAfgAfaaacsc 1008(NAG37)s(invAb)sgguuuucuUfAfCfugucauaugas(invAb) 1233 AD09623usUfsgsgaaggcauUfcUfcGfaucusc 1009(NAG37)s(invAb)sgagaucgaGfAfAfugccuuccaas(invAb) 1234 AD09624usCfsasUfcauugaaAfaUfgCfcagusc 1010(NAG37)s(invAb)sgacuggcaUfUfUfucaaugaugas(invAb) 1235 AD09625asAfsasGfacaguuuCfaUfcAfuugasc 1011(NAG37)s(invAb)sgucaaugaUfGfAfaacugucuuus(invAb) 1236 AD09626asAfscsacaaguaaCfcUfcAfuccusc 1012(NAG37)s(invAb)sgaggaugaGfGfUfuacuuguguus(invAb) 1237 AD09627asGfsascaacauugUfcAfgCfuucasg 1013(NAG37)s(invAb)scugaagcuGfAfCfaauguugucus(invAb) 1238 AD09628usCfsasacaucuuuGfcAfaUfaaagsc 1014(NAG37)s(invAb)sgcuuuauuGfCfAfaagauguugas(invAb) 1239 AD09629asGfsasUfuagucuuAfcAfaAfuccusc 1015(NAG37)s(invAb)sgaggauuuGfUfAfagacuaaucus(invAb) 1240 AD09630usCfsusUfauuccaaAfcUfuAfgucgsg 1016(NAG37)s(invAb)sccgacuaaGfUfUfuggaauaagas(invAb) 1241 AD09631usCfsasGfaaaagaaAfgUfgUfgaagsc 1017(NAG37)s(invAb)sgcuucacaCfUfUfucuuuucugas(invAb) 1242 AD09632usAfsgsAfguuugucUfcAfaAfgcugsc 1018(NAG37)s(invAb)sgcagcuuuGfAfGfacaaacucuas(invAb) 1243 AD09633usUfsgsUfuaagcagUfcAfaUfuUfcusc 1019(NAG37)s(invAb)sgagaaauuGfAfCfugcuuaacaas(invAb) 1244 AD09634usUfsgsGfaaaucugGfaUfaCfuacgsg 1020(NAG37)s(invAb)sccguaguaUfCfCfagauuuccaas(invAb) 1245 AD09635usCfsusUfgaaaaugCfcAfuCfcugcsu 1021(NAG37)s(invAb)sagcaggauGfGfCfauuuucaagas(invAb) 1246 AD09636asUfsgsAfuuuggauCfaCfaAfuugusc 1022(NAG37)s(invAb)sgacaauugUfGfAfuccaaaucaus(invAb) 1247 AD09637usAfsgsAfauuacucAfaAfaCfugccsa 1023(NAG37)s(invAb)suggcaguuUfUfGfaguaauucuas(invAb) 1248 AD09638usGfsasucaaAfAfauGfgAfcUfcagasc 1024(NAG37)s(invAb)sgucugaguCfCfAfuuuuugaucas(invAb) 1249 AD09639usAfsasGfaaagcauGfcAfgAfucuasg 1025(NAG37)s(invAb)scuagaucuGfCfAfugcuuucuuas(invAb) 1250 AD09640usCfsasgauauaagCfuCfuCfugaasg 1026(NAG37)s(invAb)scuucagagAfGfCfuuauaucugas(invAb) 1251 AD09650usAfsusGfaagccaaCfcUfuGfuAfucsc 1027(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09651usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09652usAfsusGfaagCuNAcaaCfcUfuGfuaucsc 1029(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09653usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacAfaGfgUfugicuucauas(invAb) 1253 AD09654usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacAfaGfgUfuigcuucauas(invAb) 1254 AD09655usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacAfaGfgUfugguuucauas(invAb) 1255 AD09656usAfsusGfaagucaaCfcUfuGfuaucsc 1030(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09657usAfsusGfaagcuaaCfcUfuGfuaucsc 1031(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09658cPrpusAfsusGfaagccaaCfcUfuGfuaucsc 1032(NAG37)s(invAb)sggauacAfaGfgUfuggcuucauas(invAb) 1252 AD09659usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacaaGfGfUfuggcuucauas(invAb) 1190 AD09660usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacaaGfgUfUfggcuucauas(invAb) 1256 AD09661usAfsusGfaagccaaCfcUfuGfuaucsc 1028(NAG37)s(invAb)sggauacaaGfgUfuGfgcuucauas(invAb) 1257 AD09662usCfsusUfcaugaagCfcAfaCfcuugsc 1028(NAG37)s(invAb)sgcaagguuGfGfCfuucaugaagas(invAb) 1191 AD09663cPrpusCfsusUfcaugaagCfcAfaCfcuugsc 1034(NAG37)s(invAb)sgcaagguuGfGfCfuucaugaagas(invAb) 1191 AD09664usCfsusUfcaugaagCfcAfaCfcuugsc 1033(NAG37)s(invAb)sgcaagguuGfgCfuUfcaugaagas(invAb) 1258 AD09665usCfsusUfcaUuNAgaagCfcAfaCfcuugsc 1035(NAG37)s(invAb)sgcaagguuGfgCfuUfcaugaagas(invAb) 1258 AD09724usGfsgsAfuCfugcauUfuUfuCfuCfcasc 1036(NAG37)s(invAb)sguggagaaAfAfAfugcaiauccas(invAb) 1259 AD09725usCfscsAfaAfaggguUfgUfcUfcUfggsa 1037(NAG37)s(invAb)succagagaCfAfAfcucuuuuggas(invAb) 1260 AD09726usAfsgsAfcGfaucauAfcUfuGfgAfgasg 1038(NAG37)s(invAb)scucuccaaGfUfAfugauciucuas(invAb) 1261 AD09727usCfscsUfaUfuccuuCfcAfcAfgUfugsc 1039(NAG37)s(invAb)sgcaacuguGfGfAfaggaauaggas(invAb) 1262 AD09728usAfscsAfuAfcucauGfaCfgAfuGfccsa 1040(NAG37)s(invAb)suggcaucgUfCfAfugaguauguas(invAb) 1263 AD09729usCfsasCfaGfauuucCfuUfgGfaAfggsc 1041(NAG37)s(invAb)sgccuuccaAfGfGfaaaucuguias(invAb) 1264 AD09730usGfsasAfcUfucaucUfcAfaUfgCfcasc 1042(NAG37)s(invAb)sguggcauuGfAfGfaugaaguucas(invAb) 1265 AD09731asGfscsAfuAfuucuuGfaAfcUfuCfausc 1043(NAG37)s(invAb)sga_2NugaaguUfCfAfagaauaugcus 1266 (invAb) AD09732usCfsasUfaGfgaaacAfgCfaUfaUfucsc 1044(NAG37)s(invAb)sggaauaugCfUfGfuuuccuaugas(invAb) 1267 AD09733usGfsgsAfuCfucuauGfgAfgAfgCfagsc 1045(NAG37)s(invAb)sgcugcucuCfCfAfuagaiauccas(invAb) 1268 AD09734usUfsusGfaAfugcugAfgAfaAfuAfcusc 1046(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD09735usCfsusAfuGfgacuuGfaUfcUfuGfgcsg 1047(NAG37)s(invAb)scgccaagaUfCfAfaguccauagas(invAb) 1270 AD09736asUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1048(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271 AD09737usGfsgsUfaGfuucuuCfaUfaGfgUfgasc 1049(NAG37)s(invAb)sgucaccuaUfGfAfagaacuaccas(invAb) 1272 AD09738usGfsasUfaAfuggcuGfgUfaGfuUfcusc 1050(NAG37)s(invAb)sgagaacuaCfCfAfgccauuaucas(invAb) 1273 AD09739usCfsusCfaAfuugugAfuAfaUfgGfcusg 1051(NAG37)s(invAb)scagccauuAfUfCfacaauugagas(invAb) 1274 AD09740usCfsusUfuCfucgauCfuUfcAfgCfucsa 1052(NAG37)s(invAb)sugagcugaAfGfAfucgagaaagas(invAb) 1275 AD09741usUfsusGfgAfacagcAfaUfgGfuGfcasg 1053(NAG37)s(invAb)scugcaccaUfUfGfcuguuccaaas(invAb) 1276 AD09742usGfsusAfgAfcacaaAfgAfgCfuCfcasc 1054(NAG37)s(invAb)sguggagcuCfUfUfuguguuuacas(invAb) 1277 AD09743usCfsusGfuGfuagacAfcAfaAfgAfgcsu 1055(NAG37)s(invAb)sagcucuuuGfUfGfucuacacaias(invAb) 1278 AD09744usUfscsCfaUfaauacUfcUfgAfgAfgasg 1056(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD09745usCfsusCfgUfuccauAfaUfaCfuCfugsc 1057(NAG37)s(invAb)sgcagaguaUfUfAfuggaacgaias(invAb) 1280 AD09937cPrpusUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1058(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281 AD09938cPrpusUfscsCfaUfaauacUfcUfgAfgAfgasg 1059(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD09962asAfsusGfaaacaaaCfaAfaCfccugsg 1060(NAG37)s(invAb)sccaggguuUfGfUfuuguuucauus(invAb) 1282 AD09963asAfsasUfgaaacaaAfcAfaAfcccusg 1061(NAG37)s(invAb)scaggguuuGfUfUfuguuucauuus(invAb) 1283 AD09964usGfsasAfaugaaacAfaAfcAfaaccsc 1062(NAG37)s(invAb)sggguuuguUfUfGfuuucauuucas(invAb) 1284 AD09965usUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1063(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281 AD09966cPrpusUfsgsAfaacaaacAfaAfcCfcuggsa 1064(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281 AD09967cPrpuUfgAfaacaaacAfaAfcCfcuggsa 1065(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281 AD09968cPrpuUfgAfaacaaacAfaAfcCfcugsgsa 1066(NAG37)s(invAb)succaggguUfUfGfuuuguuucaas(invAb) 1281 AD09969cPrpuUfgAfaacaaacAfaAfcCfcuggsa 1065(NAG37)s(invAb)succaggguUfuGfuUfuguuucaas(invAb) 1285 AD09970cPrpuUfgAfaacaaacAfaAfcCfcuggsa 1065(NAG37)s(invAb)succaggguUfuGfUfuuguuucaas(invAb) 1286 AD09971asGfsasCfgaucauaCfuUfgGfagagsc 1067(NAG37)s(invAb)sgcucuccaAfGfUfaugauciucus(invAb) 1287 AD09972asAfsgsGfcauucucAfaUfcUfccucsc 1068(NAG37)s(invAb)sggaggagaUfUfGfagaauiccuus(invAb) 1288 AD09973usUfsusCfcuuggaaGfgCfaUfucucsg 1069(NAG37)s(invAb)scgagaaugCfCfUfuccaaggaaas(invAb) 1289 AD09974usAfsgsAfuuuccuuGfgAfaGfgcausc 1070(NAG37)s(invAb)sgaugccuuCfCfAfaggaaaucuas(invAb) 1290 AD09975asUfsasGfgaaacagCfaUfaUfucuusg 1071(NAG37)s(invAb)sca_2NagaauaUfGfCfuguuuccuaus 1291 (invAb) AD09976usUfsgsAfugauguuCfcCfuCfcaacsg 1072(NAG37)s(invAb)scguuggagGfGfAfacaucaucaas(invAb) 1292 AD09977usAfsgsAfacuugaaGfaAfgAfagcusg 1073(NAG37)s(invAb)scagcuucuUfCfUfucaaguucuas(invAb) 1293 AD09978usAfscsCfaaugauaUfgCfcCfaacasc 1074(NAG37)s(invAb)sguguugggCfAfUfaucauugguas(invAb) 1294 AD09979usCfsasUfggUuNAguucUfgUfgUfagacsg 1075(NAG37)s(invAb)scgucuacaCfAfGfaacaccaugas(invAb) 1295 AD09980usUfsgsAfgagagauCfcUfgGfgugusc 1076(NAG37)s(invAb)sgacacccaGfGfAfucucuuucaas(invAb) 1296 AD09981usCfsasUfgauacugAfgAfgCfuugcsu 1077(NAG37)s(invAb)sagcaagcuCfUfCfaguaucaugas(invAb) 1297 AD09982usUfsgsUfcaaccucAfcUfcUfuccgsa 1078(NAG37)s(invAb)sucggaagaGfUfGfagguugacaas(invAb) 1298 AD09983usUfsusCfcaacaauUfcUfcCfuugusc 1079(NAG37)s(invAb)sgacaaggaGfAfAfuuguuggaaas(invAb) 1299 AD09984usUfsgsAfguuagucUfcAfaAfgcugsc 1080(NAG37)s(invAb)sgcagcuuuGfAfGfacuaacucaas(invAb) 1300 AD09985asUfsgsAfcaauaucUfgUfgCfggagsg 1081(NAG37)s(invAb)sccuccgcaCfAfGfauauugucaus(invAb) 1301 AD09986usCfsasUfgacaauaUfcUfgUfgcggsa 1082(NAG37)s(invAb)succgcacaGfAfUfauugucaugas(invAb) 1302 AD09987usCfsasAfagaagauAfgAfaGfcagcsc 1083(NAG37)s(invAb)sggcugcuuCfUfAfucuucuuugas(invAb) 1303 AD09988usCfsasCfguuauuaCfcUfgUfgugcsu 1084(NAG37)s(invAb)sagcacacaGfGfUfaauaacguias(invAb) 1304 AD09989usAfsgsAfacuugagGfuUfaUfacagsg 1085(NAG37)s(invAb)sccuguauaAfCfCfucaaguucuas(invAb) 1305 AD09990asUfsgsCfuuugcugUfuCfaUfuggusc 1086(NAG37)s(invAb)sgaccaaugAfAfCfagcaaagcaus(invAb) 1306 AD09991usAfsgsUfauagauuCfaAfgGfuuausg 1087(NAG37)s(invAb)sca_2NuaaccuUfGfAfaucuauacuas 1307 (invAb) AD09992asGfsasGfuaaucuuGfcUfuUfaugcsc 1088(NAG37)s(invAb)sggcauaaaGfCfAfagauuacucus(invAb) 1308 AD09993asUfsasGfcaucauuUfcUfaGfguggsa 1089(NAG37)s(invAb)succaccuaGfAfAfaugaugcuaus(invAb) 1309 AD09994asGfsasCfagaagagAfcAfgAfgcuasg 1090(NAG37)s(invAb)scuagcucuGfUfCfucuucuiucus(invAb) 1310 AD09995asGfsusAfagaaaacCfaAfgCfcuuasg 1091(NAG37)s(invAb)scua_2NaggcuUfGfGfuuuucuuacus 1311 (invAb) AD10008usUfscsCfauaauacUfcUfgAfgagasg 1092(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD10009cPrpusUfscsCfauaauacUfcUfgAfgagasg 1093(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD10010cPrpuUfcCfauaauacUfcUfgAfgagasg 1094(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD10011cPrpuUfcCfauaauacUfcUfgAfgagsasg 1095(NAG37)s(invAb)scucucucaGfAfGfuauuauggaas(invAb) 1279 AD10012cPrpuUfcCfauaauacUfcUfgAfgagasg 1094(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10013cPrpuUfccauaaUfacUfcUfgAfgagasg 1096(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10014cPrpuUfcCfauaauacUfcUfgAfgagasg 1094(NAG37)s(invAb)scucucucaGfaGfUfauuauggaas(invAb) 1313 AD10015cPrpuUfccauaaUfacUfcUfgAfgagasg 1096(NAG37)s(invAb)scucucucaGfaGfUfauuauggaas(invAb) 1313 AD10016usAfsusAfcuuggagAfgCfaUfcacusg 1097(NAG37)s(invAb)scagugaugCfUfCfuccaaguauas(invAb) 1314 AD10017usUfsgsCfagacgauCfaUfaCfuuggsc 1098(NAG37)s(invAb)sgccaaguaUfGfAfucgucuicaas(invAb) 1315 AD10018usUfsgsAfaUfaaaacUfcUfcAfugccsa 1099(NAG37)s(invAb)suggcaugaGfAfGfuuuuauucaas(invAb) 1316 AD10019cPrpusUfsgsAfaUfaaaacUfcUfcAfugccsa 1100(NAG37)s(invAb)suggcaugaGfAfGfuuuuauucaas(invAb) 1316 AD10020usUfsgsAfaUfaaaacUfcUfcAfugccsa 1099(NAG37)s(invAb)suggcaugaGfAfGfuuuua_2Nuucaas 1317 (invAb) AD10021usAfscsUfuGfaAfgAfaGfaAfgCfuGfaGfsg 1101(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318 AD10022usAfscsUfugaagaaGfaAfgCfugagsg 1102(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318 AD10023cPrpusAfscsUfugaagaaGfaAfgCfugagsg 1103(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318 AD10024cPrpuAfcUfugaagaaGfaAfgCfugagsg 1104(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318 AD10025cPrpuAfcUfugaagaaGfaAfgCfugagsg 1104(NAG37)s(invAb)sccucagcuUfCfUfucuuuaaguas(invAb) 1319 AD10026cPrpuAfcUfugaagaaGfaAfgCfugasgsg 1105(NAG37)s(invAb)sccucagcuUfCfUfucuucaaguas(invAb) 1318 AD10027cPrpuAfcUfugaagaaGfaAfgCfugagsg 1104(NAG37)s(invAb)sccucagcuUfcUfUfcuucaaguas(invAb) 1320 AD10028cPrpuAfcUfugaagaaGfaAfgCfugagsg 1104(NAG37)s(invAb)sccucagcuUfcUfuCfuucaaguas(invAb) 1321 AD10029cPrpuAfcuugAfagaaGfaAfgCfugagsg 1106(NAG37)s(invAb)sccucagcuUfcUfuCfuucaaguas(invAb) 1321 AD10030cPrpuAfcuugaaGfaaGfaAfgCfugagsg 1107(NAG37)s(invAb)sccucagcuUfcUfUfcuucaaguas(invAb) 1320 AD10091cPrpusUfsusGfaAfugcugAfgAfaAfuAfcusc 1108(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD10092cPrpusUfsusGfaaugcugAfgAfaAfuacusc 1109(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD10093cPrpusUfsusgaaUfgcugAfgAfaAfuacusc 1110(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD10094cPrpusUfsusGfaaugcugAfgAfaAfuacusc 1109(NAG37)s(invAb)sgaguauuuCfuCfAfgcauucaaas(invAb) 1322 AD10095cPrpusUfsusgaaUfgcugAfgAfaAfuacusc 1110(NAG37)s(invAb)sgaguauuuCfuCfAfgcauucaaas(invAb) 1322 AD10096cPrpuUfuGfaaugcugAfgAfaAfuacusc 1110(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD10097cPrpuUfuGfaaugcugAfgAfaAfuacsusc 1112(NAG37)s(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) 1269 AD10099asGfsasAfaAfguggaCfgAfuCfuUfgusc 1113(NAG37)s(invAb)sgacaagauCfGfUfccacuuuucus(invAb) 1323 AD10100usAfsgsUfuGfucacuGfcAfaCfaUfggsu 1114(NAG37)s(invAb)saccauguuGfCfAfgugacaacuas(invAb) 1324 AD10101asUfsusCfcUfuccacAfgUfuGfuCfacsc 1115(NAG37)s(invAb)sggugacaaCfUfGfuggaaggaaus(invAb) 1325 AD10102usGfscsAfuUfcucaaUfcUfcCfuCfcasc 1116(NAG37)s(invAb)sguggaggaGfAfUfugagaaugcas(invAb) 1326 AD10103usUfscsAfaUfgccaaUfcUfcCfgUfgusc 1117(NAG37)s(invAb)sgacacggaGfAfUfuggcauugaas(invAb) 1327 AD10104asUfsasUfuCfuugaaCfuUfcAfuCfucsg 1118(NAG37)s(invAb)scgagaugaAfGfUfucaagaaua_2Nus 1328 (invAb) AD10105usUfsasUfgGfagagcAfgUfaUfcUfccsu 1119(NAG37)s(invAb)saggagauaCfUfGfcucuccauaas(invAb) 1329 AD10106usAfsasUfgCfugagaAfaUfaCfuCfccsc 1120(NAG37)s(invAb)sggggaguaUfUfUfcucagcauuas(invAb) 1330 AD10107usGfsasAfuGfcugagAfaAfuAfcUfccsc 1121(NAG37)s(invAb)sgggaguauUfUfCfucagcauucas(invAb) 1331 AD10108usCfsasAfuGfucaucUfuCfuCfuCfcgsg 1122(NAG37)s(invAb)sccggagagAfAfGfaugacauugas(invAb) 1332 AD10109asCfsasAfaUfuccagUfuAfuGfuUfacsc 1123(NAG37)s(invAb)sgguaacauAfAfCfuggaauuugus(invAb) 1333 AD10110usUfscsAfaUfugugaUfaAfuGfgCfugsg 1124(NAG37)s(invAb)sccagccauUfAfUfcacaauugaas(invAb) 1334 AD10111asAfscsAfuUfuuugcAfaCfaAfaGfcusc 1125(NAG37)s(invAb)sgagcuuugUfUfGfcaaaaauguus(invAb) 1335 AD10112usCfsasAfcAfuuuuuGfcAfaCfaAfagsc 1126(NAG37)s(invAb)sgcuuuguuGfCfAfaaaauguugas(invAb) 1336 AD10113usUfsusCfaCfucgaaCfcAfcAfaUfccsg 1127(NAG37)s(invAb)scggauuguGfGfUfucgagugaaas(invAb) 1337 AD10176cPrpusCfsusUfaUfuccaaAfcUfuGfgUfggsg 1128(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201 AD10177cPrpuCfuUfaUfuccaaAfcUfuGfgUfggsg 1129(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201 AD10178cPrpuCfuuauucCfaaAfcUfuGfguggsg 1130(NAG37)s(invAb)scccaccaaGfUfUfuggaauaagas(invAb) 1201 AD10179cPrpuCfuuauucCfaaAfcUfuGfguggsg 1130(NAG37)s(invAb)scccaccaaGfuUfuGfgaauaagas(invAb) 1338 AD10180cPrpuCfuuauucCfaaAfcUfuGfguggsg 1130(NAG37)s(invAb)scccaccaaGfuUfUfggaauaagas(invAb) 1339 AD10181cPrpuGfcauauucacCfaUfuUfaggcsa 1131(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223 AD10182cPrpuGfcauaUfucacCfaUfuUfaggcsa 1132(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10183cPrpuGfcauauuCfacCfaUfuUfaggcsa 1133(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10184cPrpuGfcauaUfucacCfaUfuUfaggcsa 1132(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10200usGfscauauucacCfaUfuUfaggcsa 1134(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223 AD10201usGfscauaUfucacCfaUfuUfaggcsa 1135(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223 AD10202usGfscauauuCfacCfaUfuUfaggcsa 1136(NAG37)s(invAb)sugccuaAfaUfgGfugaauaugcas(invAb) 1223 AD10203usGfscauaUfucacCfaUfuUfaggcsa 1135(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10204usGfscauauuCfacCfaUfuUfaggcsa 1136(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10205usGfscauaUfucacCfaUfuUfaggcsa 1135(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10275cPrpasUfsgsAfaacaaacAfaAfcCfcuggsa 1137(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271 AD10276cPrpasUfsgsAfaacaaacAfaAfcCfcugsgsa 1138(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271 AD10277cPrpasUfsgAfaacaaacAfaAfcCfcugsgsa 1139(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271 AD10278cPrpaUfgAfaacaaacAfaAfcCfcugsgsa 1140(NAG37)s(invAb)succaggguUfUfGfuuuguuucaus(invAb) 1271 AD10279cPrpasUfsgAfaacaaacAfaAfcCfcugsgsa 1139(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10280cPrpasUfsgaaacaAfacAfaAfcCfcugsgsa 1141(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10281cPrpasUfsgaaaCfaaacAfaAfcCfcugsgsa 1142(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10282cPrpasUfsgaAfacaaacAfaAfcCfcugsgsa 1143(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10283cPrpasUfsgAfaaCfaAfacAfaAfcCfcugsgsa 1144(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10619cPrpusUfscsCfauaauacUfcUfgAfgagasg 1093(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10620cPrpusUfscCfauaauacUfcUfgAfgagasg 1145(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10621cPrpusUfscCfauaauacUfcUfgAfgagsasg 1146(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10622cPrpuUfcCfauaauacUfcUfgAfgagsasg 1095(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10623cPrpuUfcCfauaauacUfcUfgAfgagasc 1147(NAG37)s(invAb)sgucucucaGfaGfuAfuuauggaas(invAb) 1343 AD10624cPrpuUfcCfauaauacUfcUfgAfgaggsg 1148(NAG37)s(invAb)scccucucaGfaGfuAfuuauggaas(invAb) 1344 AD10625cPrpuUfcCfauaauacUfcUfgAfgaggsc 1149(NAG37)s(invAb)sgccucucaGfaGfuAfuuauggaas(invAb) 1345 AD10626cPrpuUfcCfauaauacUfcUfgAfgaggsu 1150(NAG37)s(invAb)saccucucaGfaGfuAfuuauggaas(invAb) 1346 AD10627cPrpuUfcCfauaauacUfcUfgAfgaggsa 1151(NAG37)s(invAb)succucucaGfaGfuAfuuauggaas(invAb) 1347 AD10628cPrpuUfccauAfauacUfcUfgAfgagasg 1152(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10629cPrpusGfscsauauuCfacCfaUfuUfaggcsa 1153(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10630cPrpusGfscauauuCfacCfaUfuUfaggcsa 1154(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10631cPrpusGfscauauuCfacCfaUfuUfaggscsa 1155(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10632cPrpuGfcauauuCfacCfaUfuUfaggscsa 1156(NAG37)s(invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) 1340 AD10633cPrpusGfscsauaUfucacCfaUfuUfaggcsa 1157(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10634cPrpusGfscauaUfucacCfaUfuUfaggcsa 1158(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10635cPrpusGfscauaUfucacCfaUfuUfaggscsa 1159(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10636cPrpuGfcauaUfucacCfaUfuUfaggscsa 1160(NAG37)s(invAb)sugccuaaaUfgGfUfgaauaugcas(invAb) 1341 AD10728asUfsgsAfcaauaucUfgUfgCfggagsg 1081(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10729asUfsgsacaAfuaucUfgUfgCfggagsg 1161(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10730asUfsgsacaauAfucUfgUfgCfggagsg 1162(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10731cPrpasUfsgsacaauAfucUfgUfgCfggagsg 1163(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10732cPrpusUfsgsacaauAfucUfgUfgCfggagsg 1164(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaas(invAb) 1349 AD10733cPrpaUfgacaauAfucUfgUfgCfggagsg 1165(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10734cPrpaUfgacaauAfucUfgUfgCfggasgsg 1166(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10735cPrpasUfsgacaauAfucUfgUfgCfggasgsg 1167(NAG37)s(invAb)sccuccgcaCfaGfaUfauugucaus(invAb) 1348 AD10736cPrpasUfsgsacaauAfucUfgUfgCfggasg 1168(NAG37)s(invAb)scuccgcaCfaGfaUfauugucaus(invAb) 1350 AD10737cPrpasUfsgsacaauAfucUfgUfgCfggsa 1169(NAG37)s(invAb)succgcaCfaGfaUfauugucaus(invAb) 1351 AD10952cPrpusUfsccauaaUfacUfcUfgAfgagsasg 1170(NAG37)s(invAb)scucucucaGfaGfuAfuuauggaas(invAb) 1312 AD10953cPrpusUfscCfauaauacUfcUfgAfgagsasc 1171(NAG37)s(invAb)sgucucucaGfaGfuAfuuauggaas(invAb) 1343 AD10954cPrpusUfsgaaaCfaaacAfaAfcCfcugsgsa 1172(NAG37)s(invAb)succaggguUfuGfuUfuguuucaas(invAb) 1285 AD10967asUfsgsAfaAfcaaacAfaAfcCfcUfggsa 1048(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10968asUfsgAfaAfcaaacAfaAfcCfcUfgsgsa 1173(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD10969asUfsgAfaacaaacAfaAfcCfcugsgsa 1174(NAG37)s(invAb)succaggguUfuGfuUfuguuucaus(invAb) 1342 AD12167asCfsucgUfuccauaaUfaCfucugasgsa 1672(NAG37)suscagagUfaUfUfAfuggaacgagus(invAb) 1676 AD12168asUfsccaUfaauacucUfgAfgagagsasu 1673(NAG37)scsucucuCfaGfAfGfuauuauggaus(invAb) 1677

In some aspects, an XDH RNAi agent is prepared or provided as a salt,mixed salt, or a free-acid. The RNAi agents described herein, upondelivery to a cell expressing an XDH gene, inhibit or knockdownexpression of one or more XDH genes in vivo and/or in vitro.

Targeting Ligands or Groups, Linking Groups, and Delivery Vehicles

In some aspects, an XDH RNAi agent is conjugated to one or morenon-nucleotide groups including, but not limited to, a targeting group,a linking group, a targeting ligand, a delivery polymer, or a deliveryvehicle. The non-nucleotide group can enhance targeting, delivery orattachment of the RNAi agent. Examples of targeting groups and linkinggroups are provided in Table 6. The non-nucleotide group can becovalently linked to the 3′ and/or 5′ end of either the sense strandand/or the antisense strand. In some aspects, an XDH RNAi agent containsa non-nucleotide group linked to the 3′ and/or 5′ end of the sensestrand. In some aspects, a non-nucleotide group is linked to the 5′ endof an XDH RNAi agent sense strand. A non-nucleotide group may be linkeddirectly or indirectly to the RNAi agent via a linker/linking group. Insome aspects, a non-nucleotide group is linked to the RNAi agent via alabile, cleavable, or reversible bond or linker.

In some aspects, a non-nucleotide group enhances the pharmacokinetic orbiodistribution properties of an RNAi agent or conjugate to which it isattached to improve cell- or tissue-specific distribution andcell-specific uptake of the RNAi agent or conjugate. In some aspects, anon-nucleotide group enhances endocytosis of the RNAi agent.

Targeting groups or targeting moieties enhance the pharmacokinetic orbiodistribution properties of a conjugate or RNAi agent to which theyare attached to improve cell-specific (including, in some cases, organspecific) distribution and cell-specific (or organ specific) uptake ofthe conjugate or RNAi agent. A targeting group can be monovalent,divalent, trivalent, tetravalent, or have higher valency for the targetto which it is directed. Representative targeting groups include,without limitation, compounds with affinity to cell surface molecules,cell receptor ligands, haptens, antibodies, monoclonal antibodies,antibody fragments, and antibody mimics with affinity to cell surfacemolecules.

In some aspects, a targeting group is linked to an RNAi agent using alinker, such as a PEG linker or one, two, or three abasic and/or ribitol(abasic ribose) residues, which can in some instances serve as linkers.In some aspects, a targeting ligand comprises a galactose-derivativecluster.

The XDH RNAi agents described herein can be synthesized having areactive group, such as an amino group (also referred to herein as anamine), at the 5′-terminus and/or the 3′-terminus. The reactive groupcan be used subsequently to attach a targeting moiety using methodstypical in the art.

In some aspects, a targeting group comprises an asialoglycoproteinreceptor ligand. As used herein, an asialoglycoprotein receptor ligandis a ligand that contains a moiety having affinity for theasialoglycoprotein receptor. As noted herein, the asialoglycoproteinreceptor is highly expressed on hepatocytes. In some aspects, anasialoglycoprotein receptor ligand includes or consists of one or moregalactose derivatives. As used herein, the term galactose derivativeincludes both galactose and derivatives of galactose having affinity forthe asialoglycoprotein receptor that is equal to or greater than that ofgalactose. Galactose derivatives include, but are not limited to:galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine,N-propionyl-galactosamine, N-n-butanoyl-galactosamine, andN-iso-butanoylgalactos-amine (see for example: S. T. Iobst and K.Drickamer, J. B. C., 1996, 271, 6686). Galactose derivatives, andclusters of galactose derivatives, that are useful for in vivo targetingof oligonucleotides and other molecules to the liver are known in theart (see, for example, Baenziger and Fiete, 1980, Cell, 22, 611-620;Connolly et al., 1982, J. Biol. Chem., 257, 939-945).

Galactose derivatives have been used to target molecules to hepatocytesin vivo through their binding to the asialoglycoprotein receptorexpressed on the surface of hepatocytes. Binding of asialoglycoproteinreceptor ligands to the asialoglycoprotein receptor(s) facilitatescell-specific targeting to hepatocytes and endocytosis of the moleculeinto hepatocytes. Asialoglycoprotein receptor ligands can be monomeric(e.g., having a single galactose derivative, also referred to asmonovalent or monodentate) or multimeric (e.g., having multiplegalactose derivatives). The galactose derivative or galactose derivativecluster can be attached to the 3′ or 5′ end of the sense or antisensestrand of the RNAi agent using methods known in the art. The preparationof targeting ligands, such as galactose derivative clusters, isdescribed in, for example, International Patent Application PublicationNo. WO 2018/044350 to Arrowhead Pharmaceuticals, Inc., and InternationalPatent Application Publication No. WO 2017/156012 to ArrowheadPharmaceuticals, Inc., the contents of both of which are incorporated byreference herein in their entirety.

As used herein, a galactose derivative cluster comprises a moleculehaving two to four terminal galactose derivatives. A terminal galactosederivative is attached to a molecule through its C-1 carbon. In someaspects, the galactose derivative cluster is a galactose derivativetrimer (also referred to as tri-antennary galactose derivative ortri-valent galactose derivative). In some aspects, the galactosederivative cluster comprises N-acetyl-galactosamine moieties. In someaspects, the galactose derivative cluster comprises threeN-acetyl-galactosamine moieties. In some aspects, the galactosederivative cluster is a galactose derivative tetramer (also referred toas tetra-antennary galactose derivative or tetra-valent galactosederivative). In some aspects, the galactose derivative cluster comprisesfour N-acetyl-galactosamine moieties.

As used herein, a galactose derivative trimer contains three galactosederivatives, each linked to a central branch point. As used herein, agalactose derivative tetramer contains four galactose derivatives, eachlinked to a central branch point. The galactose derivatives can beattached to the central branch point through the C-1 carbons of thesaccharides. In some aspects, the galactose derivatives are linked tothe branch point via linkers or spacers. In some aspects, the linker orspacer is a flexible hydrophilic spacer, such as a PEG group (see, e.g.,U.S. Pat. No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol. 39 p.1538-1546). In some aspects, the PEG spacer is a PEGS spacer. The branchpoint can be any small molecule which permits attachment of threegalactose derivatives and further permits attachment of the branch pointto the RNAi agent. An example of branch point group is a di-lysine ordi-glutamate. Attachment of the branch point to the RNAi agent can occurthrough a linker or spacer. In some aspects, the linker or spacercomprises a flexible hydrophilic spacer, such as, but not limited to, aPEG spacer. In some aspects, the linker comprises a rigid linker, suchas a cyclic group. In some aspects, a galactose derivative comprises orconsists of N-acetyl-galactosamine. In some aspects, the galactosederivative cluster is comprised of a galactose derivative tetramer,which can be, for example, an N-acetyl-galactosamine tetramer.

Certain aspects of the present disclosure include pharmaceuticalcompositions for delivering an XDH RNAi agent to a liver cell in vivo.Such pharmaceutical compositions can include, for example, an XDH RNAiagent conjugated to a galactose derivative cluster. In some aspects, thegalactose derivative cluster is comprised of a galactose derivativetrimer, which can be, for example, an N-acetyl-galactosamine trimer, orgalactose derivative tetramer, which can be, for example, anN-acetyl-galactosamine tetramer.

A targeting ligand or targeting group can be linked to the 3′ or 5′ endof a sense strand or an antisense strand of an XDH RNAi agent disclosedherein.

Targeting ligands include, but are not limited to (NAG37) and (NAG37)sas defined in Table 6. Other targeting groups and targeting ligands,including galactose cluster targeting ligands, are known in the art.

In some aspects, a linking group is conjugated to the RNAi agent. Thelinking group facilitates covalent linkage of the agent to a targetinggroup, delivery polymer, or delivery vehicle. The linking group can belinked to the 3′ and/or the 5′ end of the RNAi agent sense strand orantisense strand. In some aspects, the linking group is linked to theRNAi agent sense strand. In some aspects, the linking group isconjugated to the 5′ or 3′ end of an RNAi agent sense strand. In someaspects, a linking group is conjugated to the 5′ end of an RNAi agentsense strand. Examples of linking groups, can include, but are notlimited to: reactive groups such a primary amines and alkynes, alkylgroups, abasic nucleotides, ribitol (abasic ribose), and/or PEG groups.

In some aspects, a targeting group is linked internally to a nucleotideon the sense strand and/or the antisense strand of the RNAi agent. Insome aspects, a targeting group is linked to the RNAi agent via alinker.

A linker or linking group is a connection between two atoms that linksone chemical group (such as an RNAi agent) or segment of interest toanother chemical group (such as a targeting group or delivery polymer)or segment of interest via one or more covalent bonds. A labile linkagecontains a labile bond. A linkage can optionally include a spacer thatincreases the distance between the two joined atoms. A spacer canfurther add flexibility and/or length to the linkage. Spacers include,but are not be limited to, alkyl groups, alkenyl groups, alkynyl groups,aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups;each of which can contain one or more heteroatoms, heterocycles, aminoacids, nucleotides, and saccharides. Spacer groups are well known in theart and the preceding list is not meant to limit the scope of thedescription.

In some aspects, when two or more RNAi agents are included in a singlecomposition, each of the RNAi agents may be linked to the same targetinggroup or two a different targeting groups (i.e., targeting groups havingdifferent chemical structure). In some aspects, targeting groups arelinked to the XDH RNAi agents disclosed herein without the use of anadditional linker. In some aspects, the targeting group itself isdesigned having a linker or other site to facilitate conjugation readilypresent. In some aspects, when two or more XDH RNAi agents are includedin a single molecule, each of the RNAi agents may utilize the samelinker or different linkers (i.e., linkers having different chemicalstructures).

Any of the XDH RNAi agent nucleotide sequences listed in Tables 2, 3, 4,or 5C, whether modified or unmodified, can contain 3′ and/or 5′targeting group(s) or linking group(s). Any of the XDH RNAi agentsequences listed in Table 3 or 4, or are otherwise described herein,which contain a 3′ or 5′ targeting group or linking group, canalternatively contain no 3′ or 5′ targeting group or linking group, orcan contain a different 3′ or 5′ targeting group or linking groupincluding, but not limited to, those depicted in Table 6. Any of the XDHRNAi agent duplexes listed in Tables 5A, 5B and 5C, whether modified orunmodified, can further comprise a targeting group or linking group,including, but not limited to, those depicted in Table 6, and thetargeting group or linking group can be attached to the 3′ or 5′terminus of either the sense strand or the antisense strand of the XDHRNAi agent duplex.

Examples of targeting groups and linking groups (which when combined canform targeting ligands) are provided in Table 6. Table 4 and Table 5Cprovide several aspects of XDH RNAi agent sense strands having atargeting group or linking group linked to the 5′ or 3′ end.

TABLE 6 Structures Representing Various Modified Nucleotides, TargetingLigands or Targeting Groups, Capping Residues, and Linking Groups

When positioned internally:

When positioned internally:

When positioned at the 3' terminal end:

In each of the above structures in Table 6, NAG comprises anN-acetyl-galactosamine or another galactose derivative, as would beunderstood by a person of ordinary skill in the art to be attached inview of the structures above and description provided herein. Otherlinking groups known in the art may be used.

In some aspects, a delivery vehicle can be used to deliver an RNAi agentto a cell or tissue. A delivery vehicle is a compound that improvesdelivery of the RNAi agent to a cell or tissue. A delivery vehicle caninclude, or consist of, but is not limited to: a polymer, such as anamphipathic polymer, a membrane active polymer, a peptide, a melittinpeptide, a melittin-like peptide (MLP), a lipid, a reversibly modifiedpolymer or peptide, or a reversibly modified membrane active polyamine.In some aspects, the RNAi agents can be combined with lipids,nanoparticles, polymers, liposomes, micelles, DPCs or other deliverysystems available in the art. The RNAi agents can also be chemicallyconjugated to targeting groups, lipids (including, but not limited tocholesterol and cholesteryl derivatives), nanoparticles, polymers,liposomes, micelles, DPCs (see, for example WO 2000/053722, WO2008/0022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO2013/158141, each of which is incorporated herein by reference),hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesivemicrospheres, proteinaceous vectors, or other delivery systems suitablefor nucleic acid or oligonucleotide delivery as known and available inthe art.

Pharmaceutical Compositions and Formulations

The XDH RNAi agents disclosed herein can be prepared as pharmaceuticalcompositions or formulations (also referred to herein as “medicaments”).In some aspects, pharmaceutical compositions include at least one XDHRNAi agent. These pharmaceutical compositions are particularly useful inthe inhibition of the expression of the target mRNA in a target cell, agroup of cells, a tissue, or an organism.

The pharmaceutical compositions can be used to treat a subject having adisease, disorder, or condition that would benefit from reduction in thelevel of the target XDH mRNA, or inhibition in expression of the targetgene. The pharmaceutical compositions can be used to treat a subject atrisk of developing a disease, disorder, symptom, or condition that wouldbenefit from reduction of the level of the target mRNA or an inhibitionin expression the target gene. In one embodiment, the method includesadministering an XDH RNAi agent linked to a targeting ligand asdescribed herein, to a subject to be treated. In some aspects, one ormore pharmaceutically acceptable excipients (including vehicles,carriers, diluents, and/or delivery polymers) are added to thepharmaceutical compositions that include an XDH RNAi agent, therebyforming a pharmaceutical formulation or medicament suitable for in vivodelivery to a subject, including a human.

The pharmaceutical compositions that include an XDH RNAi agent andmethods disclosed herein decrease the level of the target mRNA in acell, group of cells, group of cells, tissue, organ, or subject,including by administering to the subject a therapeutically effectiveamount of a herein described XDH RNAi agent, thereby inhibiting theexpression of XDH mRNA in the subject. In some aspects, the subject hasbeen previously identified as having a pathogenic upregulation of thetarget gene in hepatocytes. In some aspects, the subject has beenpreviously identified or diagnosed as having gout or hyperuricemia. Insome aspects, the subject has been suffering from symptoms associatedwith gout or hyperuricemia. In some aspects, the subject would benefitfrom a reduction of XDH gene expression in the subject's liver.

In some aspects, the described pharmaceutical compositions including anXDH RNAi agent are used for treating or managing clinical presentationsassociated with gout or hyperuricemia. In some aspects, atherapeutically (including prophylactically) effective amount of one ormore of pharmaceutical compositions is administered to a subject in needof such treatment. In some aspects, administration of any of thedisclosed XDH RNAi agents can be used to decrease the number, severity,and/or frequency of symptoms of a disease in a subject.

The described pharmaceutical compositions that include an XDH RNAi agentcan be used to treat at least one symptom in a subject having a diseaseor disorder that would benefit from reduction or inhibition inexpression of XDH mRNA and/or a reduction in serum uric acid levels.Measuring serum uric acid levels can be conducted in accordance withestablished methods known in the art.

In some aspects, the subject is administered a therapeutically effectiveamount of one or more pharmaceutical compositions that include an XDHRNAi agent thereby treating the symptom. In other aspects, the subjectis administered a prophylactically effective amount of one or more XDHRNAi agents, thereby preventing or inhibiting the at least one symptom.

The route of administration is the path by which an XDH RNAi agent isbrought into contact with the body. In general, methods of administeringdrugs and oligonucleotides and nucleic acids for treatment of a mammalare well known in the art and can be applied to administration of thecompositions described herein. The XDH RNAi agents disclosed herein canbe administered via any suitable route in a preparation appropriatelytailored to the particular route. Thus, herein described pharmaceuticalcompositions can be administered by injection, for example,intravenously, intramuscularly, intracutaneously, subcutaneously,intraarticularly, or intraperitoneally. In some aspects, the hereindescribed pharmaceutical compositions are administered via subcutaneousinjection.

The pharmaceutical compositions including an XDH RNAi agent describedherein can be delivered to a cell, group of cells, tissue, or subjectusing oligonucleotide delivery technologies known in the art. Ingeneral, any suitable method recognized in the art for delivering anucleic acid molecule (in vitro or in vivo) can be adapted for use withthe compositions described herein. For example, delivery can be by localadministration, (e.g., direct injection, implantation, or topicaladministering), systemic administration, or subcutaneous, intravenous,intraperitoneal, or parenteral routes, including intracranial (e.g.,intraventricular, intraparenchymal and intrathecal), intramuscular,transdermal, airway (aerosol), nasal, oral, rectal, or topical(including buccal and sublingual) administration. In certain aspects,the compositions are administered by subcutaneous or intravenousinfusion or injection.

In some aspects, the pharmaceutical compositions described hereincomprise one or more pharmaceutically acceptable excipients. Thepharmaceutical compositions described herein are formulated foradministration to a subject.

As used herein, a pharmaceutical composition or medicament includes apharmacologically effective amount of at least one of the describedtherapeutic compounds and one or more pharmaceutically acceptableexcipients. Pharmaceutically acceptable excipients (excipients) aresubstances other than the Active Pharmaceutical Ingredient (API,therapeutic product, e.g., XDH RNAi agent) that are intentionallyincluded in the drug delivery system. Excipients do not exert or are notintended to exert a therapeutic effect at the intended dosage.Excipients can act to a) aid in processing of the drug delivery systemduring manufacture, b) protect, support or enhance stability,bioavailability or patient acceptability of the API, c) assist inproduct identification, and/or d) enhance any other attribute of theoverall safety, effectiveness, of delivery of the API during storage oruse. A pharmaceutically acceptable excipient may or may not be an inertsubstance.

Excipients include, but are not limited to: absorption enhancers,anti-adherents, anti-foaming agents, anti-oxidants, binders, bufferingagents, carriers, coating agents, colors, delivery enhancers, deliverypolymers, detergents, dextran, dextrose, diluents, disintegrants,emulsifiers, extenders, fillers, flavors, glidants, humectants,lubricants, oils, polymers, preservatives, saline, salts, solvents,sugars, surfactants, suspending agents, sustained release matrices,sweeteners, thickening agents, tonicity agents, vehicles,water-repelling agents, and wetting agents.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions (where water-soluble) or dispersions and sterilepowders for the extemporaneous preparation of sterile injectablesolutions or dispersion. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, Cremophor®EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).Suitable carriers should be stable under the conditions of manufactureand storage and should be preserved against the contaminating action ofmicroorganisms such as bacteria and fungi. The carrier can be a solventor dispersion medium containing, for example, water, ethanol, polyol(for example, glycerol, propylene glycol, and liquid polyethyleneglycol), and suitable mixtures thereof. The proper fluidity can bemaintained, for example, by the use of a coating such as lecithin, bythe maintenance of the required particle size in the case of dispersionand by the use of surfactants. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, polyalcohols such asmannitol, sorbitol, and sodium chloride in the composition. Prolongedabsorption of the injectable compositions can be brought about byincluding in the composition an agent which delays absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed byfilter sterilization. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle, which containsa basic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, methods of preparation include vacuumdrying and freeze-drying which yields a powder of the active ingredientplus any additional desired ingredient from a previouslysterile-filtered solution thereof.

In some aspects, pharmaceutical formulations that include the XDH RNAiagents disclosed herein suitable for subcutaneous administration can beprepared in an aqueous sodium phosphate buffer (e.g., the XDH RNAi agentformulated in 0.5 mM sodium phosphate monobasic, 0.5 mM sodium phosphatedibasic, in water). In some aspects, pharmaceutical formulations thatinclude the XDH RNAi agents disclosed herein suitable for subcutaneousadministration can be prepared in water for injection (sterile water).XDH RNAi agents disclosed herein suitable for subcutaneousadministration can be prepared in isotonic saline (0.9%).

Formulations suitable for intra-articular administration can be in theform of a sterile aqueous preparation of the drug that can be inmicrocrystalline form, for example, in the form of an aqueousmicrocrystalline suspension. Liposomal formulations or biodegradablepolymer systems can also be used to present the drug for bothintra-articular and ophthalmic administration.

Formulations suitable for oral administration of the XDH RNAi agentsdisclosed herein can also be prepared. In some aspects, the XDH RNAiagents disclosed herein are administered orally. In some aspects, theXDH RNAi agents disclosed herein are formulated in a capsule for oraladministration.

The active compounds can be prepared with carriers that will protect thecompound against rapid elimination from the body, such as a controlledrelease formulation, including implants and microencapsulated deliverysystems. Biodegradable, biocompatible polymers can be used, such asethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen,polyorthoesters, and polylactic acid. Methods for preparation of suchformulations will be apparent to those skilled in the art. Liposomalsuspensions can also be used as pharmaceutically acceptable carriers.These can be prepared according to methods known to those skilled in theart, for example, as described in U.S. Pat. No. 4,522,811.

The XDH RNAi agents can be formulated in compositions in dosage unitform for ease of administration and uniformity of dosage. Dosage unitform refers to physically discrete units suited as unitary dosages forthe subject to be treated; each unit containing a predetermined quantityof active compound calculated to produce the desired therapeutic effectin association with the required pharmaceutical carrier. Thespecification for the dosage unit forms of the disclosure are dictatedby and directly dependent on the unique characteristics of the activecompound and the therapeutic effect to be achieved, and the limitationsinherent in the art of compounding such an active compound for thetreatment of individuals.

A pharmaceutical composition can contain other additional componentscommonly found in pharmaceutical compositions. Such additionalcomponents include, but are not limited to: anti-pruritics, astringents,local anesthetics, analgesics, antihistamines, or anti-inflammatoryagents (e.g., acetaminophen, NSAIDs, diphenhydramine, etc.). It is alsoenvisioned that cells, tissues, or isolated organs that express orcomprise the herein defined RNAi agents may be used as “pharmaceuticalcompositions.” As used herein, “pharmacologically effective amount,”“therapeutically effective amount,” or simply “effective amount” refersto that amount of an RNAi agent to produce a pharmacological,therapeutic, or preventive result.

In some aspects, the methods disclosed herein further comprise the stepof administering a second therapeutic or treatment in addition toadministering an RNAi agent disclosed herein. In some aspects, thesecond therapeutic is another XDH RNAi agent (e.g., an XDH RNAi agentthat targets a different sequence within the XDH target). In otheraspects, the second therapeutic can be a small molecule drug, anantibody, an antibody fragment, or an aptamer.

In some aspects, the described XDH RNAi agent(s) are optionally combinedwith one or more additional therapeutics. The XDH RNAi agent andadditional therapeutic(s) can be administered in a single composition orthey can be administered separately. In some aspects, the one or moreadditional therapeutics is administered separately in separate dosageforms from the RNAi agent (e.g., the XDH RNAi agent is administered bysubcutaneous injection, while the additional therapeutic involved in themethod of treatment dosing regimen is administered orally). In someaspects, the described XDH RNAi agent(s) are administered to a subjectin need thereof via subcutaneous injection, and the one or more optionaladditional therapeutics are administered orally, which together providefor a treatment regimen for diseases and conditions associated with goutor hyperuricemia. In some aspects, the described XDH RNAi agent(s) areadministered to a subject in need thereof via subcutaneous injection,and the one or more optional additional therapeutics are administeredvia a separate subcutaneous injection. In some aspects, the XDH RNAiagent and one or more additional therapeutics are combined into a singledosage form (e.g., a “cocktail” formulated into a single composition forsubcutaneous injection). The XDH RNAi agents, with or without the one ormore additional therapeutics, can be combined with one or moreexcipients to form pharmaceutical compositions.

Generally, an effective amount of an XDH RNAi agent will be in the rangeof from about 0.1 to about 100 mg/kg of body weight/dose, e.g., fromabout 1.0 to about 50 mg/kg of body weight/dose. In some aspects, aneffective amount of an active compound will be in the range of fromabout 0.25 to about 5 mg/kg of body weight per dose. In some aspects, aneffective amount of an active ingredient will be in the range of fromabout 0.5 to about 4 mg/kg of body weight per dose. In some aspects, aneffective amount of an XDH RNAi agent may be a fixed dose. In someaspects, the fixed dose is in the range of from about 5 mg to about1,000 mg of XDH RNAi agent. In some aspects, the fixed does is in therange of 50 to 400 mg of XDH RNAi agent. Dosing may be weekly,bi-weekly, monthly, quarterly, or at any other interval depending on thedose of XDH RNAi agent administered, the activity level of theparticular XDH RNAi agent, and the desired level of inhibition for theparticular subject. The Examples herein show suitable levels forinhibition in certain animal species. The amount administered willdepend on such variables as the overall health status of the patient orsubject, the relative biological efficacy of the compound delivered, theformulation of the drug, the presence and types of excipients in theformulation, and the route of administration. Also, it is to beunderstood that the initial dosage administered can be increased beyondthe above upper level to rapidly achieve the desired blood-level ortissue level, or the initial dosage can be smaller than the optimum.

For treatment of disease or for formation of a medicament or compositionfor treatment of a disease, the pharmaceutical compositions describedherein including an XDH RNAi agent can be combined with an excipient orwith a second therapeutic agent or treatment including, but not limitedto: a second or other RNAi agent, a small molecule drug, an antibody, anantibody fragment, peptide and/or an aptamer.

The described XDH RNAi agents, when added to pharmaceutically acceptableexcipients or adjuvants, can be packaged into kits, containers, packs,or dispensers. The pharmaceutical compositions described herein may bepackaged in pre-filled syringes, pen injectors, autoinjectors, infusionbags/devices, or vials.

Methods of Treatment and Inhibition of Expression

The XDH RNAi agents disclosed herein can be used to treat a subject(e.g., a human or other mammal) having a disease or disorder that wouldbenefit from administration of the RNAi agent. In some aspects, the RNAiagents disclosed herein can be used to treat a subject (e.g., a human)that would benefit from reduction and/or inhibition in expression of XDHmRNA and/or XDH protein levels, which can lead to a reduction in serumuric acid levels in, for example, a subject that has been diagnosed withor is suffering from symptoms related to gout or hyperuricemia.

In some aspects, the subject is administered a therapeutically effectiveamount of any one or more XDH RNAi agents. Treatment of a subject caninclude therapeutic and/or prophylactic treatment. The subject isadministered a therapeutically effective amount of any one or more XDHRNAi agents described herein. The subject can be a human, patient, orhuman patient. The subject may be an adult, adolescent, child, orinfant. Administration of a pharmaceutical composition described hereincan be to a human being or animal.

The XDH RNAi agents described herein can be used to treat at least onesymptom in a subject having an XDH-related disease or disorder, orhaving a disease or disorder that is mediated at least in part by XDHgene expression. In some aspects, the XDH RNAi agents are used to treator manage a clinical presentation of a subject with a disease ordisorder that would benefit from or be mediated at least in part by areduction in XDH mRNA. The subject is administered a therapeuticallyeffective amount of one or more of the XDH RNAi agents or XDH RNAiagent-containing compositions described herein. In some aspects, themethods disclosed herein comprise administering a composition comprisingan XDH RNAi agent described herein to a subject to be treated. In someaspects, the subject is administered a prophylactically effective amountof any one or more of the described XDH RNAi agents, thereby treatingthe subject by preventing or inhibiting the at least one symptom.

In certain aspects, the present disclosure provides methods fortreatment of diseases, disorders, conditions, or pathological statesmediated at least in part by XDH gene expression, in a patient in needthereof, wherein the methods include administering to the patient any ofthe XDH RNAi agents described herein.

In some aspects, the RNAi agent comprises an antisense strand comprisingan unmodified nucleic acid sequence of AM15135, AM14244, AM15149,AM13882, AM14216, AM14387, AM14240, AM14238, or AM14236, and a sensestrand comprising an unmodified nucleic acid sequence of AM14284,AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, orAD14235.

In some aspects, the XDH RNAi agent comprises an antisense strandcomprising a modified nucleic acid sequence of AM15135, AM14244,AM15149, AM13882, AM14216, AM14387, AM14240, AM14238, or AM14236, and asense strand comprising a modified nucleic acid sequence of AM14284,AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, orAD14235.

In some aspects, the RNAi agent comprises an antisense strand comprisinga nucleic acid sequence of UUCCAUAAUACUCUGAGAGAG (SEQ ID NO:1448) and asense strand comprising a nucleic acid sequence of CUCUCUCAGAGUAUUAUGGAA(SEQ ID NO:1603). In some aspects, a nucleic acid sequence of theantisense strand comprises a nucleic acid sequence ofcPrpusUfscCfauaauacUfcUfgAfgagsasg (SEQ ID NO:1146) and a nucleic acidsequence of the sense strand comprises a nucleic acid sequence ofcucucucaGfaGfuAfuuauggaa (SEQ ID NO:1663) or(invAb)scucucucaGfaGfuAfuuauggaas(invAb) (SEQ ID NO:1680).

In some aspects, the RNAi agent comprises an antisense strand comprisinga nucleic acid sequence of AUGACAAUAUCUGUGCGGAGG (SEQ ID NO:1468) and asense strand comprising a nucleic acid sequence of CCUCCGCACAGAUAUUGUCAU(SEQ ID NO:1623). In some aspects, a nucleic acid sequence of theantisense strand comprises asUfsgsAfcaauaucUfgUfgCfggagsg (SEQ IDNO:1081) and a nucleic acid sequence of the sense strand comprises anucleic acid sequence of ccuccgcaCfAfGfauauugucau (SEQ ID NO:1664) or(invAb)sccuccgcaCfAfGfauauugucaus(invAb) (SEQ ID NO:1681).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UGCAUAUUCACCAUUUAGGCA (SEQ IDNO:1397) and a sense strand comprising a nucleic acid sequence ofUGCCUAAAUGGUGAAUAUGCA (SEQ ID NO:1551). In some aspects, a nucleic acidsequence of the antisense strand comprisescPrpusGfscauauuCfacCfaUfuUfaggscsa (SEQ ID NO:1155) and a nucleic acidsequence of the sense strand comprises ugccuaaaUfgGfuGfaauaugca (SEQ IDNO:1665) or (invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) (SEQ ID NO:1682).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of AUGAAACAAACAAACCCUGGA (SEQ IDNO:1440) and a sense strand comprising a nucleic acid sequence ofUCCAGGGUUUGUUUGUUUCAU (SEQ ID NO:1595). In some aspects, a nucleic acidsequence of the antisense strand comprisesasUfsgsAfaAfcaaacAfaAfcCfcUfggsa (SEQ ID NO:1048) and a nucleic acidsequence of the sense strand comprises uccaggguUfUfGfuuuguuucau (SEQ IDNO:1666) or (invAb)succaggguUfUfGfuuuguuucaus(invAb) (SEQ ID NO:1683).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of AGACGAUCAUACUUGGAGAGC (SEQ IDNO:1454) and a sense strand comprising a nucleic acid sequence ofGCUCUCCAAGUAUGAUCIUCU (SEQ ID NO:1609). In some aspects, a nucleic acidsequence of the antisense strand comprisesasGfsasCfgaucauaCfuUfgGfagagsc (SEQ ID NO:1067) and a nucleic acidsequence of the sense strand comprises gcucuccaAfGfUfaugauciucu (SEQ IDNO:1667) or (invAb)sgcucuccaAfGfUfaugauciucus(invAb) (SEQ ID NO:1684).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUUGAAUGCUGAGAAAUACUC (SEQ IDNO:1438) and a sense strand comprising a nucleic acid sequence ofGAGUAUUUCUCAGCAUUCAAA (SEQ ID NO:1593). In some aspects, a nucleic acidsequence of the antisense strand comprisescPrpuUfuGfaaugcugAfgAfaAfuacusc (SEQ ID NO:1111) and a nucleic acidsequence of the sense strand comprises gaguauuuCfUfCfagcauucaaa (SEQ IDNO:1668) or (invAb)sgaguauuuCfUfCfagcauucaaas(invAb) (SEQ ID NO:1685).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUUCCAACAAUUCUCCUUGUC (SEQ IDNO:1466) and a sense strand comprising a nucleic acid sequence ofGACAAGGAGAAUUGUUGGAAA (SEQ ID NO:1621). In some aspects, a nucleic acidsequence of the antisense strand comprisesusUfsusCfcaacaauUfcUfcCfuugusc (SEQ ID NO:1079) and a nucleic acidsequence of the sense strand comprises gacaaggaGfAfAfuuguuggaaa (SEQ IDNO:1669) or (invAb)sgacaaggaGfAfAfuuguuggaaas(invAb) (SEQ ID NO:1686).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUGUCAACCUCACUCUUCCGA (SEQ IDNO:1465) and a sense strand comprising a nucleic acid sequence ofUCGGAAGAGUGAGGUUGACAA (SEQ ID NO:1620). In some aspects, a nucleic acidsequence of the antisense strand comprisesusUfsgsUfcaaccucAfcUfcUfuccgsa (SEQ ID NO:1078) and a nucleic acidsequence of the sense strand comprises ucggaagaGfUfGfagguugacaa (SEQ IDNO:1670) or (invAb)sucggaagaGfUfGfagguugacaas(invAb) (SEQ ID NO:1687).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UCAUGAUACUGAGAGCUUGCU (SEQ IDNO:1464) and a sense strand comprising a nucleic acid sequence ofAGCAAGCUCUCAGUAUCAUGA (SEQ ID NO:1619). In some aspects, a nucleic acidsequence of the antisense strand comprisesusCfsasUfgauacugAfgAfgCfuugcsu (SEQ ID NO:1077) and a nucleic acidsequence of the sense strand comprises agcaagcuCfUfCfaguaucauga (SEQ IDNO:1671) or (invAb)sagcaagcuCfUfCfaguaucaugas(invAb) (SEQ ID NO:1688).

In some aspects, the 5′ end of the sense strand is coupled to atargeting ligand comprising the structure of (NAG37)s.

In some aspects, the gene expression level and/or mRNA level of an XDHgene in a subject to whom a described XDH RNAi agent is administered isreduced by at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%,75%, 80%, 85%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative tothe subject prior to being administered the XDH RNAi agent or to asubject not receiving the XDH RNAi agent. The gene expression leveland/or mRNA level in the subject may be reduced in a cell, group ofcells, and/or tissue of the subject. In some aspects, the XDH geneexpression is inhibited by at least about 30%, 35%, 40%, 45% 50%, 55%,60%, 65%, or greater than 65% in the cytoplasm of hepatocytes relativeto the subject prior to being administered the XDH RNAi agent or to asubject not receiving the XDH RNAi agent.

In some aspects, the XDH protein expression level in a subject to whom adescribed XDH RNAi agent has been administered is reduced by at leastabout 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subjectprior to being administered the XDH RNAi agent or to a subject notreceiving the XDH RNAi agent. The protein expression level in thesubject may be reduced in a cell, group of cells, tissue, blood, and/orother fluid of the subject.

A reduction in XDH mRNA expression levels and XDH protein expressionlevels can be assessed by any methods known in the art. As used herein,a reduction or decrease in XDH mRNA level and/or protein level arecollectively referred to herein as a reduction or decrease in XDH orinhibiting or reducing the gene expression of XDH. The Examples setforth herein illustrate known methods for assessing inhibition of XDHgene expression. The person of ordinary skill in the art would furtherknow suitable methods for assessing inhibition of XDH gene expression invivo and/or in vitro.

In some aspects, disclosed herein are methods of treatment (includingprophylactic or preventative treatment) of diseases, disorders, orsymptoms caused by caused by gout and/or hyperuricemia, wherein themethods include administering to a subject in need thereof atherapeutically effective amount of an XDH RNAi agent that includes anantisense strand that is at least partially complementary to the portionof the XDH mRNA having the sequence in Table 1. In some aspects,disclosed herein are methods of treatment (including prophylactic orpreventative treatment) of diseases or symptoms caused by caused by goutor hyperuricemia, wherein the methods include administering to a subjectin need thereof a therapeutically effective amount of an XDH RNAi agentthat includes an antisense strand comprising the sequence of any of thesequences in Tables 2, 3 or 5C, and a sense strand that comprises any ofthe sequences in Tables 2, 4, or 5C that is at least partiallycomplementary to the antisense strand. In some aspects, disclosed hereinare methods of treatment (including prophylactic or preventativetreatment) of diseases or symptoms caused by gout or hyperuricemia,wherein the methods include administering to a subject in need thereof atherapeutically effective amount of an XDH RNAi agent that includes asense strand that comprises any of the sequences in Tables 2, 4, or 5C,and an antisense strand comprising the sequence of any of the sequencesin Tables 2, 3, or 5C that is at least partially complementary to thesense strand.

In some aspects, the RNAi agent comprises an antisense strand comprisingan unmodified nucleic acid sequence of AM15135, AM14244, AM15149,AM13882, AM14216, AM14387, AM14240, AM14238, or AM14236, and a sensestrand comprising an unmodified nucleic acid sequence of AM14284,AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, orAD14235.

In some aspects, The RNAi agent comprises an antisense strand comprisinga modified nucleic acid sequence of AM15135, AM14244, AM15149, AM13882,AM14216, AM14387, AM14240, AM14238, or AM14236, and a sense strandcomprising a modified nucleic acid sequence of AM14284, AM14243,AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, or AD14235.

In some aspects, the RNAi agent comprises an antisense strand comprisinga nucleic acid sequence of UUCCAUAAUACUCUGAGAGAG (SEQ ID NO:1448) and asense strand comprising a nucleic acid sequence of CUCUCUCAGAGUAUUAUGGAA(SEQ ID NO:1603). In some aspects, a nucleic acid sequence of theantisense strand comprises cPrpusUfscCfauaauacUfcUfgAfgagsasg (SEQ IDNO:1146) and a nucleic acid sequence of the sense strand comprisescucucucaGfaGfuAfuuauggaa (SEQ ID NO:1663) or(invAb)scucucucaGfaGfuAfuuauggaas(invAb) (SEQ ID NO: 1680).

In some aspects, the RNAi agent comprises an antisense strand comprisinga nucleic acid sequence of AUGACAAUAUCUGUGCGGAGG (SEQ ID NO:1468) and asense strand comprising a nucleic acid sequence of CCUCCGCACAGAUAUUGUCAU(SEQ ID NO:1623). In some aspects, a nucleic acid sequence of theantisense strand comprises asUfsgsAfcaauaucUfgUfgCfggagsg (SEQ IDNO:1081) and a nucleic acid sequence of the sense strand comprisesccuccgcaCfAfGfauauugucau (SEQ ID NO:1664) or(invAb)sccuccgcaCfAfGfauauugucaus(invAb) (SEQ ID NO:1681).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UGCAUAUUCACCAUUUAGGCA (SEQ IDNO:1397) and a sense strand comprising a nucleic acid sequence ofUGCCUAAAUGGUGAAUAUGCA (SEQ ID NO:1551). In some aspects, a nucleic acidsequence of the antisense strand comprisescPrpusGfscauauuCfacCfaUfuUfaggscsa (SEQ ID NO:1155) and a nucleic acidsequence of the sense strand comprises ugccuaaaUfgGfuGfaauaugca (SEQ IDNO:1665) or (invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) (SEQ ID NO:1682).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of AUGAAACAAACAAACCCUGGA (SEQ IDNO:1440) and a sense strand comprising a nucleic acid sequence ofUCCAGGGUUUGUUUGUUUCAU (SEQ ID NO:1595). In some aspects, a nucleic acidsequence of the antisense strand comprisesasUfsgsAfaAfcaaacAfaAfcCfcUfggsa (SEQ ID NO:1048) and a nucleic acidsequence of the sense strand comprises uccaggguUfUfGfuuuguuucau (SEQ IDNO:1666) or (invAb)succaggguUfUfGfuuuguuucaus(invAb) (SEQ ID NO:1683).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of AGACGAUCAUACUUGGAGAGC (SEQ IDNO:1454) and a sense strand comprising a nucleic acid sequence ofGCUCUCCAAGUAUGAUCIUCU (SEQ ID NO:1609). In some aspects, a nucleic acidsequence of the antisense strand comprisesasGfsasCfgaucauaCfuUfgGfagagsc (SEQ ID NO:1067) and a nucleic acidsequence of the sense strand comprises asGfsasCfgaucauaCfuUfgGfagagsc(SEQ ID NO:1067) and a nucleic acid sequence of the sense strandcomprises gcucuccaAfGfUfaugauciucu (SEQ ID NO:1667) or(invAb)sgcucuccaAfGfUfaugauciucus(invAb) (SEQ ID NO:1684).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUUGAAUGCUGAGAAAUACUC (SEQ IDNO:1438) and a sense strand comprising a nucleic acid sequence ofGAGUAUUUCUCAGCAUUCAAA

(SEQ ID NO:1593). In some aspects, a nucleic acid sequence of theantisense strand comprises cPrpuUfuGfaaugcugAfgAfaAfuacusc (SEQ IDNO:1111) and a nucleic acid sequence of the sense strand comprisesgaguauuuCfUfCfagcauucaaa (SEQ ID NO:1668) or(invAb)sgaguauuuCfUfCfagcauucaaas(invAb) (SEQ ID NO:1685).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUUCCAACAAUUCUCCUUGUC (SEQ IDNO:1466) and a sense strand comprising a nucleic acid sequence ofGACAAGGAGAAUUGUUGGAAA (SEQ ID NO:1621). In some aspects, a nucleic acidsequence of the antisense strand comprisesusUfsusCfcaacaauUfcUfcCfuugusc (SEQ ID NO:1079) and a nucleic acidsequence of the sense strand comprises gacaaggaGfAfAfuuguuggaaa (SEQ IDNO:1669) or (invAb)sgacaaggaGfAfAfuuguuggaaas(invAb) (SEQ ID NO:1686).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UUGUCAACCUCACUCUUCCGA (SEQ IDNO:1465) and a sense strand comprising a nucleic acid sequence ofUCGGAAGAGUGAGGUUGACAA (SEQ ID NO:1620). In some aspects, a nucleic acidsequence of the antisense strand comprisesusUfsgsUfcaaccucAfcUfcUfuccgsa (SEQ ID NO:1078) and a nucleic acidsequence of the sense strand comprises ucggaagaGfUfGfagguugacaa (SEQ IDNO:1670) or (invAb)sucggaagaGfUfGfagguugacaas(invAb) (SEQ ID NO:1687).

In some aspects, the RNAi agent comprises an antisense sequencecomprising a nucleic acid sequence of UCAUGAUACUGAGAGCUUGCU (SEQ IDNO:1464) and a sense strand comprising a nucleic acid sequence ofAGCAAGCUCUCAGUAUCAUGA (SEQ ID NO:1619). In some aspects, a nucleic acidsequence of the antisense strand comprisesusCfsasUfgauacugAfgAfgCfuugcsu (SEQ ID NO:1077) and a nucleic acidsequence of the sense strand comprises agcaagcuCfUfCfaguaucauga (SEQ IDNO:1671) or (invAb)sagcaagcuCfUfCfaguaucaugas(invAb) (SEQ ID NO:1688).

In some aspects, the 5′ end of the sense strand is coupled to atargeting ligand comprising the structure of (NAG37)s.

In some aspects, disclosed herein are methods for inhibiting expressionof an XDH gene in a cell, wherein the methods include administering tothe cell an XDH RNAi agent that includes an antisense strand that is atleast partially complementary to the portion of the XDH mRNA having thesequence in Table 1. In some aspects, disclosed herein are methods ofinhibiting expression of an XDH gene in a cell, wherein the methodsinclude administering to a cell an XDH RNAi agent that includes anantisense strand comprising the sequence of any of the sequences inTables 2, 3, or 5C and a sense strand that comprises any of thesequences in Tables 2, 4, or 5C that is at least partially complementaryto the antisense strand. In some aspects, disclosed herein are methodsof inhibiting expression of an XDH gene in a cell, wherein the methodsinclude administering an XDH RNAi agent that includes a sense strandthat comprises any of the sequences in Tables 2, 4, or 5C, and anantisense strand that includes the sequence of any of the sequences inTables 2, 3, or 5C that is at least partially complementary to the sensestrand.

In some aspects, the XDH RNAi agents are administered to a subject inneed thereof as a first line therapy. In some aspects, the XDH RNAiagents are administered to a subject in need thereof as a second linetherapy. In certain aspects, the XDH RNAi agents are administered as asecond line therapy to patients who have failed one or more first linestandard of care therapies. In certain aspects, the XDH RNAi agents areadministered as a maintenance therapy following the administration ofone or more prior therapies. In certain aspects, the XDH RNAi agentsadministered as a maintenance therapy following the administration ofone or more standard of care therapies. In some aspects, the XDH RNAiagents administered in combination with one or more additionaltherapies. In some aspects, the one or more additional therapies is astandard of care therapy. In some aspects, the one or more additionaltherapies is an oral therapy.

Provided herein are methods for treating gout using the XDH RNAi agentsdescribed herein, for example, RNAi agent comprising an antisense strandcomprising an unmodified nucleic acid sequence of AM15135, AM14244,AM15149, AM13882, AM14216, AM14387, AM14240, AM14238, or AM14236, and asense strand comprising an unmodified nucleic acid sequence of AM14284,AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, orAD14235. In some aspects, the gout is uncontrolled gout. In someaspects, the oligonucleotide, composition, or pharmaceutical compositiondescribed herein is administered as a second line therapy to patientswho have failed allopurinol and/or febuxostat. In some aspects, theoligonucleotide, composition, or pharmaceutical composition describedherein is administered prior to KRYSTEXXA. In some aspects, theoligonucleotide, composition, or pharmaceutical composition describedherein is administered as a maintenance therapy following theadministration of KRYSTEXXA.

The use of XDH RNAi agents provides methods for therapeutic (includingprophylactic) treatment of diseases/disorders associated with gout,hyperuricemia, elevated serum uric acid levels, or elevated XDH geneexpression. The described XDH RNAi agents mediate RNA interference toinhibit the expression of one or more genes necessary for production ofXDH protein. XDH RNAi agents can also be used to treat or preventvarious diseases, disorders, or conditions, including gout. Furthermore,compositions for delivery of XDH RNAi agents to liver cells, andspecifically to hepatocytes, in vivo, are described.

Cells, Tissues, Organs, and Non-Human Organisms

Cells, tissues, organs, and non-human organisms that include at leastone of the XDH RNAi agents described herein are contemplated. The cell,tissue, organ, or non-human organism is made by delivering the RNAiagent to the cell, tissue, organ or non-human organism.

ILLUSTRATIVE EMBODIMENTS

Provided here are illustrative embodiments of the disclosed technology.These embodiments are illustrative only and do not limit the scope ofthe present disclosure or of the claims attached hereto.

Embodiment 1. An RNAi agent for inhibiting expression of an XDH gene,comprising:

an antisense strand comprising at least 15 contiguous nucleotidesdiffering by 0, 1, 2, or 3, nucleotides from any one of the sequencesantisense strand sequences disclosed in Table 2, Table 3, or Table 5C;and a sense strand comprising a nucleotide sequence that is at leastpartially complementary to the antisense strand.

Embodiment 2. An RNAi agent for inhibiting expression of an XDH gene,comprising:

a sense strand comprising at least 15 contiguous nucleotides differingby 0, 1, 2, or 3 nucleotides from a stretch of the same length ofnucleotides of SEQ ID NO:1; and an antisense strand comprising anucleotide sequences that is at least partially complementary to thesense strand.

Embodiment 3. The RNAi agent of embodiment 1, wherein the antisensestrand comprises nucleotides at positions 2-18 of any one of theantisense strand sequences of Table 2, Table 3, or Table 5C.

Embodiment 4. The RNAi agent of embodiment 1 or embodiment 2, whereinthe sense strand comprises a nucleotide sequence of at least 15contiguous nucleotides differing by 0 or 1 nucleotide from any one ofthe sense strand sequences of Table 2, Table 4, or Table 5C, and whereinthe sense strand has a region of at least 85% complementarily over the15 contiguous nucleotides to the antisense strand.

Embodiment 5. The RNAi agent of any one of embodiments 1-4, wherein atleast one nucleotide of the RNAi agent is a modified nucleotide orincludes a modified internucleoside linkage.

Embodiment 6. The RNAi agent of any one of aspects 1-5, wherein all orsubstantially all of the nucleotides of the sense and/or antisensestrand of the RNAi agent are modified nucleotides.

Embodiment 7. The RNAi agent of any one of aspects 5-6, wherein themodified nucleotide is selected from the group consisting of:2′-O-methyl nucleotide, 2′-fluoro nucleotide, 2′-deoxy nucleotide,2′,3′-seco nucleotide mimic, locked nucleotide, 2′-F-arabino nucleotide,2′-methoxyethyl nucleotide, abasic nucleotide, ribitol, invertednucleotide, inverted 2′-O-methyl nucleotide, inverted 2′-deoxynucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide,morpholino nucleotide, vinyl phosphonate containing nucleotide,cyclopropyl phosphonate containing nucleotide, and 3′-O-methylnucleotide.

Embodiment 8. The RNAi agent of embodiment 7, wherein all orsubstantially all of the modified nucleotides are 2′-O-methylnucleotides, 2′-fluoro nucleotides, or combinations thereof.

Embodiment 9. The RNAi agent of any one of aspects 1-8, wherein theantisense strand comprises the nucleotide sequence of any one of themodified antisense strand sequences of Table 3 or Table 5C.

Embodiment 10. The RNAi agent of any one of aspects 1-9, wherein thesense strand comprises the nucleotide sequence of any of the modifiedsense strand sequences of Table 4 or Table 5C.

Embodiment 11. The RNAi agent of embodiment 1, wherein the antisensestrand comprises the nucleotide sequence of any one of the modifiedsequences of Table 5C and the sense strand comprises the nucleotidesequence of any one of the modified sequences of Table 5C.

Embodiment 12. The RNAi agent of any one of aspects 1-11, wherein theRNAi agent is linked to a targeting ligand.

Embodiment 13. The RNAi agent of embodiment 12, wherein the targetingligand comprises n-acetyl-galactosamine.

Embodiment 14. The RNAi agent of embodiment 12 or 13, wherein thetargeting ligand comprises the structure of (NAG37) or (NAG37)s.

Embodiment 15. The RNAi agent of any one of aspects 11-14, wherein thetargeting ligand is linked to the sense strand.

Embodiment 16. The RNAi agent of embodiment 15, wherein the targetingligand is linked to the 5′ terminal end of the sense strand.

Embodiment 17. The RNAi agent of any one of aspects 1-16, wherein thesense strand is between 15 and 30 nucleotides in length, and theantisense strand is between 18 and 30 nucleotides in length.

Embodiment 18. The RNAi agent of embodiment 17, wherein the sense strandand the antisense strand are each between 18 and 27 nucleotides inlength.

Embodiment 19. The RNAi agent of embodiment 18, wherein the sense strandand the antisense strand are each between 18 and 24 nucleotides inlength.

Embodiment 20. The RNAi agent of embodiment 19, wherein the sense strandand the antisense strand are each 21 nucleotides in length.

Embodiment 21. The RNAi agent of any one of aspects 17-20, wherein theRNAi agent has two blunt ends.

Embodiment 22. The RNAi agent of any one of aspects 1-21, wherein thesense strand comprises one or two terminal caps.

Embodiment 23. The RNAi agent of any one of aspects 1-22, wherein thesense strand comprises one or two inverted abasic residues.

Embodiment 24. The RNAi agent of embodiment 1, wherein the RNAi agent iscomprised of a sense strand and an antisense strand that form a duplexsequence of any one of the duplexes as listed in Table 5A, Table 5B, orTable 5C.

Embodiment 25. The RNAi agent of any one of aspects 1-23, wherein thesense strand further includes inverted abasic residues at the 3′terminal end of the nucleotide sequence, at the 5′ end of the nucleotidesequence, or at both.

Embodiment 26. The RNAi agent of embodiment 1, comprising an antisensestrand that comprises, consists of, or consists essentially of amodified nucleotide sequence that differs by 0 or 1 nucleotide from oneof the antisense strand nucleotide sequences of Table 3 or Table 5C,wherein a, c, g, and u represent 2′-O-methyl adenosine, cytidine,guanosine, and uridine, respectively; Af, Cf, Gf, and Uf represent2′-fluoro adenosine, cytidine, guanosine, and uridine, respectively;cPrpa and cPrpu represent 5′-cyclopropyl phosphonate-2′-O-methyladenosine and 5′-cyclopropyl phosphonate-2′-O-methyl uridine,respectively; CUNA and UUNA represent 2′,3′-seco-cytidine and2′,3′-seco-uridine, respectively; s represents a phosphorothioatelinkage; and wherein all or substantially all of the nucleotides on thesense strand are modified nucleotides.

Embodiment 27. The RNAi agent of embodiment 1, wherein the sense strandcomprises, consists of, or consists essentially of a modified nucleotidesequence that differs by 0 or 1 nucleotide from one of the nucleotidesequences of Table 4 or Table 5C, wherein a, c, g, i, and u represent2′-O-methyl adenosine, cytidine, guanosine, inosine, and uridine,respectively; Af, Cf, Gf, and Uf represent 2′-fluoro adenosine,cytidine, guanosine, and uridine, respectively; a 2N represents2′-O-methyl-2-aminoadenosine; s represents a phosphorothioate linkage;and wherein all or substantially all of the nucleotides on the antisensestrand are modified nucleotides.

Embodiment 28. The RNAi agent of any one of aspects 24-27, wherein thesense strand includes inverted abasic residues at the 3′ terminal end ofthe nucleotide sequence, at the 5′ end of the nucleotide sequence, or atboth.

Embodiment 29. The RNAi agent of any one of aspects 24-28, wherein thesense strand of the RNAi agent is linked to a targeting ligand.

Embodiment 30. The RNAi agent of embodiment 29, wherein the targetingligand has affinity for the asialoglycoprotein receptor.

Embodiment 31. The RNAi agent of embodiment 30, wherein the targetingligand comprises N-acetyl-galactosamine.

Embodiment 32. The RNAi agent of embodiment 1, wherein the targetingligand comprises:

Embodiment 33. The RNAi agent of embodiment 1, wherein the antisensestrand consists of a modified nucleotide sequence of Table 3 or Table 5Cand the sense strand consists of a modified nucleotide sequence of Table4 or Table 5C, wherein a, c, g, i, and u represent 2′-O-methyladenosine, cytidine, guanosine, inosine, and uridine, respectively; Af,Cf, Gf, and Uf represent 2′-fluoro adenosine, cytidine, guanosine, anduridine, respectively; cPrpa and cPrpu represent 5′-cyclopropylphosphonate-2′-O-methyl adenosine and 5′-cyclopropylphosphonate-2′-O-methyl uridine, respectively; a 2N represents2′-O-methyl-2-aminoadenosine; CUNA and UUNA represent2′,3′-seco-cytidine and 2′,3′-seco-uridine, respectively; s represents aphosphorothioate linkage; (invAb) represents an inverted abasicdeoxyribose residue; and (NAG37)s has the following chemical structure:

Embodiment 34. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprises an unmodifiednucleic acid sequence of AM15135, AM14244, AM15149, AM13882, AM14216,AM14387, AM14240, AM14238, or AM14236, and a nucleic acid sequence ofthe sense strand comprises an unmodified nucleic acid sequence ofAM14284, AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237,or AD14235.

Embodiment 35. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprises a modifiednucleic acid sequence of AM15135, AM14244, AM15149, AM13882, AM14216,AM14387, AM14240, AM14238, or AM14236, and a nucleic acid sequence ofthe sense strand comprises a modified nucleic acid sequence of AM14284,AM14243, AM14528, AM13881, AM14215, AM13877, AD14239, AD14237, orAD14235.

Embodiment 36. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUUCCAUAAUACUCUGAGAGAG (SEQ ID NO:1448) and a nucleic acid sequence ofthe sense strand comprises CUCUCUCAGAGUAUUAUGGAA (SEQ ID NO:1603).

Embodiment 37. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpusUfscCfauaauacUfcUfgAfgagsasg (SEQ ID NO:1146) and a nucleic acidsequence of the sense strand comprises cucucucaGfaGfuAfuuauggaa (SEQ IDNO:1663), wherein lower case (n)=2′-O-Me; Nf=2′-F; cPrpn=5′-cyclopropylphosphonate-2′-O-methyl; (and s=phosphorothioate backbone modification.

Embodiment 38. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpusUfscCfauaauacUfcUfgAfgagsasg (SEQ ID NO:1146) and the sense strandcomprises (invAb)scucucucaGfaGfuAfuuauggaas(invAb) (SEQ ID NO:1680)wherein lower case (n)=2′-O-Me; Nf=2′-F; cPrpn=5′-cyclopropylphosphonate-2′-O-methyl; (invAb)=inverted abasic residue; ands=phosphorothioate backbone modification.

Embodiment 39. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesAUGACAAUAUCUGUGCGGAGG (SEQ ID NO:1468) and a nucleic acid sequence ofthe sense strand comprises CCUCCGCACAGAUAUUGUCAU (SEQ ID NO:1623).

Embodiment 40. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasUfsgsAfcaauaucUfgUfgCfggagsg (SEQ ID NO:1081) and a nucleic acidsequence of the sense strand comprises ccuccgcaCfAfGfauauugucau (SEQ IDNO:1664), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 41. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasUfsgsAfcaauaucUfgUfgCfggagsg (SEQ ID NO:1081) and the sense strandcomprises (invAb)sccuccgcaCfAfGfauauugucaus(invAb) (SEQ ID NO:1681)wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 42. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUGCAUAUUCACCAUUUAGGCA (SEQ ID NO:1397) and a nucleic acid sequence ofthe sense strand comprises UGCCUAAAUGGUGAAUAUGCA (SEQ ID NO:1551).

Embodiment 43. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpusGfscauauuCfacCfaUfuUfaggscsa (SEQ ID NO:1155) and a nucleic acidsequence of the sense strand comprises ugccuaaaUfgGfuGfaauaugca (SEQ IDNO:1665), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 44. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpusGfscauauuCfacCfaUfuUfaggscsa (SEQ ID NO:1155) and the sense strandcomprises (invAb)sugccuaaaUfgGfuGfaauaugcas(invAb) (SEQ ID NO:1682),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 45. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesAUGAAACAAACAAACCCUGGA (SEQ ID NO:1440) and a nucleic acid sequence ofthe sense strand comprises UCCAGGGUUUGUUUGUUUCAU (SEQ ID NO:1595).

Embodiment 46. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasUfsgsAfaAfcaaacAfaAfcCfcUfggsa (SEQ ID NO:1048) and a nucleic acidsequence of the sense strand comprises uccaggguUfUfGfuuuguuucau (SEQ IDNO:1666), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 47. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasUfsgsAfaAfcaaacAfaAfcCfcUfggsa (SEQ ID NO:1048) and the sense strandcomprises (invAb)succaggguUfUfGfuuuguuucaus(invAb) (SEQ ID NO:1683),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 48. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesAGACGAUCAUACUUGGAGAGC (SEQ ID NO:1454) and a nucleic acid sequence ofthe sense strand comprises GCUCUCCAAGUAUGAUCIUCU (SEQ ID NO:1609).

Embodiment 49. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasGfsasCfgaucauaCfuUfgGfagagsc (SEQ ID NO:1067) and a nucleic acidsequence of the sense strand comprises gcucuccaAfGfUfaugauciucu (SEQ IDNO:1667), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 50. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesasGfsasCfgaucauaCfuUfgGfagagsc (SEQ ID NO:1067) and the sense strandcomprises (invAb)sgcucuccaAfGfUfaugauciucus(invAb) (SEQ ID NO:1684),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 51. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUUUGAAUGCUGAGAAAUACUC (SEQ ID NO:1438) and a nucleic acid sequence ofthe sense strand comprises GAGUAUUUCUCAGCAUUCAAA (SEQ ID NO:1593).

Embodiment 52. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpuUfuGfaaugcugAfgAfaAfuacusc (SEQ ID NO:1111) and a nucleic acidsequence of the sense strand comprises gaguauuuCfUfCfagcauucaaa (SEQ IDNO:1668), wherein lower case (n)=2′-O-Me; Nf=2′-F; cPrpn=5′-cyclopropylphosphonate-2′-O-methyl; and s=phosphorothioate backbone modification.

Embodiment 53. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisescPrpuUfuGfaaugcugAfgAfaAfuacusc (SEQ ID NO:1111) and the sense strandcomprises (invAb)sgaguauuuCfUfCfagcauucaaas(invAb) (SEQ ID NO:1685),wherein lower case (n)=2′-O-Me; Nf=2′-F; cPrpn=5′-cyclopropylphosphonate-2′-O-methyl; (invAb)=inverted abasic residue; ands=phosphorothioate backbone modification.

Embodiment 54. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUUUCCAACAAUUCUCCUUGUC (SEQ ID NO:1466) and a nucleic acid sequence ofthe sense strand comprises GACAAGGAGAAUUGUUGGAAA (SEQ ID NO:1621).

Embodiment 55. The RNAi agent of any one of embodiments)-3, wherein anucleic acid sequence of the antisense strand comprisesusUfsusCfcaacaauUfcUfcCfuugusc (SEQ ID NO:1079) and a nucleic acidsequence of the sense strand comprises gacaaggaGfAfAfuuguuggaaa (SEQ IDNO:1669), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 56. The RNAi agent of any one of embodiments)-3, wherein anucleic acid sequence of the antisense strand comprisesusUfsusCfcaacaauUfcUfcCfuugusc (SEQ ID NO:1079) and the sense strandcomprises (invAb)sgacaaggaGfAfAfuuguuggaaas(invAb) (SEQ ID NO:1686),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 57. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUUGUCAACCUCACUCUUCCGA (SEQ ID NO:1465) and a nucleic acid sequence ofthe sense strand comprises UCGGAAGAGUGAGGUUGACAA (SEQ ID NO:1620).

Embodiment 58. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesusUfsgsUfcaaccucAfcUfcUfuccgsa (SEQ ID NO:1078) and a nucleic acidsequence of the sense strand comprises ucggaagaGfUfGfagguugacaa (SEQ IDNO:1670), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 59. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesusUfsgsUfcaaccucAfcUfcUfuccgsa (SEQ ID NO:1078) and the sense strandcomprises (invAb)sucggaagaGfUfGfagguugacaas(invAb) (SEQ ID NO:1687),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 60. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesUCAUGAUACUGAGAGCUUGCU (SEQ ID NO:1464) and a nucleic acid sequence ofthe sense strand comprises AGCAAGCUCUCAGUAUCAUGA (SEQ ID NO:1619).

Embodiment 61. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesusCfsasUfgauacugAfgAfgCfuugcsu (SEQ ID NO:1077) and a nucleic acidsequence of the sense strand comprises agcaagcuCfUfCfaguaucauga (SEQ IDNO:1671), wherein lower case (n)=2′-O-Me; Nf=2′-F; ands=phosphorothioate backbone modification.

Embodiment 62. The RNAi agent of any one of embodiments 1-3, wherein anucleic acid sequence of the antisense strand comprisesusCfsasUfgauacugAfgAfgCfuugcsu (SEQ ID NO:1077) and the sense strandcomprises (invAb)sagcaagcuCfUfCfaguaucaugas(invAb) (SEQ ID NO:1688),wherein lower case (n)=2′-O-Me; Nf=2′-F; (invAb)=inverted abasicresidue; and s=phosphorothioate backbone modification.

Embodiment 63. The RNAi agent of any one of embodiments 31-62, whereinthe 5′ end of the sense strand is coupled to a targeting ligandcomprising the structure of (NAG37) or (NAG37)s.

Embodiment 64. The RNAi agent of any one of embodiments 31-62, whereinthe 5′ end of the sense strand is coupled to a targeting ligandcomprising the structure of (NAG37)s.

Embodiment 65. The RNAi agent of any one of embodiments 31-64, whereinRNAi agent is a pharmaceutically acceptable salt.

Embodiment 66. A composition comprising the RNAi agent of any one ofembodiments 1-65, wherein the composition further comprises apharmaceutically acceptable excipient.

Embodiment 67. A method for inhibiting expression of an XDH gene in acell, the method comprising introducing into a cell an effective amountof an RNAi agent of any one of embodiments 1-66 or the composition ofembodiment 66.

Embodiment 68. The method of embodiment 67, wherein the cell is within asubject.

Embodiment 69. The method of embodiment 68, wherein the subject is ahuman subject.

Embodiment 70. The method of any one of embodiments 67-69, wherein theXDH gene expression is inhibited by at least about 30%.

Embodiment 71. The method of any one of embodiments 67-70, wherein theXDH activity is reduced by at least about 40%, about 45%, about 50%,about 55%, about 60%, about 65%, or about 70%.

Embodiment 72. A method of treating an XDH-related disease, disorder, orsymptom, the method comprising administering to a human subject in needthereof a therapeutically effective amount of the composition ofembodiment 66.

Embodiment 73. The method of embodiment 72, wherein the disease is gout.

Embodiment 74. The method of any one of embodiments 67-73, wherein theRNAi agent is administered at a dose of about 0.05 mg/kg to about 5.0mg/kg of body weight of the human subject.

Embodiment 75. The method of any one of embodiments 67-74, wherein theRNAi agent is administered in two or more doses.

Embodiment 76. A single-stranded antisense compound for inhibiting anXDH gene, comprising an antisense nucleotide sequence having at least 15contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides, whereinthe nucleotides are complementary to any of the target nucleotidesequences of Table 1.

Embodiment 77. A single-stranded antisense compound for inhibiting anXDH gene, comprising at least 15 contiguous nucleotides differing by 0,1, 2, or 3 nucleotides of any of the antisense strand sequencesdisclosed in Table 2, Table 3, or Table 5C.

The above provided embodiments and items are now illustrated with thefollowing, non-limiting examples.

EXAMPLES Example 1. Synthesis of XDH RNAi Agents

XDH RNAi agent duplexes shown in Tables 5A, 5B, and 5C, above, weresynthesized in accordance with the following general procedures:

A. Synthesis.

The sense and antisense strands of the RNAi agents were synthesizedaccording to phosphoramidite technology on solid phase used inoligonucleotide synthesis. Such standard synthesis is generally known inthe art. Depending on the scale, either a MerMade96E® (Bioautomation), aMerMade12® (Bioautomation), or an OP Pilot 100 (GE Healthcare) was used.Syntheses were performed on a solid support made of controlled poreglass (CPG, 500 Å or 600 Å, obtained from Prime Synthesis, Aston, Pa.,USA). The monomer positioned at the 3′ end of the respective strand wasattached to the solid support as a starting point for synthesis. All RNAand 2′-modified RNA phosphoramidites were purchased from Thermo FisherScientific (Milwaukee, Wis., USA) or Hongene Biotech (Shanghai, PRC).The 2′-O-methyl phosphoramidites included the following:(5′-O-dimethoxytrityl-N⁶-(benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite,5′-O-dimethoxy-trityl-N⁴-(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropyl-amino)phosphoramidite,(5′-O-dimethoxytrityl-N²-(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite, and5′-O-dimethoxytrityl-2′-O-methyl-uridine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite. The 2′-deoxy-2′-fluoro-phosphoramidites carried thesame protecting groups as the 2′-O-methyl amidites.5′-(4,4′-Dimethoxytrityl)-2′,3′-seco-uridine, 2′-benzoyl-3′-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite was also purchased fromThermo Fisher Scientific or Hongene Biotech.5′-dimethoxytrityl-2′-O-methyl-inosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidites were purchased from Glen Research (Virginia) or HongeneBiotech. The cyclopropyl phosphonate phosphoramidites were synthesizedin accordance with International Patent Application Publication No. WO2017/214112 (see also Altenhofer et. al., Chem. Communications (RoyalSoc. Chem.), 57(55):6808-6811 (July 2021)). The inverted abasic(3′-O-dimethoxytrityl-2′-deoxyribose-5′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidites were purchased from ChemGenes (Wilmington, Mass., USA)or SAFC (St Louis, Mo., USA).5′-O-dimethoxytrityl-N²,N⁶-(phenoxyacetate)-2′-O-methyl-diaminopurine-3′-O-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidites were obtained from ChemGenes or Hongene Biotech.

Targeting ligand-containing phosphoramidites were dissolved in anhydrousdichloromethane or anhydrous acetonitrile (50 mM), while all otheramidites were dissolved in anhydrous acetonitrile (50 mM), or anhydrousdimethylformamide and molecular sieves (3 Å) were added.5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used asactivator solution. Coupling times were 12 min (RNA), 15 min (targetingligand), 90 sec (2′-OMe), and 60 sec (2′-F). In order to introducephosphorothioate linkages, a 100 mM solution of 3-phenyl1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster,Mass., USA) in anhydrous Acetonitrile was employed. Unless specificallyidentified as a “naked” RNAi agent having no targeting ligand present,each of the XDH RNAi agent duplexes synthesized and tested in thefollowing Examples utilized N-acetyl-galactosamine as “NAG” in thetargeting ligand chemical structures represented in Table 6. (NAG37) and(NAG37)s targeting ligand phosphoramidite compounds can be synthesizedin accordance with International Patent Application Publication No. WO2018/044350 to Arrowhead Pharmaceuticals, Inc.

B. Cleavage and Deprotection of Support Bound Oligomer.

After finalization of the solid phase synthesis, the dried solid supportwas treated with a 1:1 volume solution of 40 wt. % methylamine in waterand 28% ammonium hydroxide solution (Aldrich) for 1.5 hours at 30° C.The solution was evaporated and the solid residue was reconstituted inwater (see below).

C. Purification.

Crude oligomers were purified by anionic exchange HPLC using a TSKgelSuperQ-5PW 13 μm column and Shimadzu LC-8 system. Buffer A was 20 mMTris, 5 mM EDTA, pH 9.0 and contained 20% Acetonitrile and buffer B wasthe same as buffer A with the addition of 1.5 M sodium chloride. UVtraces at 260 nm were recorded. Appropriate fractions were pooled thenrun on size exclusion HPLC using a GE Healthcare XK 26/40 column packedwith Sephadex G-25 fine with a running buffer of filtered DI water or100 mM ammonium bicarbonate, pH 6.7 and 20% Acetonitrile.

D. Annealing.

Complementary strands were mixed by combining equimolar RNA solutions(sense and antisense) in 1× Phosphate-Buffered Saline (Corning, Cellgro)to form the RNAi agents. Some RNAi agents were lyophilized and stored at−15 to −25° C. Duplex concentration was determined by measuring thesolution absorbance on a UV-Vis spectrometer in 1× Phosphate-BufferedSaline. The solution absorbance at 260 nm was then multiplied by aconversion factor and the dilution factor to determine the duplexconcentration. The conversion factor used was either 0.050 mg/(mL·cm) orwas calculated from an experimentally determined extinction coefficient.

Example 2. XDH-GLuc AAV Mouse Model

To evaluate certain XDH RNAi agents, an XDH-GLuc (Gaussia Luciferase)AAV (Adeno-associated virus) mouse model was used. Six- toeight-week-old male C57BL/6 mice were transduced with XDH-GLuc AAVserotype 8, administered at least 14 days prior to administration of anXDH RNAi agent or control. Two types of XDH-GLuc AAV were used. Thegenome of the first XDH-GLuc AAV contains the 80-2899 region of thehuman XDH cDNA sequence (GenBank NM_000379.4 (SEQ ID NO:1)) insertedinto the 3′ UTR of the GLuc reporter gene sequence. The genome of thesecond XDH-GLuc AAV contains the 2820-5715 region of the human XDH cDNAsequence (GenBank NM_000379.4 (SEQ ID NO:1)) inserted into the 3′ UTR ofthe GLuc reporter gene sequence. 5E12 to 1E13 GC/kg of the respectivevirus in PBS in a total volume of 10 mL/kg animal's body weight wasinjected into mice via the tail vein to create XDH-GLuc AAV model mice.Inhibition of expression of XDH by an XDH RNAi agent results inconcomitant inhibition of GLuc expression, which is measured. Prior toadministration of a treatment (between day −7 and day 1 pre-dose), GLucexpression levels in serum were measured by the Pierce™ GaussiaLuciferase Glow Assay Kit (Thermo Fisher Scientific), and the mice weregrouped according to average GLuc levels.

Mice were anesthetized with 2-3% isoflurane and blood samples werecollected from the submandibular area into serum separation tubes(Sarstedt AG & Co., Nümbrecht, Germany). Blood was allowed to coagulateat ambient temperature for 20 min. The tubes were centrifuged at 8,000×gfor 3 min to separate the serum and stored at 4° C. Serum was collectedand measured by the Pierce™ Gaussia Luciferase Glow Assay Kit accordingto the manufacturer's instructions. Serum GLuc levels for each animalcan be normalized to the control group of mice injected with vehiclecontrol in order to account for the non-treatment related shift in XDHexpression with this model. To do so, first, the GLuc level for eachanimal at a time point was divided by the pre-treatment level ofexpression in that animal (Day 1) in order to determine the ratio ofexpression “normalized to pre-treatment”. Expression at a specific timepoint was then normalized to the control group by dividing the“normalized to pre-treatment” ratio for an individual animal by theaverage “normalized to pre-treatment” ratio of all mice in the normalvehicle control group. Alternatively, the serum GLuc levels for eachanimal was assessed by normalizing to pre-treatment levels only.

Example 3. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 7.

TABLE 7 Targeted Positions and Dosing Groups of Example 3 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 488 2.0 mg/kgAD09218 Single injection on day 1 3 122 2.0 mg/kg AD09724 Singleinjection on day 1 4 249 2.0 mg/kg AD09599 Single injection on day 1 5252 2.0 mg/kg AD09600 Single injection on day 1 6 1285 2.0 mg/kg AD09733Single injection on day 1 7 2209 2.0 mg/kg AD09740 Single injection onday 1 8 1963 2.0 mg/kg AD09736 Single injection on day 1 9 1963 2.0mg/kg AD09937 Single injection on day 1 10 2696 2.0 mg/kg AD09744 Singleinjection on day 1 11 2696 2.0 mg/kg AD09938 Single injection on day 112 2616 2.0 mg/kg AD09663 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agent AD09218 (Group 2)included nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 488 of the gene; the XDH RNAi agent AD09724(Group 3) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 122 of the gene; the XDH RNAiagent AD09599 (Group 4) included nucleotide sequences that were designedto inhibit expression of an XDH gene at position 249 of the gene; theXDH RNAi agent AD09600 (Group 5) included nucleotide sequences that weredesigned to inhibit expression of an XDH gene at position 252 of thegene; the XDH RNAi agent AD09733 (Group 6) included nucleotide sequencesthat were designed to inhibit expression of an XDH gene at position 1285of the gene; the XDH RNAi agent AD09740 (Group 7) included nucleotidesequences that were designed to inhibit expression of an XDH gene atposition 2209 of the gene; the XDH RNAi agents AD09736 (Group 8) andAD09937 (Group 9) included nucleotide sequences that were designed toinhibit expression of an XDH gene at position 1963 of the gene; the XDHRNAi agents AD09744 (Group 10) and AD09938 (Group 11) includednucleotide sequences that were designed to inhibit expression of an XDHgene at position 2696 of the gene; and the XDH RNAi agent AD09663 (Group12) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 2616 of the gene. (See, e.g., SEQID NO:1 and Table 2 for the XDH gene referenced).

While it has been previously reported that an RNAi agent targetingposition 488 of the XDH gene can be active in vitro and in vivo in miceand in rats, the nucleotide sequence of an RNAi agent targeting thisposition is compromised and unsuitable for therapeutic use. Morespecifically, the seed region (2 to 7 nt) of the RNAi agent targetingposition 488 matches perfectly with that of a known human microRNA(miRNA), thus this agent is expected to result in undesired silencing ofhundreds of potential off-targets mimicking the known miRNA (See, e.g.,Kamola et al., The siRNA Non-seed Region and Its Target Sequences AreAuxiliary Determinants of Off-Target Effects, 11(12) PLoS Comput Biol(2015)). In addition, the core 17-mer sequence (nucleotides located atpositions 2-18 of the antisense strand (5′→3′)) of the RNAi agenttargeting position 488 is complementary to transcripts of four humangenes with only one mismatch, hence bearing an additional risk ofreducing the expression of these four genes through a differentoff-target mechanism. Thus, the RNAi agent of Group 2 is not a viablecandidate for human therapeutic treatment.

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment are shown in the following Table 8:

TABLE 8 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 3 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.105 1.000 0.020 1.000 0.096 Group 2 (2.0 mg/kg AD09218) 0.6010.094 0.505 0.085 0.531 0.103 Group 3 (2.0 mg/kg AD09724) 1.115 0.1490.890 0.095 0.964 0.208 Group 4 (2.0 mg/kg AD09599) 1.009 0.088 0.8720.096 0.991 0.092 Group 5 (2.0 mg/kg AD09600) 0.874 0.292 0.865 0.4150.927 0.348 Group 6 (2.0 mg/kg AD09733) 1.024 0.054 0.896 0.129 1.2090.262 Group 7 (2.0 mg/kg AD09740) 0.963 0.083 0.793 0.103 1.132 0.084Group 8 (2.0 mg/kg AD09736) 0.607 0.154 0.521 0.111 0.809 0.135 Group 9(2.0 mg/kg AD09937) 0.673 0.148 0.593 0.120 0.748 0.108 Group 10 (2.0mg/kg AD09744) 0.679 0.084 0.694 0.078 0.934 0.163 Group 11 (2.0 mg/kgAD09938) 0.552 0.076 0.478 0.076 0.711 0.095 Group 12 (2.0 mg/kgAD09663) 0.826 0.102 0.849 0.435 1.246 0.895As shown in Table 8, above, as expected the RNAi agent of Group 2(targeting position 488) was active and showed reductions ofapproximately 49.5% on day 15 (0.505). The RNAi agents of Group 8(AD09736) and Group 9 (AD09937), both of which target the XDH gene atposition 1963, showed generally comparable reductions of XDH (reductionsof 47.9% and 40.7% on day 15, respectively) with Group 2. Similarly, theRNAi agents of Group 10 (AD09744) and Group 11 (AD09938), both of whichtarget the XDH gene at position 2696, showed generally comparablereductions of XDH (showing reductions of 30.6% and 52.2%) with Group 2.

Example 4. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 9.

TABLE 9 Targeted Positions and Dosing Groups of Example 4 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 1963 2.0 mg/kgAD09736 Single injection on day 1 3 1963 2.0 mg/kg AD09965 Singleinjection on day 1 4 1963 2.0 mg/kg AD09937 Single injection on day 1 51963 2.0 mg/kg AD09966 Single injection on day 1 6 1963 2.0 mg/kgAD09967 Single injection on day 1 7 1963 2.0 mg/kg AD09968 Singleinjection on day 1 8 1963 2.0 mg/kg AD09969 Single injection on day 1 91963 2.0 mg/kg AD09970 Single injection on day 1 10 1964 2.0 mg/kgAD09962 Single injection on day 1 11 1965 2.0 mg/kg AD09963 Singleinjection on day 1 12 1967 2.0 mg/kg AD09964 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents AD09736 (Group 2),AD09965 (Group 3), AD09937 (Group 4), AD09966 (Group 5), AD09967 (Group6), AD09968 (Group 7), AD09969 (Group 8), and AD09970 (Group 9) allincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 1963 of the gene; the XDH RNAi agent AD09962(Group 10) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 1964 of the gene; the XDH RNAiagent AD09963 (Group 11) included nucleotide sequences that weredesigned to inhibit expression of an XDH gene at position 1965 of thegene; and the XDH RNAi agent AD09964 (Group 12) included nucleotidesequences that were designed to inhibit expression of an XDH gene atposition 1967 of the gene. (See, e.g., SEQ ID NO:1 and Table 2 for theXDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment are shown in the following Table 10:

TABLE 10 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 4 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.136 1.000 0.205 1.000 0.110 Group 2 (2.0 mg/kg AD09218) 0.6250.146 0.603 0.078 0.642 0.066 Group 3 (2.0 mg/kg AD09965) 0.812 0.1430.623 0.182 0.670 0.198 Group 4 (2.0 mg/kg AD09937) 0.502 0.045 0.5810.183 0.528 0.099 Group 5 (2.0 mg/kg AD09966) 0.486 0.093 0.469 0.1730.502 0.207 Group 6 (2.0 mg/kg AD09967) 0.644 0.065 0.490 0.141 0.4830.084 Group 7 (2.0 mg/kg AD09968) 0.551 0.244 0.599 0.234 0.554 0.168Group 8 (2.0 mg/kg AD09969) 0.603 0.105 0.573 0.078 0.611 0.118 Group 9(2.0 mg/kg AD09970) 0.659 0.228 0.618 0.230 0.621 0.110 Group 10 (2.0mg/kg AD09962) 0.820 0.161 0.818 0.132 0.744 0.093 Group 11 (2.0 mg/kgAD09963) 0.793 0.061 0.743 0.065 0.722 0.095 Group 12 (2.0 mg/kgAD09664) 0.836 0.088 0.783 0.146 0.683 0.058As shown in Table 10, above, the RNAi agents of Groups 2-9, which allincluded nucleotide sequences targeting position 1963 of the XDH gene,reported substantial inhibitory activity, with certain XDH RNAi agentsachieving greater than 50% inhibition in vivo. Further, the XDH RNAiagents of each of Groups 2-9, all of which target position 1963 of theXDH gene, generally showed an increase in inhibition of XDH geneexpression of approximately 20-35% compared to sequences targetingneighboring positions of an XDH gene, shown in Groups 10-12 (Compare,for example, Group 5 (AD09600) at day 15 showing 53.1% inhibition(0.469) with Groups 10-12 at day 15 showing 18.2% inhibition (0.818);25.7% inhibition (0.743); and 21.7% inhibition (0.783), respectively).

Example 5. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 11.

TABLE 11 Targeted Positions and Dosing Groups of Example 5 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 2696 2.0 mg/kgAD09744 Single injection on day 1 3 2696 2.0 mg/kg AD09938 Singleinjection on day 1 4 2696 2.0 mg/kg AD10008 Single injection on day 1 52696 2.0 mg/kg AD10009 Single injection on day 1 6 2696 2.0 mg/kgAD10010 Single injection on day 1 7 2696 2.0 mg/kg AD10011 Singleinjection on day 1 8 2696 2.0 mg/kg AD10012 Single injection on day 1 92696 2.0 mg/kg AD10013 Single injection on day 1 10 2696 2.0 mg/kgAD10014 Single injection on day 1 11 2696 2.0 mg/kg AD10015 Singleinjection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents of Groups 2-11 allincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 2696 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8 (and planned to be collected on days 15,and day 22), and XDH expression levels were determined pursuant to theprocedure set forth in Example 2, above. Data from the experimentthrough day 22 are shown in the following Table 12:

TABLE 12 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 5 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.183 1.000 0.274 1.000 0.213 Group 2 (2.0 mg/kg AD09744) 0.8180.161 0.615 0.092 0.800 0.255 Group 3 (2.0 mg/kg AD09938) 0.669 0.1200.606 0.099 0.699 0.128 Group 4 (2.0 mg/kg AD10008) 0.786 0.140 0.6270.248 0.744 0.102 Group 5 (2.0 mg/kg AD10009) 0.671 0.364 0.457 0.1330.550 0.241 Group 6 (2.0 mg/kg AD10010) 0.591 0.134 0.535 0.103 0.4940.105 Group 7 (2.0 mg/kg AD10011) 0.589 0.280 0.432 0.169 0.546 0.144Group 8 (2.0 mg/kg AD10012) 0.362 0.077 0.295 0.055 0.369 0.029 Group 9(2.0 mg/kg AD10013) 0.393 0.073 0.482 0.054 0.577 0.061 Group 10 (2.0mg/kg AD10014) 0.423 0.055 0.426 0.082 0.548 0.100 Group 11 (2.0 mg/kgAD10015) 0.502 0.034 0.477 0.056 0.535 0.077As shown in Table 12, each of the RNAi agents of Groups 2-11, which allincluded nucleotide sequences targeting position 2696 of the XDH gene,reported substantial inhibitory activity of XDH gene expression.

Example 6. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 13.

TABLE 13 Targeted Positions and Dosing Groups of Example 6 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 488 2.0 mg/kgAD09218 Single injection on day 1 3 231 2.0 mg/kg AD10016 Singleinjection on day 1 4 242 2.0 mg/kg AD10017 Single injection on day 1 51322 2.0 mg/kg AD09734 Single injection on day 1 6 1322 2.0 mg/kgAD10091 Single injection on day 1 7 1322 2.0 mg/kg AD10092 Singleinjection on day 1 8 1322 2.0 mg/kg AD10093 Single injection on day 1 91322 2.0 mg/kg AD10094 Single injection on day 1 10 1322 2.0 mg/kgAD10095 Single injection on day 1 11 1322 2.0 mg/kg AD10096 Singleinjection on day 1 12 1322 2.0 mg/kg AD10097 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agent AD09218 (Group 2)included nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 488 of the gene; the XDH RNAi agent AD10016(Group 3) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 231 of the gene; the XDH RNAiagent AD10017 (Group 4) included nucleotide sequences that were designedto inhibit expression of an XDH gene at position 242 of the gene; andthe XDH RNAi agents AD09734 (Group 5), AD10091 (Group 6), AD10092 (Group7), AD10093 (Group 8), AD10094 (Group 9), AD10095 (Group 10), AD10096(Group 11), and AD10097 (Group 12) included nucleotide sequences thatwere designed to inhibit expression of an XDH gene at position 1322 ofthe gene. (See, e.g., SEQ ID NO:1 and Table 2 for the XDH genereferenced).

As noted in Example 3, above, the RNAi agent targeting position 488 ofthe XDH gene (Group 2), while previously reported to be active in vivoin mice and rats, includes a compromised nucleotide sequence and isunsuitable for therapeutic use due to toxicity concerns.

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8 (and planned for days 15 and day 22),and XDH expression levels were determined pursuant to the procedure setforth in Example 2, above. Data from the experiment through day 8 areshown in the following Table 14:

TABLE 14 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 6 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.069 1.000 0.046 1.000 0.058 Group 2 (2.0 mg/kg AD09218) 0.5500.223 0.489 0.204 0.461 0.116 Group 3 (2.0 mg/kg AD10016) 0.652 0.0980.700 0.115 0.620 0.092 Group 4 (2.0 mg/kg AD10017) 0.645 0.085 0.6400.154 0.632 0.064 Group 5 (2.0 mg/kg AD09734) 0.718 0.059 0.705 0.1190.632 0.087 Group 6 (2.0 mg/kg AD10091) 0.673 0.112 0.757 0.157 0.6730.100 Group 7 (2.0 mg/kg AD10092) 0.757 0.031 0.694 0.085 0.633 0.089Group 8 (2.0 mg/kg AD10093) 0.717 0.039 0.752 0.117 0.634 0.082 Group 9(2.0 mg/kg AD10094) 0.728 0.071 0.727 0.219 0.664 0.106 Group 10 (2.0mg/kg AD10095) 0.805 0.193 0.776 0.110 0.767 0.170 Group 11 (2.0 mg/kgAD10096) 0.536 0.044 0.587 0.147 0.561 0.093 Group 12 (2.0 mg/kgAD10097) 0.839 0.383 0.952 0.450 1.033 0.632

Example 7. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 2820-5715 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 15.

TABLE 15 Targeted Positions and Dosing Groups of Example 7 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 3083 2.0 mg/kgAD09325 Single injection on day 1 3 2995 2.0 mg/kg AD09981 Singleinjection on day 1 4 3016 2.0 mg/kg AD09982 Single injection on day 1 53041 2.0 mg/kg AD09983 Single injection on day 1 6 3498 2.0 mg/kgAD09984 Single injection on day 1 7 3598 2.0 mg/kg AD09985 Singleinjection on day 1 8 3877 2.0 mg/kg AD09987 Single injection on day 1 94394 2.0 mg/kg AD09989 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agent AD09325 (Group 2)included nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 3083 of the gene; the XDH RNAi agent AD09981(Group 3) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 2995 of the gene; the XDH RNAiagent AD09982 (Group 4) included nucleotide sequences that were designedto inhibit expression of an XDH gene at position 3016 of the gene; theXDH RNAi agent AD09983 (Group 5) included nucleotide sequences that weredesigned to inhibit expression of an XDH gene at position 3041 of thegene; the XDH RNAi agent AD09984 (Group 6) included nucleotide sequencesthat were designed to inhibit expression of an XDH gene at position 3498of the gene; the XDH RNAi agent AD09985 (Group 7) included nucleotidesequences that were designed to inhibit expression of an XDH gene atposition 3598 of the gene; the XDH RNAi agent AD09987 (Group 8) includednucleotide sequences that were designed to inhibit expression of an XDHgene at position 3877 of the gene; and the XDH RNAi agent AD09989 (Group9) included nucleotide sequences that were designed to inhibitexpression of an XDH gene at position 4394 of the gene. (See, e.g., SEQID NO:1 and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment are shown in the following Table 16:

TABLE 16 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 7 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.375 1.000 0.397 1.000 0.397 Group 2 (2.0 mg/kg AD09325) 0.5130.078 0.823 0.154 0.823 0.154 Group 3 (2.0 mg/kg AD09981) 0.600 0.0400.681 0.129 0.681 0.129 Group 4 (2.0 mg/kg AD09982) 0.592 0.058 0.6310.137 0.631 0.137 Group 5 (2.0 mg/kg AD09983) 0.596 0.066 0.574 0.0870.574 0.087 Group 6 (2.0 mg/kg AD09984) 0.724 0.043 0.941 0.221 0.9410.221 Group 7 (2.0 mg/kg AD09985) 0.472 0.076 0.449 0.092 0.449 0.092Group 8 (2.0 mg/kg AD09987) 0.691 0.225 0.751 0.149 0.751 0.149 Group 9(2.0 mg/kg AD09989) 0.585 0.076 0.757 0.120 0.757 0.120As shown in Table 16, each of the RNAi agents of Groups 2-9, reportedinhibition of XDH gene expression.

Example 8. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 2820-5715 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 17.

TABLE 17 Targeted Positions and Dosing Groups of Example 8 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 3083 2.0 mg/kgAD09325 Single injection on day 1 3 3600 2.0 mg/kg AD09986 Singleinjection on day 1 4 3930 2.0 mg/kg AD09988 Single injection on day 1 54513 2.0 mg/kg AD09990 Single injection on day 1 6 4531 2.0 mg/kgAD09991 Single injection on day 1 7 4666 2.0 mg/kg AD09992 Singleinjection on day 1 8 4843 2.0 mg/kg AD09993 Single injection on day 1 95234 2.0 mg/kg AD09994 Single injection on day 1 10 5411 2.0 mg/kgAD09995 Single injection on day 1 11 4136 2.0 mg/kg AD09608 Singleinjection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-11 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at the specific positions of the gene as set forth inTable 17, above. (See, e.g., SEQ ID NO:1 and Table 2 for the XDH genereferenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8 (and planned to be collected on days 15,and day 22), and XDH expression levels were determined pursuant to theprocedure set forth in Example 2, above. Data from the experimentthrough day 8 are shown in the following Table 18:

TABLE 18 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 8 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.119 1.000 0.059 1.000 0.177 Group 2 (2.0 mg/kg AD09325) 0.6500.022 0.628 0.083 0.548 0.143 Group 3 (2.0 mg/kg AD09986) 0.999 0.1450.628 0.090 0.625 0.086 Group 4 (2.0 mg/kg AD09988) 0.616 0.163 0.7460.284 0.756 0.149 Group 5 (2.0 mg/kg AD09990) 0.617 0.190 0.901 0.1970.971 0.283 Group 6 (2.0 mg/kg AD09991) 0.883 0.154 0.782 0.134 0.7280.156 Group 7 (2.0 mg/kg AD09992) 1.020 0.074 0.808 0.039 0.788 0.074Group 8 (2.0 mg/kg AD09993) 0.961 0.048 0.775 0.122 0.831 0.169 Group 9(2.0 mg/kg AD09994) 1.334 0.237 1.005 0.121 1.193 0.357 Group 10 (2.0mg/kg AD09995) 0.795 0.095 0.729 0.120 0.777 0.137 Group 11 (2.0 mg/kgAD09608) 0.993 0.103 0.744 0.267 0.435 0.088

Example 9. In Vivo Testing of XDH RNAi Agents in Wild-Type Mice

Certain XDH RNAi agents have sufficient homology with the mouse XDH genetranscript that they are suitable to be examined for XDH gene expressioninhibitory activity in wild-type mice. At day 1, six- to eight-week-oldfemale C57bl/6 mice were given a single subcutaneous administration of200 μl/20 g animal weight containing 1.0 mg/kg (mpk) of an XDH RNAiagent formulated in isotonic saline, or vehicle control (isotonic salinewith no RNAi agent), according to the following Table 19.

TABLE 19 Targeted Positions and Dosing Groups of Example 9 Targeted GenePosition (within SEQ Group ID NO: 1) RNAi Agent and Dose Dosing Regimen1 N/A Saline (no RNAi agent) Single injection on day 1 2 488 1.0 mg/kgAD09217 Single injection on day 1 3 488 1.0 mg/kg AD09218 Singleinjection on day 1 4 1612 1.0 mg/kg AD09219 Single injection on day 1 51614 1.0 mg/kg AD09220 Single injection on day 1 6 1617 1.0 mg/kgAD09221 Single injection on day 1 7 2128 1.0 mg/kg AD09222 Singleinjection on day 1 8 2130 1.0 mg/kg AD09223 Single injection on day 1 92131 1.0 mg/kg AD09224 Single injection on day 1 10 2132 1.0 mg/kgAD09225 Single injection on day 1 11 2153 1.0 mg/kg AD09226 Singleinjection on day 1 12 2185 1.0 mg/kg AD09227 Single injection on day 113 2186 1.0 mg/kg AD09228 Single injection on day 1 14 3272 1.0 mg/kgAD09229 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-14 eachincluded nucleotide sequences that, while also being homologous to themouse XDH gene transcript, were designed to inhibit expression of an XDHgene at the specific positions of the human XDH gene as set forth inTable 19, above. (See, e.g., SEQ ID NO:1 and Table 2 for the XDH genereferenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Mice wereeuthanized on study day 10, and total RNA was isolated from both liversfollowing collection and homogenization. Mouse XDH mRNA expression wasquantitated by probe-based quantitative PCR, normalized to mousebeta-actin expression, and expressed as fraction of vehicle controlgroup (geometric mean, +/−95% confidence interval).

TABLE 20 Average Relative Mouse XDH mRNA at Sacrifice (Day 10) inExample 9 Average Relative Low High Group ID mXDH mRNA (error) (error)Group 1 (No Treatment) 1.000 0.197 0.246 Group 2 (1.0 mg/kg AD09217)0.600 0.100 0.119 Group 3 (1.0 mg/kg AD09218) 0.628 0.132 0.167 Group 4(1.0 mg/kg AD09219) 0.649 0.071 0.080 Group 5 (1.0 mg/kg AD09220) 0.9430.157 0.188 Group 6 (1.0 mg/kg AD09221) 1.174 0.205 0.249 Group 7 (1.0mg/kg AD09222) 1.098 0.242 0.310 Group 8 (1.0 mg/kg AD09223) 1.196 0.1910.228 Group 9 (1.0 mg/kg AD09224) 1.348 0.179 0.207 Group 10 (1.0 mg/kgAD09225) 1.663 0.241 0.281 Group 11 (1.0 mg/kg AD09226) 1.711 0.1260.136 Group 12 (1.0 mg/kg AD09227) 0.912 0.047 0.050 Group 13 (1.0 mg/kgAD09228) 0.983 0.114 0.128 Group 14 (1.0 mg/kg AD09229) 1.023 0.1170.132

The data were normalized to the non-treatment group (Group 1). As notedabove in, for example, Example 3, the RNAi agent targeting position 488of the XDH gene of Group 2 (AD09217) and Group 3 (AD09218), while beingpreviously identified as having activity in mice and rats in vivo,includes a compromised nucleotide sequence and is unsuitable fortherapeutic use due to toxicity concerns. As shown in Table 20, above,the XDH RNAi agent AD09219 (Group 4), which targets position 1612 of theXDH gene transcript, showed mRNA reductions of approximately 35.1%(0.649) in mice, which was generally comparable to the reductionsexhibited by the XDH RNAi agents of Group 2 (40% inhibition; (0.600))and Group 3 (37.2% inhibition; (0.628)), which both included RNAi agentshaving sequences targeting position 488 of the XDH gene which as notedabove has toxicity concerns.

Example 10. In Vivo Testing of XDH RNAi Agents in Wild-Type Mice

Certain XDH RNAi agents have sufficient homology with the mouse XDH genetranscript that they are suitable to be examined for XDH gene expressioninhibitory activity in wild-type mice. At day 1, six- to eight-week-oldmale C57bl/6 mice were given a single subcutaneous administration of 200μl/20 g animal weight containing 1.0 mg/kg (mpk) of an XDH RNAi agentformulated in isotonic saline, or vehicle control (isotonic saline withno RNAi agent), according to the following Table 21.

TABLE 21 Targeted Positions and Dosing Groups of Example 10 TargetedGene Position (within SEQ Group ID NO: 1) RNAi Agent and Dose DosingRegimen 1 N/A Saline (no RNAi agent) Single injection on day 1 2 16121.0 mg/kg AD09219 Single injection on day 1 3 1612 1.0 mg/kg AD10021Single injection on day 1 4 1612 1.0 mg/kg AD10022 Single injection onday 1 5 1612 1.0 mg/kg AD10023 Single injection on day 1 6 1612 1.0mg/kg AD10024 Single injection on day 1 7 1612 1.0 mg/kg AD10025 Singleinjection on day 1 8 1612 1.0 mg/kg AD10026 Single injection on day 1 91612 1.0 mg/kg AD10027 Single injection on day 1 10 1612 1.0 mg/kgAD10028 Single injection on day 1 11 1612 1.0 mg/kg AD10029 Singleinjection on day 1 12 1612 1.0 mg/kg AD10030 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-14 eachincluded nucleotide sequences that, while also being homologous to themouse XDH gene transcript, were designed to inhibit expression of an XDHgene at positions 1612 of the human XDH gene. (See, e.g., SEQ ID NO:1and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Mice wereeuthanized on study day 8, and total RNA was isolated from both liversfollowing collection and homogenization. Mouse XDH mRNA expression wasquantitated by probe-based quantitative PCR, normalized to mousebeta-actin expression, and expressed as fraction of vehicle controlgroup (geometric mean, +/−95% confidence interval).

TABLE 22 Average Relative Mouse XDH mRNA at Sacrifice (Day 8) in Example10 Average Relative Low High Group ID mXDH mRNA (error) (error) Group 1(No Treatment) 1.000 0.242 0.319 Group 2 (1.0 mg/kg AD09219) 0.607 0.0440.048 Group 3 (1.0 mg/kg AD10021) 0.653 0.139 0.177 Group 4 (1.0 mg/kgAD10022) 0.711 0.055 0.060 Group 5 (1.0 mg/kg AD10023) 0.609 0.067 0.076Group 6 (1.0 mg/kg AD10024) 0.703 0.116 0.139 Group 7 (1.0 mg/kgAD10025) 0.659 0.083 0.095 Group 8 (1.0 mg/kg AD10026) 0.561 0.093 0.111Group 9 (1.0 mg/kg AD10027) 0.540 0.090 0.108 Group 10 (1.0 mg/kgAD10028) 0.631 0.054 0.059 Group 11 (1.0 mg/kg AD10029) 0.440 0.0420.046 Group 12 (1.0 mg/kg AD10030) 0.550 0.118 0.150

The data were normalized to the non-treatment group (Group 1). As shownin Table 22, above, each of the XDH RNAi agents targeting position 1612(Groups 2-12) showed mouse mRNA reductions.

Example 11. In Vivo Testing of XDH RNAi Agents in Wild-Type Rats

Certain XDH RNAi agents have sufficient homology with the rat XDH genetranscript that they are suitable to be examined for XDH gene expressioninhibitory activity in wild-type rats. At day 1, male Sprague Dawleyrats were given a single subcutaneous administration of 4 mL/1 kg animalweight containing a dose of an XDH RNAi agent formulated in isotonicsaline, or vehicle control (isotonic saline with no RNAi agent),according to the following Table 23.

TABLE 23 Targeted Positions and Dosing Groups of Example 11 TargetedGene Position (within Group SEQ ID NO: 1) RNAi Agent and Dose DosingRegimen 1 N/A Saline (no RNAi agent) Single injection on day 1 2 48810.0 mg/kg AD09218 Single injection on day 1 3 488 3.0mg/kg AD09218Single injection on day 1 4 488 1.0 mg/kg AD09218 Single injection onday 1 5 488 0.3 mg/kg AD09218 Single injection on day 1 6 2612 10.0mg/kg AD09651 Single injection on day 1 7 2612 3.0 mg/kg AD09651 Singleinjection on day 1 8 2612 1.0 mg/kg AD09651 Single injection on day 1 92612 0.3 mg/kg AD09651 Single injection on day 1 10 2616 10.0 mg/kgAD09663 Single injection on day 1 11 2616 3.0 mg/kg AD09663 Singleinjection on day 1 12 2616 1.0 mg/kg AD09663 Single injection on day 113 2616 0.3 mg/kg AD09663 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agent in Groups 2-5 (AD09218)included nucleotide sequences that, while also being homologous to therat XDH gene transcript, were designed to inhibit expression of an XDHgene at position 488 of the human XDH gene; the XDH RNAi agent in Groups6-9 (AD09651) included nucleotide sequences that, while also beinghomologous to the rat XDH gene transcript, were designed to inhibitexpression of an XDH gene at position 2612 of the human XDH gene; andthe XDH RNAi agents in Groups 10-13 (AD09663) included nucleotidesequences that, while also being homologous to the rat XDH genetranscript, were designed to inhibit expression of an XDH gene atposition 2616 of the human XDH gene. (See, e.g., SEQ ID NO:1 and Table 2for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) rats in each group were tested (n=4). Rats wereeuthanized on study day 10, and total RNA was isolated from both liversfollowing collection and homogenization. Rat XDH mRNA expression wasquantitated by probe-based quantitative PCR, normalized to ratbeta-actin expression, and expressed as fraction of vehicle controlgroup (geometric mean, +/−95% confidence interval).

TABLE 24 Average Relative Mouse XDH mRNA at Sacrifice (Day 10) inExample 11 Average Relative Low High Group ID rXDH mRNA (error) (error)Group 1 (No Treatment) 1.000 0.164 0.197 Group 2 (10.0 mg/kg AD09218)0.207 0.079 0.128 Group 3 (3.0 mg/kg AD09218) 0.295 0.105 0.163 Group 4(1.0 mg/kg AD09218) 0.369 0.061 0.072 Group 5 (0.3 mg/kg AD09218) 0.5560.086 0.102 Group 6 (10.0 mg/kg AD09651) 0.209 0.056 0.076 Group 7 (3.0mg/kg AD09651) 0.271 0.045 0.054 Group 8 (1.0 mg/kg AD09651) 0.625 0.1110.135 Group 9 (0.3 mg/kg AD09651) 0.828 0.114 0.132 Group 10 (10.0 mg/kgAD09663) 0.122 0.045 0.072 Group 11 (3.0 mg/kg AD09663) 0.213 0.0600.083 Group 12 (1.0 mg/kg AD09663) 0.428 0.094 0.120 Group 13 (0.3 mg/kgAD09663) 0.481 0.112 0.146

The data were normalized to the non-treatment group (Group 1). As notedabove in, for example, Example 3, the RNAi agent targeting position 488of the XDH gene of Groups 2-5 (AD09218), while being previouslyidentified as having activity in rats in vivo, includes a compromisednucleotide sequence and is unsuitable for therapeutic use due totoxicity concerns. As shown in Table 24, the XDH RNAi agent AD09651(Groups 6-9), which targets position 2612 of the XDH gene transcript,and the XDH RNAi agent AD09663 (Groups 10-13), which targets position2616, both showed dose-dependent mRNA reductions that were comparable toAD09218 (targeting position 488 of the XDH gene).

Example 12. In Vivo Testing of XDH RNAi Agents in Cynomolgus Monkeys

XDH RNAi agents AD09325 and AD09307 were evaluated in cynomolgus monkeys(cynos). On day 1, three male cynos for each group (n=3) wereadministered a subcutaneous injection of 0.3 mL/kg (approximately 1.5 mLvolume, depending on animal mass) containing 3.0 mg/kg (10 mg/mL) of therespective XDH RNAi agent, formulated in isotonic saline.

TABLE 25 Targeted Positions and Dosing Groups of Example 12 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen (on day 1) A 3083 3.0 mg/kg AD09325 Single subcutaneousinjection B 4725 3.0 mg/kg AD09307 Single subcutaneous injection

The XDH RNAi agents included modified nucleotides that were conjugatedat the 5′ terminal end of the sense strand to a targeting ligand thatincluded three N-acetyl-galactosamine groups (tridentate ligand) havingthe modified sequences as set forth in the duplex structures herein.(See Tables 3, 4, 5A, 5B, 5C, and 6 for specific modifications andstructure information related to the XDH RNAi agents, including (NAG37)sligand). The XDH RNAi agent in Groups A (AD09325) included nucleotidesequences that were designed to inhibit expression of a human XDH geneat position 3083; and the XDH RNAi agent in Group B (AD09307) includednucleotide sequences that were designed to inhibit expression of an XDHgene at position 4725. (See, e.g., SEQ ID NO:1 and Table 2 for the XDHgene referenced).

On days −8 (8 days before dose) and 15, survival liver biopsies weretaken. On the date of each biopsy collection, cynos were anesthetizedand laparoscopy was used to extract two liver tissue samplesapproximately 80 mg to 120 mg each, and aliquots of approximately 50 mgwere snap-frozen and stored at −70° C. until analysis. On day 29, cynoswere euthanized and aliquots of approximately 50 mg liver samples werecollected. The biopsy samples were then homogenized, and levels of cynoXDH (cXDH) mRNA in the cyno livers were measured by RT-qPCR using ahousekeeping gene as reference. Resulting values were then normalized tothe pre-dose (in this case, at day −8) cXDH mRNA measurements. Theresulting mRNA data are reflected in the following Table 26:

TABLE 26 Cyno XDH mRNA Levels Normalized to Pre-Dose (Day-8) fromExample 12 for each Group (n = 3) Day-8 Day 15 Relative Relative cXDHcXDH mRNA Low High mRNA Low High Expression Error Error Expression ErrorError Group A: 1.000 0.211 0.268 0.609 0.097 0.115 AD09325 Group B:1.000 0.339 0.512 1.139 0.316 0.437 AD09307 Day 29 Relative cXDH mRNALow High Expression Error Error Group A: 1.178 0.286 0.378 AD09325 GroupB: 1.591 0.509 0.748 AD09307As shown in Table 26, XDH RNAi agent AD09325, which was designed totarget position 3083 of the XDH gene, showed 39% inhibition of cXDH mRNAat Day 15 and returned to baseline by day 29. XDH RNAi agent AD09307,which was designed to target position 4725 of the XDH gene, showed noinhibitory activity at either of the time points measured.

Example 13. In Vivo Testing of XDH RNAi Agents in Cynomolgus Monkeys

XDH RNAi agents AD09734, AD09651, AD09663, and AD09611 were evaluated incynomolgus monkeys (cynos). On days 1 and 31, three male cynos for eachgroup (n=3) were administered a subcutaneous injection of 0.3 mL/kg(approximately 1.5 mL volume, depending on animal mass) containing 3.0mg/kg (10 mg/mL) of the respective XDH RNAi agent, formulated inisotonic saline.

TABLE 27 Targeted Positions and Dosing Groups of Example 13 TargetedGene Position (within SEQ RNAi Agent Dosing Regimen (on days 1 Group IDNO: 1) and Dose and 31) 1 1322 3.0 mg/kg AD09734 Two subcutaneousinjections 2 2612 3.0 mg/kg AD09651 Two subcutaneous injections 3 26163.0 mg/kg AD09663 Two subcutaneous injections 4 4289 3.0 mg/kg AD09611Two subcutaneous injections

The XDH RNAi agents included modified nucleotides that were conjugatedat the 5′ terminal end of the sense strand to a targeting ligand thatincluded three N-acetyl-galactosamine groups (tridentate ligand) havingthe modified sequences as set forth in the duplex structures herein.(See Tables 3, 4, 5A, 5B, 5C, and 6 for specific modifications andstructure information related to the XDH RNAi agents, including (NAG37)sligand). The XDH RNAi agents included nucleotide sequences that weredesigned to inhibit expression of a human XDH gene at the specificpositions as shown in Table 27, above. (See, e.g., SEQ ID NO:1 and Table2 for the XDH gene referenced).

On days −14 or −7 (pre-dose), 15, 43, and 80 (for Group 4 only) liverbiopsies were taken. On the date of each biopsy collection, cynos wereanesthetized and laparoscopy was used to extract two liver tissuesamples approximately 80 mg to 120 mg each, and aliquots ofapproximately 50 mg were snap-frozen and stored at −70° C. untilanalysis. The biopsy samples were then homogenized, and levels of cXDHmRNA in the cyno livers were measured by RT-qPCR using a housekeepinggene as reference. Resulting values were then normalized to the pre-dose(in this case, at day −14 or −7, depending on the animals) cXDH mRNAmeasurements. Batch analysis of samples across timepoints was performedwhere applicable. The resulting mRNA data are reflected in the followingTable 28:

TABLE 28 Cyno XDH mRNA Levels Normalized to Pre-Dose (Day-14 or -7) fromExample 13 for each Group (n = 3) Pre-Dose (Day-14 or Day-7) Day 15Relative Relative cXDH cXDH mRNA Low High mRNA Low High Expression ErrorError Expression Error Error Group 1: 1.000 0.127 0.145 0.351 0.0280.031 AD09734 Group 2: 1.000 0.170 0.205 0.433 0.131 0.188 AD09651 Group3: 1.000 0.374 0.597 0.621 0.274 0.489 AD09663 Group 4: 1.000 0.2020.254 0.570 0.122 0.156 AD09611 Day 43 Day 80 Relative Relative cXDHcXDH mRNA Low High mRNA Low High Expression Error Error Expression ErrorError Group 1: 0.434 0.134 0.194 AD09734 Group 2: 0.342 0.074 0.094AD09651 Group 3: 0.605 0.316 0.662 AD09663 Group 4: 0.239 0.015 0.0160.493 0.090 0.110 AD09611As shown in Table 28, each of the XDH RNAi agents showed inhibition ofXDH gene expression.

XDH Activity Assay. Using RNAScope (see, e.g., RNAscope, A Novel in SituRNA Analysis Platform for Formalin-Fixed, Paraffin-Embedded Tissues, JMol Diagn. 2012 January; 14(1): 22-29), it was determined that XDH mRNAtranscripts are partitioned between both nuclear and cytosoliccompartments. As translation to XDH protein only occurs in thecytoplasm, inhibition of cytoplasmic mRNA transcripts is consideredtherapeutically relevant. Measurement of XDH mRNA transcripts usingq-PCR from whole liver homogenate, as explained in Table 28, istherefore not necessarily reflective of determining therapeuticallyrelevant XDH inhibition as it measures the presence of XDH mRNA in boththe cytosolic and nucleic compartments. Thus, to obtain a more accurateassessment of the inhibitory activity of the various XDH RNAi agentsdisclosed herein, an XDH activity assay was developed capable ofindirectly measuring the amount of XDH protein inhibited by the XDH RNAiagents through the RNA interference mechanism.

More specifically, XDH activity was assessed using the following method:frozen cyno liver biopsy samples were homogenized in buffer containing100 mM oxonic acid to inhibit endogenous uricase activity which is knownto degrade uric acid. Liver homogenates were purified using Sephadex G25spin columns, and protein concentrations adjusted to 0.5 μg/μl totalprotein (lysate). XDH activity was measured by liquid-chromatographymass spectrometry (LCMS) as the conversion of xanthine to uric acid at37° C. within a 30-minute timeframe. The amount of uric acid generatedover time is an indirect measure of the amount of cXDH protein presentin the lysate; accordingly, the less uric acid identified, the less cXDHprotein was present in lysate, thereby indicating a more potent XDH RNAiagent for reducing XDH protein. The resulting XDH activity data(normalized to pre-dose) are shown in Table 29.

TABLE 29 Cyno XDH Activity Levels Normalized to Pre-Dose (Day-14 or -7)from Example 13 for each Group (n = 3) Pre-Dose (Day-14 or Day-7) Day 15Day 43 Day 80 Relative Relative Std Relative Std Relative Std XDH StdDev XDH Dev XDH Dev XDH Dev Activity (+/−) Activity (+/−) Activity (+/−)Activity (+/−) Group 1: 1.000 0.042 0.363 0.056 0.240 0.056 AD09734Group 2: 1.000 0.026 0.511 0.121 0.289 0.053 AD09651 Group 3: 1.0000.003 0.412 0.219 0.247 0.164 AD09663 Group 4: 1.000 0.025 0.555 0.1150.226 0.057 0.268 0.082 AD09611As shown in Table 29, through day 43 each of the RNAi agents testedabove showed XDH activity reductions of greater than 70%. Further, RNAiagent AD09611 showed substantial reductions of XDH activity that weremaintained for seven weeks post the last dose (day 31).

Example 14. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 2820-5715 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 30.

TABLE 30 Targeted Positions and Dosing Groups of Example 14 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 42892.0 mg/kg AD09611 Single injection on day 1 3 4289 2.0 mg/kg AD10183Single injection on day 1 4 4289 2.0 mg/kg AD10629 Single injection onday 1 5 4289 2.0 mg/kg AD10630 Single injection on day 1 6 4289 2.0mg/kg AD10631 Single injection on day 1 7 4289 2.0 mg/kg AD10632 Singleinjection on day 1 8 4289 2.0 mg/kg AD10184 Single injection on day 1 94289 2.0 mg/kg AD10633 Single injection on day 1 10 4289 2.0 mg/kgAD10634 Single injection on day 1 11 4289 2.0 mg/kg AD10635 Singleinjection on day 1 12 4289 2.0 mg/kg AD10636 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-12 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 4289 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, and day 15, and XDH expression levelswere determined pursuant to the procedure set forth in Example 2, above.Data from the experiment through day 22 are shown in Table 31:

TABLE 31 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 14 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.164 1.000 0.044 1.000 0.085 Group 2 (2.0 mg/kg AD09611) 0.8770.113 0.710 0.100 0.629 0.148 Group 3 (2.0 mg/kg AD10183) 0.585 0.0840.402 0.082 0.432 0.098 Group 4 (2.0 mg/kg AD10629) 0.548 0.119 0.4430.127 0.501 0.195 Group 5 (2.0 mg/kg AD10630) 0.708 0.076 0.609 0.1300.497 0.045 Group 6 (2.0 mg/kg AD10631) 0.523 0.035 0.398 0.090 0.4770.080 Group 7 (2.0 mg/kg AD10632) 0.679 0.248 0.583 0.125 0.574 0.314Group 8 (2.0 mg/kg AD10184) 0.573 0.051 0.501 0.029 0.529 0.070 Group 9(2.0 mg/kg AD10633) 0.686 0.153 0.544 0.080 0.562 0.111 Group 10 (2.0mg/kg AD10634) 0.680 0.136 0.572 0.088 0.615 0.092 Group 11 (2.0 mg/kgAD10635) 0.764 0.178 0.678 0.105 0.674 0.083 Group 12 (2.0 mg/kgAD10636) 0.555 0.068 0.440 0.091 0.488 0.126

Example 15. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 80-2899 region of the human XDH cDNA sequence wasused. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 1.0 mg/kg(mpk) or 3.0 mg/kg (mpk) of an XDH RNAi agent formulated in isotonicsaline, or vehicle control (isotonic saline with no RNAi agent),according to Table 32.

TABLE 32 Targeted Positions and Dosing Groups of Example 15 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 19633.0 mg/kg AD09736 Single injection on day 1 3 1963 1.0 mg/kg AD09736Single injection on day 1 4 1963 3.0 mg/kg AD09937 Single injection onday 1 5 1963 1.0 mg/kg AD09937 Single injection on day 1 6 1963 3.0mg/kg AD09967 Single injection on day 1 7 1963 1.0 mg/kg AD09967 Singleinjection on day 1 8 1963 3.0 mg/kg AD10278 Single injection on day 1 91963 1.0 mg/kg AD10278 Single injection on day 1 10 1963 3.0 mg/kgAD10281 Single injection on day 1 11 1963 1.0 mg/kg AD10281 Singleinjection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents of Groups 2-11 allincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 1963 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, and day 22, and XDH expression levelswere determined pursuant to the procedure set forth in Example 2, above.Data from the experiment through day 22 are shown in Table 33:

TABLE 33 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 15 Day 8 Day 22 Avg Std Dev Avg Std Dev Group IDXDH (+/−) XDH (+/−) Group 1 (Saline vehicle) 1.000 0.202 1.000 0.112Group 2 (3.0 mg/kg AD09736) 0.587 0.080 0.682 0.182 Group 3 (1.0 mg/kgAD09736) 1.100 0.292 1.063 0.212 Group 4 (3.0 mg/kg AD09937) 0.554 0.2110.547 0.214 Group 5 (1.0 mg/kg AD09937) 0.914 0.175 0.851 0.175 Group 6(3.0 mg/kg AD09967) 0.638 0.035 0.696 0.139 Group 7 (1.0 mg/kg AD09967)0.838 0.103 0.790 0.149 Group 8 (3.0 mg/kg AD10278) 0.518 0.036 0.6780.112 Group 9 (1.0 mg/kg AD10278) 1.209 0.116 0.940 0.266 Group 10 (3.0mg/kg AD10281) 0.769 0.184 0.762 0.145 Group 11 (1.0 mg/kg AD10281)1.224 0.172 0.995 0.160

Example 16. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 2820-5715 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 4.0 mg/kg(mpk), 2.0 mg/kg (mpk), 1.0 mg/kg (mpk) of an XDH RNAi agent formulatedin isotonic saline, or vehicle control (isotonic saline with no RNAiagent), according to Table 34.

TABLE 34 Targeted Positions and Dosing Groups of Example 16 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 42894.0 mg/kg AD09611 Single injection on day 1 3 4289 2.0 mg/kg AD09611Single injection on day 1 4 4289 1.0 mg/kg AD09611 Single injection onday 1 5 4289 4.0 mg/kg AD10183 Single injection on day 1 6 4289 2.0mg/kg AD10183 Single injection on day 1 7 4289 1.0 mg/kg AD10183 Singleinjection on day 1 8 4289 4.0 mg/kg AD10631 Single injection on day 1 94289 2.0 mg/kg AD10631 Single injection on day 1 10 4289 1.0 mg/kgAD10631 Single injection on day 1 11 4289 4.0 mg/kg AD10184 Singleinjection on day 1 12 4289 2.0 mg/kg AD10184 Single injection on day 113 4289 1.0 mg/kg AD10184 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-13 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 4289 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2.Data from the experiment through day 22 are shown in Table 35:

TABLE 35 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 16 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.167 1.000 0.099 1.000 0.048 Group 2 (4.0 mg/kg AD09611) 0.8080.086 0.810 0.089 0.958 0.118 Group 3 (2.0 mg/kg AD09611) 1.100 0.2240.998 0.383 1.245 0.476 Group 4 (1.0 mg/kg AD09611) 0.917 0.198 0.9410.224 0.780 0.544 Group 5 (4.0 mg/kg AD10183) 0.636 0.140 0.642 0.0440.797 0.112 Group 6 (2.0 mg/kg AD10183) 0.768 0.059 0.672 0.206 0.8700.079 Group 7 (1.0 mg/kg AD10183) 0.841 0.111 0.792 0.266 0.938 0.122Group 8 (4.0 mg/kg AD10631) 0.755 0.110 0.677 0.094 0.664 0.126 Group 9(2.0 mg/kg AD10631) 0.852 0.066 0.755 0.103 0.869 0.149 Group 10 (1.0mg/kg AD10631) 0.884 0.153 0.954 0.128 1.060 0.071 Group 11 (4.0 mg/kgAD10184) 0.640 0.079 0.663 0.055 0.680 0.068 Group 12 (2.0 mg/kgAD10184) 0.729 0.049 0.746 0.126 0.811 0.116 Group 13 (1.0 mg/kgAD10184) 0.807 0.069 0.730 0.090 0.796 0.119

Example 17. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 2820-5715 region of the human XDH cDNA sequence wasused. At day 1, each mouse was given a single subcutaneousadministration of 200 μl/20 g animal weight containing either 4.0 mg/kg(mpk), 2.0 mg/kg (mpk), 1.0 mg/kg (mpk) of an XDH RNAi agent formulatedin isotonic saline, or vehicle control (isotonic saline with no RNAiagent), according to Table 36.

TABLE 36 Targeted Positions and Dosing Groups of Example 17 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 35984.0 mg/kg AD09985 Single injection on day 1 3 3598 2.0 mg/kg AD09985Single injection on day 1 4 3598 1.0 mg/kg AD09985 Single injection onday 1 5 3598 4.0 mg/kg AD10729 Single injection on day 1 6 3598 2.0mg/kg AD10729 Single injection on day 1 7 3598 1.0 mg/kg AD10729 Singleinjection on day 1 8 3598 4.0 mg/kg AD10730 Single injection on day 1 93598 2.0 mg/kg AD10730 Single injection on day 1 10 3598 1.0 mg/kgAD10730 Single injection on day 1 11 3598 4.0 mg/kg AD10734 Singleinjection on day 1 12 3598 2.0 mg/kg AD10734 Single injection on day 113 3598 1.0 mg/kg AD10734 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-13 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 3598 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment through day 22 are shown in Table 37:

TABLE 37 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 17 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.294 1.000 0.350 1.000 0.156 Group 2 (4.0 mg/kg AD09985) 0.3420.061 0.340 0.052 0.320 0.074 Group 3 (2.0 mg/kg AD09985) 0.464 0.0650.443 0.076 0.457 0.108 Group 4 (1.0 mg/kg AD09985) 0.527 0.163 0.5090.075 0.487 0.094 Group 5 (4.0 mg/kg AD10729) 0.393 0.081 0.379 0.0740.359 0.045 Group 6 (2.0 mg/kg AD10729) 0.504 0.176 0.447 0.132 0.3940.176 Group 7 (1.0 mg/kg AD10729) 0.480 0.168 0.535 0.279 0.486 0.205Group 8 (4.0 mg/kg AD10730) 0.322 0.035 0.316 0.046 0.244 0.064 Group 9(2.0 mg/kg AD10730) 0.467 0.076 0.397 0.052 0.360 0.113 Group 10 (1.0mg/kg AD10730) 0.560 0.114 0.540 0.079 0.536 0.068 Group 11 (4.0 mg/kgAD10734) 0.369 0.048 0.340 0.074 0.278 0.025 Group 12 (2.0 mg/kgAD10734) 0.574 0.338 0.467 0.255 0.432 0.299 Group 13 (1.0 mg/kgAD10734) 0.616 0.198 0.617 0.086 0.389 0.076

Example 18. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 80-2899 and 2820-5715 regions of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 200 μl/20 g animal weight containing either 4.0 mg/kg(mpk), 2.0 mg/kg (mpk), 1.0 mg/kg (mpk) of an XDH RNAi agent formulatedin isotonic saline, or vehicle control (isotonic saline with no RNAiagent), according to Table 38.

TABLE 38 Targeted Positions and Dosing Groups of Example 18 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 2696 Saline (no Single injection on day 1 RNAi agent) 2 26964.0 mg/kg AD09744 Single injection on day 1 3 2696 2.0 mg/kg AD09744Single injection on day 1 4 2696 1.0 mg/kg AD09744 Single injection onday 1 5 2696 4.0 mg/kg AD10621 Single injection on day 1 6 2696 2.0mg/kg AD10621 Single injection on day 1 7 2696 1.0 mg/kg AD10621 Singleinjection on day 1 8 1963 4.0 mg/kg AD09736 Single injection on day 1 91963 2.0 mg/kg AD09736 Single injection on day 1 10 1963 1.0 mg/kgAD09736 Single injection on day 1 11 1963 4.0 mg/kg AD09937 Singleinjection on day 1 12 1963 2.0 mg/kg AD09937 Single injection on day 113 1963 1.0 mg/kg AD09937 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-13 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at positions 2696 and 1963 of the gene. (See, e.g., SEQID NO:1 and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2.Data from the experiment through day 22 are shown in Table 39:

TABLE 39A Average XDH Normalized to Pre-Treatment in XDH-GLUC AAV Micefrom Example 18 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev Avg Std DevGroup ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle) 1.1830.346 1.164 0.468 1.448 0.573 Group 2 (4.0 mg/kg AD09744) 0.538 0.1130.404 0.106 0.601 0.062 Group 3 (2.0 mg/kg AD09744) 0.704 0.210 0.6630.165 0.950 0.214 Group 4 (1.0 mg/kg AD09744) 0.903 0.100 0.842 0.1541.101 0.249 Group 5 (4.0 mg/kg AD10621) 0.406 0.226 0.366 0.293 0.6500.532 Group 6 (2.0 mg/kg AD10621) 0.521 0.261 0.411 0.225 0.640 0.343Group 7 (1.0 mg/kg AD10621) 0.580 0.202 0.467 0.227 0.669 0.361 Group 8(4.0 mg/kg AD09736) 0.870 0.117 0.732 0.045 1.084 0.195 Group 9 (2.0mg/kg AD09736) 0.867 0.088 0.809 0.100 1.187 0.254 Group 10 (1.0 mg/kgAD09736) 1.313 0.177 1.199 0.185 1.344 0.185 Group 11 (4.0 mg/kgAD09937) 0.540 0.164 0.588 0.268 0.780 0.247 Group 12 (2.0 mg/kgAD09937) 0.636 0.249 0.812 0.480 0.846 0.312 Group 13 (1.0 mg/kgAD09937) 0.927 0.215 0.932 0.127 1.011 0.057

TABLE 39B Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice 2 from Example 18 Day 8 Day 15 Day 22 Avg Std Dev Avg Std DevAvg Std Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Salinevehicle) 1.000 0.292 1.000 0.403 1.000 0.396 Group 2 (4.0 mg/kg AD09744)0.455 0.095 0.347 0.091 0.415 0.043 Group 3 (2.0 mg/kg AD09744) 0.5950.178 0.570 0.142 0.656 0.147 Group 4 (1.0 mg/kg AD09744) 0.763 0.0840.724 0.132 0.760 0.172 Group 5 (4.0 mg/kg AD10621) 0.343 0.191 0.3150.252 0.449 0.367 Group 6 (2.0 mg/kg AD10621) 0.441 0.220 0.353 0.1930.442 0.237 Group 7 (1.0 mg/kg AD10621) 0.491 0.171 0.402 0.195 0.4620.249 Group 8 (4.0 mg/kg AD09736) 0.736 0.099 0.629 0.039 0.748 0.135Group 9 (2.0 mg/kg AD09736) 0.733 0.075 0.696 0.086 0.820 0.175 Group 10(1.0 mg/kg AD09736) 1.110 0.150 1.031 0.159 0.928 0.128 Group 11 (4.0mg/kg AD09937) 0.457 0.139 0.505 0.230 0.538 0.171 Group 12 (2.0 mg/kgAD09937) 0.538 0.210 0.698 0.413 0.584 0.216 Group 13 (1.0 mg/kgAD09937) 0.783 0.182 0.801 0.109 0.698 0.039

Example 19. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 80-2899 region of the human XDH cDNA sequence wasused. At day 1, each mouse was given a single subcutaneousadministration of 200 μl/20 g animal weight containing either 4.0 mg/kg(mpk), 2.0 mg/kg (mpk) of an XDH RNAi agent formulated in isotonicsaline, or vehicle control (isotonic saline with no RNAi agent),according to Table 40.

TABLE 40 Targeted Positions and Dosing Groups of Example 19 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 1963 Saline (no Single injection on day 1 RNAi agent) 2 19634.0 mg/kg AD09736 Single injection on day 1 3 1963 2.0 mg/kg AD09736Single injection on day 1 4 1963 4.0 mg/kg AD10967 Single injection onday 1 5 1963 2.0 mg/kg AD10967 Single injection on day 1 6 1963 4.0mg/kg AD10968 Single injection on day 1 7 1963 2.0 mg/kg AD10968 Singleinjection on day 1 8 1963 4.0 mg/kg AD10969 Single injection on day 1 91963 2.0 mg/kg AD10969 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-9 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 1963 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2.Data from the experiment through day 22 are shown in Table 41:

TABLE 41 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 19 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.158 1.000 0.166 1.000 0.077 Group 2 (4.0 mg/kg AD09736) 0.6070.088 0.704 0.077 0.635 0.230 Group 3 (2.0 mg/kg AD09736) 0.738 0.1990.742 0.085 0.991 0.061 Group 4 (4.0 mg/kg AD10967) 0.468 0.115 0.5420.083 0.714 0.131 Group 5 (2.0 mg/kg AD10967) 0.746 0.099 0.826 0.0470.940 0.203 Group 6 (4.0 mg/kg AD10968) 0.520 0.131 0.488 0.149 0.6850.176 Group 7 (2.0 mg/kg AD10968) 0.534 0.148 0.597 0.135 0.827 0.155Group 8 (4.0 mg/kg AD10969) 0.614 0.194 0.617 0.211 0.758 0.264 Group 9(2.0 mg/kg AD10969) 0.728 0.274 0.711 0.244 0.984 0.440

Example 20. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 2820-5715 region of the human XDH cDNA sequence wasused. At day 1, each mouse was given a single subcutaneousadministration of 200 μl/20 g animal weight containing either 4.0 mg/kg(mpk), 2.0 mg/kg (mpk), 1.0 mg/kg (mpk) of an XDH RNAi agent formulatedin isotonic saline, or vehicle control (isotonic saline with no RNAiagent), according to Table 42.

TABLE 42 Targeted Positions and Dosing Groups of Example 20 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 42894.0 mg/kg AD09611 Single injection on day 1 3 4289 2.0 mg/kg AD09611Single injection on day 1 4 4289 1.0 mg/kg AD09611 Single injection onday 1 5 4289 4.0 mg/kg AD10631 Single injection on day 1 6 4289 2.0mg/kg AD10631 Single injection on day 1 7 4289 1.0 mg/kg AD10631 Singleinjection on day 1 8 3598 4.0 mg/kg AD09985 Single injection on day 1 93598 2.0 mg/kg AD09985 Single injection on day 1 10 3598 1.0 mg/kgAD09985 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-10 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at positions 4289 and 3598 of the gene. (See, e.g., SEQID NO:1 and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2.Data from the experiment through day 22 are shown in Table 43:

TABLE 43 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 20 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.209 1.000 0.098 1.000 0.222 Group 2 (4.0 mg/kg AD09611) 0.8920.047 0.777 0.181 0.829 0.213 Group 3 (2.0 mg/kg AD09611) 0.703 0.1680.699 0.159 0.789 0.209 Group 4 (1.0 mg/kg AD09611) 0.868 0.183 0.8430.071 0.729 0.136 Group 5 (4.0 mg/kg AD10631) 0.642 0.082 0.651 0.0580.644 0.153 Group 6 (2.0 mg/kg AD10631) 0.660 0.192 0.594 0.082 0.5570.102 Group 7 (1.0 mg/kg AD10631) 0.626 0.060 0.649 0.089 0.720 0.143Group 8 (4.0 mg/kg AD09985) 0.600 0.360 0.600 0.341 0.586 0.209 Group 9(2.0 mg/kg AD09985) 0.576 0.119 0.519 0.025 0.619 0.088 Group 10 (1.0mg/kg AD09985) 0.710 0.163 0.641 0.086 0.631 0.136

Example 21. In Vivo Testing of XDH RNAi Agents in Cynomolgus Monkeys

XDH RNAi agent AD09611, which was previously evaluated in cynomolgusmonkeys (cynos) in the study described in Example 13, was furtherevaluated in cynomolgus monkeys (cynos). On days 1, 15, and 29, threemale cynos for each group (n=3) were administered a subcutaneousinjection of 0.3 mL/kg (approximately 1.5 mL volume, depending on animalmass) containing 3.0 mg/kg (10 mg/mL) of the respective XDH RNAi agent,formulated in isotonic saline.

TABLE 44 Targeted Positions and Dosing Groups of Example 21 TargetedGene Position (within SEQ RNAi Agent Dosing Regimen Group ID NO: 1) andDose (on days 1, 15, and 29) 1 4289 3.0 mg/kg AD09611 Three subcutaneousinjections 2 4289 3.0 mg/kg AD09611 Three subcutaneous injections

The XDH RNAi agents included modified nucleotides that were conjugatedat the 5′ terminal end of the sense strand to a targeting ligand thatincluded three N-acetyl-galactosamine groups (tridentate ligand) havingthe modified sequences as set forth in the duplex structures herein.(See Tables 3, 4, 5A, 5B, 5C, and 6 for specific modifications andstructure information related to the XDH RNAi agents, including (NAG37)sligand). The XDH RNAi agents included nucleotide sequences that weredesigned to inhibit expression of a human XDH gene at the specificpositions as shown in Table 43, above. (See, e.g., SEQ ID NO:1 and Table2 for the XDH gene referenced).

On days −14, 29, 57, and 85, liver biopsies were taken from Group 1animals. On days −7, 43, 71, and 99, liver biopsies were taken fromGroup 2 animals. On the date of each biopsy collection, cynos weresedated and Menghini technique was used to extract two liver tissuesamples, and aliquots of approximately 10 mg were snap-frozen and storedat −70° C. until analysis. The biopsy samples were then homogenized, andlevels of cXDH mRNA in the cyno livers were measured by RT-qPCR using ahousekeeping gene as reference. Resulting values were then normalized tothe pre-dose (in this case, at day −14 or −7, depending on the animals)cXDH mRNA measurements. The resulting mRNA data are reflected in thefollowing Table 45:

TABLE 45 Cyno XDH mRNA Levels Normalized to Pre-Dose (Day −14 or −7)from Example 21 for each Group (n = 3) Pre-Dose (Day −14 or Day −7) Day29 Relative Relative cXDH cXDH mRNA Low High mRNA Low High ExpressionError Error Expression Error Error Group 1: 1.000 0.177 0.215 0.5950.097 0.116 AD09611 Group 2: 1.000 0.083 0.091 NA NA NA AD09611 Day 43Day 57 Relative Relative cXDH cXDH mRNA Low High mRNA Low HighExpression Error Error Expression Error Error Group 1: 0.429 0.105 0.138AD09611 Group 2: 0.604 0.060 0.067 AD09611 Day 71 Day 85 RelativeRelative cXDH cXDH mRNA Low High mRNA Low High Expression Error ErrorExpression Error Error Group 1: 0.560 0.079 0.092 AD09611 Group 2: 0.7580.121 0.144 AD09611 Day 99 Relative cXDH mRNA Low High Expression ErrorError Group 1: AD09611 Group 2: 0.950 0.066 0.071 AD09611

Additionally, XDH activity was assessed using the XDH Activity Assaymethod described in Example 13. The resulting XDH activity data areshown in Table 46.

TABLE 46 Cyno XDH Activity Levels Normalized to Pre-Dose (Day −14 or −7)from Example 21 for each Group (n = 3) Pre-Dose (Day −14 or Day −7) Day29 Day 43 Day 57 Relative Std Relative Std Relative Std Relative Std XDHDev XDH Dev XDH Dev XDH Dev Activity (+/−) Activity (+/−) Activity (+/−)Activity (+/−) Group 1: 1.000 0.01 0.290 0.004 0.391 0.15 AD09611 Group2: 1.000 0.012 0.394 0.066 AD09611 Day 71 Day 85 Day 99 Relative StdRelative Std Relative Std XDH Dev XDH Dev XDH Dev Activity (+/−)Activity (+/−) Activity (+/−) Group 1: 0.341 0.079 AD09611 Group 2:0.357 0.098 0.465 0.067 AD09611As shown in Table 46, AD09611 showed XDH activity reductions of up to70% as measured on day 29, and reductions were maintained at greaterthan 50% through day 99.

Example 22. In Vivo Testing of XDH RNAi Agents in Cynomolgus Monkeys

XDH RNAi agents AD10631, AD09736, AD10621, and AD09985 were evaluated incynomolgus monkeys (cynos). On days 1, 15, and 29, three male cynos foreach group (n=3) were administered a subcutaneous injection of 0.3 mL/kg(approximately 1.5 mL volume, depending on animal mass) containing 3.0mg/kg (10 mg/mL) of the respective XDH RNAi agent, formulated inisotonic saline.

TABLE 47 Targeted Positions and Dosing Groups of Example 22 TargetedGene Position (within SEQ RNAi Agent Dosing Regimen Group ID NO: 1) andDose (on days 1, 15, and 29) 1 4289 3.0 mg/kg AD10631 Three subcutaneousinjections 2 1963 3.0 mg/kg AD09736 Three subcutaneous injections 3 26963.0 mg/kg AD10621 Three subcutaneous injections 4 3598 3.0 mg/kg AD09985Three subcutaneous injections

The XDH RNAi agents included modified nucleotides that were conjugatedat the 5′ terminal end of the sense strand to a targeting ligand thatincluded three N-acetyl-galactosamine groups (tridentate ligand) havingthe modified sequences as set forth in the duplex structures herein.(See Tables 3, 4, 5A, 5B, 5C, and 6 for specific modifications andstructure information related to the XDH RNAi agents, including (NAG37)sligand). The XDH RNAi agents included nucleotide sequences that weredesigned to inhibit expression of a human XDH gene at the specificpositions as shown in Table 47. (See, e.g., SEQ ID NO:1 and Table 2 forthe XDH gene referenced). As noted herein, AD10631 was designed totarget position 4289 and was comprised of a chemically modifiednucleotide sequence similar to AD09611, but included a5′-cyclopropyl-phosphonate modified nucleotide at the 5′ terminal end ofthe antisense strand.

On days −7, 43, 71, and 99, liver biopsies were taken. On the date ofeach biopsy collection, cynos were sedated and 3.5 mm×310 mm clamshellbiopsy forceps were used to extract one liver tissue sampleapproximately 160 mg to 240 mg, and aliquots of approximately 50 mg weresnap-frozen and stored at −70° C. until analysis. The biopsy sampleswere then homogenized, and levels of cXDH mRNA in the cyno livers weremeasured by RT-qPCR using a housekeeping gene as reference. Resultingvalues were then normalized to the pre-dose (in this case, at day −7)cXDH mRNA measurements. The resulting mRNA data are reflected in Table48:

TABLE 48 Cyno XDH mRNA Levels Normalized to Pre-Dose (Day −7) fromExample 22 for each Group (n = 3) Pre-Dose (Day −7) Day 43 RelativeRelative cXDH cXDH mRNA mRNA Expression Low Error High Error ExpressionLow Error High Error Group 1: 1.000 0.093 0.102 0.459 0.062 0.072AD10631 Group 2: 1.000 0.120 0.136 0.420 0.076 0.092 AD09736 Group 3:1.000 0.113 0.127 0.373 0.025 0.027 AD10621 Group 4: 1.000 0.084 0.0910.413 0.081 0.101 AD09985 Day 71 Day 99 Relative Relative cXDH cXDH mRNAmRNA Expression Low Error High Error Expression Low Error High ErrorGroup 1: 0.413 0.036 0.040 0.595 0.055 0.060 AD10631 Group 2: 0.4780.072 0.085 0.502 0.126 0.168 AD09736 Group 3: 0.397 0.029 0.031 0.4770.038 0.042 AD10621 Group 4: 0.339 0.047 0.055 0.459 0.107 0.140 AD09985

Additionally, XDH activity was assessed using the XDH Activity Assaymethod described in Example 13. The resulting XDH activity data areshown in Table 49.

TABLE 49 Cyno XDH Activity Levels Normalized to Pre-Dose (Day −7) fromExample 22 for each Group (n = 3) Pre-Dose (Day −7) Day 43 Day 71 Day 98Relative Std Relative Std Relative Std Relative Std XDH Dev XDH Dev XDHDev XDH Dev Activity (+/−) Activity (+/−) Activity (+/−) Activity (+/−)Group 1: 1 0.000 0.268 0.060 0.273 0.049 0.553 0.135 AD10631 Group 2: 10.000 0.091 0.019 0.130 0.036 0.232 0.069 AD09736 Group 3: 1 0.000 0.0520.004 0.161 0.063 0.186 0.080 AD10621 Group 4: 1 0.000 0.074 0.011 0.1460.044 0.199 0.149 AD09985

As noted above, each of AD09736 (Group 2), AD010621 (Group 3), andAD09985 (Group 4) obtained 90% or greater reductions in XDH activity,indicating these are highly potent XDH RNAi agents capable of reducingXDH protein expression by 90% in liver cells (hepatocytes). AD10631 wasreported to have a 74% reduction in XDH activity, which is similar towhat was seen with the XDH activity assay performed on cyno liver biopsysamples administered AD09611 (which targeted the same position on theXDH gene as AD10631) as reported in Example 13 and Example 21.

Example 23. In Vitro Testing of XDH RNAi Agents

Candidate sequence duplexes shown below in Table 50 were tested invitro. The XDH RNAi agents were prepared in accordance with theprocedures set forth in Example 1. The XDH RNAi agents included modifiednucleotides that were conjugated at the 5′ terminal end of the sensestrand to a targeting ligand that included three N-acetyl-galactosaminegroups (tridentate ligand) having the modified sequences as set forth inthe duplex structures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 forspecific modifications and structure information related to the XDH RNAiagents, including (NAG37)s ligand).

TABLE 50 XDH RNAi Agents Tested for In Vitro Free Uptake Assay inPrimary Human and Cynomolgus Monkey Hepatocytes Targeted Gene Position(within RNAi Agent SEQ ID NO: 1) AD09218 488 AD09744 2696 AD10012 2696AD10621 2696 AD09736 1963 AD09937 1963 AD10278 1963 AD09218 488 AD099853598 AD10731 3598 AD09611 4289 AD10184 4289 AD10631 4289

Evaluation of XDH RNAi agents in vitro was performed by seeding primaryhuman or cynomolgus monkey hepatocytes cells. Cells were seeded at25,000 cells per well in 50 μL culture medium in 96-well collagen coatedplate. Cells were treated with each of the XDH RNAi agent duplexes shownin Table 50 immediately after cells were seeded by adding 504 per wellat 2× the final concentration, followed by gentle mixing and incubationat 3TC, 5% CO2, for 48 hours without disturbing the cells. Isolation andpurification of RNA was completed using a commercially available kitaccording to the manufacturer's instructions (Zymo Quick-RNA MiniprepKit (Zymo Research, Irvine, Calif.)). Relative expression of each of theXDH RNAi agents was determined by qRT-PCR by comparing the expressionlevels of XDH mRNA to an endogenous control (PPIA).

A serial dilution of the RNAi agents was performed and the data curvefit to calculate the dose (concentration) required to knock down geneexpression by 50% (“EC50,” or effective concentration estimated toreduce gene expression by 50%). Residual XDH gene activity and EC50 ofthe XDH RNAi agents are shown below in Tables 51 and 52. Thus, forexample, for RNAi agent AD10012, in primary human hepatocytes, at 1 nM,results in 0.2485 residual XDH gene relative expression, or 75.15% XDHgene knockdown. As further provided in Table 51, AD10012 was reported tohave an EC50 of 0.012 nM (6 point repeat with free uptake in primaryhuman hepatocytes), meaning AD10012 achieves 50% XDH gene knockdown at0.012 nM concentration.

TABLE 51 In vitro inhibition of XDH RNAi Agents by free uptake inprimary human hepatocytes RNAi Agent Concentration EC50 RNAi 0.01 nM 0.11 10 100 1000 EC50 Agent Avg SD nM SD nM SD nM SD nM SD nM SD (nM)AD09218 1.1908 0.4415 0.7427 0.2296 0.3515 0.1042 0.3459 0.1794 0.26240.0653 0.3672 0.1138 0.073 AD09744 1.1048 0.2004 0.6711 0.0780 0.61220.0581 0.1599 0.0769 0.3055 0.0624 0.3551 0.1225 0.098 AD10012 0.87350.0804 0.3435 0.0463 0.2485 0.0293 0.1707 0.1403 0.1840 0.0354 0.28820.1552 0.012 AD10621 0.6962 0.1486 0.3373 0.0537 0.2388 0.0516 0.16140.0148 0.1714 0.0338 0.1947 0.0297 0.033 AD09736 0.6916 0.0306 0.39050.0993 0.2970 0.0661 0.1534 0.0956 0.2394 0.0955 0.1572 0.0313 0.059AD09937 0.7534 0.1915 0.3373 0.0449 0.1919 0.0562 0.2224 0.0745 0.13090.0274 0.1282 0.0160 0.029 AD10278 0.8245 0.1510 0.3776 0.0823 0.26350.0463 0.2347 0.0524 0.1359 0.0275 0.1295 0.0362 0.036 AD09218 0.75780.4480 0.4888 0.0416 0.4312 0.1623 0.2016 0.0565 0.1651 0.0731 0.20390.0753 0.035 AD09985 0.9439 0.0347 0.7353 0.1957 0.3808 0.1059 0.26420.0402 0.2657 0.0527 0.2820 0.1093 0.190 AD10731 0.9885 0.0470 0.55030.0816 0.3282 0.0367 0.3649 0.1127 0.2777 0.0134 0.2634 0.0412 0.042AD09611 0.9968 0.0629 1.0893 0.2769 0.9445 0.0773 0.7137 0.1343 0.47350.0527 0.3751 0.0702 9.607 AD10184 0.9568 0.1924 0.6296 0.0664 0.32720.0500 0.2448 0.0108 0.1962 0.0357 0.1766 0.0323 0.117 AD10631 0.93860.0626 0.4900 0.1062 0.3561 0.0780 0.3252 0.1326 0.2606 0.0450 0.15940.0271 0.040

TABLE 52 In vitro inhibition of XDH RNAi Agents by free uptake inprimary cynomolgus monkey hepatocytes EC50, number of RNAi AgentConcentration repeat points RNAi 0.06 0.49 3.91 31.25 250 2000 EC50(nM), Agent nM SD nM SD nM SD nM SD nM SD nM SD 6x AD09218 0.7835 0.11580.5673 0.0789 0.5559 0.1965 0.3457 0.1295 0.3402 0.0323 0.3044 0.05323.767 AD09744 0.7400 0.0417 0.5543 0.0606 0.4657 0.0987 0.3451 0.09010.3667 0.0903 0.3446 0.1180 0.5439 AD10012 0.6654 0.0098 0.4408 0.11390.3365 0.0168 0.2600 0.0335 0.2525 0.0334 0.2234 0.0236 0.3707 AD106210.5571 0.1315 0.4494 0.1035 0.3046 0.1092 0.3036 0.0667 0.2430 0.07640.1819 0.0379 1.03 AD09736 0.5093 0.0602 0.3650 0.0643 0.2476 0.03250.2683 0.0184 0.1759 0.0188 0.2002 0.0517 0.4216 AD09937 0.5609 0.04440.3441 0.0388 0.2705 0.0203 0.2531 0.0565 0.1845 0.0197 0.1933 0.03940.2249 AD10278 0.4772 0.0029 0.3957 0.0457 0.2929 0.0667 0.2837 0.02100.1784 0.0163 0.2003 0.0536 1.918 AD09218 0.8383 0.2444 0.6405 0.12840.5279 0.0812 0.3616 0.0964 0.2885 0.0710 0.3272 0.0644 2.04 AD099850.8656 0.0630 0.5815 0.0823 0.5065 0.0684 0.4399 0.0955 0.2934 0.05120.2938 0.0481 0.4581 AD10731 0.7837 0.1459 0.4582 0.1026 0.3867 0.11690.4410 0.1221 0.2709 0.0683 0.2992 0.0018 0.09407 AD09611 0.6219 0.06790.8340 0.1089 0.6923 0.1597 0.5281 0.1568 0.4321 0.0247 0.3780 0.013720.19 AD10184 0.6263 0.0080 0.4306 0.0235 0.4214 0.0468 0.3293 0.06100.2743 0.0341 0.1787 0.0679 0.5228 AD10631 0.5973 0.0231 0.5815 0.07130.5537 0.1817 0.5543 0.1779 0.3033 0.0283 0.3341 0.0497 77.08

Example 24. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, using the XDH-GLucAAV containing the 80-2899 region of the human XDH cDNA sequence wasused. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing 2.0 mg/kg (mpk)of an XDH RNAi agent formulated in isotonic saline, or vehicle control(isotonic saline with no RNAi agent), according to Table 53.

TABLE 53 Targeted Positions and Dosing Groups of Example 24 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 2696 Saline (no Single injection on day 1 RNAi agent) 2 26962.0 mg/kg AD09744 Single injection on day 1 3 2696 2.0 mg/kg AD10012Single injection on day 1 4 2696 2.0 mg/kg AD10619 Single injection onday 1 5 2696 2.0 mg/kg AD10620 Single injection on day 1 6 2696 2.0mg/kg AD10621 Single injection on day 1 7 2696 2.0 mg/kg AD10622 Singleinjection on day 1 8 2696 2.0 mg/kg AD10623 Single injection on day 1 92696 2.0 mg/kg AD10624 Single injection on day 1 10 2696 2.0 mg/kgAD10625 Single injection on day 1 11 2696 2.0 mg/kg AD10626 Singleinjection on day 1 12 2696 2.0 mg/kg AD10627 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents in Groups 2-12 eachincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at position 2696 of the gene. (See, e.g., SEQ ID NO:1 andTable 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15, and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2.Data from the experiment through day 22 are shown in Table 54:

TABLE 54 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 24 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.107 1.000 0.172 1.000 0.233 Group 2 (2.0 mg/kg AD09744) 0.5850.079 0.616 0.024 0.659 0.088 Group 3 (2.0 mg/kg AD10012) 0.336 0.0340.305 0.014 0.343 0.018 Group 4 (2.0 mg/kg AD10619) 0.397 0.034 0.4150.011 0.415 0.046 Group 5 (2.0 mg/kg AD10620) 0.394 0.049 0.326 0.0460.306 0.053 Group 6 (2.0 mg/kg AD10621) 0.403 0.038 0.312 0.049 0.3480.026 Group 7 (2.0 mg/kg AD10622) 0.382 0.068 0.317 0.061 0.338 0.065Group 8 (2.0 mg/kg AD10623) 0.280 0.124 0.268 0.053 0.258 0.137 Group 9(2.0 mg/kg AD10624) 0.302 0.069 0.362 0.091 0.376 0.174 Group 10 (2.0mg/kg AD10625) 0.341 0.048 0.342 0.096 0.412 0.079 Group 11 (2.0 mg/kgAD10626) 0.436 0.078 0.394 0.063 0.415 0.035 Group 12 (2.0 mg/kgAD10627) 0.317 0.041 0.325 0.023 0.322 0.041

Example 25. In Vivo Testing of XDH RNAi Agents in Cynomolgus Monkeys

XDH RNAi agents AD10621 and AD09985 were evaluated in cynomolgus monkeys(cynos). On day 1, three male cynos for each group (n=3) wereadministered a subcutaneous injection of 0.3 mL/kg (approximately 1.5 mLvolume, depending on animal mass) containing 3 mg/kg or 1 mg/kg of therespective XDH RNAi agent, formulated in isotonic saline.

TABLE 55 Targeted Positions and Dosing Groups of Example 22 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen (on day 1) 1 2696 3.0 mg/kg AD10621 Single subcutaneousinjection 2 3598 3.0 mg/kg AD09985 Single subcutaneous injection 3 26961.0 mg/kg AD10621 Single subcutaneous injection 4 3598 1.0 mg/kg AD09985Single subcutaneous injection

The XDH RNAi agents included modified nucleotides that were conjugatedat the 5′ terminal end of the sense strand to a targeting ligand thatincluded three N-acetyl-galactosamine groups (tridentate ligand) havingthe modified sequences as set forth in the duplex structures herein.(See Tables 3, 4, 5A, 5B, 5C, and 6 for specific modifications andstructure information related to the XDH RNAi agents, including (NAG37)sligand). The XDH RNAi agents included nucleotide sequences that weredesigned to inhibit expression of a human XDH gene at the specificpositions as shown in Table 55. (See, e.g., SEQ ID NO:1 and Table 2 forthe XDH gene referenced).

On days −6 (day −3 for one of the animals), 29, 55, and 99 (day 100 forone of the animals), liver biopsies were taken. On the date of eachbiopsy collection, cynos were sedated and needles were used to extracttwo liver tissue samples approximately 20 mg each. Samples were weighed,snap-frozen and stored at −70° C. until analysis. The biopsy sampleswere then homogenized, and levels of cXDH mRNA in the cyno livers weremeasured by RT-qPCR using a housekeeping gene as reference. Resultingvalues were then normalized to the pre-dose (in this case, at day −6 orday −3) cXDH mRNA measurements. The resulting mRNA data are reflected inTable 56:

TABLE 56 Cyno XDH mRNA Levels Normalized to Pre-Dose (Day −6 or Day −3)from Example 25 for each Group (n = 3) Pre-Dose (Day −6 or Day −3) Day29 Relative Relative cXDH cXDH mRNA Low High mRNA Low High ExpressionError Error Expression Error Error Group 1: 1.000 0.107 0.120 0.5850.098 0.118 AD10621 Group 2: 1.000 0.039 0.041 0.695 0.072 0.080 AD09985Group 3: 1.000 0.114 0.128 0.864 0.138 0.165 AD10621 Group 4: 1.0000.121 0.138 0.691 0.131 0.162 AD09985 Day 55 Day 99 or Day 100 RelativeRelative cXDH cXDH mRNA Low High mRNA Low High Expression Error ErrorExpression Error Error Group 1: 0.687 0.052 0.056 0.793 0.082 0.092AD10621 Group 2: 0.708 0.087 0.100 0.678 0.121 0.148 AD09985 Group 3:0.666 0.148 0.190 0.693 0.125 0.153 AD10621 Group 4: 0.720 0.112 0.1320.676 0.149 0.191 AD09985

Additionally, XDH activity was assessed using the XDH Activity Assaymethod described in Example 13. The resulting XDH activity data areshown in Table 57.

TABLE 57 Cyno XDH Activity Levels Normalized to Pre-Dose (Day −6) fromExample 25 for each Group (n = 3) Pre-Dose (Day −6 or Day −3) Day 29 Day55 Day 99 or Day 100 Relative Std Relative Std Relative Std Relative StdXDH Dev XDH Dev XDH Dev XDH Dev Activity (+/−) Activity (+/−) Activity(+/−) Activity (+/−) Group 1: 1 0.000 0.153 0.0048 0.399 0.2224 0.8550.2914 AD10621 Group 2: 1 0.000 0.109 0.0139 0.221 0.1523 0.649 0.1959AD09985 Group 3: 1 0.000 0.236 0.0452 0.343 0.3047 0.681 0.0675 AD10621Group 4: 1 0.000 0.506 0.2290 0.517 0.2206 1.215 0.1157 AD09985

As noted above, each of AD10621 (Group 1) and AD09985 (Group 2) obtained˜85% or greater reductions in XDH activity, indicating these are highlypotent XDH RNAi agents capable of reducing XDH protein expression by˜85% in liver cells (hepatocytes).

Example 26. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) of an XDH RNAi agent formulated in isotonic saline, or vehiclecontrol (isotonic saline with no RNAi agent), according to the followingTable 58.

TABLE 58 Targeted Positions and Dosing Groups of Example 26 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 488 2.0mg/kg AD09218 Single injection on day 1 3 139 2.0 mg/kg AD09725 Singleinjection on day 1 4 235 2.0 mg/kg AD09598 Single injection on day 1 5239 2.0 mg/kg AD09726 Single injection on day 1 6 332 2.0 mg/kg AD09727Single injection on day 1 7 2320 2.0 mg/kg AD09741 Single injection onday 1 8 2357 2.0 mg/kg AD09742 Single injection on day 1 9 2361 2.0mg/kg AD09743 Single injection on day 1 10 2696 2.0 mg/kg AD09744 Singleinjection on day 1 11 2701 2.0 mg/kg AD09745 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents of Groups 2-11 allincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at the positions of the gene listed on Table 58. (See,e.g., SEQ ID NO:1 and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15 and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment through day 22 are shown in thefollowing Table 59:

TABLE 59 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 26 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 (Saline vehicle)1.000 0.066 1.000 0.104 1.000 0.084 Group 2 2.0 mg/kg AD09218 0.3500.043 0.376 0.038 0.400 0.079 Group 3 2.0 mg/kg AD09725 0.748 0.1340.853 0.059 0.871 0.129 Group 4 2.0 mg/kg AD09598 0.729 0.070 0.9350.235 1.073 0.092 Group 5 2.0 mg/kg AD09726 0.651 0.104 0.747 0.1540.806 0.161 Group 6 2.0 mg/kg AD09727 0.885 0.051 0.927 0.127 0.9290.140 Group 7 2.0 mg/kg AD09741 0.616 0.090 0.693 0.064 0.708 0.110Group 8 2.0 mg/kg AD09742 0.724 0.101 0.896 0.143 0.863 0.139 Group 92.0 mg/kg AD09743 0.803 0.060 0.907 0.107 0.841 0.130 Group 10 2.0 mg/kgAD09744 0.477 0.051 0.576 0.170 0.558 0.132 Group 11 2.0 mg/kg AD097450.568 0.045 0.626 0.062 0.719 0.045

Example 27. In Vivo Testing of XDH RNAi Agents in XDH-GLuc AAV Mice

The XDH-GLUC AAV mouse model described in Example 2, above, using theXDH-GLuc AAV containing the 80-2899 region of the human XDH cDNAsequence was used. At day 1, each mouse was given a single subcutaneousadministration of 250 μl/25 g animal weight containing either 2.0 mg/kg(mpk) or 4.0 mg/kg (mpk) of an XDH RNAi agent formulated in isotonicsaline, or vehicle control (isotonic saline with no RNAi agent),according to the following Table 60.

TABLE 60 Targeted Positions and Dosing Groups of Example 27 TargetedGene Position (within SEQ RNAi Agent Group ID NO: 1) and Dose DosingRegimen 1 N/A Saline (no Single injection on day 1 RNAi agent) 2 26962.0 mg/kg AD10621 Single injection on day 1 3 2696 4.0 mg/kg AD10621Single injection on day 1 4 2701 2.0 mg/kg AD09745 Single injection onday 1 5 2701 4.0 mg/kg AD09745 Single injection on day 1 6 2701 2.0mg/kg AD12167 Single injection on day 1 7 2701 4.0 mg/kg AD12167 Singleinjection on day 1 8 2696 2.0 mg/kg AD12168 Single injection on day 1 92696 4.0 mg/kg AD12168 Single injection on day 1

Each of the XDH RNAi agents included modified nucleotides that wereconjugated at the 5′ terminal end of the sense strand to a targetingligand that included three N-acetyl-galactosamine groups (tridentateligand) having the modified sequences as set forth in the duplexstructures herein. (See Tables 3, 4, 5A, 5B, 5C, and 6 for specificmodifications and structure information related to the XDH RNAi agents,including (NAG37)s ligand). The XDH RNAi agents of Groups 2-9 allincluded nucleotide sequences that were designed to inhibit expressionof an XDH gene at positions 2696 and 2701 of the gene. (See, e.g., SEQID NO:1 and Table 2 for the XDH gene referenced).

The injections were performed between the skin and muscle (i.e.subcutaneous injections) into the loose skin over the neck and shoulderarea. Four (4) mice in each group were tested (n=4). Serum was collectedon day 1 (pre-treatment), day 8, day 15 and day 22, and XDH expressionlevels were determined pursuant to the procedure set forth in Example 2,above. Data from the experiment through day 22 are shown in thefollowing Table 60.

TABLE 60 Average XDH Normalized to Pre-Treatment & Control in XDH-GLUCAAV Mice from Example 27 Day 8 Day 15 Day 22 Avg Std Dev Avg Std Dev AvgStd Dev Group ID XDH (+/−) XDH (+/−) XDH (+/−) Group 1 Saline (no RNAiagent) 1.000 0.064 1.000 0.152 1.000 0.247 Group 2 2.0 mg/kg AD106210.449 0.072 0.317 0.108 0.410 0.095 Group 3 4.0 mg/kg AD10621 0.3170.040 0.184 0.038 0.232 0.059 Group 4 2.0 mg/kg AD09745 0.809 0.2140.567 0.196 0.690 0.281 Group 5 4.0 mg/kg AD09745 0.590 0.090 0.3470.047 0.408 0.026 Group 6 2.0 mg/kg AD12167 0.712 0.072 0.546 0.1240.650 0.211 Group 7 4.0 mg/kg AD12167 0.522 0.087 0.297 0.093 0.3850.092 Group 8 2.0 mg/kg AD12168 0.881 0.126 0.497 0.029 0.631 0.120Group 9 4.0 mg/kg AD12168 0.500 0.019 0.327 0.028 0.359 0.060

As shown in Table 60, the XDH RNAi agent of Group 2 and 3 (AD010621)showed superior XHD inhibition compared to each of the RNAi agents inGroups 4-9 in vivo. For example, a single dose of 2.0 mg/kg of AD10621reported approximately 59% inhibition of XDH (0.410) and a single 4.0mg/kg dose reported approximately 77% inhibition (0.232) on day 22.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A pharmaceutical composition for inhibitingexpression of an XDH gene, comprising an RNAi agent comprising a sensestrand and an antisense strand, wherein the sense strand comprises anucleic acid sequence of ccuccgcaCfAfGfauauugucau (SEQ ID NO: 1664) andthe antisense strand comprises a nucleic acid sequence ofasUfsgsAfcaauaucUfgUfgCfggagsg (SEQ ID NO: 1081), wherein lower case(n)=2′-O-Me modified nucleotide; Nf=2′-F modified nucleotide; ands=phosphorothioate backbone modification.
 2. The pharmaceuticalcomposition of claim 1, wherein the sense strand further comprises aninverted abasic residue at each of the 5′ end and the 3′ end.
 3. Thepharmaceutical composition of claim 2, wherein the inverted abasicresidue is coupled to an adjacent nucleoside via a phosphorothioatebackbone.
 4. The pharmaceutical composition of claim 1, wherein the 5′end of the sense strand is coupled to a targeting ligand.
 5. Thepharmaceutical composition of claim 4, wherein the targeting ligandcomprises:


6. The pharmaceutical composition of claim 4, wherein the targetingligand is


7. The pharmaceutical composition of claim 1, wherein the sense strandconsists of a nucleic acid sequence of(invAb)sccuccgcaCfAfGfauauugucaus(invAb) (SEQ ID NO: 1681) and theantisense strand consists of a nucleic acid sequence ofasUfsgsAfcaauaucUfgUfgCfggagsg (SEQ ID NO: 1081), wherein lower case(n)=2′-O-Me modified nucleotide; Nf=2′-F modified nucleotide;(invAb)=inverted abasic residue; and s=phosphorothioate backbonemodification.
 8. The pharmaceutical composition of claim 7, wherein the5′ end of the sense strand is coupled to a targeting ligand.
 9. Thepharmaceutical composition of claim 8, wherein the targeting ligandcomprises:


10. The pharmaceutical composition of claim 8, wherein the targetingligand is


11. The pharmaceutical composition of claim 7, wherein the RNAi agent isa pharmaceutically acceptable salt.
 12. The pharmaceutical compositionof claim 11, wherein the pharmaceutically acceptable salt is a sodiumsalt.
 13. The pharmaceutical composition of claim 10, wherein the RNAiagent is a pharmaceutically acceptable salt.
 14. The pharmaceuticalcomposition of claim 13, wherein the pharmaceutically acceptable salt isa sodium salt.